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ABSTRACT 
Streptococcus pneumoniae is a Gram-positive bacterium that is associated with a 
range of diseases including pneumonia, otitis media and invasive pneumococcal disease 
(IPD) including meningitis and septicaemia. It is estimated that approximately 800 000 
children under five die each year, worldwide, from pneumococcal diseases (O’Brien et 
al., 2009). As well as this, S. pneumoniae causes high morbidity (estimated 14.5 million 
episodes of serious pneumococcal disease in 2000) and high economic burden globally, 
especially in underdeveloped countries (O’Brien et al., 2009). As a result, a number of 
strategies to combat pneumococcal diseases have been implemented, including 
antibiotics and vaccines. Unfortunately, despite initial decreases in pneumococcal 
diseases, this bacterium has managed to overcome the effects of drugs and vaccines by 
developing resistance or evasive mechanisms, and hence pneumococcal diseases 
continue to persist throughout the world. 
After the introduction of the first childhood vaccine, called Prevenar®  or 7-valent 
pneumococcal conjugate vaccine (7vPCV; Wyeth Pharmaceuticals) in Australia during 
2005, IPD was reported to decline as observed worldwide (Roche et al., 2008). 
Unfortunately, due to a phenomenon called serotype replacement, incidences of IPD 
began to increase. Therefore an upgraded vaccine, Prevenar13® (13vPCV; Pfizer) was 
licensed in Australia in July 2011 (Selvey, 2011). Since then, there has been no 
published study on the genetic population of S. pneumoniae in Queensland. Surveying S. 
pneumoniae is important to detect changes in the population, particularly after the 
introduction of the vaccine. 
Therefore, a number of genotyping methods have been used worldwide to study 
the pneumococcal population. Multi-Locus Sequence Typing (MLST) is considered the 
‘gold standard’ genotyping method for S. pneumoniae. However, due to the fact that 
MLST is expensive and better suited for evolutionary studies rather than epidemiology 
studies, another genotyping method has been developed, called Multi-Locus Variable 
Number of Tandem Repeat Analysis (MLVA). This new method has been shown to be 
cheaper, faster and highly discriminatory compared to MLST. However, current MLVA 
methods also pose limitations, which include failure to obtain complete genetic profiles 
for all pneumococcal strains, and the fact that there is no universally accepted method 
that has been tested worldwide. This study firstly aims to investigate the current MLVA 
methods and propose modifications to the protocol for improved genetic typing of S. 
pneumoniae. Comparisons of our modified MLVA4 method has been made against 
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MLST and two other published MLVA methods (Elberse et al., 2011a; Van Cuyck et al., 
2012). 
Characterisation of the Queensland pneumococcal population was performed as 
our second aim. A time frame from 2007 to 2012 was used, and S. pneumoniae isolates, 
taken from children under the age of 15 years, were genotyped using two MLVA 
methods (including the modified MLVA4 method) and MLST.  The major findings, 
indicated that there were a number of clonal complexes (CC) of pneumococcus causing 
invasive disease in children, with the dominant sequence types (ST) and MLVA types 
(MT) including S. pneumoniae serotype 1 (ST306; MT36), 3 (ST1230; MT8), 7F (ST191; 
MT27) and 19A (ST411; MT59 and ST63; MT60). Following on from this, our third aim 
was to determine whether any changes of non-13vPCV serotypes could be detected. At 
this point there is no observable increase in non-13vPCV serotypes causing IPD, 
however these serotypes still cause approximately 33% of IPD in Queensland children. 
Upon examination of the pneumococcal population in Queensland, it was 
observed that several pneumococcal strains appeared to have switched their protective 
capsule, the outer-most layer covering the cell wall. This polysaccharide capsule is 
thought to play a role in pneumococcal virulence, and there are at least 98 capsule 
types, (also called serotypes) known worldwide (Bentley et al., 2006; Bratcher et al., 
2010; Calix & Nahm, 2010; Calix et al., 2012; Ko et al., 2013; Oliver et al., 2013; Park et 
al., 2007; Park et al., 2015). The phenomenon of capsule switching is thought to occur 
when the bacteria take up naked DNA from the external environment through a process 
called horizontal transformation. This new DNA is incorporated into the genome, and a 
capsule switch occurs when capsular genes are taken up. The result is a transformed 
polysaccharide capsule which could enable the bacteria to evade the vaccine and 
potentially lead to vaccine escape strains. 
Therefore, despite the widely used ‘gold standard’ capsular typing method, the 
serotyping/Quellung reaction, there are also a number of limitations. As a result, we 
proposed to develop a novel capsule typing method based on the use of a 
bioinformatics program called Minimum SNPs and molecular PCR methods. A number 
of molecular PCR methods for capsule typing have been published however they are 
limited to the most common capsule types associated with pneumococcal disease. We 
wanted to expand on these methods and develop a technique which could enable the 
ability to type any of the 98 known pneumococcal capsules. As well as this, due to 
potential capsule switching detected previously, we can combine this capsule typing 
method with the previous MLVA4 method to determine capsule switching events. 
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The major outcomes of this project include the development of a modified 
MLVA4 method and the development of a novel capsule typing method, which have 
both been applied to Queensland invasive S. pneumoniae isolates. A database of our 
MLVA4 profiles has been made available, and isolates with a MLST type has also been 
submitted to the open-access international MLST database 
(http://pubmlst.org/spneumoniae/). MLVA4 is highly discriminatory, and the 
application of MLVA to other bacterial and non-bacterial organisms is becoming more 
popular, particularly because of the cheaper costs and speed of the method. This has 
been particularly important for epidemiology studies of outbreaks and bioterrorism 
events. 
Furthermore, the novel capsule typing method based on the Minimum SNPs 
bioinformatics program can characterise the pneumococcal capsule types in 
Queensland, although further optimisation of the method is required. The combination 
of the novel capsule typing with MLVA4 allows the identification of capsule switching 
events, of which a switch from serotype 19A to 15C and switch from serotype 1 to 4 has 
been observed in the Queensland pneumococcal population. Minimum SNPs 
bioinformatics program could also be applied for developing molecular capsule typing 
methods of other microorganisms, particularly since a number of Gram-negative, Gram-
positive and even certain fungus carry a polysaccharide capsule. 
Future directions for research include the increased collaboration to investigate 
or establish a universal MLVA genotyping method and database for genotyping S. 
pneumoniae. Continued monitoring of the pneumococcal population in Queensland is 
advised, particularly for at least five years after the introduction of the most recent 
vaccine in 2011 to gain insight into the effects of the vaccine and whether serotype 
replacement will occur. Future investigation into the novel capsule typing method can 
be performed, including the ability to multiplex the PCR reactions so that the protocol 
is faster and potentially cheaper, the addition of other capsule genes that identify 
capsulated or non-capsulated pneumococci, the ability to capsule type directly from 
clinical samples (e.g. blood, sputum, etc.) without the need to culture, and the 
verification of whether capsule switching can be confidently determined using this 
simple PCR method or whether whole genome sequence or capsule sequencing is 
required. The significance of this PhD thesis provides further insight into S. pneumoniae 
epidemiology studies and the interpretation of S. pneumoniae population structures 
using genotyping methods, and the information may impact future vaccine production 
and health preventative measures. 
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PSGS Pneumococcal Serotyping and Genotyping 
QHFSS Queensland Health Forensic and Scientific Services 
QUT Queensland University of Technology 
rtPCR real-time PCR 
SLV Single Locus Variant 
SNP Single Nucleotide Polymorphism 
ssDNA single-stranded DNA 
ST Sequence Type 
TE Tris Ethylenediaminetetraacetic-acid 
TLV Triple Locus Variant 
URT Upper Respiratory Tract 
VNTR Variable Number of Tandem Repeats 
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LIST OF DEFINITIONS 
BOX loci – a type of VNTR loci, and is specifically identified as a 45-base pair tandem 
repeat located between boxA and boxC loci in Streptococcus pneumoniae 
Capsule cassette – the collection of genes that code for the polysaccharide capsule in S. 
pneumoniae 
Capsule switching – the process when pneumococci exchange capsule genes through 
horizontal transformation so that the expressed capsule (serotype) 
changes to another 
Clonal Complex (CC) – a group of isolates that are genetically related either by single 
or double locus variants in the genetic profile 
Competence - the stage during a microorganism’s life where transformation 
occurs, indicating that it has the ability to take up DNA and transform 
Cross protection – (also referred to as cross-immunity) occurs when the antibodies in 
the pneumococcal vaccine bind to more than one specific capsule type, 
providing protection against both capsule types 
Emergent serotype - a non-vaccine targeted serotype that becomes a carrier in 
>5% of the population after the introduction of a vaccine, unless 
already exceeding this before introduction of a vaccine 
Epidemiology – the study of patterns, effects and causes of disease and health 
conditions in a defined population 
Fratricide  - the killing of neighbouring pneumococcal bacteria by another 
pneumococcal bacterium 
Genotype – the combination of alleles situated within the bacterial genome 
Herd immunity – a form of immunity that occurs when a large population (or herd) is 
vaccinated to the point that it provides a measure of protection for 
individuals who have not developed immunity 
Horizontal transformation – the transfer of genes from one bacterium to another via 
genetic manipulation of the cells so that the foreign genetic material can be 
expressed in the new cell 
Invasive pneumococcal disease (IPD) – the isolation of S. pneumoniae from normally 
sterile body specimens such as blood, cerebral spinal fluid, pleural fluid and 
tissues   
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Minimum SNPs – a computer software program that traditional identifies SNPs within 
a genome, but has been utilised to identify highly variable genes within a 
cassette 
Mother template – a manually engineered string of pneumococcal capsule genes that 
could be present in any pneumococcal serotype; used for creating 
‘pseudoDNA’ sequences for the MinimumSNPs program 
Multiplex – a chemical reaction designed to target more than one DNA region 
Opsonophagocytosis - a mechanism of the host to clear out streptococcal infection via 
phagocytosis enhanced by an opsonin molecule 
Pneumococcal conjugate vaccine (PCV) - a vaccine that conjugates a polysaccharide 
antigen to an immunogenic carrier protein so that it can elicit an immune 
memory response to protect against S. pneumoniae 
PseudoDNA sequence – a mock DNA sequence that only contains A and T (A=absent 
and T=present) that is based on the pneumococcal capsule cassette and is 
used by the Minimum SNPs program to identify highly variable “SNPs” 
(each SNP position codes for a capsule gene) 
Serogroup – designates a group of bacteria sharing a common antigen 
Serotype – a distinct characterisation of microorganisms based on the specific antigens 
on the cell surface as determined by serological testing (e.g. Quellung 
reaction). This provides further differentiation within a serogroup. 
Serotype replacement - the increase in non-vaccine targeted serotypes after a 
noticeable decrease in vaccine-targeted serotypes in a given population 
Serotyping – a method to detect pneumococcal serotypes by using antibodies to bind 
and react to the pneumococcal polysaccharide capsule, causing it to 
become opaque and enlarged when visualised under a microscope 
Singleplex – a chemical reaction that only targets one DNA region  
Syntenic – when two or more genomic regions (such as the pneumococcal capsule 
cassette) derive from a common ancestral genomic region 
Vaccine escape - to describe a pneumococcal strain that has increased in numbers in a 
given population after switching its capsule from a vaccine-targeted 
serotype to a non-vaccine-targeted serotype 
VNTR loci – a sequence in a genome where a short nucleotide sequence is organized in 
a tandem repeat 
 
 
 
 XX 
 
 
LIST OF PUBLICATIONS 
Journal Papers 
Rayner RE., Savill J., Hafner LM., and Huygens F. (2015). Genotyping 
Streptococcus pneumoniae. Future Microbiology, 10(4): 653-664. 
Rayner RE., Savill J., Hafner LM., and Huygens F. (2015). Modified MLVA for 
genotyping Queensland invasive Streptococcus pneumoniae. PLoS One, 10(4): 
e0121870. doi:10.1371/journal.pone.0121870. 
Rayner RE., Savill J., Hafner LM., Huygens F. The changing population structure of 
invasive S. pneumoniae in Queensland children. Draft (to be submitted to PLoS 
One). 
 
Conferences and Presentations 
Rayner RE., Savill J., Hafner LM., Huygens F. A novel capsular typing method for 
Streptococcus pneumoniae using Minimum SNPs.  
- Microbiology in Maleny – Queensland section of Australian Society of 
Microbiology (ASM), Annual scientific meeting, November 29, 2014, 
Maleny, Australia. 
- IHBI Inspires Postgraduate Student Conference, Annual Scientific meeting, 
November 20 - 21, 2014, Gold Coast, Australia. 
- XIX Lancefield International Symposium on Streptococci and Streptococcal 
Diseases (LISSSD), Scientific Meeting, November 9 -12, 2014, Buenos 
Aires, Argentina. 
--Australian Society of Microbiology, Annual Scientific meeting, July 12 – 15, 
2015, Canberra, Australia. 
Rayner RE., Savill J., Hafner LM., Huygens F. The changing population structure of 
invasive pneumococci in Queensland children.  
- Microbiology at QUT and Beyond, Scientific meeting. October 2014, 
Brisbane, Australia. 
 XXI 
 
- Australian Society for Microbiology (ASM), Annual Scientific Meeting. 
July 2013, Adelaide, Australia. 
Rayner RE., Savill J., Hafner LM., Huygens F. A novel approach to detect capsule 
types of the pneumococcus bacteria. 3-Minute Thesis Competition – Faculty of 
Health Final (QUT), August 2014, Kelvin Grove, Australia. 
Rayner RE., Savill J., Hafner LM., Huygens F. The war against the pneumococcus. 
IHBI Inspires Postgraduate Student Conference, Annual Scientific meeting, 
November 2013, Brisbane, Australia. 
Rayner RE., Savill J., Hafner LM., Huygens F. The population structure of 
Queensland invasive Streptococcus pneumoniae isolates in children: identified 
using a modified Multi-Locus Variable Number of Tandem Repeat Analysis BOX 
Typing. IHBI Inspires Postgraduate Student Conference, Annual Scientific 
meeting, November, 2012, Gold Coast, Australia. 
 
Awards 
Rayner RE., Savill J., Hafner LM., Huygens F. The war against the pneumococcus. 
3-Minute Thesis Competition – Faculty of Health Final (QUT), August 2013, 
Kelvin Grove, Australia. (Runner-up finalist) 
 
 
 
 
 
 
 
 
 
 
 
 
 XXII 
 
 
 
 
 
STATEMENT OF ORIGINAL AUTHORSHIP 
The work contained in this thesis has not been previously submitted to meet 
requirements for an award at this or any other higher education institution. To the best 
of my knowledge and belief, the thesis contains no material previously published or 
written by another person except where due reference is made. 
 
 
 
Signature:     
 
Date:             28/07/2015 
QUT Verified Signature
 XXIII 
 
ACKNOWLEDGEMENTS 
There are a number of people I would like to thank for assisting and enabling me to 
articulate from a Masters of Applied Science (Research) into a Doctor of Philosophy 
(PhD).  
Firstly, I would like to thank my principal supervisor, Flavia Huygens, for her unfailing 
help and directing me on my studious path towards John Savill at the Queensland 
Health Forensic and Scientific Services. I am incredibly indebted for the opportunity to 
begin my study within a ‘real-world’ laboratory, and also the focussed push to begin 
practical work within my first two weeks of my Masters. I thank John for also being 
concerned about my welfare in the laboratory and assisting in my transfer back to IHBI, 
QUT, once I had articulated to my PhD. 
I would also like to thank all of my three supervisors, Flavia, John and Louise, for their 
support in regards to writing papers, suggesting conferences (and pushing me to 
actually go), and encouraging and supporting any other activities associated to my PhD, 
university life and even my extracurricular lifestyle outside of university. I have found 
that the more things that I do (as long as I’m keeping a balanced schedule), the better I 
can apply my time and focus. So I appreciated their support in all the different areas 
and activities that I participated in. 
I would like to thank the Public Health Microbiology, QHFSS members including 
Lawrence Ariotti, Megan Staples, Amy Jennison and Ricki Graham, for their assistance 
in the initial Masters research with culturing the bacteria and other assistance in 
experimental work. I would similarly like to thank the members of the Molecular 
Microbiology Pathogenesis Group (MMPG) - Sumeet, Irani, Imalka, Nadeesha, Asif, 
Leanne and James for their support and recommendations in our fortnightly meetings, 
and around the laboratory. 
Finally I would like to thank the support of my family - Mum and Dad, my brothers 
Daniel, Luke and Josh, and Grandma, William, Nana, Marg, Lucy and Abigail. I also want 
to thank all my friends for supporting me in completing my PhD, showing interest in 
the subject I am researching and allowing me to de-stress away from my studies. Lastly 
and most importantly I would like to thank God and Jesus for being a constant and 
loving presence in my life. 
CHAPTER 1 Introduction, Aims, Objectives and Hypothesis 
24 
 
CHAPTER 1 Introduction, Aims, Objectives and Hypothesis 
25 
 
CHAPTER 1: INTRODUCTION, AIMS, OBJECTIVES AND 
HYPOTHESES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 Introduction, Aims, Objectives and Hypothesis 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 Introduction, Aims, Objectives and Hypothesis 
27 
 
1.1 Introduction 
S. pneumoniae is a common but potentially deadly Gram-positive bacterium that 
causes high mortality and morbidity worldwide – over 800 000 children under five die 
from pneumococcal diseases each year globally (O’Brien et al., 2009). In Australia, 
invasive pneumococcal disease (IPD) is still a major health risk especially in children 
under two years and in the Aboriginal population (Lehmann et al., 2010).  
An important feature of the pneumococcus is the polysaccharide capsule that 
surrounds the bacterium, protecting it from opsonophagocytosis (a mechanism of the 
host to clear out streptococcal infection via phagocytosis enhanced by an opsonin 
molecule) (Todar, 2012). Pneumococcal strains are often characterised by their capsule 
type, also called a serotype. Determining the serotype of pneumococci has traditionally 
been performed by a serotyping method e.g. Quellung reaction. The Quellung method 
uses polyclonal antibodies that bind to the capsule and produce a “swelling” reaction 
observed under a microscope (Statens Serum Institut, 2013). There are 98 published 
serotypes of S. pneumoniae, of which at least 23 serotypes are targeted by a vaccine, 
although potentially all 98 serotypes  can cause disease (Bentley et al., 2006; Bratcher 
et al., 2010; Calix & Nahm, 2010; Calix et al., 2012; Ko et al., 2013; Oliver et al., 2013; 
Park et al., 2007; Park et al., 2015). 
To combat increasing incidences of IPD, a 7-valent pneumococcal conjugate 
vaccine (7vPCV; Prevenar®, Wyeth Pharmaceuticals) was introduced for all Australian 
children aged younger than two in 2005, targeting the seven most common serotypes 
(serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) that caused IPD at that time (Johnson et al., 
2010). Since the introduction of the vaccine, IPD cases have decreased globally as 
expected, however IPD caused by non-vaccine (non-7vPCV) serotypes increased due to 
two phenomena: serotype replacement and capsule switching (Elberse et al., 2011a; 
Elberse et al., 2012; Guevara et al., 2009; Hanage et al., 2005; Hanna et al., 2008; Hicks 
et al. 2007; Lehmann et al., 2010; Marsh et al., 2007; McChlery et al., 2005; Nunes et al., 
2005; Reingold et al., 2005; Singleton et al., 2007; Tyrrell et al., 2009; Whitney et al., 
2003).  
Serotype replacement, the increase in non-vaccine targeted serotypes after the 
decrease in vaccine-targeted serotypes, has largely contributed to a shift in the 
pneumococcal population and increasing IPD (Weinberger et al., 2011). Pneumococcal 
serotype 19A has been the most common non-7vPCV serotype causing IPD in the USA 
after the introduction of the 7vPCV (Pai et al., 2005; Reingold et al., 2005). The 
Queensland Health Pneumococcal Reference Laboratory has recorded that since 2007, 
there has been an increase in IPD cases caused by non-vaccine targeted serotypes from 
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113 (2000-2004) to 244 (2007-2011) in children under five years (raw numbers 
provided only - J. Savill, personal communication, 2012). From the previous 
observation, four serotypes included in an upgraded 13-valent pneumococcal conjugate 
vaccine (13vPCV; Pfizer) (targets the additional serotypes 1, 3, 7F and 19A) have 
contributed to over 140 IPD cases. Serotype 19A is mainly responsible for this increase 
and is the subject of another genotyping study at Queensland Health Forensic and 
Scientific Services (QHFSS). It is unknown whether there were any changes in 
pneumococcal surveillance, changes in guidelines for blood cultures, etc. that may have 
impacted this increase in non-vaccine targeted serotypes during this time period. 
However, the Commonwealth-funded Enhanced Invasive Pneumococcal Disease 
Surveillance Working Group was established in 2000 by the Communicable Diseases 
Network Australia to improve surveillance of IPD in Australia; all isolates of S. 
pneumoniae recovered from IPD are referred to reference laboratories, including 
QHFSS, for serotyping, except for the few that have been identified by PCR detection 
(Staples et al., 2015). Serotype information of S. pneumoniae isolates sent to QHFSS was 
obtained for 94-99% of IPD cases during 2010 and 2012 for QLD, WA and NT (Staples 
et al., 2015), indicating that the majority of isolates during this time period at least was 
identified. 
Due to increases in 19A and other non-7vPCV serotypes, the 13vPCV was 
introduced in July 2011 in Australia, targeting an extra six serotypes as well as those 
targeted by the 7vPCV (Slaon-Gardner et al., 2011). IPD caused by serotypes 8, 15B, 
15C, 22F, 33F and 38 (non-13vPCV) have increased from 21 cases (2000-2004) to 46 
cases (2007-2011) (QHFSS – Pneumococcal Reference Laboratory Database; raw 
numbers provided only). Studies have begun to emerge, examining what initial effects 
the 13vPCV is having on the pneumococcal population in respective countries or states. 
The outcomes of these studies are presented in Chapter 2 of this thesis. To date, no 
study has been published in Australia regarding the pneumococcal population 
structure after the introduction of the 13vPCV in July 2011.  
The other phenomenon, capsule switching, is due to pneumococci switching 
capsule genes, which can result in a changed expressed capsule (Brueggemann et al., 
2007). Capsular switching is a natural phenomenon known to exist for a long time, 
clearly occurring before molecular typing methods existed (Avery et al., 1944; Griffith, 
1928; Nesin et al., 1998). Multiple fragments of genetic material up to 44kb in length, 
including the capsule genes, have been reported to undergo recombination. In some 
settings there has been no evidence that capsule switching has increased following the 
introduction of PCVs (Simões et al., 2011), however this ability to change the capsule 
CHAPTER 1 Introduction, Aims, Objectives and Hypothesis 
29 
 
means that the vaccine no longer targets that serotype. This may lead to “vaccine 
escape” strains, already detected in the USA and Italy (Ansaldi et al., 2011; 
Brueggemann et al., 2007; Wyres et al., 2013). The alarming ability to change the 
polysaccharide capsule via horizontal transformation renders the pneumococci 
effectively “immune” to the vaccine.  
Therefore, bacterial fingerprinting methods, or more scientifically, genotyping 
methods are crucial to detect these capsule switches, whereas other traditional 
methods (e.g. serotyping) have limitations. Investigating the pneumococcal population 
has also been difficult in the past as no nationally agreed-on method has been accepted. 
It is important to monitor the changing epidemiology and population structure of S. 
pneumoniae in Australia and worldwide since the 13vPCV still only covers 13 serotypes 
out of at least 98 potentially invasive serotypes. 
Currently, Multi-Locus Sequence Typing (MLST) is considered the “gold 
standard” for genotyping S. pneumoniae, superseding Pulse Field Gel Electrophoresis 
(PFGE) (Enright & Spratt, 1998; Malachowa et al., 2005). MLST directly examines seven 
housekeeping genes and their single nucleotide polymorphisms (SNPs) that slowly 
change over time to characterise each pneumococcal strain. However, MLST is 
laborious, expensive and more suited to evolutionary studies rather than epidemiology 
studies (Hyytiä-Trees et al., 2007). Another method, Multi-Locus Variable number of 
tandem repeat Analysis (MLVA) has been reported to be a more discriminatory 
genotyping method compared to MLST and PFGE (Elberse et al., 2011a; Koeck et al., 
2005; Pichon et al. 2010; Van Cuyck et al., 2012). MLVA detects Variable Number of 
Tandem Repeats (VNTRs) within the genome, and assigns a numeric profile to each 
pneumococcal isolate based on the length polymorphisms of each VNTR. There are at 
least four published MLVA methods for S. pneumoniae, each targeting different genetic 
regions in the pneumococcal genome (Elberse et al. 2011a; Koeck et al., 2005; Rakov et 
al., 2011; Van Cuyck et al., 2012). Despite this, MLVA also has limitations particularly 
concerning the non-amplification of some loci, the lack of a large international database 
and no universally accepted method. Neither MLVA nor MLST has been used to 
determine the population structure of S. pneumoniae in Queensland after the 
introduction of the 13vPCV, and these will both be used in this study. By investigating 
the S. pneumoniae population structure post 13vPCV introduction, an understanding of 
the impact of the vaccine on S. pneumoniae genotypes will be possible. 
In addition, serotyping methods are used to characterise the pneumococcus. 
However this technique is ambiguous, requires personal training, is expensive, cannot 
distinguish between all serotypes unless a combination of Factor serum are used, and 
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does not determine capsule switches without a genotyping method. As a consequence, 
many molecular serotyping methods utilising PCR have been developed such as long-
template PCR (Bentley et al., 2006), allele-specific PCR focused on specific serotypes 
(Bratcher et al., 2011; Elberse et al., 2011c; Mavroidi et al., 2004), or multiplex-PCR 
(Ahn et al., 2012; Pai et al., 2006). These molecular methods directly examine the 
cassette of genes that code for each capsule. To date there is no universally accepted 
molecular serotyping method, and the Quellung reaction has remained as the universal 
serotyping technique.  
This study will be focusing on determining the genotypic population of invasive S. 
pneumoniae prior to the introduction of the 13vPCV and a year after, using a modified 
MLVA4 technique and a novel capsular typing technique. From the fourteen published 
MLVA loci, the best combination (e.g. seven oligonucleotide loci) has been chosen for a 
modified MLVA4 method for genotyping invasive S. pneumoniae in Queensland. This 
modified MLVA4 aims to be more discriminatory, cheaper and faster than the “gold 
standard” MLST, as well as overcoming the problems in existing MLVA methods such as 
the failure to amplify certain loci. Determining the pneumococcal population structure 
using the modified MLVA4 method will allow us to determine whether any changes 
have occurred since the introduction of the 13vPCV. We expect that the new vaccine 
will apply selection pressure on the population structure and hence observable changes 
may be seen.  
A novel capsular typing technique was also developed. A bioinformatics 
Minimum SNPs program, developed by researchers at Queensland University of 
Technology (QUT) was used. Minimum SNPs uses a binary marker system of T = 
present and A = absent of each capsule gene to create a “pseudoDNA sequence” (only 
contains A and T) for each of the known capsule cassettes with published sequences on 
the NCBI database (Robertson et al., 2004; Stephens et al., 2007).  The program then 
analyses the pseudoDNA sequences and identified a minimum set of ‘targets’ (i.e. 
capsule genes) to determine each serotype.  The capsule genes selected were amplified 
using real-time PCR to determine the serotype of invasive pneumococcal isolates. 
Combining the novel capsular typing method with MLVA4 genotyping allows the 
determination of capsule switching, which enhances information in epidemiology 
studies. 
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1.2 Hypotheses, Aims and Objectives 
1.2.1 Hypotheses 
There are four main hypotheses being investigated in this study: 
1) The modified MLVA4 method for genotyping invasive S. pneumoniae will be 
more discriminatory, faster, cheaper and technically less-demanding than 
previously published MLVA methods and the ‘gold standard’ MLST. 
2) The population structure of invasive S. pneumoniae isolated from Queensland 
children are clonally unrelated from post-7vPCV to post-13vPCV, meaning that 
the majority of the pneumococcal isolates will not share similar genetic profiles 
or form genetic complexes as demonstrated by MLVA4 and MLST typing. The 
rationale for this is that it is expected that the 13vPCV vaccine would provide 
selection pressure on the population structure. 
3) Serotype replacement and capsule switching has occurred since the freely 
available 7vPCV in Australia 2005. 
4) Capsule types and sub-types can be detected by a novel capsular typing method 
based on the MinimumSNPs program, and capsule switching can be verified by 
combining the novel capsular typing with modified MLVA4. 
1.2.2 Aims and Objectives 
Aim 1: To modify a Multi-Locus Variable number of tandem repeat Analysis (MLVA) 
procedure for genotyping invasive S. pneumoniae.  
 Objectives 
a) To develop a faster, cheaper, highly discriminatory and technically less-
demanding genotyping method for S. pneumoniae compared to the 
‘gold standard’ MLST method, and improves on published MLVA 
methods by reducing the percentage of incomplete profiles due to 
non-amplified loci. 
b) To ensure that a highly discriminatory MLVA4 method will provide a 
more accurate reflection of the S. pneumoniae population structure 
than what MLST currently provides. 
Aim 2: To determine the population structure of invasive S. pneumoniae in Queensland 
isolated from children 15 years or younger post-7vPCV and one year post-13vPCV by 
MLVA, MLST and our modified MLVA4. 
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 Objectives 
a) To compare the ‘gold standard’ MLST genotyping method with 
published MLVA and the modified MLV4 method when used to 
represent the pneumococcal population structure. 
b) To provide a current study and baseline of the Queensland invasive 
pneumococcal population, particularly post-13vPCV introduction in 
July 2011. 
Aim 3: To determine whether the genetic population of non-vaccine (non-13vPCV) 
serotypes is changing in the Queensland pneumococcal population. 
 Objectives 
a) To assess the initial and possible future impact of the newly introduced 
13vPCV into Queensland. 
b) To possibly predict which non-vaccine serotypes may become serotype 
replacement, indicating that a new vaccine may be required in the 
future. Public health strategies may also be influenced by these 
results. 
Aim 4:  To develop a novel capsular typing method based on a bioinformatics Minimum 
SNPs program to characterise the pneumococcal capsule cassette for each published 
pneumococcal serotype. 
 Objectives 
a) To improve on current molecular capsule typing methods by using a 
Minimum SNPs program to select a minimum set of highly informative 
genetic targets to be utilised with real-time PCR. 
b) To combine the novel capsular typing method with modified MLVA4 to 
determine capsule switching. 
1.3 Significance 
A number of significant points must be made regarding the four aims of this 
study. Firstly, the significance of developing and modifying existing MLVA genotyping 
methods will enable a potentially faster, cheaper and more discriminatory genotyping 
method for S. pneumoniae. A more discriminatory genotyping method will ensure a 
more accurate reflection of the S. pneumoniae population structure. MLST relies on 
stable housekeeping genes which are good for determining evolutionary and long term 
changes however it is not discriminatory enough to reveal changes in the short-term. 
Also, we want to improve on the published methods by minimising the percentage of 
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incomplete profiles due to non-amplified loci, thereby providing a more accurate 
reflection of the true pneumococcal population. 
Secondly, since the introduction of 13vPCV in 2011, no studies have been 
published investigating invasive S. pneumoniae in Queensland. This study will examine 
any changes in the population structure by comparing post-7vPCV (2007-2010) and 
post-13vPCV (2011-2012). Results obtained from this study will contribute to MLST 
international database and MLVA database. 
By examining in further detail the potential changes in the pneumococcal 
population structure, particularly the non-13vPCV population, we can determine 
whether any capsule switching or serotype replacement is emerging. Both these 
phenomena are important as they can result in increased IPD cases and vaccine escape 
strains that are not targeted by the current childhood vaccine. The significance of 
understanding these changes is that it may impact on further development of vaccines 
particularly in the choice of serotypes in future vaccines. Also public health strategies 
(e.g. advice to parents, child care centres, etc.) may be influenced by these results. 
Further study of the extra serotypes included in a new vaccine (15vPCV) that is in trial 
at the moment will enable us to determine whether this new vaccine could be a 
potential candidate for the next childhood pneumococcal vaccine or whether 
alternative vaccines need to be considered. It is important to understand this because it 
may impact the necessity of this new vaccine, such as an increase in serotype 22F 
and/or 33F targeted by the 15vPCV, or alternatively no increases or cases of IPD 
caused by these two extra serotypes. 
Finally, the development of a novel capsule typing method, to be used in 
conjunction with MLVA genotyping to detect capsule switching, will provide a faster 
and cheaper serotyping method. Determining whether capsule switching has occurred 
as indicated by the results from previous aims of this study is important as it may 
indicate the emergence of a vaccine escape strain. 
1.4 Account of scientific progress linking the chapters 
This thesis is presented in the ‘Thesis by monograph’ style. It contains a literature 
review presented at two major milestones during the PhD candidature, an independent 
literature review article, and three Chapters written covering the four Aims of this 
study, with each chapter designed to be adapted into a publication. A final chapter 
summarises the major findings and future directions of this thesis. 
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Following the introductory chapter, Chapter 2 is the literature review which 
focuses on an in-depth examination and discussion of S. pneumoniae and the 
associations of epidemiology with genotyping methods. Also stated at the beginning of 
Chapter 2 is a literature review article titled “Genotyping Streptococcus pneumoniae” 
that was published by Future Microbiology in April 2015 (Rayner et al., 2015a). This 
review paper focuses on the current genotyping methods used for characterising 
Streptococcus pneumoniae.  
Chapter 3 contains the general methods used and developed for this thesis. Each 
chapter hereafter still contain a brief methodology section as well as any specific 
methodology for the aim. 
Since there was no nationally accepted genotyping method of S. pneumoniae in 
Australia, examination of the current methods available was performed as the first 
contributions to this PhD. Chapter 4 examines the current genotyping methods and the 
modification of MLVA to minimise its limitations (relates to Aim 1). Stated at the 
beginning of Chapter 4 is a scientific article titled “Modified MLVA for genotyping 
invasive Streptococcus pneumoniae in Queensland children” that was published by PLoS 
One in April 2015 (Rayner et al., 2015b). This research was also presented as an 
abstract (poster form) at the IHBI Inspires QUT conference at the Gold Coast 
(November 2012). 
By using our modified MLVA4 (Chapter 4) to determine the population structure 
of S. pneumoniae in Queensland, we continued to research whether the Queensland S. 
pneumoniae population structure was changing from 2007 to 2012, particularly since a 
new childhood vaccine, 13vPCV, was recently introduced in 2011. Chapter 5 examines 
these changes in the pneumococcal population (relates to Aim 2 and Aim 3). This 
abstract was presented in poster form at the Australian Society for Microbiology 
conference held in Adelaide (July 2013) and at the Microbiology at QUT and Beyond 
Scientific Meeting in Brisbane (October 2014). An abstract was presented in oral form 
at the IHBI Inspires QUT conference in Brisbane (November 2013) and the 3-Minute 
Thesis Competition Faculty of Health Final QUT in Brisbane (August 2013). 
From our findings and published research, since capsule switching has been 
noticed in the S. pneumoniae population structure, we wanted to improve capsule 
typing methods by focusing on molecular typing but take a novel approach by using the 
Minimum SNPs program. Chapter 6 examines the research and development of this 
novel capsular typing method which has been applied to the Queensland pneumococcal 
isolates. This novel capsule typing method was combined with the MLVA4 genotyping 
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method to determine whether capsule switching has occurred in Queensland (relates to 
Aim 4). This abstract was presented at the XIX Lancefield International Symposium of 
Streptococci and Streptococcal Diseases in Buenos Aires, Argentina (November 2014 -
oral presentation), the QUT IHBI Inspires Postgraduate Student Conference  at the Gold 
Coast, Australia (November 2014 - oral presentation), the Australian Society for 
Microbiology state meeting Microbiology in Maleny  at Maleny, Australia (November 
2014 - oral presentation), the Australian Society for Microbiology Annual Conference at 
Canberra, Australia (July 2015 – poster presentation) and the 3-Minute Thesis 
Competition Faculty of Health Final QUT in Brisbane (August 2014).  
Chapter 7 summarises the over-arching discussion points from the literature 
review and three following chapters, the major findings and future directions. 
The relationship between the various chapters/papers is shown in Figure 1. 
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Figure 1: Outline of chapters and aims linking the PhD work. 
 
CHAPTER 2 Literature Review 
37 
 
CHAPTER 2: LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 Literature Review 
38 
 
 
CHAPTER 2 Literature Review 
39 
 
2.1 Introduction 
A review paper entitled: “Genotyping Streptococcus pneumoniae”, published in 
Future Microbiology (April, 2015), is available (Appendix B8: Published manuscript 
“Genotyping Streptococcus pneumoniae” to Future Microbiology (April 2015)) which 
outlines the current S. pneumoniae genotyping methods and highlights the importance 
of further development of a robust and universal genotyping method (Rayner et al., 
2015a). This review is designed to be part of the literature review. The following 
literature review is updated from what was written for the Stage 2 milestone and 
confirmation/articulation of the PhD. It contains information regarding the bacterium 
Streptococcus pneumoniae, its prevalence in Australia, and the trends observed in 
epidemiology studies worldwide and nationwide. 
2.2 Streptococcus pneumoniae 
Streptococcus pneumoniae is a medically important bacterium as it can cause 
numerous diseases such as invasive pneumococcal disease (IPD) (including 
bacteraemia and meningitis), pneumonia, and otitis media (Hermans et al., 1995; Koeck 
et al., 2005; Todar et al., 2012; Yaro et al., 2006). This Gram-positive diplococcus 
bacterium normally inhabits the human upper respiratory tract (URT) without 
triggering any symptoms. However S. pneumoniae is associated with high morbidity 
(estimated 14.5 million episodes of serious pneumococcal disease in 2000), high 
mortality (11% of deaths in children aged younger than five, globally) and high 
economic burden especially in underdeveloped countries (O’Brien et al., 2009). 
An important feature of this bacterium is the protective polysaccharide capsule 
that forms the outer layer surrounding the bacterial cell. The pneumococcal capsule is 
also referred to as a serotype, a name given from the serological typing method to 
distinguish each capsule type. There are at least 98 known serotypes of S. pneumoniae, 
and a number of serotypes are associated with high mortality and morbidity (Bentley et 
al., 2006; Bratcher et al., 2010; Calix & Nahm, 2010; Calix et al., 2012; Ko et al., 2013; 
Oliver et al., 2013; Park et al., 2007; Park et al., 2015). The pneumococcal capsule is an 
important virulence factor as it can provide resistance to opsonophagocytosis (Bentley 
et al., 2006; Elberse et al., 2011c; Kelly et al., 1994; Sabharwal et al., 2014; Schouls & 
Van der Heide, 2012), although Jefferies et al. (2004) theorised that clonal properties 
may also be important in invasiveness. It is believed that the large number of different 
capsular serotypes is due to a mechanism to evade the human immune response 
(Bentley et al., 2006).  
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Beside from resistance to opsonophagocytosis, some capsular types are more 
invasive than others as they have been shown to have increased binding to a specific 
host protein inhibitor factor H (FH) (Hyams et al., 2013; Scott et al., 1996). For example, 
serotype 19A is particularly virulent and causes the majority of pneumococcal disease 
in USA, especially one particular clonal cluster CC199 (Pai et al., 2005). Increases in 
serotype 19A in USA were also accompanied by significant increases in penicillin non-
susceptibility and multi-drug resistance (Pai et al., 2005). Since serotype 19A was not 
targeted by early vaccines, there has been a huge effort involved in monitoring this 
serotype. However other countries have significant increases in other serotypes, not 
serotype 19A. 
As well as this, some serotypes are more commonly isolated from different 
clinical sites, for example pneumococcal serogroup 1 and 14 are commonly isolated 
from blood  while others are commonly isolated from middle ear fluid (serogroup 3, 19 
and 23) (Hausdorff et al., 2000b;  Scott et al., 1996). A study reported that there may be 
two classes of S. pneumoniae – major invasive serotypes such as serotypes 1, 4, 7F and 
9V that are highly clonal and found to be geographically confined, and common carriers 
such as serotypes 6A, 6B, 14 and 19F ( Sá-Leão et al., 2011; Sandgren et al., 2004). Two 
other key studies by Hausdorff et al., (2000a; 2000b) were fundamental in showing the 
serotypes most frequently associated with invasive disease and determining vaccine 
formulations. These studies indicated that at the time, the serotypes targeted by the 
7vPCV caused 70%-88% of IPD in young children in the USA and Canada, Oceania, 
Africa and Europe (Hausdorff et al., 2000a). They also pointed out that several 
serogroups that were not targeted by the 7vPCV, 9vPCV or 11vPCV were significant 
causes of disease in older children and adults (Hausdorrf et al., 2000a).  By 
understanding the prevalence and virulence of these major worldwide serotypes, this 
has led to further development of vaccines to target them. 
In addition, there are studies that clearly show the importance of the genotype in 
invasiveness. Irrespective of the serotype’s overall invasive potential, genetic clones 
displayed heterogeneous behaviour in invasiveness (Sá-Leão et al., 2011). This 
highlights the importance that both the serotype and the genetic clonal type determine 
invasiveness. Even biofilm formation varied between isolates with the same serotype 
and same genotype, indicating that different clinical sites (e.g. blood or ear) have an 
impact on colonisation and invasiveness (Trapetti et al., 2013). 
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2.3 Invasive pneumococcal disease (IPD) 
The World Health Organisation (WHO) estimated that 1.6 million people died 
from pneumococcal diseases in 2005, and it is estimated that more than 800 000 
children under five die each year globally from pneumococcal disease (O’Brien et al., 
2009). IPD encompasses a range of diseases caused by S. pneumoniae, including 
meningitis and septicaemia. Pneumonia is the most common pneumococcal disease, 
although is not termed as “invasive” in the sense of being isolated from a sterile body 
site (Centers for Disease Control Prevention, 2015). The most common pneumococcal 
diseases observed are pneumonia and meningitis in children, and pneumonia in adults 
(O’Brien et al., 2009). The symptoms of IPD vary depending on the specific disease and 
can be non-specific in children, even including sporadic fever (Randle et al., 2011).   
In Queensland, Australia, all cases of IPD are referred to the Queensland Health 
Pneumococcal Reference Laboratory, Brisbane, for serological typing. The notification 
rate of IPD in Queensland in 2014 was 4.9 per 100 000, a decline from 7.6 per 100 000 
in 2011 (NNDSS, 2015). Australian Aborigines still maintain the highest rates of IPD in 
the worldwide. 
For clinicians to make a diagnosis of IPD, the pneumococcus needs to be isolated 
from normally sterile body sites, for example blood, cerebrospinal fluid (CSF), joint 
fluid, pericardial fluid, pleural fluid and certain tissues (pneumococci can colonise the 
nasopharyngeal tissue without causing disease) (Centers for Disease Control 
Prevention, 2015). Diagnostic of IPD is obtained by culture or detecting bacterial cell 
surface antigens (Randle et al., 2011). Depending on the severity of the disease and the 
type of disease, treatment will vary. Generally, antibiotic treatment is provided for most 
pneumococcal diseases. Unfortunately, a number of pneumococcal strains have 
developed resistance to certain antibiotics, as further discussed in section 2.4. 
2.4 Introduction of Public Health Preventative Measures to control 
Streptococcus pneumoniae 
Due to high rates of mortality and morbidity, a number of preventative measures 
have been implemented worldwide to combat pneumococcal diseases. Antibiotic 
therapy was one of the first public health preventative measures against S. pneumoniae 
after the Second World War (WWII). Unfortunately this also led to the first description 
of a penicillin-resistant S. pneumoniae in Australia in 1967 (Hansman & Bullen, 1967). 
Since then, penicillin-resistant strains have spread across the globe. Multiple-drug 
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resistant (MDR) pneumococcal strains, first reported in 1977 in Johannesburg, South 
Africa, have also populated the world (Jacobs et al., 1978). The first description of a 
MDR S. pneumoniae (serotype 6B) in Australia was in Far North Queensland in 
February 1995 (Hanna et al., 1997).  
One mechanism to acquire antimicrobial resistance is the horizontal gene 
transfer of resistant genes on chromosomally located transposons, not plasmid 
mediated like most other bacterial species (Cornick & Bentley, 2012; Hall et al., 1998). 
Horizontal transformation or recombination can rapidly introduce novel phenotypes, 
and is thus a major driving force behind the evolution of S. pneumoniae, particularly in 
response to stressful conditions such as antimicrobials (Cornick & Bentley, 2012). 
Other mechanisms include hyper-mutation and hetero-resistance (Cornick & Bentley, 
2012). Hyper-mutation phenotype can lead to an increased rate of DNA mutations, for 
example, modification of penicillin binding proteins (PBPs) reduces affinity to penicillin 
drug (Cornick & Bentley, 2012). Hetero-resistance is a function not fully understood in 
pneumococci but has been studied in Staphylococci, where a subpopulation has the 
ability to tolerate higher antimicrobial conditions (Cornick & Bentley, 2012). 
The Pneumococcal Molecular Epidemiology Network (PMEN) was established in 
1997 to provide a nomenclature to the most important pneumococcal sequence types 
that were MDR (Klugman et al., 1990; McGee et al., 2001; PMEN, 2015). There is a 
criterion for the assignation of PMEN to a S. pneumoniae strain (Figure 2).  
Figure 2: PMEN criteria for S. pneumoniae (PMEN, 2015). 
 
 Since the discovery of MDR S. pneumoniae, vaccines have been developed that 
target the polysaccharide capsule (Hanna et al., 1997). Interestingly, the earliest 
vaccine against S. pneumoniae was developed more than 100 years ago using whole 
pneumococcal cell to vaccinate South African miners in 1911 (Wright et al., 1914). 
Several decades later a four-valent pneumococcal polysaccharide vaccine (PPV) was 
trialled in military recruits before developing a six-valent PPV to vaccinate the military 
- Clone should have wide geographic distribution (≥2 continents) 
- Clone resistant to one or more antibiotics that are in wide clinical 
use; or a global susceptible clone known to be important in 
disease 
- Data on clone published 
- New clones proposed at annual PMEN meeting 
- Representative isolate made available for analyses and confirmation 
- Available to deposit in ATCC collection of clones 
- Available through Streptococcus Reference Laboratory in Germany 
and Emory University in USA 
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from 1946 to 1948 (MacLeod et al., 1945; Moberley et al., 2013). Trials continued to 
vaccinate South African gold miners with a 13-valent PPV (Austrian, 1977) and Papua 
New Guinean highlanders with a 14-valent PPV (Riley et al., 1977), which was licensed 
in the USA the same year. 
In more recent times, a 23-valent PPV (23PPV; Pneumovax®23, Merck & 
Co. Inc.) was developed in 1983 to target 23 serotypes (Table 1) (Moberley et 
al., 2013; Robbins & Schneerson, 1983; Roche et al., 2003; Whitney et al., 2003;). 
However, the 23PPV was poorly immunogenic in children, which was 
problematic since the majority of pneumococcal diseases occurred in children 
(Roche et al., 2003; Swiatlo & Ware, 2003). 
Table 1: The S. pneumoniae serotypes that are targeted by the available polysaccharide 
conjugate vaccines (PCV) or pneumococcal polysaccharide vaccine (PPV). 
Pneumococcal 
vaccine 
Targeted S. pneumoniae 
serotypes  
Production company Commercially 
available in AUS 
7vPCV; 
Prevenar® 
4, 6B, 9V, 14, 18C, 19F, 23F Wyeth 
Pharmaceuticals Inc. 
No 
9vPCV 7vPCV serotypes + 1, 5 Wyeth 
Pharmaceuticals Inc. 
No 
10vPCV; 
Synflorix® 
7vPCV serotypes + 1, 5, 7F GlaxoSmithKline 
Australia 
Yes 
11vPCV 7vPCV serotypes + 1, 3, 5, 
7F 
Sanofi Pasteur No 
13vPCV; 
Prevenar 13 
7vPCV serotypes + 1, 3, 5, 
6A, 7F, 19A 
Pfizer Australia Pty 
Ltd 
Yes 
15vPCV (in trial) 13vPCV serotypes + 22F, 
33F 
Pfizer Australia Pty 
Ltd 
No 
23PPV; 
Pneumovax® 23 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 
23F, 33F 
Merck & Co. Inc. Yes 
 
As a result, the 7vPCV (Prevenar®, Wyeth Pharmaceuticals Inc.) was developed. It 
was licensed for use in Australia in 2001 after a USA trial demonstrated vaccine efficacy 
of 93.9% in 2-15 month old children (Hills et al., 2002). A conjugate vaccine consists of 
an immunogenic carrier protein linked to polysaccharide antigens, which elicits an 
immune memory response through antigen-specific memory B-cell production 
(Duggan, 2010). The 7vPCV couples a mutated diphtheria toxoid to a protein carrier 
CMR197 (Centers for Disease Control Prevention, 2010). The difference between the PPV 
and PCV is that the PCV contains the serotype antigens conjugated to protein so that 
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children have a higher response when forming antibodies, whereas the PPV only has 
antigens which by themselves failed to induce high levels of antibodies in children 
(Swiatlo & Ware, 2003).  Unfortunately, due to the nature of the vaccine, only seven 
serotypes were targeted (Table 1) (Roche et al., 2003; Whitney et al., 2003). Countries 
with different dominating serotypes than those targeted by the 7vPCV and increasing 
IPD caused by non-7vPCV serotypes prompted the development of the 9vPCV, 10vPCV, 
11vPCV and 13vPCV, as further discussed below. 
The 9vPCV (Wyeth Pharmaceuticals Inc.) targeted additional serotypes 1 and 5 
which are prominent in the UK and USA, but not Australia, however the vaccine itself 
has never been commercialised (Goldblatt et al., 2006). The 10vPCV (Synflorix®, 
GlaxoSmithKline) includes all the 7vPCV serotypes as well as serotypes 1, 5 and 7F, 
however in Australia the vaccine was only introduced to Northern Territory 
vaccination programs since serotype 5 is not common elsewhere in Australia (Hanna et 
al., 2010). Eventually, the 13vPCV (Prevenar 13®, Pfizer Australia Pty Ltd.) was 
introduced in the USA in February 2010 and Australia in 2011 (Duggan, 2010; Selvey, 
2011). The 13vPCV contains an additional six serotypes as well as those targeted by the 
7vPCV. Serotypes are again conjugated to a non-toxic diphtheria protein with cross-
reactive material, CRM197 (Table 1) (Centers for Disease Control Prevention, 2015; 
Duggan, 2010; Hanna et al., 2010; Rakov et al., 2011; ).  
The 13vPCV elicited strong immunological responses against all 13 serotypes 
(Duggan, 2010).  A polysaccharide conjugate vaccine has been added to routine infant 
immunisation schedules of 112 (58%) of 194 WHO member states as of November 
2014 with the help of funding from Global Alliance for Vaccines and Immunisation 
(GAVI) Alliance (Table 2) (Murray et al., 2014). An additional benefit of the vaccine is 
that even though children are vaccinated at 2, 4 and 12 months of age (or a variation in 
other countries), by the time they reach pre-school age the majority of children have 
been shown to maintain protective levels of serotype-specific antibodies (Trück et al., 
2014). 
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Table 2: The year that countries have introduced a Polysaccharide Conjugate Vaccine 
(PCV) into their National Immunisation Program, or have made the vaccine commercially 
available only.  
BFA (Burkina Faso); CAF (Central African Republic); COD (Congo, The Democratic); CZE (Czech 
Republic); DOM (Dominican Republic); GNB (Guinea-Bissau); LBY (Libyan Arab Jamahiriya); 
PNG (Papua New Guinea); STP (Sao Tome and Principe); TTO (Trinidad and Tobago); ARE 
(United Arab Emirates); UK (United Kingdom); USA (United States of America) 
Country/state 7vPC
V 
13vPCV Country/state 7vPCV 13vPCV Country/state 7vPCV 13vPCV 
Afghanistan - 2013 France 2006 2010 Mozambique - 2013 
Alaska 2001 2010 Gambia 2009 - Netherlands 2006 - 
Albania - 2011 Georgia - 2013 New Zealand 2008 - 
Andorra 2007 - Germany 2006 - Nicaragua 2010 - 
Angola - 2013 Ghana - 2012 Niger - 2013 
Argentina - 2012 Greece 2005 - Nigeria - 2013 
Armenia - 2013 Greenland 2007 - Niue 2009 - 
Australia 2005 2011 Guatemala - 2012 Norway 2006 - 
Austria 2002 - GNB - 2013 Oman 2008 - 
Azerbaijan - 2013 Guyana - 2011 Pakistan - 2012 
Bahamas 2009 - Haiti - 2013 Palau 2008 - 
Bahrain 2008 - Honduras - 2011 Panama 2010 - 
Bangladesh - 2013 Hungary 2009 - PNG - 2013 
Barbados 2009 - Iceland 2011 - Paraguay - 2012 
Belgium 2006 - Ireland 2008 - Peru 2009  
Belize   Israel 2009 - Philippines - 2013 
Benin - 2011 Italy 2005 - Portugal 2001 - 
Bolivia - 2014 Jamaica - 2010 Qatar 2005 - 
Botswana - 2012 Japan 2011 - Rwanda 2009 - 
Brazil 2010 - Jordan 2011 - STP - 2012 
Bulgaria 2010 - Kazakhstan 2011 - Saudi Arabia 2009 - 
BFA - 2013 Kenya - 2011 Senegal - 2013 
Burundi - 2011 Kiribati - 2013 Sierra Leone - 2011 
Cambodia - Apply Korea, Rep. 2004 - Singapore 2009 - 
Cameroon - 2011 Kuwait 2007 - Slovakia 2009 - 
Canada 2002 - Lao PDR - 2013 Slovenia 2005 - 
CAF  2011 Latvia 2010 - South Africa 2009 - 
Chile 2009 2011 Lebanon 2010 - Spain 2003 - 
Colombia - 2011 Lesotho - 2013 Sudan - 2013 
Comoros - Apply Liberia - 2014 Sweden 2009 - 
COD - 2011 LBY - 2013 Switzerland 2006 - 
Congo - 2012 Lithuania - 2011 Tanzania - 2012 
Costa Rica 2008 - Luxembourg 2005 - Togo - 2013 
Cyprus 2007 - Madagascar - 2011 TTO 2009 - 
CZE 2005 2010 Malawi  - 2011 Turkey 2008 - 
Denmark 2007 - Mali - 2011 Uganda - 2013 
Djibouti - 2012 Malta 2007 - ARE 2007 - 
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Country/state 7vPC
V 
13vPCV Country/state 7vPCV 13vPCV Country/state 7vPCV 13vPCV 
Dominica - 2010 Marshall Is. 2009 - UK 2006 2010 
DOM 2009 - Mauritania - 2013 USA 2000 2010 
Ecuador - 2010 Mexico 2009 - Uruguay 2008 2010 
El Salvador - 2010 Micronesia 2008 - Yemen - 2011 
Ethiopia - 2011 Moldova, R. - 2013 Zambia - 2013 
Fiji - 2012 Mongolia - 2012 Zimbabwe - 2012 
Finland - 2010 Morocco 2010 -    
2.5 Impact of the Pneumococcal Conjugate Vaccines Globally 
Worldwide, including Australia, epidemiology studies have been conducted to 
assess the local impact of these polysaccharide vaccines on the pneumococcal 
population structure. Since the introduction of the 7vPCV globally, there were reports 
of an overall decrease in IPD in children, which was a positive outcome of vaccine 
administration (Poehling et al., 2006; Reingold et al., 2005; Singleton et al., 2007; 
Whitney et al., 2003). For instance, in Native Alaskan children under two years there 
was an overall 67% decrease in IPD between 2002 to 2004 after the introduction of the 
7vPCV in January 2001 (96% were 7vPCV serotypes) (Singleton et al., 2007). Similarly, 
in the USA there was a 78% drop in 7vPCV serotypes in children under two years by 
2003 (licensed in 2000 for under five years) (Reingold et al., 2005; Whitney et al., 
2003). 
This decrease in IPD in children has either been a direct result of the introduction 
of the vaccine, or an indirect effect such as herd immunity or herd protection (Hanna et 
al., 2008; Isaacman et al., 2007). Reingold et al. (2005) theorised herd immunity when 
69% of IPD in their study was prevented through indirect effects of the vaccine, 
possibly because vaccinated children are less likely to transmit colonising pneumococci 
to other members of the family. Similar results of herd immunity have been reported 
elsewhere (Rodgers & Klugman, 2011). Since then, there has been a significant impact 
on IPD and carriage by herd immunity (Davis et al., 2013).  
Interestingly, Hicks et al. (2007) stated that the 7vPCV also has residual effects; 
non-vaccine serotypes 6A and 12F decreased significantly after the introduction of the 
7vPCV despite not being included in the vaccine. Serotype 6A has been shown to 
decrease due to cross-protection against 6B, however since the detection of serotype 
6C, it has been difficult to determine the impact of the 7vPCV on serogroup 6 (Park et 
al., 2007). On the other hand, it is thought that the decrease in 12F is due to natural 
fluctuations over time. Hence any increases in 12F may not necessarily be due to 
serotype replacement. Serotype 12F is often reported in outbreaks of IPD rather than 
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gradual replacement of vaccine-serotypes in the population and is considered an 
‘epidemic’ serotype (Gratten et al., 1995; Jorgensen et al., 2005). 
Following the introduction of the new 13vPCV in the USA, France and the UK in 
2010, reports are emerging that investigate the effects of this expanded vaccine on the 
S. pneumoniae population. In France there was a noticeable drop in non-7vPCV 
serotypes (19A, 6C and 7F) in carriers with at least one dose of 13vPCV compared to 
children only vaccinated with the 7vPCV (Cohen et al., 2012). Two reports have 
observed decreases in 13vPCV serotypes in Alaska, one observing a significant decline 
of 13vPCV S. pneumoniae in nasopharyngeal colonisation of Alaskan rural children 
(25% to 5%) (Gounder et al., 2014; Singleton et al., 2013). A decline in 13vPCV was also 
observed in Madrid, Spain, from 2010-2011 compared to 2007-2010 (Picazo et al., 
2013), and in Germany where an overall decline in 13vPCV serotypes in 2010 to 2011 
was observed in children despite an increase in serotype 19A (Van der Linden et al., 
2013). 
The 13vPCV has also been shown to hold residual effects similar to the 7vPCV. 
Cooper et al. (2011) and Miller et al. (2011) determined that serotype 6A, included in 
the 13vPCV, provides cross-protection for serotype 6C, as well as cross-protection of 
serotypes 7A by 7F. A noticeable drop in serotypes 7F and 19A was observed in the UK 
after the introduction of 13vPCV in 2010 (Miller et al., 2011). In the USA, after the 
13vPCV was introduced in 2010, there has been a 53% decline in IPD in children aged 
under two years compared to the calculated average rate of IPD in 2007 to 2009 
(Kaplan et al., 2013). The decline in IPD was attributed to decreases in serotype 19A 
(58%), serotype 7F (54%) and serotype 3 (68%), all targeted by the 13vPCV (Kaplan et 
al., 2013). Currently, there are no reports from Australia regarding the impact of the 
13vPCV. Despite these promising results from other countries, further studies around 
the globe are required to determine the short-term and long-term effects of the 
13vPCV. 
2.6 Impact of the Pneumococcal Conjugate Vaccines in Australia and 
Queensland 
Australia has kept up-to-date with the introduction of the polysaccharide 
conjugate vaccines, particularly since Australian Aborigines are 6.7 times more likely to 
have IPD than non-Aboriginals in 2010, demonstrating that Australian Aborigines still 
suffer from IPD more than non-Indigenous citizens (Giele et al., 2007; Lehmann et al., 
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2010). The 23PPV was introduced for at-risk Indigenous adults in 1986 (Hanna et al., 
1997). However, since the 23PPV is not as effective in children, the 7vPCV was 
introduced for Australian Aboriginal children younger than two years in 2001 and 
became freely available for all children in 2005. The 7vPCV was given at 2, 4 and 6 
months of age, followed by a booster dose of 23PPV (Pneumovax23®) only for 
Aboriginal and Torres Strait Islander children living in NT, SA, QLD and WA, and 
children with specified underlying medical conditions, administered between 18-
24months (NCIRS, 2015). Invasive diseases caused by the 7vPCV serotypes decreased 
by 78% in children younger than two between 2002 and 2006, mirroring statistics 
observed elsewhere in the world (Lehmann et al., 2010, Roche et al., 2008).  
Decreases of IPD in 2-14 year olds by 2005 were also observed, indicating herd 
protection since these older children did not have access to the 7vPCV (Roche et al., 
2007). There was a more pronounced decrease of IPD cases in non-Indigenous children 
than Indigenous children, most likely because there was a wider range of serotypes in 
the Indigenous population and the vaccine only targeted a few of these serotypes 
(Fagan et al., 2001; Roche et al., 2007; Williams et al., 2011).  
Eventually, the National Notifiable Diseases Surveillance System (NNDSS) began 
recording the number of IPD cases in Australia from 2001. By 2012, the NNDSS 
recorded 7.6 per 100 000 notification rate of IPD in Queensland, an increase from 6.0 
per 100 000 notifications in 2009, possibly due to increasing IPD caused by non-7vPCV 
serotypes (Figure 3) (NNDSS, 2015). Roche et al. (2007) predicted that rates of IPD 
cases under two years may not fall much further with only the 7vPCV. By 2007, the 
7vPCV only covered 55% of serotypes under two year old Indigenous children but 86% 
in non-Indigenous children, highlighting the difference in vaccine effectiveness. A 
decline in pneumococcal disease can be seen after the introduction of the 7vPCV in 
2005 and possibly after the 13vPCV in 2011 (Figure 3).  
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Figure 3: Invasive pneumococcal disease (IPD) notification rates in Queensland from 
2001 to 2014 as recorded by the National Notifiable Diseases Surveillance System.  
Green bars represent the introduction of 7vPCV in 2005 and 13vPCV in 2011. 
 
Similarly, epidemiology studies observed a 98% decline in IPD caused by 7vPCV 
serotypes in Australian children from 2002-2004 compared to 2007-2009, however 
there was a slight increase in 13vPCV serotypes (Johnson et al., 2012). Barry et al. 
(2012) reported a 168% increase in non-7vPCV serotypes in children aged under five 
in Australia in 2008 compared to 2002, with a fourfold increase due to serotype 19A. 
This was not promising news. 
Therefore, the 13vPCV was licensed for use in Australia and was introduced into 
the Prevenar13® Immunisation Program for 2, 4 and 6 month old Australian children in 
October 2011 (Selvey et al., 2011). A fourth dose of 13vPCV could be administered as a 
booster for Aboriginal and Torres Strait Islander children at age 12-18months living in 
NT, SA, QLD and WA, replacing the 23PPV booster shot (NCIRS, 2015). By 2013, the 
NNDSS notification rates of IPD in Queensland had appeared to drop to 5.9 per 100 000 
notifications, the lowest rates ever since records were kept from 2001 (Figure 3). Even 
in 2014, decreasing rates of IPD have been documented, with notifications of 5.0 per 
100 000 by the end of December being recorded (NNDSS, 2015). During May 2014, the 
latest change to the immunisation schedule was the extension of the 13vPCV registered 
use in children from 6 weeks of age (NCIRS 2015). To date, there have been no other 
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reports on the impact of the 13vPCV on the pneumococcal population; however this 
may be due to the recent introduction of this vaccine.  
2.7 Future Pneumococcal Vaccines 
Despite the significant decreases in IPD due to 7vPCV, Hicks et al. (2007) 
suggested that multivalent vaccines should be expanded further to include the common 
replacement serotypes, particularly those prevalent in third world countries. Therefore 
additional multivalent vaccines have been produced including 9vPCV, 10vPCV, 11vPCV 
and 13vPCV. Additionally, pre-clinical trials of a 15-valent pneumococcal conjugate 
vaccine (15vPCV) on infant rhesus monkeys have been carried out (Skinner et al., 
2011). The serotypes included in the 15vPCV are those in the 13vPCV plus serotypes 
22F and 33F, the “two most prevalent emerging serotypes” in the USA (Skinner et al., 
2011). The prevalence of different serotypes does depend on locale (McIntosh & 
Reinert, 2011), therefore it is unknown whether these two serotypes will become 
emergent in the Australian population. Besides from this, conjugate vaccines have been 
designed to target specific pneumococcal serotypes, which is a limitation when 
determining which serotypes are to be included in the next vaccine. The cost of the 
vaccine increases as more serotypes are included, hindering the use of these vaccines in 
developing countries. Therefore alternative vaccines are being investigated. 
A cheaper, species-wide protein antigen vaccine is required since the 7vPCV and 
also 13vPCV are expensive. The expense of the current vaccines particularly impacts on 
third world countries where IPD is widely prevalent (Kadioglu et al., 2008; Saha et al., 
1997; Yaro et al., 2006). Therefore the use of proteomic screening to identify target 
antigens for a pneumococcal vaccine has been investigated (Moffitt et al., 2011). 
Common antigens for future vaccines (and combinations thereof) are being studied 
such as pneumococcal surface protein A (PspA), choline binding proteins (PcpA), 
pneumococcal surface adhesin A (PsaA), non-toxin pneumolysin derivative (PlyD1), 
metal-binding lipoproteins (PsaA/PiaA), poly-histidine triad proteins (PhtB, PhtD and 
PhtE), a murein hydrolase (-LytB), and neuraminidase (NanA) (Hicks et al., 2007; 
Kadioglu et al., 2008; Sharma et al., 2013; Swiatlo & Ware, 2003). A study on rhesus 
macaques (Macaca mulatta) vaccinated with an AS02-adjuvanted PhtD-dPly vaccine 
demonstrated protection against S. pneumoniae-induced pneumonia (Denoël et al., 
2011). Another study demonstrated that a trivalent recombinant protein vaccine 
(PcpA-PhtD-PlyD1) protected infant mice from lethal pneumonia caused by 
pneumococcal serotypes 6A and 3 (Verhoeven et al., 2014). It was hypothesised that 
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this trivalent vaccine reduced pneumococcal binding to the epithelium in the airway 
(Verhoeven et al., 2014). Utilising antigens that mediate CD4+ T cells has been observed 
to reduce nasopharyngeal carriage of S. pneumoniae, although responses vary between 
adults and children, demonstrating that future vaccines could use the natural clearance 
mechanisms in the human body (Sharma et al., 2013).  
Vaccines that attack more than one species of bacteria have been developed. In 
2012 there was a report on the production of a bivalent vaccine that was shown to 
protect mice from S. pneumoniae colonisation and disease, and Salmonella typhi which 
causes typhoid fever (Lu et al., 2012). This bivalent vaccine consists of an antigen 
SP1572 (pneumococcal protection protein A) fused to non-haemolytic pneumolysoid 
(Pdt) that is conjugated to a pneumococcal cell wall polysaccharide to target S. 
pneumoniae. It also targets S. typhi using another antigen SP2070 (surface-exposed 
glucose-6-phosphate isomerase) fused to a Pdt that is conjugated to a Vi 
polysaccharide, an importance virulence factor of S. typhi, to elicit functional antibodies 
against the Vi polysaccharide (Lu et al., 2012). The two antigens in this vaccine were 
shown to be conserved in all known sequences of pneumococcal strains, and thus 
should confer protection across a wide range of pneumococci, while the current PCV 
vaccines are limited to specific pneumococcal serotypes (Lu et al., 2012). 
Additionally, another recently developed vaccine injects killed cells of a non-
capsulated S. pneumoniae which has been shown to illicit a “bifunctional immunity” by 
causing plasma antibodies to protect against pneumonia as well as IL-IIA-mediated 
nasopharyngeal clearance (Malley & Anderson, 2012). Other vaccines include live 
attenuated vaccines, such as SPY1 pneumococcal strain, which has been shown to 
protect mice from pneumococcal infections (Wu et al., 2014). The SPY1 pneumococcal 
strain has significantly reduced virulence properties however provides protection 
against other pneumococcal strains (Wu et al., 2014). Finally, a Phase I trial of a Triple-
Protein vaccine which contains PhtD, dPly and nontypeable Haemophilus influenzae 
protein D (PD) has shown that two doses induced humoral immunity and antigen-
specific CD4+ T cell responses (Berglund et al., 2014). Increasing IPD associated with 
existing vaccines could be resolved with these alternative vaccine development 
strategies, but until then studies of the changing genetic population structure due to the 
PCVs are required. It is unknown whether these protein-antigen vaccines are also 
susceptible to genetic variation in the pneumococcal populations. This could be 
explored by interrogating the available pneumococcal whole genomes. 
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2.8 Risk factors associated with S. pneumoniae diseases: age, gender 
and race 
A number of risk factors have been examined and associated with pneumococcal 
diseases, particularly age, gender and race. The sex of a child is considered to have little 
influence on IPD despite higher observed rates in males. This is thought to be more 
likely associated with other risk factors (Scott et al., 1996). For example, a ratio of 
2.05:1 male vs. female children in Bangladesh was observed for pneumococcal disease, 
however it was thought that the male dominant society meant that male children were 
more likely to be taken to hospital and therefore reported, leading to the hypothesis 
that the sex doesn’t have an influence on IPD, but gender does (Saha et al., 1997). There 
have been a number of epidemiology studies that have observed a slightly higher IPD 
rate in male patients, however the ratio has not been significant or otherwise 
researchers have failed to comment on the differences (Moore et al., 2015; Scott et al., 
1996;). 
Age has been known to be an important factor in IPD rates (Singleton et al., 
2007), and therefore important to consider in epidemiology studies.  IPD cases are 
largely bimodal in developed countries, usually peaking in children younger than two 
years and peaking in adults over 65 years, generally due to poorer immune systems 
(Roche et al., 2003; Scott et al., 1996). However, serotype distribution is different in 
children younger than five years compared to people over five years (Elberse et al., 
2011b; Scott et al., 1996). For example, in The Netherlands the incidence of IPD caused 
by serotype 1 decreases as age increases; similarly IPD caused by  serogroups 6, 14 and 
19 abruptly decreases after ten years of age, and serogroup 18 gradually decreases 
until 30 years (Elberse et al., 2011b). On the other hand, IPD caused by serogroups 3, 8, 
7 and 23 increases as age increases (Scott et al., 1996). It was known in 1996 that when 
children were vaccinated with the S. pneumoniae antigens, the maturation of their 
antibodies varied widely with serotype (Scott et al., 1996). Alternatively some 
serotypes are more prevalent in adults compared to children, for example Gratten et al. 
(1995) found that serotype 12F was more frequent in Aboriginal adults than in 
children, however Saha et al. (1997) identified 12F (and 7F) predominant in children in 
Bangladesh in a 1995-1997 study. Torzillo et al. (2007) described an outbreak of 12F in 
1993 in Australia with no further reports of 12F outbreaks until 2001. Serotype 12F is 
not included in the 13vPCV. No known further study of 12F in Australia has been 
published.  
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Race is also known to be associated with high incidence rates of IPD, however it 
is important to keep in mind that there is no good evidence for genetic predisposition 
to pneumococcal disease related to race. The most overwhelming risk factor is 
exposure to high rates of pneumococcal colonisation in the population; this is 
associated with factors such as overcrowding (Jacups & Cheng, 2011; Mehr & Wood, 
2012). Indigenous patients are known to acquire IPD at a younger age compared to 
non-Indigenous patients and there is a higher incidence of IPD in Indigenous citizens 
than non-Indigenous citizens (Hanna et al., 1997; Mak, 2004). Weatherholtz et al. 
(2010) stated that the Navajo citizens in America are five to ten times more likely to 
contract IPD than the general US population, and Australian Aborigines are four to ten 
times more likely to be hospitalised with pneumoniae or influenza than non-Aborigines 
(Hanna et al., 1997). Gratten et al. (1995) observed higher IPD cases in Aborigines in 
North Queensland, and identified risk factors such as alcohol abuse, which was high in 
these communities. Most Aborigines with IPD have at least one other risk factor e.g. 
alcohol abuse, other medical condition, etc. (Hanna et al. 1997).  
There are also differences in rank order of serotypes that cause disease in 
different ethnic groups. IPD in Australian Aboriginal citizens was mostly caused by 
serotype 7F (Gratten et al., 1997; Hanna et al., 1997), which has also been described in 
Native Alaskan adults (Weatherholtz et al., 2010). Fagan et al. (2001) identified a 
greater variety of serotypes causing IPD in Indigenous than non-Indigenous 
individuals. According to Hicks et al. (2007), there are reports of race-specific trends of 
serotype replacement (however there are no reports on age-specific trends). It is 
unknown whether there could be genetic variances in Indigenous populations that pre-
determine a higher rate of infectious disease.  
2.9 Genetics of Streptococcus pneumoniae serotypes 
A number of hypotheses have been postulated for the increase in non-vaccine 
serotypes. A phenomenon called serotype replacement describes the increase in non-
vaccine serotypes due to an opening in the niche that vaccine-targeted serotypes once 
occupied (Weinberger et al., 2011). Serotype replacement has been observed in 
numerous studies worldwide, and has prompted the development of additional 
vaccines to cover these emerging serotypes. Further discussion of serotype 
replacement is provided in Section 2.11. Preliminary identification of serotype 
replacement can be observed through the ‘emergent serotype(s)’, which is a non-
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vaccine serotype that becomes a carrier in >5% of the population unless already 
exceeding this before introduction of a vaccine (Cohen et al., 2012).  
As well as serotype replacement, the pneumococcus has successfully evaded 
vaccine pressure by utilising its ability to undergo natural genetic transformation 
(Straume et al., 2014). Frederick Griffiths described the first evidence of transformation 
in the 1920’s when a non-encapsulated pneumococcus incorporated free DNA into its 
genome to become capsulated in an in vivo (mice) study (Griffith, 1928). Oswald T. 
Avery also demonstrated this in vitro in 1930’s-1940’s (Avery et al., 1944). This stage of 
transformation occurs when the bacterium becomes competent, meaning that it has the 
ability to take up DNA and transform (Johnston et al., 2014; Knutsen et al., 2006). All S. 
pneumoniae can become competent but only briefly in the growth stage.  
Competence, for general transformation, is regulated by competence stimulating 
peptide (CSP) through a signal transduction pathway including histidine kinase comD 
and cognate response regulator comE (Knutsen et al., 2006). This process of taking 
naked DNA from the external environment and incorporating it into its genome has 
enabled the uptake of new capsular genes, hence transforming its expressed capsule 
into a non-vaccine targeted capsule. Termed “capsule switching”, it has been observed 
in several studies. A number of studies have demonstrated that multiple fragments, 
some up to 44kb in length, are exchanged between pneumococci (Brueggemann et al., 
2007; Golubchik et al., 2012; Wyres et al., 2012). Further discussion of capsule 
switching is provided in Section 2.10. Interestingly, it is thought that BOX elements play 
an important role in fine-tuning of the development of spontaneous competence, which 
may play a role in evolution of the pneumococcal genome (Knutsen et al., 2006). BOX 
elements are also used for genotyping as explained in Appendix B8: Published 
manuscript “Genotyping Streptococcus pneumoniae” to Future Microbiology (April 2015).  
2.10 Pneumococcal capsule switching 
Capsule switching is defined as the horizontal transfer of pneumococcal capsular 
genes from one pneumococcus to another so that even though the genome is very 
similar to the original, the expressed capsule polysaccharide is different (Brueggemann 
et al., 2007). Capsule switching is usually identified when two pneumococci have the 
same background DNA (e.g. same MLST sequence type) but have different capsular 
types (Hanage et al., 2005). For example, Moore et al. (2008) demonstrated through 
MLST that ST695 (sequence type) and ST899 were both previously serotype 4 but now 
both had 19A capsules, indicating capsular switching from vaccine serotype to non-
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vaccine serotype. The terminology ‘capsule switching’ has been considered misleading 
because it connotes that only the capsule cassette is switched, when in reality genes 
lying outside of the capsule cassette region can also be included in the switch 
(Golubchik et al., 2012). For this thesis, capsule switching is recognised as a process 
where capsule genes are exchanged through horizontal transformation so that the 
expressed capsule changes. 
It is important to keep in mind that capsular switching has been observed before 
the vaccination era. Therefore “natural” capsular switching (not the result of vaccine 
pressure) should be differentiated from “vaccine-selected” capsule switching (selective 
pressure of conjugate vaccination) (Beall et al., 2006; Jefferies et al., 2004; Temime et 
al., 2008).  Natural capsule switching has been found to occur at a rate of 1.5x10-3 per 
week; however there was not enough evidence to determine the rate of vaccine-
selected capsule switching (Temime et al., 2008).  
Interestingly, environmental stresses such as antibiotics or vaccines can induce 
competence in pneumococci, enabling the pathogen to adapt (Johnston et al., 2014). 
Recent studies have shown that once competent, the pneumococcus can capture 
foreign dsDNA using a long transformation pilus located mid-cell (Figure 4) (Croucher 
et al., 2012; Johnston et al., 2014). The dsDNA is then passed to a comEA receptor at the 
pore complex which transfers the dsDNA to the EndA nuclease to have one strand of 
DNA degraded (Croucher et al., 2012; Johnston et al., 2014). The resulting ssDNA is 
cleaved into fragments of approximately 6.6kb in length and crosses the membrane via 
the ComEC pore (Croucher et al., 2012; Johnston et al., 2014). A nucleoprotein filament 
is formed when ssDNA is protected by SsdB proteins (RecA and DprA) from further 
degradation in the cytosol before eventually being incorporated into the genome at 
regions of similar sequence (Croucher et al., 2012; Johnston et al., 2014).  
The total size of alternative coding at the capsular locus is more than 1.8Mbp 
which is almost the equivalent of an entire S. pneumoniae chromosomal complex 
(Bentley et al., 2006). The capsular genes have low G/C content which may allow new 
serotypes to form by lateral gene transfer of novel capsule polysaccharide genes 
(Bentley et al., 2006). The pneumococcus has been known to undergo transformation 
more frequently than most other bacterial species (Hall et al., 1998). 
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Figure 4: The process of horizontal transformation in Streptococcus pneumoniae via use 
of a transformation pilus. (Reprinted from Streptococcus pneumoniae, le transformiste, Vol. 22 /3, 
Calum Johnston, Nathalie Campo, Matthieu J. Bergé, Patrice Polard, Jean-Pierre Claverys, 
Streptococcus pneumoniae, le transformiste, Trends in Microbiology: 113-119, Copyright (2014), 
with permission from Elsevier). 
The transformation pilus (GC) captures double-stranded DNA (dsDNA) once the cell becomes 
competent (1). The dsDNA is passed to the ComEA receptor (EA) before being transferred to the 
EndA nuclease for degradation. The resulting single-stranded DNA (ssDNA) moves across the 
membrane via the ComEC pore (EC; 2). SsdB (green ovals) coat the ssDNA to protect it from 
nucleases, while DprA (blue ovals) also bind to ssDNA to promote nucleation of the recombinase 
RecA (yellow pentagons) onto the ssDNA. The ssDNA can then be polymerised by RecA, and 
promote homology search and strand exchange. Green lines, host chromosome; red lines, 
transforming ssDNA; M, membrane; EA, ComEA; EC, ComEC. 
 
 
Due to high colonisation of various serotypes in the nasopharynx, this has led to 
the hypothesis that genetic transfer occurs here (Marsh et al., 2007; Singleton et al., 
2007). However, only recently Marks et al. (2012) have demonstrated in vivo that 
nasopharyngeal carriage provides extremely efficient (10-2) and high genetic transfer 
between multiple strains of S. pneumoniae. They demonstrated that the SP670 (Penr) 
strain took up genetic DNA from a dead D39-CO8P2 pneumococcal (Ermr) strain via 
fratricide (Marks et al., 2012).  
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Evidence of capsule switching has been recorded worldwide. In particular, MDR 
pneumococcal isolates are the focus and have been recorded in the PMEN database. 
The PMEN Spain23F-1 clone has many variants worldwide including serotypes 19F, 14, 
19A, 9N and 3 and serogroup 6 (McGee et al., 2001). Similarly Spain9V-3 has many 
variants including serotypes 14 and 9A and serogroup 19 (McGee et al., 2001). These 
clones are important to monitor in Queensland since Spain23F-1 has been reported in 
Australia (as well as Spain6B-2, England14-9 and Taiwan19F-14) (McGee et al., 2001). No 
other PMEN strains have been reported in Australia, however surveillance is important 
to determine whether PMEN clones appear and whether capsule switching occurs. 
Another focus is the MLST online database where isolates of the same MLST profile 
may have different serotypes. Serotype 19F has the highest strain diversity, indicating 
that the 19F capsular gene complex is transferred horizontally quite frequently, and 
this can be seen in the MLST database (Elberse et al., 2011a; Enright & Spratt, 1998). 
Unfortunately, there is no Australian national database that records detected 
pneumococcal genotypes and evidence of capsule switching, therefore little has been 
published in this area. 
Most capsule switches have been detected amongst serotypes 19A, 19F, 11A, 
15A, 15B and 22F as seen in the MLST database (Aanensen & Spratt, 2005). Serotype 
19F was targeted by the 7vPCV, suggesting vaccine pressure has caused this serotype 
to become readily susceptible to undergo capsule switching. Serotype 19A has been the 
most successful serotype replacement worldwide, and has been associated with 
capsule switching e.g. serotype 4 to 19A (Brueggemann et al., 2007). It is unknown why 
the other serotypes 11A, 15A, 15B and 22F are also commonly observed in switches as 
they are currently not targeted by any vaccines, however it is not surprising since 
pneumococci can undergo natural capsule switching. The significance of understanding 
the ability of S. pneumoniae to exchange genetic information will be important when 
examining capsule switching in the Queensland population. Capsule switching is of 
major concern particularly if vaccine type serotypes (7vPCV serotypes) transform to 
non-vaccine capsule types and become “vaccine escape” strains.  
The emergence of “vaccine escape” isolates is an alarming possibility of capsule 
switching. Brueggemann et al. (2007) reported that within four years (2003-2007) 37 
vaccine escape strains were detected in the USA. It has been shown that multiple and 
large DNA fragments (sizes ranging from 0.04 – 44kb) were simultaneously transferred 
in five independent vaccine escape recombination events (Golubchik et al., 2012). 
Vaccine escape recombinant P1 (ST695 and ST2363) was particularly virulent after 
switching its capsule from a serotype 4 to a 19A, spreading westward across the USA 
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after being detected in New York and Connecticut in 2003 (Figure 5) (Golubchik et al., 
2012). Pai et al. (2005) also described a ST695 serotype 4 isolate with a switched 
capsule to serotype 19A in USA. In Italy in 2009 and 2010 vaccine escape ST695 was 
also detected, although it is unsure whether these strains migrated from the USA or 
whether they independently evolved within the Italian pneumococcal population 
(Ansaldi et al., 2011). According to the MLST database, a pneumococcus with a MLST 
profile ST2702, a double locus variant of ST899 serotype 19A (contains two sequence 
differences in the MLST profile) has been detected in Australia, however it remains as 
serotype 4 (Aanensen & Spratt, 2005).  
Figure 5: Spread of the P1 S. pneumoniae vaccine escape strain in the USA during 2003 to 
2007. (Reprinted by permission from Macmillan Publishers Ltd: [Nature Genetics] (Golubchik et 
al., 2012), Copyright (2012))  
Bar graphs represent the percentage of serotype 19A isolated within that year; red represents 
the P1 serotype 19A strain and blue represents other serotype 19A lineages. Years are from 
2003 to 2007, left to right across each bar graph. Surveillance in New Mexico began in 2004, 
hence data from 2003 is missing. 
 
Vaccine escape due to capsular switching is a major concern, especially since the 
transformation of a serotype can affect the virulence properties. Kelly et al. (1994) 
demonstrated in vitro that when a serotype 2 switches to a serotype 3, it had no effect 
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on virulence; however a serotype 6B strain switching to a serotype 3 became more 
virulent. Virulence was determined by comparing the serotype 3 derivatives to the 
parental strains, and measuring the median time to death when female mice were 
inoculated with the bacteria.  Sabharwal et al., (2014) has also demonstrated that 
pneumococcal virulence properties can change after capsular switching from serotype 
6A to 6C. This was demonstrated through infection of mice nasopharynx and detection 
of viable organisms 48-72 hours later. The significance of identifying capsule switching 
and vaccine escape isolates in Australia may impact the selection of serotypes for new 
childhood pneumococcal vaccines. 
2.11 Serotype replacement: Prevalence of non-vaccine Streptococcus 
pneumoniae globally  
Since the introduction of 7vPCV in the USA in 2000, there has been verified 
concern that vaccinations will induce serotype replacement. Serotype replacement is 
“an increase in the incidence of IPD caused by non-vaccine serotypes after the 
introduction of a vaccine” (Weinberger et al., 2011). It is a gradual and steady process 
that has been observed all over the world including the USA (Hicks et al., 2007; 
Reingold et al., 2005; Whitney et al., 2003), Australia (Hanna et al., 2008; Lehmann et 
al., 2010; Marsh et al., 2007), The Netherlands (Elberse et al., 2011a, Elberse et al., 
2012), Portugal (Nunes et al., 2005), Alaska (Singleton et al., 2007), Spain (Guevara et 
al., 2009), Finland (Hanage et al., 2005), Scotland (McChlery et al., 2005), Canada 
(Tyrrell et al., 2009) and other countries such as The Gambia, Israel, South Africa, 
France and Greece (Weinberger et al., 2011). The rate of colonisation of non-vaccine 
serotypes increases in vaccinated populations, therefore serotype replacement is 
observed mostly in first world countries where the vaccines are readily available and 
administered (Mehr & Wood, 2012; Weinberger et al., 2011). 
The introduction of pneumococcal conjugate vaccines is thought to have created 
an ecological niche resulting in serotype replacement (Hicks et al., 2007). In the USA 
insignificant increases were reported in 2003, three years after the introduction of 
7vPCV in 2000 (Reingold et al., 2005) but by 2004 non-vaccine serotypes (namely 3, 15, 
19A, 22F, and 33F) caused 88% of IPD cases in American children under five years; 
however this remained minor compared to the overall decrease in IPD (Hicks et al., 
2007, Reingold et al., 2005). By 2007, Singleton et al. (2007) reported a 140% increase 
of IPD caused by non-vaccine serotypes in Native Alaskan children younger than two 
years old, six years after the introduction of 7vPCV. Predominant serotypes were 3, 6A, 
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7F, 8, 12F and 19A (Singleton et al., 2007). Globally serotype 19A has been the 
predominant non-vaccine serotype causing IPD (Hicks et al., 2007). However, Canada 
had a more significant increase in serotype 5, with a total increase of 236.3% non-
7vPCV serotypes causing IPD from 2002 (7vPCV introduction) to 2006 (Tyrrell et al., 
2009). In contrast, no overall increase in non-7vPCV serotypes causing IPD has been 
observed in the Navajo population in the USA apart from specific serotypes (1, 3, 7F 
and 19A) (Weatherholtz et al., 2010). It is hypothesised that the observed difference in 
the Navajo population may be because before the 7vPCV trial, only 50% of IPD were 
caused by serotypes targeted by this vaccine, and the introduction of the vaccine into 
this population was gradual (Weatherholtz et al., 2010). Serotype replacement would 
not have been observable since a majority of IPD cases were already caused by 
serotypes not targeted by the 7vPCV. 
There are regional differences in non-vaccine serotype emergence patterns 
(McIntosh & Reinert, 2011). Serotypes that have low carriage rates (such as serotype 1) 
have different strains that are found only in certain areas of the globe. For instance, 
serotype 1 ST306 is found in continental Europe but serotype 1 ST227 is found in 
England (Brueggemann & Spratt, 2003). Due to low carriage rates of serotype 1, the 
strains do not spread throughout populations as quickly. This phenomenon has also 
been observed by Sandgren et al. (2004). On the other hand, serotypes that have high 
carriage rates (such as 19F) have spread across the globe with strains found in many 
countries, however these serotypes don’t frequently cause IPD (Sandgren et al., 2004). 
Some serotypes are also more highly clonal than others, meaning that most isolates 
have the same genotype and have not undergone a lot of genetic variation. For example 
serotype 7F has been found to be highly clonal with the dominant sequence type ST191 
found in Australia, Scotland, Sweden and the USA (Jefferies et al., 2004; Sandgren et al., 
2004). Similar reports of serotype replacement in Australia are discussed in the 
following section. 
2.12 Serotype replacement: Prevalence of non-vaccine Streptococcus 
pneumoniae in Australia and Queensland 
Serotype replacement has been detected in Australia, mirroring observations 
worldwide. Initially, since the introduction of 7vPCV to Indigenous children in 2001, 
epidemiology studies focused on this population. From 1996 to 2004, Giele et al. (2007) 
determined that there was no significant increase non-7vPCV serotypes causing IPD in 
Indigenous children less than five years in Western Australia (WA). This may be 
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because the 7vPCV had low coverage (54%) in WA compared to other Australian states, 
and that the number of isolates in their study was too few to identify changes in specific 
serotypes (Giele et al., 2007). Hanna et al. (2006) reported that in North Queensland, 
serotypes 6A and 19A were the leading non-vaccine serotypes causing IPD in 
Indigenous children under five from 2002-2004, a period where only Indigenous 
children were vaccinated with 7vPCV. There was no observation that these serotypes 
6A and 19A were serotype replacements as yet, but it was recommended that further 
surveillance was required (Hanna et al., 2006). By 2005 when the 7vPCV was freely 
available for all children, IPD cases caused by non-7vPCV serotypes remained 
unchanged although there were decreases in 7vPCV serotypes (Roche et al., 2007; 
Roche et al., 2008). A slight increase of serotype 19A in non-Indigenous children under 
five in 2006 was observed but was considered to be natural fluctuations (Roche et al., 
2008). 
However, between 2006-2009 the 11 most common serotypes in north 
Queensland were serotypes 1, 3, 4, 6A, 7F,  9V, 14, 19A, 22F, 23F and 38 of which only 
4, 9V, 14 and 23F were targeted by the 7vPCV (Hanna et al., 2010). There was also a 
gradual increase in non-vaccine serotypes in the Indigenous population in North 
Queensland, the dominant serotypes being 6A and 33F in Indigenous children, and 22F, 
10F and 18A in Indigenous adults (Hanna et al., 2008). Similarly, Giele et al. (2009) 
stated that from 2001 to 2007 there was an increase in 19A (from 2.5% to 20%) in 
non-Indigenous Australians in North Queensland.  
Interestingly, Williams et al. (2011) stated that were was no observable increase 
in serotype 19A in Indigenous children under two years from 2002 to 2007, although 
this may be because there were lower number of isolates collected from Indigenous 
children (n=148 compared to n=1441 non-Indigenous children) in this study. Also the 
incidence of non-7vPCV serotypes remained 10 times higher in Indigenous children 
than non-Indigenous children, indicating the effects of the 7vPCV would not be as 
pronounced in the Indigenous population. Overall, significant increases in non-7vPCV 
serotypes were observed in non-Indigenous children (from 9.7 – 15.7 per 100 000, 
P<0.001), particularly serotype 19A which caused 38% IPD by 2007 (Williams et al., 
2011). Similarly, Lehmann et al. (2010) observed in WA that there was an increase in 
serotype 19A from 1997 to 2007 in both Indigenous children (8 to 12.6 per 100 000) 
and non-Indigenous children (0.6 to 4.9 per 100 000). Overall, non-7vPCV serotypes 
had increased in WA Indigenous children (40%) and non-Indigenous children (74%) by 
2007 (Lehmann et al., 2010). 
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There are no published studies on the impact of the 13vPCV in Australia 
(introduced 2011), although Torzillo et al. (2007) reported that the 13vPCV serotypes 
accounted for 80% of IPD isolates in central Australia, indicating it should provide good 
coverage. Hanna et al. (2010) reported that 22F has emerged as a dominant non-
vaccine serotype in North Queensland adults. Serotype 22F is not covered by any of the 
current vaccines. Other serotypes to monitor include 3, 7F and 33F, although serotypes 
3 and 7F are targeted by the 13vPCV (Williams et al., 2011). Collins et al. (2013) 
identified that ten years after the 7vPCV introduction, 7vPCV accounted for a small 
proportion of carried pneumococci in Australian Aboriginal children, and that many 
non-13vPCV serotypes are in circulation. Reingold et al. (2005) emphasised the need to 
continue surveillance studies to ensue vaccination strategies encompass all of the 
present and emerging invasive serotypes and thus reduce and maintain low levels of 
IPD. 
2.13 Streptococcus pneumoniae epidemiological surveillance 
The increasing emergence of drug resistant strains and the phenomenon of 
serotype replacement and capsular switching have demonstrated the importance of 
epidemiological surveillance (Hall et al., 1998; Hermans et al., 1995). Molecular typing 
profiles are used to study transmission routes of infectious diseases, assess sources of 
infections and assess the impact of human intervention (i.e. vaccinations/antibiotics) 
(Schouls & Van der Heide, 2012). As there are 98 serotypes of S. pneumoniae, highly 
informative tools for analysis are required. To accurately assess vaccine impact, it is 
recommended that data are required two years pre-vaccine introduction and five years 
post-vaccine introduction (Murray et al., 2014). Epidemiology studies have been useful 
in the past when determining which serotypes to include in the new vaccine i.e. 
serotype 19A in the 13vPCV after increase of IPD caused by this serotype. Alternatively 
advice can be given when a vaccine is not required e.g. the 10vPCV was only introduced 
into Northern Territory, Australia since serotype 5, which was a newly added in this 
vaccine, was not prevalent elsewhere in Australia. The first beginnings of a 
pneumococcal surveillance program began in Queensland in 1989 at the Acute 
Respiratory Infections Unit, Centre for Public Health Sciences, Queensland Health, 
Brisbane (Gratten et al., 1997). Traditional characterisation methods for epidemiology 
studies, such as serotyping (Quellung of Neufeld) only provide a broad picture of 
changes and cannot differentiate genotypes or capsule switching (Neufeld, 1902). 
Serotyping methods require multiple Factor serum to distinguish, for example, 
serotype 6C (first described in 2007) from serotype 6A, and more Factor serum are 
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being developed as more pneumococcal serotypes are identified (Hanna et al., 2010). 
However this method is very expensive compared to molecular typing methods, and 
currently has the ability to distinguish up to 91 types. Further discussion of this method 
is provided in Section 2.16. 
The suitability of genotyping tools for epidemiology studies depends on its ability 
to distinguish different fingerprint patterns for unrelated isolates from identical 
patterns for related isolates (Hermans et al., 1995). The current ‘gold standard’ 
genotyping method for S. pneumoniae is Multi-Locus Sequence Typing (MLST). MLST 
provides high discriminatory powers, good resolution and good reproducibility; 
however it also has limitations as described in Appendix B8: Published manuscript 
“Genotyping Streptococcus pneumoniae” to Future Microbiology (April 2015). Another 
promising genotyping method has emerged, namely Multi-Locus Variable Number 
Tandem Repeat Analysis (MLVA), also discussed in Appendix B8: Published manuscript 
“Genotyping Streptococcus pneumoniae” to Future Microbiology (April 2015). 
Unfortunately Australian states are limited when comparing epidemiology studies due 
to lack of a national database, and because of this no nationally accepted genotyping 
method is used. Most Australian epidemiology studies still favour Quellung serotyping 
and carriage surveillance.  
2.14 Capsule typing Streptococcus pneumoniae 
Characterisation of bacteria below the species level enable the assessment of 
the impact of human interventions such as vaccines and antibiotics, the  relatedness of 
bacterial isolates, and the sources and transmission routes of infections (Elberse et al., 
2011a). Traditional characterisation techniques, such as Quellung serotyping, has been 
used for decades in pneumococcal epidemiology studies (Neufeld, 1902). 
Unfortunately, less than 98 published serotypes can be determined when using 
serotyping, compared to thousands of genotypes identified within these 98 serotypes 
when using a molecular based method such as MLST. As well as this, not all serotypes 
can be distinguished, and capsule switching cannot be detected without the assistance 
of a genotyping method. Capsule typing of S. pneumoniae based exclusively on DNA-
based methods has several advantages but also has the limitation that capsular 
expression is not really accessed. For example, the entire capsular operon may be 
present but due to mutations no capsule is being produced (Salter et al., 2012). A 
number of molecular based methods using PCR to directly type the capsule cassette 
sequence have been developed as discussed in the following sections.  
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2.15 Streptococcus pneumoniae capsule cassette 
Using PCR methods to determine the capsule type of S. pneumoniae relies on the 
knowledge of the polysaccharide capsule and its associated genes. Almost all 98 
serotypes have had the capsule locus (cassette) sequenced, and cassette lengths vary 
from 10kb to 31kb (Bentley et al., 2006). There has been an estimated 1.8Mbp of 
alternative capsule coding sequence in the S. pneumoniae genome (Bentley et al., 2006). 
The general structure of the capsule cassette (cps) includes four highly conserved 
translocation and regulation genes at the 5’ end (wzg, wzh, wzd and wze), often 
followed by a gene wchA that encodes for the initial glucose phosphate transferase 
(Bentley et al., 2006) (Figure 6). A polysaccharide polymerase gene wzy and flippase 
gene wzx are often present downstream with a varying set of other genes for acetyl 
transferase, glycosyl transferases, nucleotide diphosphate, sugar biosynthesis and 
modifying enzymes (Bentley et al., 2006).  
The complete capsule cassette is located between conserved regions dexB and 
aliA except for serotypes 3 and 37. In these two serotypes a wchE synthase gene is 
defect; therefore the tts gene located elsewhere in the genome is active, replacing the 
function of wchE (Bentley et al., 2006). The region between the dexB and aliA genes and 
the rest of the cps locus contain mobile genetic elements which may account for some 
of the capsule switching (Bentley et al., 2006). The entire capsule cassette has a lower 
G/C content than the rest of the genome (Bentley et al., 2006; Mavroidi et al., 2007).  
Published data on already sequenced S. pneumoniae capsule loci show that 
differences between serotypes can be major or minor. For example, the only difference 
between serotype 6A and serotype 6B are SNP differences in the wciP gene, whilst 
serotype 6C has a unique wciN gene and serotype 6D has a wciPβ gene (Bratcher et al., 
2011). The wciPβ is an allele associated to serotype 6B and 6D, while the wciP allele is 
associated to serotype 6A and 6C; this can be used to distinguish these two sub-groups 
of serogroup 6 (Bratcher et al., 2011). 
The ability to switch the capsule genes is a concern because the current 
childhood vaccines (7vPCV, 10vPCV and 13vPCV) act to target the polysaccharide 
capsules of those serotypes included in the vaccine (i.e. for 13vPCV it targets serotype 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).  
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Figure 6: Example of S. pneumoniae capsule cassettes and polysaccharide structure for 
serotypes 5, 6A, 6B, 7F and 7A (adapted from Bentley et al., 2006). 
Gene designations are indicated above each coloured box, and genes are presented on forward 
and reverse strands. Polysaccharide structures (right side) are coloured by grey, housekeeping 
sugars; orange, N-acetylfucosamine; green, rhamnose; white, N-acetylgalactosamine. 
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2.16 Molecular capsule typing 
Since capsule switching has been identified as an important phenomenon to 
investigate, particularly due to vaccine escape serotypes, several techniques for 
sequencing the capsule locus have been published. Traditional serotyping methods 
such as Quellung reaction do not distinguish between all serotypes e.g. between 20A 
and 20B, or otherwise require multiple Factor serum. PCR and sequencing methods to 
determine serotypes are more specific and less expensive (Pai et al., 2006). Serotyping 
only detects the present capsule – it cannot determine what capsule type the 
bacterium previously had. Serotyping combined with a genotyping method can give 
preliminary identification that a capsule switch has occurred if given the history of 
the clone or genotype; however a more accurate detection would require detecting 
the specific switch within the capsule cassette sequence. Bentley et al. (2006) 
determined the capsule sequences of 90 serotypes using the Expand Long Template 
PCR System from Roche which sequences up to 20kb. A similar technique has also been 
used by Brueggemann et al. (2007) and Ansaldi et al. (2011). However less expensive 
and faster PCR techniques have been developed to determine capsule types. One of the 
earliest multiplex PCR methods was developed by Lawrence et al. (2003) for 
determining serotypes 1, 3, 6, 14, 19F and 23F. Primers were combined in 3 multiplex 
reactions and fragment sizes of PCR products were separated by capillary 
electrophoresis. 
Pai et al. (2006) developed a sequential multiplex PCR based on amplifying short 
regions within the capsule cassette for serotypes common in the Burkina Faso and 
Togo regions. A seven multiplex PCR with 29 primer pairs could identify 17 serotypes. 
This sequencing multiplex has been widely applied and optimised to regional 
pneumococcal populations around the world. Ahn et al. (2012) modified this multiplex 
PCR to a 35 primer pair. Both these methods still require gel electrophoresis to detect 
the amplification products.  
Elberse et al. (2011c) also used a different long-PCR method to sequence the 
capsule locus of serogroup 6 and serotype 19A and 19F, and also created an allele-
specific PCR (e.g. sequence only wzy and rmlC for serogroup 6) to characterise a batch 
of isolates. The genes wzg, rmlA and rmlB had the highest degree of sequence variation 
(Elberse et al., 2011c). Beside from differences between serotypes (e.g. there is a SNP 
difference in wciP gene to distinguish serotype 6A from 6B), capsular subtypes were 
also found within each serotype (Elberse et al., 2011c). There are six subtypes of 
serotype 6A, three subtypes of serotype 19A and four subtypes of serotype 19F 
CHAPTER 2 Literature Review 
67 
 
(Elberse et al., 2011c). Elberse et al. (2011c) theorised that 6C was a descendent from 
6A subtype II (6A-II), as well as suggesting that serotype 19A-II may have enhanced 
polysaccharide production due to a difference in the wzg locus compared to 19A-I, 
particularly since 19A-II has been more successful in vaccinated children. By examining 
these subtypes, a further understanding of capsule switching and the evolution process 
can be determined. Elberse et al. (2011c) has demonstrated the proposed idea to 
sequence the complete cps cassette and then select polymorphic genes within the 
cassette to identify potential subtypes. However, this published method lacks details on 
the allele-specific PCR procedure to identify capsular subtypes. Information for 
sequencing the complete capsular gene is also lacking compared to other published 
long-template methods.  
Wyres et al. (2013) has also demonstrated evolution of the cps locus among 
pneumococcal clonal complexes (CC) of a particular serotype (contains genetically 
related pneumococci based on their genotypes), for example a serotype 7F in CC191 
can have a substitution in the wzg locus (7F/5b) or instead in the wchF locus (CDC1087-
00). However since they have used whole genome sequencing, this is not a practical 
and cost-effective method for this project particularly since we are only interested in a 
small section of the whole S. pneumoniae genome.  
Bratcher et al. (2011) and Mavroidi et al. (2004) have also examined serogroup 6 
using an allele-specific PCR. Bratcher et al. (2011) identified differences in the cps 
cassette, which has allowed them to examine the possible evolution of serotype 6C 
from 6A. They also used allele-specific sequencing of wciP, wzy and wzx for serogroup 6 
(Bratcher et al., 2011). However since they have only examined serogroup 6, these 
allele-specific PCR primers may not be suitable for other serotypes, particularly if these 
alleles aren’t present in other serotypes. This thesis will examine all the published csp 
loci and determine gene-specific PCR and allele-specific PCR for these loci.  
 
2.17 Summary and Implications 
S. pneumoniae is a common but deadly bacterium that causes high mortality and 
morbidity worldwide. Despite decreases in IPD after the introduction of the 7vPCV, 
epidemiology studies have been deemed extremely important particularly due to the 
shifting genotype population to non-vaccine serotypes. Two phenomenon, serotype 
replacement and capsule switching, have been the main reasons for the changing 
population structure. S. pneumoniae populations differ within age groups, geographic 
locality and ethnicity; therefore it is vital that studies are continued in each area. 
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Although Australia is considered as a first-world country, the Australian Aborigines 
retain the highest rates of pneumococcal diseases in the world. A 13vPCV was 
introduced for Australian children under two in July 2011, targeting an extra six 
pneumococcal serotypes that was not included in the 7vPCV. Studies are emerging 
examining the effect of the 13vPCV in different countries, however currently no studies 
have been published investigating whether the genetic population has changed in 
Australia. 
Genotyping S. pneumoniae is important for pneumococcal epidemiology studies. 
By adopting genotyping methods in conjunction with serotyping methods, further 
genetic information of invasive pneumococcal strains can be obtained. The most 
favourable genotyping methods ideally have high throughput, high discrimination, 
good typeability and low costs. There are a number of different genotyping methods 
available, however MLVA is emerging as a highly discriminatory, quick and inexpensive 
method compared to the ‘gold standard’ MLST for genotyping S. pneumoniae. There 
have been at least four different MLVA methods published for genotyping S. 
pneumoniae, each method containing different targets in the pneumococci genome. 
Unfortunately, no universal MLVA method currently exists and limitations remain such 
as non-amplified genotyping profiles, therefore further study is required so that 
comparison of pneumococcal MLVA types between countries can be easily achieved.  
The future direction of genotyping methods may continue to see the combination 
of many genes, including BOX loci and housekeeping genes, with mass spectrometry 
(MS) or Next Generation Sequencing (NGS). The benefits of these new technologies (MS 
and NGS) may decrease cost and time. The choice of VNTR or BOX loci raises the 
question of whether they are stable in vitro and in vivo, particularly since it is known 
that S. pneumoniae has high mutation rates within the genome. Published literature has 
demonstrated that these genes are stable in various conditions, although it is unknown 
whether all VNTR loci remain stable depending on how many times and in what 
manner the clinical isolates have been sub-cultured before they reach a research 
laboratory.  
As well as methods for genotyping S. pneumoniae, investigations examining 
capsule typing have been performed. The S. pneumoniae polysaccharide capsule plays 
an important role in virulence, and is the target of a number of pneumococcal vaccines 
that are implemented in national immunisation schemes worldwide. Multiple and large 
fragments of DNA have been reported to undergo recombination, resulting in vaccine 
escape strains in the USA and Italy. This is a major concern since vaccine escape strains 
have the ability to become immune to the pneumococcal vaccine. Traditional 
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serotyping methods, mainly the Quellung reaction, allow the detection of pneumococcal 
serotypes. However serotyping is expensive, laborious and cannot distinguish all 
serotypes, therefore a number of molecular based capsular typing methods have been 
developed. Capsular sub-types within each serotype have also been detected and 
associated with the emergence and persistence of certain pneumococcal strains after 
the introduction of the vaccines. Currently, no molecular capsular typing method has 
been applied to all 98 known S. pneumoniae capsule types. 
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CHAPTER 3: GENERAL METHODOLOGY 
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3.1 Bacterial isolates 
In Australia, all cases of IPD caused by invasive S. pneumoniae are reported by 
general practitioners, public and private hospitals to the State Communicable Disease 
Department in the Department of Health, where data and isolates are collated. The 
national data is updated annually. All Queensland invasive pneumococcal isolates are 
required to be sent to the Public Health Microbiology Laboratory at Queensland Health 
Forensic and Scientific Services. Invasive S. pneumoniae is identified as the isolation of 
the bacteria from normally sterile body specimens such as blood, cerebral spinal fluid, 
pleural fluid and tissues. There can be a difference between the total number of IPD 
cases reported and the total number of pneumococcal serotypes reported for each 
interval and year. 
The state of Queensland, Australia, has a population of 4.7 million people spread 
across an area of ~1.7 million km2 (Queensland Government, 2015). The National 
Notifiable Diseases Surveillance System recorded a 7.6 per 100 000 notification rate of 
confirmed cases of IPD in Queensland in 2012 (NNDSS, 2015).  
3.2 Phenotypic methods 
Invasive S. pneumoniae isolates taken from normally sterile body sites (blood, 
tissues, cerebrospinal fluid) were serotyped by the Pneumococcal Reference 
Laboratory, QHFSS, using Quellung reaction (Statens Serum Institut, 2013). Serotyping 
(Quellung) is mandatory, however further genotyping has only been performed for 
research purposes. Serotyping was performed by staff at QHFSS. 
3.3 Genotypic methods 
3.3.1 Preparation of genomic DNA 
A total of 394 S. pneumoniae isolates were identified as isolated from children 
under 15 years old (Table 3). Two S. pneumoniae ATCC strains, ATCC49619 
(serotype 19F) and ATCC6306 (serotype 6A) were also obtained from Cryosite, 
Australia. These S. pneumoniae isolates were cultured (24hrs, 37oC, 5% CO2) on Horse 
Blood Agar (HBA, Oxoid Australia) with the 16-streak technique using a 1mm white 
loop. A single pneumococcal colony was re-cultured on fresh HBA to ensure isolates 
were genetically identical. A loopful of colonies was boiled in 400µL TE buffer (~pH8.0) 
for eight minutes to prepare a thermolysate containing template DNA. A boiler or a 
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Ratek Dry Block Heater (model no. DBH30D, Ratek) was used to boil the samples at 
100oC. The thermolysates were stored at -20oC until further use. Thermolysate DNA 
was used for genotyping work, including MLST, MLVA and the capsule typing method. 
Table 3: S. pneumoniae isolates, used in this study, were taken from Queensland children 
15 years or younger from 2007 to 2012. 
Isolates were collected from sterile body sites. No patient information was available (e.g. age, 
gender, geographic location, vaccination history, etc.) 
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1 2011 19F 81 2011 19A 219 2008 33F 319 2007 19A 
2 2011 19F 82 2011 19A 220 2008 34 320 2007 19A 
3 2011 22F 84 2011 19A 221 2008 35B 321 2007 19A 
4 2011 23A 85 2011 19A 222 2008 38 322 2007 19A 
5 2011 23B 86 2011 19A 223 2008 4 323 2007 19A 
6 2011 23B 87 2011 19A 224 2008 6A 324 2007 19A 
7 2011 23B 88 2011 19A 225 2008 6A 325 2007 19A 
8 2011 3 89 2011 19A 226 2008 6A 326 2007 19A 
9 2011 3 90 2010 1 227 2008 6B 327 2007 19A 
10 2011 3 91 2010 1 228 2008 7F 328 2012 1 
11 2011 3 92 2010 1 229 2008 7F 329 2012 1 
12 2011 3 93 2010 11A 230 2008 7F 330 2012 1 
13 2011 3 94 2010 15B 231 2008 7F 331 2012 1 
14 2011 3 95 2010 15C 232 2008 8 332 2012 1 
15 2011 33F 96 2010 18A 233 2008 8 333 2012 1 
16 2011 35B 98 2010 18C 234 2008 9N 334 2012 1 
17 2011 38 99 2010 19F 255 2008 22F 335 2012 11A 
18 2011 6C 100 2010 19F 256 2008 18C 336 2012 15B 
19 2011 6C 101 2010 19F 257 2008 19A 337 2012 19A 
20 2011 6C 102 2010 23A 258 2008 19A 338 2012 19A 
21 2011 7F 103 2010 23A 259 2008 19A 339 2012 9A 
22 2011 7F 104 2010 3 260 2008 1 340 2012 19A 
23 2011 7F 105 2010 33F 261 2008 12F 341 2012 19A 
24 2011 7F 106 2010 35B 262 2008 12F 342 2012 19A 
25 2011 7F 107 2010 6C 263 2008 18A 343 2012 19F 
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26 2011 7F 108 2010 6C 264 2008 18C 344 2012 23B 
27 2011 7F 109 2010 6C 265 2007 1 345 2012 33F 
28 2011 7F 110 2010 6C 266 2007 1 346 2012 6C 
29 2011 7F 111 2010 6C 267 2007 1 347 2012 6C 
30 2011 7F 112 2010 6C 268 2007 1 348 2012 7F 
31 2011 7F 113 2010 7F 269 2007 1 349 2012 7F 
32 2011 7F 114 2010 7F 270 2007 1 350 2012 7F 
33 2011 7F 115 2010 7F 271 2007 1 351 2012 7F 
34 2011 9V 142 2009 19F 272 2007 3 352 2012 35B 
35 2011 1 143 2009 22F 273 2007 3 353 2012 7F 
36 2011 1 144 2009 23B 274 2007 3 354 2012 7F 
37 2011 1 145 2009 23F 275 2007 3 355 2012 1 
38 2011 1 146 2009 23F 276 2007 4 356 2012 1 
39 2011 1 147 2009 3 277 2007 14 357 2012 3 
40 2011 1 148 2009 3 278 2007 14 358 2012 4 
41 2011 1 149 2009 3 279 2007 38 359 2012 15C 
42 2011 1 150 2009 33F 280 2007 38 360 2012 15C 
43 2011 1 151 2009 35B 281 2007 10A 361 2012 19A 
44 2011 1 152 2009 35F 282 2007 10A 362 2012 19A 
45 2011 1 153 2009 38 283 2007 10A 363 2012 23B 
46 2011 1 154 2009 38 284 2007 15B 364 2012 23B 
47 2011 11A 155 2009 38 285 2007 15C 365 2012 33F 
48 2011 12F 156 2009 38 286 2007 15C 366 2012 33F 
49 2011 12F 157 2009 4 287 2007 15C 367 2012 33F 
50 2011 15B 158 2009 6A 288 2007 15C 368 2012 35F 
51 2011 15B 159 2009 6C 289 2007 15C 369 2012 7F 
52 2011 15C 160 2009 7F 290 2007 18A 370 2012 1 
53 2011 15C 161 2009 7F 291 2007 18B 371 2012 7F 
54 2011 15C 162 2009 8 292 2007 18C 372 2012 7F 
55 2011 18A 163 2009 8 293 2007 19F 373 2012 9N 
56 2011 18A 164 2009 9N 294 2007 19F 374 2012 34 
57 2011 19A 165 2009 9V 295 2007 19F 375 2012 16F 
58 2011 19 166 2009 19F 296 2007 19F 376 2012 22F 
59 2011 19A 167 2009 1 297 2007 22F 377 2012 19A 
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60 2011 19A 168 2009 1 298 2007 22F 378 2012 4 
61 2011 19A 169 2009 10F 299 2007 23A 379 2012 35F 
62 2011 19A 170 2009 10F 300 2007 23F 380 2012 19A 
63 2011 19A 171 2009 14 301 2007 23F 381 2012 7F 
64 2011 19A 172 2009 15B 302 2007 33F 382 2012 14 
65 2011 19A 173 2009 18C 303 2007 33F 383 2012 3 
66 2011 19A 174 2009 18C 304 2007 6B 384 2012 35F 
67 2011 19A 205 2008 19F 305 2007 7F 385 2012 33B 
68 2011 19A 206 2008 19F 306 2007 7F 386 2012 6A 
69 2011 19A 207 2008 19F 307 2007 9V 387 2012 19A 
70 2011 19A 208 2008 22A 308 2007 19A 388 2012 7F 
71 2011 19A 209 2008 22F 309 2007 19A 389 2012 6C 
72 2011 19A 210 2008 23A 310 2007 19A 390 2012 19A 
73 2011 19A 211 2008 23F 311 2007 19A 391 2012 19A 
74 2011 19A 212 2008 23F 312 2007 19A 392 2012 7F 
75 2011 19A 213 2008 23F 313 2007 19A 393 2013 23B 
76 2011 19A 214 2008 24F 314 2007 19A 394 2013 1 
77 2011 19A 215 2008 3 315 2007 19A    
78 2011 19A 216 2008 3 316 2007 19A    
79 2011 19A 217 2008 33F 317 2007 19A    
80 2011 19A 218 2008 33F 318 2007 19A    
 
Pneumococcal colonies from the second HBA plate were also prepared for long-
term storage. Colonies were grown for a further 24hrs in Brain Heart Infusion (BHI, 
Becton Dickenson, Australia) broth at 37oC, 5% CO2 and were spun down in a 
centrifuge at 8000rcf for 30min. The broth was carefully removed by pipette and 200µL 
saline wash was added to the cells. The colonies were mixed using a vortex and 
centrifuged a second time and the saline wash carefully removed. Cell pellets were left 
at the bottom of the Nunc tubes (Sigma-Aldrich, Australia) and placed in -80oC freezer 
until further use. 
Extraction of purified S. pneumoniae DNA was performed following the QIAamp 
DNA Mini Kit (50) (Qiagen, Australia). Concentration of extracted DNA was measured 
on NanoDrop ND-1000 (Thermo Scientific) with genomic yields of 8ng/µL to 50ng/µL. 
Extraction of purified DNA for two S. pneumoniae ATCC strains, Streptococcus pyogenes 
CHAPTER 3 General Methodology 
77 
 
and Streptococcus agalactiae was also performed using the QIAamp DNA Mini Kit. 
Purified DNA was stored in -20oC freezer until further use. QIAGEN extracted DNA was 
prepared for samples tested in Chapter 6 regarding the capsule typing method, in case 
the high resolution melt (HRM) with real-time PCR was not effective when using the 
thermolysate DNA. HRM is much more sensitive than conventional PCR and the 
thermolysate DNA may not be of high enough purity and contain PCR inhibitors. 
3.3.2 Gel electrophoresis 
Gel electrophoresis was used for the visualisation of the amplified PCR products. 
Agarose Low EEO powder (Roche, Spain) was added to 100mL of TAE or TBE buffer 
and heated in the microwave for 2min (e.g. 2g agarose for 2% gel). A staining dye, such 
as ethidium bromide or SYBR® Safe DNA Gel Stain (InvitrogenTM, Australia) was added 
to the heated gel. The gel was poured into a mould with a comb and left to set. Once set, 
the comb was removed and gel was transferred to an electrophoresis bath and covered 
with the appropriate buffer (TAE or TBE depending on what the gel was made from). A 
loading dye was added to PCR samples before pipetting into the gel wells. An 
appropriate DNA ladder was also used per gel, such as DNA Molecular Weight Marker 
VIII or XIV (Roche, Germany). PCR products were run usually at 400mA and 80V. Time 
would vary depending on the gel and the percentage of agarose in the gel (higher 
percentage agarose gel means longer run time). Gels were visualised under UV light 
using the GelDoc XR system (Bio-Rad, Australia) or the G-BOX Syngene system 
(SynGene, England). 
3.3.3 MLST genotyping 
Isolates of S. pneumoniae selected for MLST genotyping included 13vPCV 
serotypes (except serotype 19A) and non-13vPCV serotypes to minimise labour and 
costs, but also to allow examination of changes in these vaccine targeted or non-
targeted serotypes. MLST was applied to selected isolates for comparison purposes as 
previously described using the Corbett Cas1200 Robotics (Qiagen, Australia) for 
automation (Enright & Spratt, 1998; Jefferies et al., 2003). Housekeeping genes for 
MLST were blasted in NCBI database against five known S. pneumoniae strains (R6, 
Hungary19A-6, CGSP14, G54 and TIGR4) (Appendix A1: Position of MLST housekeeping 
primers in five S. pneumoniae genomes). 
Seven housekeeping genes (aroE, gdh, gki, recP, spi, xpt and ddl) were amplified 
using PCR (Table 4). PCR reactions (total volume 28µL) consisted of 10X PCR Reaction 
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Buffer (Roche, USA), 25mM MgCl2 (Invitrogen, Australia), 20mM PCR Grade Nucleotide 
Mix (Roche, USA), 5.6mol of forward and reverse primers (Geneworks, Australia), Taq 
DNA Polymerase (Roche, USA) and reverse-osmosis water (PALL, Australia). 
Thermocycler (Eppendorf, Australia) parameters were as follows: activation of 
AmpliTaq Gold at 95oC for 9min, 35 cycles of 94oC for 30sec, 55oC for 60sec and 72oC 
for 30sec, followed by 72oC for 10min and hold at 4oC. PCR products were run on 1.5% 
agarose gel to check for amplification.  
Table 4: MLST housekeeping gene primers for sequencing S. pneumoniae (Enright & 
Spratt, 1998). 
Primer Forward Reverse 
aroE 5’-GCCTTTGAGGCGACAGC 5’-TGCAGTTCA(G/A)AAACAT(A/T)TCTAA 
gdh 5’-ATGGACAAACCAGC(G/A/T/C)AG(C/T)TT 5'-GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC 
gki 5'-GGC ATT GGA ATG GGA TCA CC 5'-TCT CCC GCA GCT GAC AC 
recP 5'-GCC AAC TCA GGT CAT CCA GG 5'- TGC AAC CGT AGC ATT GTA AC 
spi 5'-TTA TTC CTC CTG ATT CTG TC 5'-GTG ATT GGC CAG AAG CGG AA 
xpt 5'-TTA TTA GAA GAG CGC ATC CT 5'-AGA TCT GCC TCC TTA AAT AC 
ddl 5'-TGC (C/T)CA AGT TCC TTA TGT GG 5'-CAC TGG GT(G/A) AAA CC(A/T) GGC AT 
 
The amplified DNA fragments were washed with exoSAP solution (X10 Buffer, 
5U/µL phosphatase, 20U/µL exonuclease and reverse osmosis water (PALL, Australia)) 
to eliminate un-incorporated primers and dNTPs. ExoSAP was then inactivated by 
heating at 37oC for 45min, then 80oC for 15min, and held at 4oC. A quantitative gel 
check was performed to determine the suitable amount of PCR product required for 
sequencing.  
Appropriate dilutions of the PCR+exoSAP (inactivated) were made according to 
the quantitative gel. BigDye fluorescent label was incorporated to the PCR+exoSAP 
products during a second PCR run of 95oC for 30sec, 25 cycles of 95oC for 10sec, 50oC 
for 5sec and 60oC for 4min, before hold at 4oC. Fluorescently labelled PCR products 
were transferred to 96-well plate for purification.  
A plate washing protocol was performed as follows: 52µL of a 95% ethanol (7mL 
fresh) and 3M NaOAc (ph4.6; 280µL) solution was added to each well, vortexed and 
incubated at room temperature for 45min; the sealed plate was centrifuged at 
4500rpm for 60min; the seal was removed, the plate inverted and placed upside down 
on paper towels in a centrifuge before spinning at 1100rpm for 1min; the plate was 
removed and 150µL of 70% ethanol (fresh) was added, vortexed and centrifuged 
upright and sealed at 4500rpm for 10min; the plate was inverted on paper towels in 
the centrifuge and spun again at 1100rpm for 1 min; the plate was removed and 
allowed to dry in a fume cupboard before sealing and storing at -20oC.  
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Before sequencing on the AB3130 DNA sequencer (Applied Biosystems, 
Australia), the plate was resuspended with 10µL formamide. A denaturing step was 
performed by heating the plate to 95oC for 5min before quickly centrifuging to get rid of 
any air bubbles. The plate was placed in AB3130 for sequencing.  
3.3.4 MLVA primer design and multiplexing 
MLVA4 primers were re-designed to improve annealing for BOX-10, BOX-12, 
BOX-13 and Spneu19 using Oligo v6.57 software (Wojciech Rychlik). Primer dimer 
check was performed using PriDimerCheck (Qu et al., 2009), which is available from 
http://biocompute.bmi.ac.cn/MPprimer/primer_dimer.html. From this it was 
determined that certain primers would not be combined in the same multiplex reaction 
due to primer-dimer formation. All MLVA primers and newly re-designed primers were 
blasted against five known S. pneumoniae strains (strain R6, Hungary 19A-6, G54, 
CGSP14 and TIGR4) in the NCBI database (Appendix A2: BOX primer position in five S. 
pneumoniae genomes). These five strains were chosen since R6 and TIGR4 have been 
used in other published papers, and the other strains are vaccine targeted serotypes, 
specifically serotype 19A (Hungary19A-6), serotype 19F (G54) and serotype 14 
(CGSP14). 
Multiplex Manager v1.2 software (Holleley & Geerts, 2009) was used to 
determine the optimal combination of MLVA4 primers and the minimum number of 
multiplexes.  
The Tandem Repeat Finder algorithm was used for detecting tandem repeats in 
the NCBI S. pneumoniae sequences, particularly when designing the new primers, 
available from http://tandem.bu.edu/trf/trf.html (Benson, 1999). It was also used to 
verify the number of tandem repeats expected to be seen in silico when using the 
published primers. Tandem repeats were found under the following parameters: 
alignment parameter (match, mismatch, indels) = 2, 7, 7; minimum alignment score = 
50; maximum period size = 50.  
3.3.5 MLVA genotyping methods 
The MLVA1 calibration set was sent from researcher Karin Elberse (National 
Institute for Public Health and the Environment, The Netherlands), to verify the correct 
lengths of the alleles on our DNA sequencer.  
Non-fluorescent MLVA1 primers (Geneworks, Australia) were diluted in 500µL of 
TE buffer and placed on an orbital mixer for 1 hour. Fluorescently labelled MLVA1 
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primers (Table 5) (Applied Biosystems, Australia) at 5’ end with F (FAM), N (NED), V 
(VIC) or P (PET) were also diluted in 500µL of TE buffer. Primer concentration was 
measured by NanoDrop 1000 (Thermo Scientific, Australia) at 260nm, ssDNA-33.0. A 
working dilution at 10mol/µL was used.  
A mastermix was made consisting of MLVA1 primers, HotStarTaq Master Mix 
(Qiagen, Australia) and reverse osmosis water (PALL, Australia). The Corbett Cas1200 
Robotic system (Qiagen, Germany) was used to combine 18µL of mastermix to 2µL of S. 
pneumoniae thermolysate DNA into 96-well plates. A protective film was used to seal 
the wells. The PCR protocol was optimised to 15min at 95oC, 30 cycles of 95oC for 
30sec, 58oC for 60sec and 72oC for 60sec, followed by extension of 72oC for 10min and 
held at 4oC. Gel electrophoresis was performed to verify amplification of PCR products.  
Table 5: MLVA1 primer sequences for genotyping S. pneumoniae (Elberse et al., 2011a). 
 Primer Forward Reverse 
M
u
lt
ip
le
x 
1 BOX-01 CCAGAGACATTGATGAAGAGA – F CGCTTTGATGAACTTGAGTT 
BOX-02 TTGCTTGGTACAGAAAACAAA – N CCCCATAAAACCCTCCTTATA 
BOX-03 TCCAACACGACCTTTATCC – V TTCAGTAAACCCAGCTCGTA 
BOX-04 a)TGGGTAAAAGTAGACAGGACT 
b)AGGGGATTTACCCACTACAAA 
CACTTCTACACTAGTTTGTAAAGCA – P 
M
u
lt
ip
le
x 
2 
BOX-06 TTATGATTTTTGTCATTTTGCA TCACTTGAGACAATCAGCC – N 
BOX-11 TCCAATAATGACAGGTTTTCCTC – V TTCCAATCTACGCCTTTGAAG 
BOX-12 TTGCCCTTTTCATCTTCGA – P CAGCAACCATTGAAACGC 
BOX-13 TCGCCTTTGCTAATCAAACA - F CTGATTATATCGCTCACAAACCC 
 
PCR products were diluted (1:150) semi-automatically using an eight-channel 
pipette with reverse-osmosis water (PALL, Australia).  The use of formamide instead of 
water was attempted as other published papers had used this for the dilution of 
amplified products, however poor results were obtained and using water instead 
produced better results. Furthermore, poor results when using formamide has been 
noticed by other researchers and additional limitations are that formamide degrades 
DNA when stored for some time, has a limited shelf life and when shelf-life is reached 
there is a dramatic drop in efficacy of the formamide to denature the DNA (L. Schouls, 
personal communication, 2012).  
The GeneScanTM 1200LIZ® dye Size Standard internal ladder (Life Technologies, 
Australia) was diluted (1:30) with reverse-osmosis water (PALL, Australia), and 10µL 
of diluted ladder was combined with 2µL of diluted PCR product. A heat denaturation 
step of 95oC for 5min, followed by a hold step at 4oC was performed on a thermocycler 
(Eppendorf, Australia) to separate the dsDNA. Fragment sizing was performed on 
AB3130 (Applied Biosystems, Australia) or AB3500 (Applied Biosystems, Australia). 
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Optimisation of MLVA1 method was performed to achieve the best amplification 
results. 
MLVA2 utilised published primers from Van Cuyck et al. (2012). A single 
multiplex was performed with the four forward and reverse primers (Geneworks, 
Australia) (Table 6) and the protocol as outlined for MLVA1 was followed.  
Table 6: MLVA2 primer sequences for genotyping S. pneumoniae (Van Cuyck et al., 2012). 
Primer Forward Reverse 
Spneu17 F-TCGAAAATCTCTGCAAACCA CGGACTAGGCGGCTGATTA 
Spneu19 V-TCGGGTGTAGTCGTGTTTACT AACTGATGTAGCTAAACCTAAAAAGAA 
Spneu27 N-TCAGGAACAGCTATTATCCC CCAACCTCCTTTTCGTTTCA 
Spneu39 P-CCTTGGACTACCACCTCGTT GCCGTGACAGACTTCTGGAA 
 
The modified MLVA4 is a proposed genotyping method for S. pneumoniae. It also 
utilises BOX elements, which are amplified and separated according to fragment sizes, 
but alternative BOX elements already published by Koeck et al. (2005), Elberse et al. 
(2011a), Rakov et al. (2011) and Van Cuyck et al. (2012) were also included. MLVA4 
also consisted of an alternative combination of BOX primers in master-mixes other than 
those already used in other MLVA methods, based on the Multiplex Manager results. 
The MLVA4 protocol is similar to MLVA1 except ten primers (Geneworks, Australia) 
and three multiplexes were used instead (Table 7). Four primers were newly re-
designed. 
Table 7: MLVA4 primer sequences, taken from Van Cuyck et al. (2012), Elberse et al., 
(2011c) or newly designed in this study. 
 VNTR Forward primer Reverse primer 
Master 
Mix 1 
BOX-01 F- CCAGAGACATTGATGAAGAGA CGCTTTGATGAACTTGAGTT 
BOX-10 (new) N- GGAGCCGAGTAGGAGATTCTCAC TCGTAGGCTGCTACATTGACCAG 
Spneu19 
(new) 
V- CACTCACCGTTAGCATTGACTCG TAATCAGGGAGTAGTTGGTTGGG 
Spneu39 P-CCTTGGACTACCACCTCGTT GCCGTGACAGACTTCTGGAA 
Master 
Mix 2 
BOX-12 (new) P- GAGATTGCCCTTTTCATCTTCG AGCAACCATTGAAACGCCTG 
BOX-13 (new) F- TCAAAAGATTGGAGAGTTCCGC GGATTTGGAGAGCAAGCAGATC 
Master 
Mix 3 
BOX-02 N- TTGCTTGGTACAGAAAACAAA CCCCATAAAACCCTCCTTATA 
BOX-03 V- TCCAACACGACCTTTATCC TTCAGTAAACCCAGCTCGTA 
BOX-04 TGGGTAAAAGTAGACAGGACT P- 
CACTTCTACACTAGTTTGTAAAGCA 
Spneu17 F-TCGAAAATCTCTGCAAACCA CGGACTAGGCGGCTGATTA 
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3.3.6 Real-time PCR 
Real-time PCR was determined to be a faster and easier method to type the 
capsule genes of S. pneumoniae. An 18µL reaction containing SybrGreen mastermix 
(Invitrogen, Australia), DNase and RNase free water (Invitrogen, Australia) and primers 
(10µM) was combined with 2µL S. pneumoniae DNA thermolysate in real-time PCR 
tubes. These were placed into a 72-well ring on a real-time PCR Qiagen RotorGene 
(Qiagen, Australia). Real-time PCR conditions were as follows: initialise for 10min at 
52oC, cycle 40 times at 95oC for 15sec, 67oC for 20sec and 72oC for 20sec, followed by a 
standard melt curve (60oC – 90oC) rising 1degree/step, and finally performing a High 
Resolution Melt curve (60oC – 95oC) rising 0.02degrees/step. 
3.4 Data analysis 
All MLVA results were analysed using PeakScanner V1.0 software (Applied 
Biosystems, Australia). A MLVA type (MT) using MLVA1 was assigned to each isolate 
using the MLVA database (http://www.mlva.net) (Schouls & Van der Heide, 2012). MT 
types for MLVA2, and MLVA4 was manually assigned from our own database. Van 
Cuyck et al. (2012) did not provide a database or published MLVA2 types that could be 
used in the Queensland pneumococcal population.  
The pneumococcal population structure using MLVA1, MLVA2 and MLVA4 were 
displayed as eBurst diagrams produced from PHYLOViZ software (Francisco et al., 
2012). The eBurst diagram attempts to represent the possible evolutionary 
relationships between strains identified by allelic profiles, including the ability to 
overlay information data (e.g. serotype, geographic location) on the analysis algorithm 
results (Francisco et al., 2012). Clonal complexes (CC) are defined as two or more 
isolates that are genetically related according to their genotypes and linked by single 
locus variants (SLV) or double locus variants (DLV). The programme can expand to 
include triple locus variants (TLV) if required since when using MLST, a difference of 
three or more in the ST (out of seven) indicates a distinctly different clone (McGee et al., 
2001). Founding genotypes are identified by the eBurst model and is based on the 
genotype or ST with the most SLV links. Where an international or larger database is 
available, Queensland isolates were compared so as to be more confident of a founder 
assignment.  
MLST sequences for each of the seven housekeeping genes were analysed using 
ChromasPro v1.6 software (Technelysium Pty Ltd.) and ClustalW batch alignment 
analysis. Template sequences available from the MLST database (www.mlst.net) were 
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used to shave down the fragment size to the correct length for submission to the MLST 
database. An allele number was assigned to each housekeeping gene from the MLST 
database based on the unique SNPs within each sequence. The combination of seven 
allele numbers (one for each housekeeping gene) was compiled and submitted to the 
MLST database to provide the sequence types (ST). The Queensland pneumococcal 
sequence types were displayed as an eBurst diagram using PHYLOViZ software. 
The Simpson’s Index of Diversity (S) was calculated to compare the 
discriminatory powers of the MLVA1, MLVA2, MLVA4 and MLST methods 
(http://darwin.phyloviz.net/ComparingPartitions/index.php?link=Tool). If the 95% 
confidence intervals (CI) overlapped between methods, the hypothesis that the 
methods had similar discriminatory power could not be excluded. The Adjusted 
Wallace coefficient (AW) was used to measure the congruence between typing methods 
(Severiano et al., 2011; Wallace, 1983). The Adjusted Wallace coefficient provides an 
“effective comparison of the results of different molecular typing studies, providing a 
better evaluation of the strengths and weaknesses of each study and of each typing 
method” (Severiano et al., 2011) whereas Simpson’s Index of Diversity is simply a 
measurement of diversity in a given population. 
The frequency of non-amplified loci (‘99’) was compared between each MLVA 
method to determine whether this was a limitation of a particular method or associated 
with specific serotypes. Hunter-Gaston Diversity Index (DI) (http://www.hpa-
bioinformatics.org.uk/cgi-bin/DICI/DICI.pl) was used to calculate the genetic diversity 
of VNTR genes within the Queensland population (Platt, 2015). DI is a measure of the 
variation of the number of repeats at each locus, ranging from 0.0 (no diversity) to 1.0 
(complete diversity) (Hunter & Gaston, 1988).  
3.5 Ethics statement 
Ethical clearance was not required for this study since patient information such 
as birth date, gender, race or location has not been examined. This epidemiology study 
only examines the S. pneumoniae isolates, changing genotypes and pneumococcal 
population structure within Queensland. Pneumococcal isolates were labelled with a 
coded number so that the original identification number could not be traced back to a 
particular patient. 
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4.1 Introduction 
To combat the changing pneumococcal population, the 13vPCV was introduced 
in Australia in July 2011, targeting an extra six S. pneumoniae serotypes that were not 
targeted by the original 7vPCV childhood vaccine (Selvey, 2011). So far, there have 
been few published studies examining the pneumococcal population structure in 
Australia since the introduction of 13vPCV, and no studies examining Queensland 
isolates (Johnson et al., 2012). For decades, serotyping pneumococci with antisera, such 
as the Quellung reaction, has been used for surveillance of serotype distribution and 
serotype replacement (Statens Serum Institut, 2013). However serotyping methods are 
expensive, laborious, sometimes ambiguous, and reveals no information about genetic 
recombination and capsule switching. Therefore several genotyping methods have 
since developed. 
Commonly, MLST is used to genotype S. pneumoniae based on the original 
technique involving housekeeping genes developed by Enright and Spratt (1998). 
However, MLST is expensive and laborious, not suitable for large-scale genotyping or 
routine use (Elberse et al., 2011a; Koeck et al., 2005; Schouls & Van der Heide, 2012; 
Hermans et al., 1995; Malachowa et al., 2005). To reduce cost and labour intensity, 
MLVA was developed for genotyping S. pneumoniae. It is reported to be more 
discriminatory, inexpensive and faster than MLST, however more suitable for short-
term epidemiology changes and localised outbreaks (Elberse et al., 2011a; Koeck et al., 
2005; Van Cuyck et al., 2012).  
Different MLVA protocols exist including Koeck’s et al. (2005) MLVA that 
amplifies seventeen VNTRs, each in a singleplex PCR. This technique was used to 
genotype pneumococcal isolates in Burkina Faso (Yaro et al., 2006). Recently this 
protocol has been modified by Van Cuyck et al. (2012) by reducing the number of 
VNTRs to seven, a number that was experimentally determined to have the highest 
discrimination (Hunter-Gaston Diversity >0.8) within a population of 331 UK isolates 
(pre-7vPCV). This seven marker MLVA is claimed to be a minimum universal set, ideal 
for genotyping pneumococcal isolates. However it is known that pneumococcal 
populations differ between countries, therefore the selection of these seven MLVA 
markers may not be suitable for typing Australian isolates. These seven MLVA markers 
will be tested in this study. 
Another MLVA protocol was developed by Elberse et al. (2011a), that utilises 
eight BOX VNTR loci amplified in two multiplex PCRs with fluorescently labelled 
probes. BOX fragments contain varying numbers of boxB repeat regions found between 
boxA and boxC which remain stable under laboratory conditions (Figure 7) (Elberse et 
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al., 2011a; Martin et al., 1992). Elberse’s MLVA protocol has been applied to genotype 
pneumococci in the Netherlands, and has been used in England to track a localised 
outbreak of serotype 5 (Pichon et al. 2010). However, a limitation of this MLVA method 
is that approximately 25% of BOX loci fail to amplify (assigned ‘99’) therefore leaving 
profiles incomplete, an issue that remains unresolved. It is unknown why BOX loci are 
failing to amplify but we hypothesise that these amplification failures may be of one of 
two reasons, 1) that primers are unable to anneal to the primer-binding site due to 
mutations in the S. pneumoniae genome, or 2) the BOX element is no longer present at 
all.  Only sequencing of unusual size fragments have been reported (Elberse et al., 
2011a). 
Figure 7: Three S. pneumoniae strains demonstrate the difference between BOX repeats 
for BOX-01 used in the MLVA method. boxA and boxC genes are conserved between all S. 
pneumoniae strains. 
 
A number of theories and hypothesis for the function of BOX elements have been 
suggested. BOX loci are located in regions between promoters and the first downstream 
gene. They are presented at the 5’ end of transcripts and are therefore thought to be 
involved in regulation of these genes (Knutsen et al., 2006; Martin et al., 1992). Most 
BOX elements have been located near virulence genes such as neuA, which encodes one 
of two neuraminidase, a putative pneumococcal virulence factor (Camara et al., 1991; 
Martin et al., 1992), and ply, which encodes pneumolysin (Walker et al., 1987), or genes 
involved in gene transformation such as comA, which is required for induction of 
competence for genetic transformation (Hui & Morrison, 1991; Martin et al., 1992) 
hexB, which is required for Hex mismatch repair system (Martin et al., 1992; 
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Prudhomme et al., 1989) and mmSA which is involved in recombination (Martin et al., 
1992).  
BOX loci can also form stable stem-loop structures which is functionally 
important as it could moderate the expression of neighbouring genes (Knutsen et al., 
2006). Secondary structure rather than the orientation of the BOX element is thought to 
be more important (Knutsen et al., 2006). It is also possible that BOX can stimulate the 
expression of downstream genes by increasing the half-life of mRNA, which is stabilised 
by 5’ stem-loop structure (Martin et al., 1992).  
BOX elements have also been thought to play a role in transcription termination 
since approximately 3 times more BOX elements are located between genes orientated 
3’ to 3’ than genes orientated 5’ to 5’ (Hoskins et al., 2001). Specifically, boxB modules 
are thought to have inhibitory effects depending on the orientation, for example a 
forward orientated boxB residing at 5’ end of transcript down regulates the expression 
of co-transcribed genes (Knutsen et al., 2006). BOX elements may also enhance gene 
expression by stabilising mRNAs (Hoskins et al., 2001). As well as this it has been 
investigated whether BOX loci regulate the level of expression of early competence 
(com) genes qsrAB and comAB, which are important for genetic transformation 
(Knutsen et al., 2006). ComAB encodes and ABC transporter (comA) and its accessory 
protein comB. BOX elements at the 5’ end transcript enhanced the expression of qsrAB, 
which encodes an ABC transporter with unknown function (Martin et al., 1992). Also 
BOX elements were shown to have a strong positive effect on lacZ expression when a 
lacZ was artificially introduced in pneumococci immediately downstream of a specific 
promoter (Knutsen et al., 2006). The authors observed effects in CSP-induced 
expression, however had lacZ been inserted elsewhere, other effects might have been 
seen. 
Despite the uncertainty of the specific functions of these genes, BOX elements 
have long been recognised as a potential means for genotype classification. Hermans et 
al. (1995) determined that BOX fingerprinting (different technique to MLVA but still 
utilises BOX loci) was restricted to only S. pneumoniae since the BOX probes used in the 
experiment did not hybridise to 15 other Gram-positive bacteria. Likewise Van Belkum 
et al. (1996) and Koeuth et al. (1995) verified boxB typing with a single oligonucleotide 
primer was restricted to S. pneumoniae and some other streptococci. This may possibly 
be useful to limit the environmental contamination of other bacteria since BOX probes 
will not bind and amplify them. BOX typing by probe fingerprinting and by PCR 
fingerprinting has been claimed to be an accurate technique for typing pneumococcal 
strains since it provides a high degree of discrimination (Hermans et al., 1995; Van 
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Belkum et al., 1996). Hermans et al. (1995) demonstrated that BOX fingerprinting could 
be used to classify 21 types out of 28 isolates, and shows that it had a higher 
discriminatory power than PFGE, ribotyping, PCR fingerprinting and serotyping. 
Despite using a different method, this does indicate that the use of BOX loci can be 
highly discriminatory. BOX-PCR is less reliable as it produces a multi-band pattern of 
“added polymorphisms of multiple BOX elements” (Koeck et al., 2005). MLVA however 
analyses each BOX locus separately (Koeck et al., 2005). 
Finally, Rakov et al. (2011) developed Multi-Locus boxB Typing (MLBT), a 
variation of MLVA by sequencing VNTR loci to detect Single Nucleotide Polymorphisms 
(SNPs) as well as fragment length variations. MLBT contains VNTRs that have been 
used in the other MLVA protocols, however the complexities of MLBT does not enable 
ease of comparison with other MLVA methods (Elberse et al., 2011a; Koeck et al., 2005; 
Rakov et al., 2011). These complexities come out of the fact that VNTRs are sequenced, 
and pneumococcal profiles are based on SNPs within these sequences.  
The aim of the present study was to generate a fast, inexpensive and highly 
discriminatory MLVA method (hereby called MLVA4) for genotyping invasive S. 
pneumoniae in Queensland. The objective of developing MLVA4 was to ensure that it 
would provide a more accurate reflection of the S. pneumoniae population structure 
compared to MLST and previously published MLVA methods. As there is no nationally 
accepted MLVA technique for S. pneumoniae, previously published MLVA methods were 
used for comparison, as well as MLST. 
4.2 Methods 
4.2.1 Laboratory methods 
MLVA markers were selected from Elberse et al. (2011a) (BOX-01, BOX-02, 
BOX-03, BOX-04a, BOX-04b, BOX-06a, BOX-06b, BOX-11, BOX-12 and BOX-13), Koeck et 
al. (2005) (Spneu17, Spneu19, Spneu27, Spneu31, Spneu39), Van Cuyck et al. (2012) 
and Rakov et al. (2011) (B10). In this study, four primer sets were redesigned due to 
difficulties in amplification, including BOX-12 (F: 5’-GAGATTGCCCTTTTCATCTTCG-3’; 
R: 5’-AGCAACCATTGAAACGCCTG-3’), BOX-13 (F: 5’-TCAAAAGATTGGAGAGTTCCGC-3’; 
R: 5’-GGATTTGGAGAGCAAGCAGATC-3’), Spneu19 (F: 5’-
CACTCACCGTTAGCATTGACTCG-3’; R: 5’-TAATCAGGGAGTAGTTGGTTGGG-3’) and B10 
(F: 5’-GGAGCCGAGTAGGAGATTCTCAC-3’; R: 5’-TCGTAGGCTGCTACATTGACCAG-3’) 
(Geneworks, Australia). All MLVA markers were analysed in silico using nBlast and the 
Tandem Repeat Finder algorithm to determine the expected fragment sizes and copy 
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numbers against five known S. pneumoniae genomes (R6, G54, CGSP14, TIGR4 and 
Hungary19A-6) from the NCBI database. 
Elberse’s MLVA1 contained two multiplexes with eight BOX elements (Elberse 
et al., 2011a). The MLVA2 procedure was based on Van Cuyck’s MLVA method and 
contained seven VNTRs (Spneu17, Spneu19, Spneu25, Spneu27, Spneu33, Spneu37 and 
Spneu39). A single multiplex reaction was performed with Spneu17, Spneu19, Spneu27 
and Spneu39 as the other three had already been typed in MLVA1. Spneu31 and B10 
were separately amplified to determine whether they provided high discrimination 
within the pneumococcal population, and therefore suitable for the modified MLVA 
method. 
Hence, MLVA4 was the modified MLVA method based on the discrimination of 
the fourteen loci previously used, and the ability to amplify all loci across 35 different 
serotypes detected in Queensland. Three multiplexes were developed with primers 
BOX-01, BOX-02, BOX-03, BOX-04, B10, BOX-12, BOX-13, Spneu17, Spneu19 and 
Spneu39. The loci used in each multiplex reaction are presented for each of the MLVA 
typing methods (Table 8). 
Table 8: The Multiplex arrangement of VNTR loci in each MLVA method used in this study. 
Genotyping method Multiplex # Loci Reference 
MLVA1 1 BOX-01, BOX-02, BOX-03, BOX-04 Elberse et 
al., 2011a 2 BOX-06, BOX-11, BOX-12, BOX-13 
MLVA2 1 Spneu17, Spneu19, Spneu27, 
Spneu39 
Van Cuyck 
et al., 2012 
2 Spneu25, Spneu33, Spneu37 
MLVA4 1 BOX-01, B10, Spneu19, Spneu39 This study 
2 BOX-12, BOX-13 
3 BOX-02, BOX-03, BOX-04, 
Spneu17 
 
MLVA genotyping was performed as described in Chapter 3. The MLVA4 method 
initially was applied to three S. pneumoniae control strains with known MLVA profiles 
for all loci. A further 170 isolates, covering all 35 serotypes detected in Queensland 
from 2007-2012 were genotyped using MLVA4 for validation, before a further 144 
isolates (total of 317 isolates) were also genotyped using MLVA4. The MLVA4 method 
has novel aspects as four sets of primers and the three multiplex PCR has been newly 
designed in this study. 
Finally, MLST was also applied to 202 selected isolates for comparison purposes 
using the Corbett Cas1200 Robotics (Qiagen, Germany) for automation (Enright & 
Spratt, 1998; Jefferies et al., 2003). Isolates selected for MLST included 13vPCV 
serotypes (except serotype 19A) and non-13vPCV serotypes to minimise labour and 
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costs, but also to allow examination of changes in these recently targeted or non-
targeted serotypes. 
4.2.2 Analysis 
MLVA results were analysed using PeakScanner V1.0 software (Applied 
Biosystems, Australia). A MLVA type (MT) was assigned to each pneumococcal isolate 
depending on the MLVA protocol – refer to Chapter 3. The pneumococcal population 
structure using MLVA1, MLVA2 and MLVA4 were displayed as eBurst diagrams 
produced from PHYLOViZ software (Francisco et al., 2012).  
MLST results were analysed using ChromasPro software (Technelysium Pty Ltd.) 
using batch alignment analysis. Allele numbers and sequence types (ST) were assigned 
to each isolate from the MLST database (www.mlst.net) and displayed as an eBurst 
diagram using PHYLOViZ software. 
Simpson’s Index of Diversity (S) was calculated to compare the pneumococcal 
population discrimination when using MLVA1, MLVA2, MLVA4 and MLST methods 
(http://darwin.phyloviz.net/ComparingPartitions/index.php?link=Tool). The Adjusted 
Wallace coefficient (AW) was used to measure the congruence between typing methods 
(Severiano et al., 2011; Wallace, 1983).  
The frequency of non-amplified loci (‘99’) was compared between each MLVA 
method to determine whether this was a limitation of a particular method or associated 
with specific serotypes. Hunter-Gaston Diversity Index (DI) (http://www.hpa-
bioinformatics.org.uk/cgi-bin/DICI/DICI.pl) was used to calculate the genetic diversity 
of VNTR genes within the Queensland population (Hunter & Gaston, 1988).  
4.3 Results 
All 317 S. pneumoniae Queensland isolates in this study were assigned an MLVA 
genotype, covering all 35 serotypes detected in Queensland from 2007-2012. The 
MLVA4 method has novel aspects as four sets of primers and the three multiplex PCRs 
have been newly designed in this study. Isolates selected for MLST comparison 
included 13vPCV serotypes (excluding those originally in the 7vPCV i.e. serotype 4, 6B, 
9V, 14, 18C, 19F and 23F, and excluding serotype 19A) and non-13vPCV serotypes to 
minimise labour and costs. Studies have already shown that a number of 7vPCV 
serotypes have significantly declined, so this study focused on the examination of these 
recently targeted or non-targeted serotypes.  
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In early experimental stages, amplification of MLST sequences and MLVA1 
fragments were verified using gel electrophoresis (Figure 8 and Figure 9, respectively). 
Strong amplification of all seven housekeeping genes is observed for MLST. When 
observing the MLVA multiplexes, some isolates only have three bands observed rather 
than four, however it is possible that some bands have similar fragment size and 
therefore cannot be distinguished using gel electrophoresis. This can be observed in 
Figure 10.  
Figure 8: Quantitative gel electrophoresis and amplification check of MLST genes in S. 
pneumoniae. 
The Low Marker DNA Ladder (LMDL) is used as a comparison to determine the quantity of 
amplified housekeeping genes. The seven housekeeping genes are shown to successfully amplify 
for S. pneumoniae isolates (ID for S. pneumoniae isolate is above each lane). S. pneumoniae 
control 1, C1; S. pneumoniae control 2, C2. 
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Figure 9: Gel electrophoresis of MLVA1 – multiplex 2 applied to S. pneumoniae isolates.  
Multiplex 2 contains BOX-06, BOX-10, BOX-11 and BOX-12. S. pneumoniae isolates ID 1-13 have 
been used to show the amplification of the four BOX loci. A negative control is included in lane 
14 and a DNA ladder 123bp in the final lane. Negative control, -ve. Positive control 1 (serotype 
19F). 
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Figure 10: MLVA4 applied to three S. pneumoniae isolates. 
S. pneumoniae isolates are listed above each grouping with respective serotype in brackets. 
Master Mix (MM) lane contains all four loci (BOX-10, BOX-12, BOX-13 and Spneu19) and the 
respective BOX-10 (B10), BOX-12 (B12), BOX-13 (B13) and Spneu19 (S19) singleplex in 
following lanes. A DNA marker ladder 123bp and 100bp is present in lane 1 and lane 20, 
respectively. It is unknown why B12 for isolate 173 is not appearing in the MM, although it is 
hypothesised that it could be due to faint amplification or primer dimers in MM. 
 
 
Furthermore, Multiplex Manager was used to determine the best combination of 
MLVA primer in the minimum number of multiplexes. The results indicated that three 
multiplex would be optimal for amplifying all 10 VNTRs with the minimum number of 
reactions (Figure 11). 
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Figure 11: Multiplex Manager shows the grouping of 10 VNTRs into three multiplexes for 
MLVA4. 
 
 
Using Microsoft Excel software, a database was generated containing all the 
MLVA fragment sizes as analysed by PeakScanner. The fragment sizes were interpreted 
into tandem repeats (Table 9) and the combination of fragment sizes provided the 
allele code for each fragment (Figure 12).  
Table 9: Size alleles for each BOX locus, assigned according to the fragment size that is 
identified by the DNA sequencer for MLVA4. 
BOX locus Allele Size BOX locus Allele Size 
BOX-01 0 237.0 BOX-12 (new) 0 472.0     NEW 
45bp consensus size 1 280.0 45bp consensus size 1 517.0 
 2 325.0  2 562.0 
 3 370.0  3 607.0 
 4 415.0  4 652.0 
 5 460.0  5 697.0 
 6 505.0  6 742.0 
 7 550.0  7 787.0 
 8 595.0  8 833.0 
 9 639.7  9 877.0 
 10 685.6  10 922.0 
 11 731.9  11 967.0 
 12 775.3  12 1012.0 
BOX-02 0 279.0 BOX-13 (new) 0 389.0 
45bp consensus size 1_01 286.0 45bp consensus size 1 434.0 
 1 322.5  2 479.0 
 2_01 330.0  3 524.0 
 2_02 359.0  4 569.0 
 2 366.0  5 614.0 
 3 411.0  6 659.0 
 4 454.5  7 704.0 
 5 499.0  8 749.0 
 6 545.2  9 794.0 
BOX-03 1 393.0  10 839.0 
45bp consensus size 2 435.4  11 884.0 
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BOX locus Allele Size BOX locus Allele Size 
 3 480.0  12 929.0 
 4_01 490.0 Spneu17 0 75.0 
 4 525.0 45bp consensus size 1 120.0 
 5 570.0  2 165.0 
 5_01 578.0  3 210.0 
 6 614.3  4 255.0 
 7 657.0  5 300.0 
 8 702.0     NEW  6 345.0 
 8_01 732.0  7 390.0 
 9 747.0  8 435.0 
 9_01 753.0  9 480.0 
 10 789.0  10 525.0 
 11 834.0  11 570.0 
 12_01 860.7  12 615.0 
 12 879.0  13 660.0 
 13 918.0  14 705.0 
 14 963.0  15 750.0 
 15 1003.2 Spneu19 (new) 0 122.0 
 16 1048.8 60bp consensus size 1 182.0 
BOX-04 0 189.0  2 242.0 
45bp consensus size 1 234.9  3 302.0 
 2 279.5  4 362.0 
 3 325.6  5 422.0 
 4 370.1  6 482.0 
 5 415.2  7 542.0 
 6_01 453.8  8 602.0 
 6 459.3  9 662.0 
 7 504.6  10 722.0 
 8 548.3  11 782.0 
 9 595.3  12 842.0 
 10 638.3     NEW BOX-39 0 222.0 
 11 683.3     NEW 45bp consensus size 1 267.0 
 12 728.3     NEW  2 312.0 
BOX-10 (new) 0 420.0  3 357.0 
45bp consensus size 1 465.0  4 402.0 
 2 510.0  5 447.0 
 3 555.0  6 492.0 
 4 600.0  7 537.0 
 5 645.0  8 582.0 
 6 690.0  9 627.0 
 7 735.0  10 672.0 
 8 780.0  11 717.0 
 9 825.0  12 762.0 
 10 870.0    
 11 915.0    
 12 960.0    
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Figure 12: Example of MLVA1 fragment sizing as recorded in Microsoft Excel program.  
The isolate ID is presented as QRRJS # followed by the serotype below. Multiplex 1 and 2 
represent the two multiplexes used in MLVA1. The fluorescent markers are colour-coded for 
each BOX locus (e.g. FAM is blue for BOX-01 and BOX-13). ‘Size’ of the fragment (bp) is recorded 
from the DNA sequencer, followed by the ‘height’ of each fluorescent peak. The ‘MLVA size’ is 
determined from the MLVA database, which is the closest to the fragment ‘size’ recorded. From 
this the ‘allelic profile’ is assigned to each fragment size based from the MLVA database. 
MLVA Protocol 
1 Isolate
Serotype
Multiplex
Size Height MLVA size Allelic profile Size Height MLVA size Allelic profile
FAM (1, 13) 0 0 99 473.9 8292 476.1 4
NED (2, 6) 365.1 8740 366 2 284 1740 289 2
VIC (3, 11) 611 8849 614.3 6 548.2 3227 549.7 1
PET (4, 12) 726.4 1050 728.3 12 469.8 7179 471 0
88 Isolate
Serotype
Multiplex
Size Height MLVA size Allelic profile Size Height MLVA size Allelic profile
FAM (1, 13) 458.3 8322 460 5 475 8293 476.1 4
NED (2, 6) 410.3 8636 411 3 284 1261 289 2
VIC (3, 11) 523.3 8978 525 4 547.3 3985 549.7 1
PET (4, 12) 367.7 7510 370.1 4 559.6 2386 562.3 2
89 Isolate
Serotype
Multiplex
Size Height MLVA size Allelic profile Size Height MLVA size Allelic profile
FAM (1, 13) 458.3 2306 460 5 475.3 8231 476.1 4
NED (2, 6) 410 4517 411 3 283.9 2151 289 2
VIC (3, 11) 523.3 3142 525 4 547.2 7553 549.7 1
PET (4, 12) 367.6 3692 370.1 4 559.6 4396 562.3 1
90 Isolate
Serotype
Multiplex
Size Height MLVA size Allelic profile Size Height MLVA size Allelic profile
FAM (1, 13) 324 3259 325 2 518.1 4142 521.3 5
NED (2, 6) 409.7 1822 411 3 335.7 1884 334 3
VIC (3, 11) 435.6 2765 435.4 2 547.3 2775 549.7 1
PET (4, 12) 367.5 825 370.1 4 782.6 134 784.1 7
QRRJS 90
1
1 2
QRRJS 89
19A
1 2
QRRJS 88
19A
1 2
QRRJS 1
19F
1 2
 
 
All three MLVA genotyping methods had a higher discriminatory power 
compared to MLST when examining Simpson’s Index of Diversity (s) (Table 10). MLVA4 
had the highest discrimination of S=0.990 with 203 MLVA types (n=317) when 
compared to the other two MLVA techniques (MLVA1 S=0.984, and MLVA2 S=0.987); 
however given that the 95% CI overlap between MLVA1, MLVA2 and MLVA4, the 
Simpson Index of Diversity is not significantly different, or in other words, the diversity 
is comparable. MLVA4 also had a significantly higher discriminatory power S=0.978 
with 106 MLVA types (n=202) when compared to MLST method (n=202). In 
comparison, MLVA1 had a discrimination of S=0.963 (n=202; 71 MLVA types) and 
MLVA2 with S=0.977 (n=202; 97 MLVA types), both comparable to MLVA4 as 95% CI 
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overlap between all three MLVA methods. MLST had the lowest discrimination of 
S=0.936 and 49 STs (n=202). When examining MLVA1, 20.2% of isolates still contain at 
least one non-amplified locus. Even MLVA2 contained 21.1% of isolates with non-
amplified loci. MLVA4 method reduces the ‘99’ to 12.6%. 
Table 10: Calculation of Simpson’s Index of Diversity for serotyping (Quellung), MLST, 
MLVA1, MLVA2 and MLVA4 methods. 
Total Number of S. pneumoniae isolates = 202 
Molecular 
method 
Total 
number of 
genotypes 
Simpson’s 
Index of 
Diversity (S) 
CI (95%) Average 
time to 
genotype 
48 isolates 
(days) 
Cost per 
isolate (PCR 
to 
genotype) 
(AUS$) 
Non-
amplified 
loci (%) 
Serotyping 29 0.912 0.893-
0.930 
- - N/A 
MLST 49 0.936 0.920-
0.952 
16-20 346.65  N/A 
MLVA1 71 0.963 0.953-
0.974 
3-4 17.10  20.8  
MLVA2 97 0.977 0.970-
0.985 
3-4 16.37  24.3  
MLVA4 106 0.978 0.971-
0.986 
3-4 23.71  12.4  
Total Number of S. pneumoniae isolates = 317 
Serotyping 35 0.914 0.897-
0.932 
- - N/A 
MLVA1 163 0.984 0.980-
0.989 
3-4 17.10  20.2 
MLVA2 175 0.987 0.983-
0.991 
3-4 16.37  21.1 
MLVA4 203 0.990 0.987-
0.994 
3-4 23.71  12.6 
 
However, when comparing the Adjusted Wallace Coefficient of MLVA4 with the 
other two MLVA methods, all MLVA methods had similar discriminatory powers (Table 
11). It indicates that MLVA4 has high congruence with MLVA1 (AW = 0.883), MLVA2 
(AW = 0.766) and MLST (AW = 0.966). This indicates that the MLVA4 genotypes will 
have a 96.6% probability that it will have the same MLST type. Conversely, the 
congruency of MLST with MLVA4 (AW = 0.314) indicates that the MLST types will have 
a 31.4% probability of having the same MLVA4 type, indicating that MLVA4 is more 
discriminatory. 
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Table 11: Adjusted Wallace Coefficient with 95% confidence intervals (CI) for four 
genotyping and one serotyping method applied to invasive S. pneumoniae. 
Total number of S. pneumoniae isolates = 202 
Typing method MLVA1 MLVA2 MLVA4 Serotyping MLST 
MLVA1  0.524 (0.461-
0.5287) 
0.512 (0.442-
0.582) 
0.940 (0.891-
0.989) 
0.984 (0.974-
0.995) 
MLVA2 0.871 (0.800-
0.942) 
 0.739 (0.667-
0.810) 
0.880 (0.804-
0.956) 
0.916 (0.887-
0.945) 
MLVA4 0.883 (0.823-
0.942) 
0.766 (0.690-
0.843) 
 0.918 (0.842-
0.994) 
0.966 (0.927-
1.000) 
Serotyping 0.372 (0.301-
0.442) 
0.209 (0.157-
0.262) 
0.211 (0.161-
0.260) 
 0.648 (0.587-
0.709) 
MLST 0.552 (0.456-
0.648) 
0.309 (0.244-
0.374) 
0.314 (0.254-
0.374) 
0.919 (0.869-
0.969) 
 
 
New MLVA1 BOX alleles were also found with varying numbers of repeats 
including BOX-04 fragment sizes with 10 repeats (n=1), 11 repeats (n=1) and 12 
repeats (n=3), BOX-03 fragment size 8 repeats (n=2), BOX-12 fragment size 0 repeats 
(n=2) and BOX-13 fragment size >2000bp (unsure how many repeats until sequenced; 
n=8). There are 107 new MLVA1 type (MT) types not recorded by the MLVA database 
(Schouls & Van der Heide, 2012). The BOX lengths for MLVA4 were previously 
calculated (Table 9). A total of 219 MLST types were submitted to the MLST 
international database (id # 23211 – 23429) of which 19 isolates had new MLST types 
(Table 12). 
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Table 12: New pneumococcal MLST genotypes identified in Queensland from 2007 to 
2012. 
The MLST genotypes were submitted to the MLST international database for assignation of the 
new sequence types. Sequence type, ST; Australia, AUS; Queensland, QLD. 
ST 
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8969 2 13 4 1 9 19 14 QRRJS20 AUS 6C QLD 2007 
9673 26 1 2 14 9 16 19 QRRJS275 AUS 3 QLD 2007 
9662 2 40 17 19 10 1 27 QRRJS281 AUS 10A QLD 2007 
9671 25 13 4 16 6 1 17 QRRJS283 AUS 10A QLD 2007 
9665 5 43 6 1 9 127 18 QRRJS220 AUS 34 QLD 2008 
9670 18 12 4 44 9 77 97 QRRJS221 AUS 35B QLD 2008 
9672 25 31 17 16 32 1 44 QRRJS263 AUS 18A QLD 2008 
9664 5 5 9 9 6 1 19 QRRJS144 AUS 23B QLD 2009 
9661 2 8 62 16 6 19 309 QRRJS170 AUS 10F QLD 2009 
9673 26 1 2 14 9 16 19 QRRJS11 AUS 3 QLD 2010 
9663 2 264 29 18 42 395 18 QRRJS143 AUS 22F QLD 2011 
9666 7 41 47 16 6 1 44 QRRJS52 AUS 15C QLD 2011 
9664 5 5 9 9 6 1 19 QRRJS6 AUS 23B QLD 2011 
9082 25 31 4 16 32 1 44 QRRJS96 AUS 18A QLD 2011 
9082 25 31 4 16 32 1 44 QRRJS290 AUS 18A QLD 2012 
9668 10 11 10 1 6 8 1 QRRJS335 AUS 11A QLD 2012 
9669 10 41 2 6 10 3 1 QRRJS336 AUS 15B QLD 2012 
9660 1 8 9 2 6 20 6 QRRJS363 AUS 23B QLD 2012 
9667 8 5 27 5 1 1 1 QRRJS375 AUS 16F QLD 2013 
4.3.1 VNTR loci and ‘99’ 
A Hunter-Gaston Diversity Index (DI) indicated that BOX-01, BOX-04, BOX-12, 
BOX-13 and Spneu17 had the highest diversity (DI ≥ 0.80) while BOX-02, BOX-11, 
Spneu19 and Spneu27 had the lowest diversity (DI ≤ 0.66) (Table 13). BOX-02 had low 
discriminatory power and was used in MLVA4 as an anchor marker. Spneu19 was used 
in MLVA4 because it had highest discrimination for specific serotypes such as serotype 
8, 18A and 18C (Table 14). A graphical representation of the different alleles for each 
locus is provided in Appendix A3: Graphical representation of the diversity of MLVA genes 
in S. pneumoniae. In this study ‘99’ was assigned to VNTR loci that failed to amplify. In 
particular, BOX-06, BOX-13 and Spneu19 resulted in the most ‘99’ even after singleplex 
PCR. Singleplex PCR resolved >70% of BOX-02, BOX-03 and BOX-12 that previously 
didn’t amplify. Singleplex PCR follows the same protocol as multiplex PCR, however 
only one VNTR locus is amplified per reaction.  
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Table 13: The Hunter-Gaston Diversity for all selected MLVA loci used in this study 
(n=317 S. pneumoniae isolates) and frequency of non-amplified loci ‘99’.  
The respective MLVA method that the loci were included in is shown followed by the Hunter-
Gaston Diversity (DI) and the 95% confidence interval (CI). The number of alleles for each locus 
(K) is listed. The number of non-amplified loci is shown before and after singleplex 
amplification, and the identification of specific serotypes that contain non-amplified loci even 
after singleplexing is shown.  
MLVA 
method 
locus is 
used in 
Locus DI CI Size of 
tandem 
repeat 
(bp) 
K # non-
amplified 
loci before 
singleplex 
# non-
amplified 
loci after 
singleplex 
Non-
amplified 
serotypes 
(#) 
MLVA2, 
MLVA4 
Spneu17 0.853 0.840 – 
0.866 
45 12 6 0 - 
MLVA1, 
MLVA2, 
MLVA4 
BOX-13 0.821 0.806 – 
0.836 
45 10 23 13 33F (5); 6C 
(7); 19F 
(1) 
MLVA1, 
MLVA2, 
MLVA4 
BOX-12 0.805 0.778 – 
0.833 
45 13 89 4 3 (3); 23B 
(1) 
MLVA1, 
MLVA4 
BOX-01 0.801 0.785 – 
0.817 
45 10 11 4 19F (3), 
33B (1) 
MLVA1, 
MLVA4 
BOX-04 0.797 0.771 – 
0.823 
45 12 7 0 - 
MLVA2, 
MLVA4 
Spneu39 0.794 0.775 – 
0.812 
45 10 0 0 - 
MLVA1, 
MLVA4 
BOX-03 0.789 0.754 – 
0.824 
45 14 28 0 - 
MLVA4 BOX-10 0.784 0.748 – 
0.821 
45 11 54 4 15C (2); 
19A (2) 
 Spneu31 0.729 0.696 – 
0.762 
45 11 7 2 14 (1); 
18A (1) 
MLVA1, 
MLVA2 
BOX-06 0.696 0.653 – 
0.739 
45 8 53 31 7F (26); 
19A (4); 
19F (1) 
MLVA2, 
MLVA4 
Spneu19 0.663 0.632 – 
0.694 
60 9 24 16 3 (12); 38 
(4) 
MLVA1, 
MLVA4 
BOX-02 0.651 0.628 – 
0.674 
45 5 1 0 - 
MLVA2 Spneu27 0.637 0.601 – 
0.674 
45 8 13 3 18A (1); 
22A (1); 
23B (1) 
MLVA1 BOX-11 0.392 0.341 – 
0.443 
45 3 14 7 19A (2); 
6A (2); 6C 
(1): 15C 
(2) 
 TOTAL - - - - 330 121  
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For further interest, the number of VNTRs was collated to determine which 
VNTR loci had the highest discrimination within each of the 30 serotypes found in 
Queensland (Table 14). This was used to aid in the selection of highly discriminatory 
loci for the MLVA4 method, based on the discriminatory value within each serotype. 
Some pneumococcal serotypes were few in number in the Queensland population; 
therefore there may be more variance than detected here. 
Table 14: Assignation of the VNTR allele for each S. pneumoniae serotype from this study.  
A total of 30 serotypes that were detected in Queensland are presented, followed by the number 
of alleles for each VNTR locus. For example, this study detected 4 alleles of BOX-01 in serotype 3, 
but only 1 allele in serotype 1. Yellow highlighted numbers indicate the BOX loci with the 
highest observed number of polymorphisms for each serotype, e.g. BOX06 and BOX13 had the 
highest observable number of polymorphisms (4 polymorphisms) for S. pneumoniae serotype 1. 
 VNTR Loci used in any MLVA method 
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1 1 2 2 1 4 2 2 3 4 2 2 1 2 2 
3 4 2 1 2 1 4 2 2 4 6 3 1 3 2 
4 4 3 2 3 2 2 1 3 3 2 3 2 2 2 
6A 4 2 5 3 2 3 2 3 5 3 2 2 2 5 
6B 2 1 2 2 2 2 1 2 2 1 2 2 2 2 
6C 2 2 5 4 2 4 3 5 5 6 3 3 5 2 
7F 2 2 2 1 4 7 1 1 1 3 1 1 1 2 
8 1 1 1 2 1 1 1 1 1 1 3 1 1 1 
9N 2 1 2 1 1 3 1 2 1 1 2 2 1 1 
9V 1 2 1 2 2 3 1 3 1 2 1 1 2 2 
10A 2 2 2 3 2 1 2 2 2 2 2 2 2 3 
10F 1 1 1 1 1 2 1 1 1 1 1 1 1 1 
11A 2 2 2 2 2 2 1 2 2 2 1 2 2 2 
12F 1 1 1 1 1 1 1 1 1 1 1 2 1 1 
14 3 2 1 2 2 1 2 3 1 1 2 2 3 1 
15B 2 2 2 5 1 3 2 4 2 1 2 2 1 1 
15C 3 3 2 4 2 3 3 2 3 3 2 2 2 3 
18A 3 2 1 1 1 2 1 1 1 1 3 2 2 1 
18C 1 1 2 1 2 1 1 3 2 1 4 1 1 3 
19A 6 3 8 6 6 7 3 10 5 6 5 7 8 5 
19F 5 5 7 7 3 6 2 6 5 7 4 4 8 5 
22F 1 1 3 3 2 1 2 2 2 2 1 2 1 2 
23A 1 1 1 3 1 2 1 1 1 1 2 1 2 3 
23B 5 3 4 3 2 3 2 6 3 4 4 3 1 3 
23F 3 3 3 2 2 4 2 4 2 3 2 1 3 4 
33F 2 2 1 3 2 4 1 2 3 2 3 7 2 2 
34 1 1 2 2 1 1 2 2 2 1 1 1 2 1 
35B 4 2 3 2 1 1 2 1 1 2 2 1 2 2 
35F 1 1 3 1 1 1 1 1 1 2 2 2 2 2 
38 2 1 2 3 1 2 1 2 1 1 1 1 1 1 
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In total, MLVA1 contained 20.8% isolates with at least one non-amplified gene, 
MLVA2 had 24.3% non-amplified and MLVA4 had the lowest at 12.4% non-amplified. 
These VNTR loci failed to amplify in specific serotypes. BOX-06 failed to amplify in 75% 
of serotype 7F (27 isolates), BOX-13 failed to amplify in 42% of serotype 33F (5 
isolates) and in 54% of serotype 6C (7 isolates), Spneu19 failed to amplify in 63% of 
serotype 3 (12 isolates) and in 50% of serotype 38 (4 isolates), and BOX-01 failed to 
amplify in 20% of serotype 19F isolates (3 isolates) (Table 13). Spneu19 allele 
sequences were not found in serotype 3 genomes using BlastN (strains OXC141, SP3, 
SPN021198, SPN034156, SPN034183, SPN072838, SPN994038 and SPN994039). 
Similarly Spneu19 failed to amplify in serotype 38; however no serotype 38 genome 
has been sequenced to date to allow us to determine whether the Spneu19 locus exists. 
No match was found for BOX-13 in serotype 6C NCBI genomes, and failed to amplify in 
serotype 33F, however gel electrophoresis showed a large >2000bp fragment (Figure 
13). 
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Figure 13: Amplification of >2000bp fragments of BOX-13 in S. pneumoniae serotype 33F 
isolates.  
A 100bp and 123bp DNA marker ladder is shown in lanes 1 and 20, respectively. S. pneumoniae 
serotype 33F ID number is listed above each lane. A negative control was included in lane 19 (-
ve). A white box surrounds the large >2000bp fragment that was detected in eight of the twelve 
S. pneumoniae isolates. 
 
 
Since BOX-06 failed to amplify in 75% of Queensland serotype 7F isolates, we 
verified whether the primers would anneal to the NCBI published genomes. BOX-06 
primers appear to anneal to a serotype 7F contig (CDC 1087-00 contig 
ABFT01000005.1) however the fragment size exceeds 1200bp which would not be 
detected with the AB3130 internal size ladder LIZ1200. Gel electrophoresis did not 
reveal any bands, corresponding to BOX-06 in serotype 7F except for three isolates, two 
of which were very faint bands (Figure 14). 
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Figure 14: Non-amplification of BOX-06 fragments in S. pneumoniae serotype 7F.  
A 123bp DNA marker ladder is shown in the first lane, followed by the S. pneumoniae isolates 
with ID number above each lane. Isolate ID 158 was a positive control S. pneumoniae serotype 
6A with BOX-06 amplification. All isolates in other lanes are serotype 7F, with only isolate ID 22, 
115 and 161 with a positive amplification of BOX-06. A negative control was included in the last 
lane (-ve).  
 
 
4.3.2 Examination of potential VNTR function in NCBI pneumococcal 
genomes 
In silico examination of the S. pneumoniae R6 and TIGR4 strains for positions of 
VNTR loci used in the various MLVA methods was also performed. Location of the 
VNTR loci and their proximities to other transcripts was recorded (Table 15). 
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Table 15: Location of VNTRs in proximity to various proteins and regulators in R6 and 
TIGR4 S. pneumoniae strains.  
Closest transcript to the VNTR is at the top of each list (“Upstream of…” and “Downstream of…”). 
*DNA binding response regulator and sensor histidine kinase work together in a two component 
regulatory system. 
VNTR 
Locus 
Upstream of… Downstream of… 
BOX-01 NP_359231.1 Catabolite control protein NP_359229.2 Anthranilate synthase 
component I 
 NP_359228.1 Anthranilate synthase 
component II 
 NP_359227.1 Anthranilate 
phosphoribosyltransferase 
BOX-02 NP_358159.1 β-galactosidase NP_358158.1 PTS System transporter 
subunit IIC 
 NP_358157.1 Hypothetical protein 
 NP_358156.1 PTS system transporter 
subunit IIA 
BOX-03 NP_359196.1 Aquaporin NP_359195.1 7-cyano-7-deazaguanine 
reductase 
BOX-04 NP_358291.1 hypothetical protein NP_358290.2 methionyl-tRNA 
synthetase 
NP_358292.1 hypothetical protein  
BOX-06 NP_359522.1 histidyl-tRNA synthetase NP_359521.1 hypothetical protein 
BOX-10 NP_358172.1 DNA Binding Response 
Regulator* 
NP_359520.1 transcriptional regulator 
NP_358173.1 Sensor Histidine kinase*  
NP_358174.1 hypothetical protein  
NP_358175.1 zinc metalloprotease (ZmpB)  
NP_358176.1 Para-aminobenzoate 
synthetase 
 
NP_358177.1 Pneumococcal surface 
protein 
 
NP_358172.1 DNA Binding Response 
Regulator 
 
BOX-11 NP_358009.1 formate acetyltransferase NP_358008.1 DNA polymerase IV 
BOX-12 NP_358962.1 transcription elongation 
factor GreA 
NP_358961.2 hypothetical protein 
BOX-13 NP_357687.1 phosphoglycolate 
phosphatase 
NP_357686.1 capsule polysaccharide 
biosynthesis capD 
NP_357688.1 L-serine dehydratase subunit 
alpha 
 
Spneu17 NP_359405.1 Catabolite control protein A NP_359404.1 L-asparaginase 
Spneu19 
(overlaps) 
NP_359536.1 Choline binding protein PcpA  
Spneu27 NP_357850.1 ribosomal small subunit 
pseudouridine 
NP_357849.1 hypothetical protein 
 NP_357848.1 aminopeptidase 
Spneu31 NP_358151.1 ABC transporter ATP-binding 
protein 
NP_358150.1 SOS ribosomal protein L1 
Spneu39 NP_359526.1 dihydroxy-acid dehydratase NP_359525.1 hypothetical protein 
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4.3.3 Comparison of MLVA and MLST eBurst 
Comparison of MLST and MLVA4 eBurst analysis clearly showed two different 
population structures (Figure 15). The pneumococcal population structure is displayed 
according to the MLVA4 genotypes, and it was observed that there are 32 clonal 
complexes (CC), with the larger eleven complexes labelled in the figure. The MLST 
results are overlayed on the MLVA4 results; therefore each colour circle represents a 
different MLST type. It can be seen that several MLVA4 complexes would appear as a 
single MLST type, for example CC1 which predominantly contains serotype 7F isolates 
has as many as ten different MLVA4 types however only one MLST type as depicted by 
the single green colour of the circles. 
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PLEASE SEE FOLLOWING PAGE FOR FIGURE 15. 
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Figure 15: Comparison of MLST genotyping to MLVA4 genotyping (see opposite page).  
Clonal complexes (CC) are circled and contain single locus variants (SLV) and double locus variants (DLV). MLVA4 genotype is presented inside each circle. Size of each 
circle represents the number of isolates detected in this study. Grey circles indicate an MLVA4 type but no MLST type. Coloured circles indicate that an MLST type was 
obtained, and isolates of the same colour have the same MLST type. Circles with split colours indicate that two or more MLST types were obtained for a single MLVA4 
type.
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Using MLVA4 to type strains of S. pneumoniae for localised Queensland studies 
showed that most of the 32 CCs predominantly contained a common serotype (e.g. CC1 
contains serotype 7F, CC4 contains serotype 3). However closer examination of the data 
revealed that some complexes contained more than one serotype. These complexes 
included CC11 (serotypes 19A and 19F), CC8 (serotypes 15B, 15C and 19A), CC9 
(serotypes 18B and 18C), CC10 (serotypes 1 and 4), CC3 (serotypes 6A and 6C), CC12 
(serotypes 8 and 11A), CC13 (serotypes 33F and 22F).  Use of MLST identified most of 
these CCs but many appear as a singleton, meaning only one sequence type was 
observed. 
MLST results were also overlayed with the MLVA1 and MLVA2 results. Both 
MLVA methods were found to be more discriminatory than MLST, as evident by the 
diversification of MLST types into many MLVA types (e.g. CC10 contains at least five 
different MLVA1 types with the same MLST type) (Figure 16 and Figure 17). 
Interestingly, MLVA1 grouped serotypes 1, 3 and 7F into the same complex (CC10) 
according to the genotype profile (Figure 16).  
Similarly, MLVA2 grouped most of the CCs together as isolates appear to be 
single locus variants (SLV) or double locus variants (DLV) of another isolate (Figure 
17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4           Modified MLVA for genotyping Queensland invasive Streptococcus pneumoniae 
113 
 
PLEASE SEE FOLLOWING PAGE FOR FIGURE 16. 
 
CHAPTER 4           Modified MLVA for genotyping Queensland invasive Streptococcus pneumoniae 
114 
 
Figure 16: Comparison of MLST genotyping to MLVA1 genotyping (see opposite page).  
Clonal complexes (CC) are circled and contain single locus variants (SLV) and double locus variants (DLV). MLVA4 genotype is presented inside each circle. Size of each 
circle represents the number of isolates detected in this study. Grey circles indicate an MLVA4 type but no MLST type. Coloured circles indicate that an MLST type was 
obtained, and isolates of the same colour have the same MLST type. Circles with split colours indicate that two or more MLST types were obtained for a single MLVA4 
type. 
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Figure 17: Comparison of MLST genotyping to MLVA2 genotyping (see opposite page).  
Clonal complexes (CC) are circled and contain single locus variants (SLV) and double locus variants (DLV). MLVA4 genotype is presented inside each circle. Size of each 
circle represents the number of isolates detected in this study. Grey circles indicate an MLVA4 type but no MLST type. Coloured circles indicate that an MLST type was 
obtained, and isolates of the same colour have the same MLST type. Circles with split colours indicate that two or more MLST types were obtained for a single MLVA4 
type.
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However for some serotypes, MLVA4 provides higher discrimination than MLST 
and other MLVA methods, evident by the high diversification of serotype 7F and 
serotype 3 (Figure 18). When genotyping S. pneumoniae strains with MLST, only a 
single sequence type is observed for most serotype 7F (ST191) and serotype 3 
(ST1230). However these isolates diverge into a number of different MLVA genotypes 
(all genetically related). MLVA4 identifies at least eight different genotypes for serotype 
7F isolates, and thirteen different genotypes for serotype 3. Particular loci that can 
discriminate serotype 3 further using MLVA4 is Spneu17, and BOX-10 further 
discriminates serotype 7F. 
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Figure 18: Comparing the population structure of S. pneumoniae serotype 3 and serotype 7F when using MLST, MLVA1, MLVA2 and MLVA4 (see opposite 
page).  
The MLST genotype for serotype 3 (blue) and serotype 7F (maroon) is shown to diversify (i.e. break into distinctive genotypes) when using MLVA1, MLVA2 and 
MLVA4. The respective genotype is presented inside each circle (e.g. MLST identifies ST1230, whereas MLVA1 identifies MT423). Other coloured circles depict other 
serotypes that were genetically related to serotype 3 according to MLVA1.  
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4.3.4 Capsule switching 
MLST and MLVA4 used in combination with serotyping can identify potential 
capsule switching. MLST identifies seven potential capsule switches including a switch 
from serotype 22F to serotype 33F (ST1012), a switch from serotype 18B to serotype 
18C (ST1255), a switch from serotype 15B to serotype 15C (ST199), a switch from 
serotypes 1 to serotype 4 (ST306), a switch from serotype 19A to serotype 15B and 
serotype 15C (ST411), a switch from serotype 6A to serotype 6C (ST4237) and a switch 
from serotypes 8 to serotype 11A (ST53) (Table 16). On the other hand, MLVA4 only 
detects two capsule switches including serotypes 15C to 19A (MT59; ST411), and 
serotypes 1 to 4 (MT36; ST306). The Queensland S. pneumoniae isolates are listed in 
the supplementary data which contains MLVA1, MLVA4, MLST and serotype for 
comparison. 
Table 16: Potential capsule switches detected by MLST, MLVA1 and MLVA4 methods. The 
potential capsule switches (boxed) have been consistently detected with all three 
genotyping methods. 
MLST (ST) Serotype (year observed); number of isolates 
1012 22F (2007-2008); n=3 
33F (2012);n=1 
1255 18B (2007);n=1 
18C (2008,2010);n=3 
199 15B (2007,2010,2011);n=4 
15C (2007,2010,2012);n=4 
306 1(2007-2012);n=23 
4(2012);n=1 
411 19A (2007-2012);n=12 
15B (2009);n=1 
15C (2007);n=2 
4237 6A (2008);n=1 
6C (2010-2012);n=6 
53 8 (2008-2009);n=3 
11A (2011);n=1 
MLVA1 Serotype (year observed); number of isolates 
1190 19A (2007-2012);n=3 
19F (2007,2010);n=2 
1374 6A (2008);n=1 
6C (2010-2012);n=5 
18 8 (2008-2009);n=3 
11A (2011);n=1 
2002 18B (2007);n=1 
18C (2008-2010);n=3 
261 1 (2007-2012);n=15 
4 (2012);n=1 
58 15B (2011);n=1 
15C (2007, 2012);n=3 
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MLST (ST) Serotype (year observed); number of isolates 
67 15C (2007);n=1 
19A (2007-2012);n=12 
904 15B (2012);n=1 
15C (2011);n=2 
MLVA4 Serotype (year observed); number of isolates 
59 15C (2007) ; n= 1 
19A (2007); n = 10 
36 1 (2007-2012); n=16 
4 (2012); n= 1 
107 6A (2008); n= 1 
6C (2010-2012); n= 3  
 
Finally, Van Cuyck et al. (2012) suggested that MLST sequence types could be 
inferred from the MLVA type, although they commented that serotype 19F could not be 
inferred. MLVA4 and the Queensland MLST types were examined to determine whether 
some ST could be inferred (Table 17). Due to the fact that several sequence types 
cannot be inferred from a single MLVA4 type, it is not advisable to adopt this method of 
inferring one genotype from another. 
Table 17: Identification of multiple MLST types to a single MLVA4 type when genotyping 
S. pneumoniae. 
Serotype Sequence type (MLST) MLVA4 type 
15C 1262; 5216 53 
15B/15C/19A 199; 11 59 
11A 557; 9668 93 
22F/33F 1012; 5599 209 
 
4.4 Discussion 
MLST is considered the ‘gold standard’ genotyping method for studying 
invasive S. pneumoniae. However MLVA has also emerged as an alternative genotyping 
technique as it has higher discriminatory power, is quick and inexpensive than MLST 
(Koeck et al., 2005; Elberse et al., 2011a). Results presented in this study support this 
verdict, although MLVA would be more suitable for short-term and localised/state-
wide epidemiology studies rather than long term and global studies because of the 
higher rate of diversification of VNTR loci compared to housekeeping genes used for 
MLST. Currently there are a variety of MLVA protocols for typing S. pneumoniae, some 
of which fail to amplify a number of loci in different serotypes; hence this study 
describes the development of a modified MLVA4 method in an attempt to resolve this 
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issue as well as to maintain a highly discriminatory, inexpensive and quick genotyping 
technique. 
Variations in interpreting the population structure of S. pneumoniae have been 
observed when using different genotyping protocols (MLVA1, MLVA2, MLVA4 and 
MLST methods). The choice of the ten VNTRs for our MLVA4 method was based on a 
Hunter-Gaston Diversity of ≥0.8, as well as an anchor locus with low discrimination to 
determine long-term changes (BOX-02), and an extra locus with high discriminatory 
power for specific serotypes (Spneu19). Of the eight highly discriminatory (Hunter-
Gaston Diversity ≥0.8) VNTR loci used in previously published MLVA papers (Elberse et 
al., 2011a; Koeck et al., 2005; Rakov et al., 2011; Van Cuyck et al., 2012), seven VNTRs 
are included in the modified MLVA4 method. MLVA4 maintains high congruence with 
the other MLVA methods and MLST. 
MLST proved to be less discriminatory (S=0.936) than either of the MLVA1 
(S=0.963) and MLVA4 methods (S=0.978). However MLST remains as an ideal method 
for long-term and global epidemiology studies as the housekeeping genes change 
slowly over a longer period of time (Bentley et al., 2006). A less discriminatory protocol 
is only problematic if it does not detect emerging genotypes or outbreaks therefore 
inaccurately representing the pneumococcal population structure, justifying why 
MLVA4 may be more suitable. 
MLVA4 method maintains a high discriminatory power whilst minimising the 
number of non-amplifiable ‘99’, and is significantly more accurate in representing the 
Queensland pneumococcal population structure compared to MLST when observing 
short-term changes or localised outbreaks. Complexes of isolates can be observed in 
more detail and more information can be gleaned when combined with isolate 
information such as antibiotic resistance or disease type (not used in this study). 
Admittedly, additional markers have increased resolution (ten loci instead of seven or 
eight) however we have minimised laboratory work to three multiplex reactions. The 
main purpose of modifying MLVA was to eliminate or minimise the number of non-
amplified loci as detected in the Elberse et al. (2011a) method, and this has been 
achieved in this study. 
Results of the present study confirm the problem of particular loci failing to 
amplify, resulting in incomplete genotypes. Non-amplification could also be due to 
primer-dimer forming in the mastermix, therefore alternative combination or pooling 
of primers could be performed. Alternatively a mutation in the primer binding site or a 
missing locus could explain non-amplification. It was noticed that singleplex PCR 
resolved >70% of certain loci, indicating that the genes can be amplified but a multiplex 
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may be inhibiting amplification in MLVA1. A number of primers were also re-designed 
in this study (including BOX-10, BOX-12, BOX-13 and Spneu19) in an attempt to 
successfully amplify the previous failing. 
Elberse et al. (2011b) reported that 24% of their S. pneumoniae isolates still 
contained one or more non-amplified BOX loci even after repeated rounds of PCR on 
these isolates.  Results from the present study provided a similar figure of 20.8% in 
Queensland isolates. It also found that some loci failed to amplify in specific serotypes, 
such as BOX-06 failing to amplify in 75% of serotype 7F, indicating that primers should 
be redesigned, or VNTR fragments were absent. No serotype 7F genome is available in 
the NCBI database. Elberse et al. (2011b) similarly have detected a large number of 
non-amplified BOX-06 genes associated with serotype 7F (89% isolates). BOX-06 was 
not used in MLVA4 due to a high percentage of ‘99’ associated with serotype 7F and a 
low Hunter-Gaston diversity. Since serotype 7F was the second most common serotype 
(9%) found in Queensland, using higher discriminatory loci was favoured. Croucher et 
al. (2011) identified that “the greater the average number of boxB repeats in a BOX 
element, the more likely that element is to vary by losing or acquiring these modules”. 
This may explain why it has been difficult to amplify certain loci because they are less 
stable and have the capacity to transpose more easily. In the present study it was also 
noticed that MLVA2 had similar numbers of non-amplification, with 24.3% of 
Queensland isolates with incomplete MLVA genotypes. MLVA4 was able to decrease 
this percentage to 12.4% of Queensland isolates, and the non-amplifications were 
thought to be serotype-specific. If the absence of these BOX loci is real for these 
serotypes, this could be a discriminatory feature. 
Similarly, Spneu19 loci could not be detected in several serotype 3 genomes in 
the NCBI database, explaining why experimentally Spneu19 is assigned ‘99’ for several 
serotype 3 isolates. The failure to amplify Spneu19 in serotype 3 has also been 
observed by Koeck et al. (2005), suggesting that serotype 3 lack pcpA which codes for a 
non-essential surface protein involved in cell adhesion (Koeck et al., 2005; Sanchez-
Beato et al., 1998). On the other hand, large BOX-13 fragments (>2000bp) have been 
identified in serotype 33F isolates, accounting for the ‘99’ results since the AB3130 
internal size ladder only reaches 1200bp. Large fragments could be explained by the 
placement of an insertion sequence (IS) element, making the BOX element appear to be 
larger than 2kb. The presence of IS elements has been described in other MLVA studies 
(Hoang et al., 2007). Further experiments could investigate the use of other types of 
VNTRs for example RUP (Repeat Units of Pneumococcus) and SPRITE elements. 
However little is known about these elements in S. pneumoniae. RUP elements have 
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108bp repeat units and are located in recA – dinF intergenic regions (Claverys & Martin, 
1998; Oggioni & Claverys, 1999). There are 32 copies of RUP found in the NCBI S. 
pneumoniae R6 strain genome and are thought to be insertion sequence (IS) derivatives 
that could be mobile (Oggioni & Claverys, 1999). 
Previous studies have investigated the question of whether or not BOX/VNTR 
loci are stable in vitro and in vivo (Elberse et al., 2011a; Martin et al., 1992). The 
stability of repetitive sequences and PCR patterns was observed in six species of 
bacteria after 72hours and 15 sub-cultures (although this was investigated in other 
bacterial species, not S. pneumoniae) (Kang & Dunne, 2003). Importantly, Elberse et al., 
(2011c) demonstrated BOX stability in S. pneumoniae after sub-culture of the organism 
for 29 days. Sixteen VNTRs were also shown to be stable in Mycobacterium 
intracellulare strains when 30 sub-cultures over 180 days demonstrated in vitro 
stability and that 14 patients’ isolates recovered from 2 – 1551 with identical MLVA 
profiles at each interval demonstrated in vivo stability (Ichikawa et al., 2010). MLVA 
performed for Acinetobacter baumannii provided stable VNTR profiles after two sub-
cultures (Pourcel et al., 2011). McAuliffe et al. (2007) also demonstrated MLVA stability 
in Mycoplasma mycoides when three strains were sub-cultured 50 times. All these 
studies have demonstrated that within a short experimental time frame, at least, VNTR 
loci are stable and MLVA profiles should accurately reflect the organism’s genotype. 
Out of interest, examination of potential VNTR function was investigated by 
inspecting the NCBI database of S. pneumoniae strains R6 and TIGR4 as examples. It 
was interesting to note the close proximity the majority of VNTR loci have to other 
transcribable elements. BOX-01 was located upstream of a catabolite control protein, 
which functions in colonization (Iyer et al., 2005). BOX-02 was located upstream of β-
galactosidase, which catalyses the hydrolysis of β-galactosidases into monosaccharides. 
Upstream of an aquaporin, which forms pores in a membrane, was BOX-03. BOX-10 
was located upstream of a number of transcriptional regions. For instance, it was 
located near a two-component regulatory system (DNA binding response 
regulator/sensor histidine kinase) which allows the organism to sense and respond to 
changes in different environmental conditions. External stimuli activate histidine 
kinase which transfers a phosphoryl group to a response regulator (Stock et al., 2000). 
Another possible function of BOX-10 may be to effect zinc metalloprotease ZmpB, which 
requires zinc metal with the enzyme protease to function in proteolysis (the 
breakdown of proteins into smaller peptides/amino acids). Zinc metalloprotease 
strongly contributes to virulence (Chiavolini et al., 2003). Also, BOX-11 was found 
upstream of formate acetyl transferase which catalyses acetyl-CoA and formate to CoA 
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and pyruvate. It would be interesting to further investigate whether or not the VNTR 
elements affect these particular downstream elements.  
MLVA4 combined with serotyping, increases our understanding of the 
Queensland pneumococcal epidemiology. Serotyping alone identifies 35 serotypes but 
prohibits our understanding of genetic relationships and capsule switching. MLST 
identifies eleven clonal complexes (n=202) circulating throughout Queensland, 
whereas MLVA4 identifies eighteen clonal complexes (n=202) and also enables closer 
examination of eleven MLST singletons, one of which is serotype 7F which is commonly 
associated with IPD in Australian Aborigines. Further discussion of the Queensland 
pneumococcal population is discussed in Chapter 5. Unfortunately the Queensland 
MLST results cannot contribute to a national Australian study/database because none 
currently exists. Few Australian isolates have been submitted to the international MLST 
database, and we have submitted the MLST results from this study to the MLST 
database. MLVA4 reveals diverse genetic relationships within the Queensland 
population, including between serotypes 18B and 18C (CC7), serotypes 19A, 15C and 
15B (CC6), serotype 8 and 11A (CC21), serotype 7F (CC1) and serotype 3 (CC3) which 
MLST does not reveal. Overlaying patient information with diverse genotypes may 
reveal further information about outbreaks, patient susceptibility, vaccine 
immunisation and tracking of disease.  
Genetically related isolates of S. pneumoniae may engage in capsule switching 
more frequently than other bacteria. Potential capsule switches have already been 
observed between serotypes 19A and 15C in CC6 (MT59; ST411), and serotypes 1 and 
4 (MT36; ST306) in CC8 in our Queensland population using MLVA4 (Table 16). MLST 
also identifies these capsule switches, as well as many others which may indicate false 
capsule switching since MLST is less discriminatory in discerning the true genetic 
background of S. pneumoniae isolates. Alternatively, MLVA4 is also noted as being too 
discriminatory and even though true capsule switching occurs, MLVA4 identifies two 
distinct genotypes therefore the assumption is that no capsule switching has occurred. 
Further investigation is required to determine whether MLVA4 could fail to detect 
capsule switches or whether MLST detects false capsule switches. Since MLVA4 is 
highly discriminatory for short-term studies, it may enable detection of capsule 
switching earlier than MLST would.   
Accurately and quickly detecting relationships between S. pneumoniae 
serotypes may have an impact on the selection of serotypes for future vaccine 
strategies. Ideally vaccine strategies should benefit the whole of a nation, however 
differences in state pneumococcal populations have prompted localised strategies, for 
CHAPTER 4           Modified MLVA for genotyping Queensland invasive Streptococcus pneumoniae 
128 
 
example the 10vPCV was only introduced into Northern Territory in October 2009 
since the additional serotypes were not common elsewhere in Australia. If a vaccine 
targets only one serotype in a CC and not the other, this may provide pressure for 
capsule switching or serotype replacement. The 13vPCV targets serotype 19A, 
therefore there might be a selective pressure for the serotype 19A to switch capsules to 
15C or 15B (CC6), which are known to be genetically related. Serotype 15B and 15C are 
not included in any current childhood vaccines, or the in-trial 15vPCV which targets the 
extra serotypes 22F and 33F, therefore future surveillance is recommended. It is 
unknown how many serotypes in a vaccine are acceptable for long-term decrease of 
IPD. 
Furthermore, genotyping methods have revealed that certain pneumococci of a 
particular genotype are more commonly associated with invasive disease. For instance, 
serotype 1 is a prevalent pneumococcal type in Australia - this has been widely 
established via serotyping (e.g. Quellung reaction). However with the use of MLST 
genotyping, we have gained further understanding that particular serotype 1 strains 
are more commonly associated with virulence and disease than others, for instance 
ST306 (serotype 1) is very prominent (Staples et al., 2015). It is unknown why different 
genotypes of serotype 1 are associated with virulence more than others; however 
research has shown that genetic pneumococcal clones have displayed heterogeneous 
behaviour in invasiveness (Sá-Leão et al., 2011). If we use MLVA4 genotyping, because 
it is more discriminatory than MLST, the pneumococcal isolates are further 
distinguished by their MLVA genotype; hence serotype ST306 is also associated with 
several different MLVA types, of which MT35 and MT36 appears to be more common 
with invasiveness. This demonstrates the importance of molecular surveillance, 
particularly following the introduction of vaccines, as not only serotypes can be 
associated with invasiveness but the genotypes (either MLST or MLVA) can also be 
associated with virulence. This could then inform not only which serotype but even 
which specific strain/genotype could be targeted. 
In addition, the ability to examine CC with higher discrimination using MLVA4 
can provide insight into which genes are changing, for example serotype 7F (MLVA CC1 
or ST191) largely diversifies due to BOX-10 and serotype 3 diversifies due to Spneu17. 
Investigation into specific VNTR loci may indicate whether there are additional 
advantages that these serotypes may have based on the VNTR proximity to virulence 
elements. This could offer these isolates a selective advantage over others (Table 15). It 
is unknown what the specific functions of these genes are, however it is known that 
VNTRs and BOX elements play a role in bacterial competence and virulence (Knutsen et 
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al., 2006; Martin et al., 1992). VNTR loci with high diversity (e.g. Spneu17) would allow 
increased discrimination within localised or short-term studies, whereas VNTR loci 
with low diversity (e.g. BOX-02 and BOX-11) would allow identification of long term 
changes.  
MLVA4 also identified founding genotypes in Queensland whereas MLST did 
not, however this is only a probable founder based on an eBurst model, and the more 
data available the more confident about the founder assignment, therefore it is advised 
to use the whole database if possible. MLST may require a larger population sample or 
national/international sample before founding genotypes are discerned, therefore the 
international database has been used for comparison. Unfortunately MLVA4 has no 
larger database to compare to, although MLVA1 has an international database available 
with predominantly isolates from the Netherlands. Identification of founding genotypes 
provides a preliminary understanding of the originating/parent genotype and hence 
how CCs may have evolved over time. The MLST eBurst limits our understanding of 
these changes occurring over a short period of time within the state of Queensland. It 
would be possible to overlay geographic information with genotypes in order to track 
the spread of specific pneumococcal strains. 
In conclusion, we have developed a MLVA4 method for genotyping invasive 
strains of S. pneumoniae. The main advantage of this new method over other MLVA 
methods for typing S. pneumoniae is the ability to achieve complete MLVA profiles for 
serotypes whilst also maintaining a highly discriminatory and quick genotyping 
method. Loci of invasive serotypes of S. pneumoniae that failed to amplify were found to 
be serotype specific, which may indicate that these BOX elements in these serotypes are 
unstable and have the capacity to transpose. Further research is required to 
understand the VNTR genetics of these serotypes as VNTRs and BOX loci are thought to 
play a role in virulence. MLVA4 is also more suitable for genotyping S. pneumoniae in 
Queensland than MLST as a more diverse population can be visualised and allows 
accurate tracking of strains across the state. MLST may be more suitable for a national 
study, rather than by state, however as MLVA4 is more discriminatory it is possible to 
utilise this for national studies also as Australia-wide outbreaks have been observed 
e.g. pneumococcal ST1. MLVA4 has been applied to analyse the pneumococcal 
population in Queensland from 2007 to 2012. This study, following the introduction of 
13vPCV in 2011, establishes a baseline and it is expected that future monitoring will 
comprehensively and accurately depict the changes in the pneumococcal population in 
Queensland. Currently, no MLVA database exists for S. pneumoniae however there is an 
opportunity for this to be established. The future perspective of MLVA is that it will 
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emerge as an inexpensive and quick genotyping method for localised and national 
studies that can be used in conjunction with the currently traditional and slower 
serotyping and MLST methods for characterising S. pneumoniae. 
A low numbers of available sequences, transposable elements make it difficult to 
design suitable primers, and selection pressures can lead to genetic variation of two 
identical clones (Lindstedt, 2005). MLVA4 has not been tested directly on clinical 
samples (without culture), but has the potential to obtain similar results as MLST 
(Elberse et al., 2011a). It is also limited by size homoplasy – the “independent evolution 
of the same repeat array sizes in different strains” (Rakov et al., 2011). MLVA profiles 
would not be able to differentiate between independently evolved strains with the 
same profile. However, the choice of the 45bp boxB tandem repeat sequence means 
that it is less prone to size homoplasy (Rakov et al., 2011).  
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5.1 Introduction 
The pneumococcal population structure causing IPD in Queensland children 
could be determined using the modified MLVA4 method developed in Chapter 4. 
Despite a decline in circulating 7vPCV-serotypes worldwide and associated IPD due to 
the pneumococcal vaccines, non-7vPCV serotypes started to increase globally due to 
two phenomena; serotype replacement and capsule switching (Brueggemann et al., 
2007; Weinberger et al., 2011). Serotype replacement is the main reason for the 
shifting pneumococcal population structure. Alarmingly, capsule switching events have 
led to vaccine escape pneumococcal isolates, where strains with genetic backgrounds 
providing robustness, virulence, antibiotic resistance, etc. are switching from 7vPCV to 
non-7vPCV capsules to escape vaccines, and that this is leading to higher rates of non-
7vPCV disease/carriage. No vaccine escape isolates of pneumococci have been reported 
in Australia; however serotype replacement in these bacteria has been reported 
(Hanna et al., 2010). IPD notification rates in Queensland have increased from 6.0 per 
100 000 to 7.6 per 100 000 from 2009 to 2012 (NNDSS, 2015). This is possibly due to 
the increase of non-7vPCV serotypes in Queensland. Young children (under 2 years) 
and the elderly (over 65 years) are more susceptible to pneumococcal infections (Scott 
et al., 1996).  
To combat changing pneumococcal populations and increasing invasive diseases, 
a 13vPCV was developed (Pfizer Australia Pty Ltd) to replace the 7vPCV. This decision 
and selection of serotypes was based on international pneumococcal serotype 
surveillance data (Centers for Disease Control Prevention, 2010).  In July 2011 the 
13vPCV was added to the National Vaccine Immunisation Schedule in Australia, 
targeting an extra six serotypes not covered by the earlier 7vPCV (Selvey, 2011). Since 
the introduction of 13vPCV in Australia, there have been no publications examining the 
effect of this new vaccine on the pneumococcal population structure in Queensland or 
Australia. A 15vPCV is currently on trial targeting an extra two serotypes (serotype 22F 
and 33F), and may be a potential future vaccine (Skinner et al., 2011).  
The second aim of this thesis was to determine the population structure of 
invasive S. pneumoniae in Queensland children younger than 15 years from January 
2007 to December 2012 using the modified MLVA4 method, and also to determine 
whether or not the genetic diversity of non-vaccine serotypes (non-13vPCV serotypes) 
is changing in the Queensland pneumococcal population. The population structure will 
be determined by using the modified MLVA4 method from Chapter 4 and the ‘gold 
standard’ MLST method. A number of objectives will be fulfilled in this current chapter.  
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Firstly, the objective was to determine the differences when interpreting the 
population structure when using either genotyping method. The second objective was 
to provide a current study and baseline of the Queensland invasive pneumococcal 
population in children prior to the introduction of the 13vPCV. Thirdly, research 
outlined in this Chapter aims to assess the initial and possible future impact of the 
newly introduced 13vPCV into Queensland by examining the potential changes in the 
population structure. The final objective was to possibly predict which non-vaccine 
serotypes may become serotype replacements, indicating that a new vaccine may be 
required in the future.  We hypothesise that the population structure of invasive S. 
pneumoniae isolated from Queensland children are not clonally related from post-
7vPCV to post-13vPCV, meaning that the majority of the pneumococcal isolates will not 
share similar genetic profiles and form genetic complexes as demonstrated by MLVA4 
typing and MLST. The rationale for this is that due to the introduction of the 13vPCV, 
the vaccine is expected to provide pressure on the population structure and we expect 
to observed differences over time. Finally we hypothesise that serotype replacement 
and capsule switching has occurred since the freely available 7vPCV in Australia 2005. 
5.2 Materials and Methods 
5.2.1 Laboratory methods 
S. pneumoniae isolates were serotyped (n=397) using Quellung reaction at the 
Pneumococcal Reference Laboratory, QHFSS. Invasive S. pneumoniae isolated from 
children 15 years or younger from January 2007 to December 2012 were used in this 
study. The introduction of the 13vPCV occurred July 2011, which was included in the 
National Immunisation Program. 
MLVA1 was performed as previously described in Chapter 3 (Elberse et al., 
2011a). Briefly, eight fluorescently labelled BOX MLVA primers were used to amplify 
invasive S. pneumoniae isolates using PCR and Qiagen Mastermix reagent (Qiagen, 
Australia). An AB3130 sequencer (Applied Biosystems, Australia) was used to size PCR 
fragment products with a LIZ1200 internal size ladder (Applied Biosystems, Australia). 
Our modified MLVA4 method was also applied as described in Chapter 3 and 
Chapter 4. Briefly ten fluorescently labelled VNTR primers were used to amplify 
invasive S. pneumoniae isolates using PCR, and Qiagen Mastermix reagent (Qiagen, 
Australia). An AB3130 sequencer (Applied Biosystems, Australia) was used to size PCR 
fragment products with a LIZ1200 internal size ladder (Applied Biosystems, Australia). 
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MLST was also performed on selected isolates, namely non-13vPCV serotypes. 
These isolates were selected because important changes in the pneumococcal 
population structure may be associated with these isolates. MLST was performed as 
previously described in Chapter 3 (Enright & Spratt, 1998), using the Corbett Cas 1200 
liquid handling robot (Qiagen, Australia) for automated sample and mastermix 
additions (Jefferies et al., 2003). 
5.2.2 Analysis 
MLVA results were analysed on PeakScanner V1.0 software (Applied Biosystems, 
Australia). A MLVA1 type (MT) was assigned to each isolate using the MLVA database 
(http://www.mlva.net) (Schouls & Van der Heide, 2012). For MLVA4 method, a 
database was devised and MT types were assigned to each isolates from this database. 
The population structure for both MLVA methods were analysed by PhyloViz analysis 
software and displayed as an eBurst diagram. 
MLST results were analysed using ChromasPro software (Technelysium Pty Ltd.) 
for batch alignment analysis. Sequence types (ST) were assigned to each isolate using 
the MLST database. The MLST population structure was displayed as an eBurst 
diagram. 
Simpson’s Index of Diversity (D) was also calculated to compare the 
discrimination ability of MLVA and MLST methods (accessed from 
http://alyoung.com/labs/biodiversity_calculator.html). 
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5.3 Results 
5.3.1 Epidemiology of invasive pneumococci 
A total of 397 invasive S. pneumoniae isolates that had been isolated from 
children under 15 years old in the years 2007 to 2012 were stored at the pneumococcal 
reference laboratory, QHFSS. A total of 317 invasive S. pneumoniae isolates were 
genotyped using the MLVA1 and MLVA4 method. MLST was used to only sequence 202 
invasive S. pneumoniae isolates due to time and cost limitations.  
When examining invasive pneumococcal isolates from children 15 years or 
younger that had been referred to the laboratory, a total of 35 different serotypes were 
associated with invasive disease. The most common pneumococcal serotypes in this 
study were serotypes 1 (9%), 3 (5%), 6C (3%), 7F (9%), 15C (3%), 19A (36%), 19F 
(4%) and 33F (3%) (Table 18). Of these isolates, 9% (serotype 6C, 15C and 33F) were 
not targeted by the 13vPCV. It was noticed that 68.5% of isolates were associated with 
children under five years old (Table 18). The total number of pneumococcal isolates 
has appeared to decline from 37% (147/397) to 31% (125/397) from 2007 to 2012 in 
children under 5 years, however isolates have increased in older children from 11% 
(44/397) to 30% (81/397) from 2007 to 2012, although this does not appear to be 
significant (p=0.1301) (Table 18).  
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Table 18: The distribution of S. pneumoniae serotypes causing invasive disease in 
Queensland children age <5 years and >5 years in the time periods of 2007-2009 and 
2010-2012.  
Number of isolates, N; percentage of isolates, (%). 
 Pneumococcal Isolation Year  
 2007-2009 2010-2012 TOTAL 
 <5 yr ≥5 yr <5 yr ≥5 yr  
Serotype N (%) N (%) N (%) N (%) N (%) 
1 1 (0.7) 9 (20) 6 (5) 19 (23) 35 (9) 
3 7 (5) 2 (5) 5 (4) 5 (6) 19 (5) 
4 1 (0.7) 2 (5) 1 (0.8) 1 (1) 5 
6A 3 (2) 1 (2)  1 (1) 5 
6B 2 (1)    2 
6C  1 (2) 4 (3) 7 (9) 12 (3) 
7F 4 (3) 4 (9) 16 (13) 12 (15) 36 (9) 
8 4 (3)    4 
9N 2 (1)   1 (1) 3 
9V 2 (1)   1 (1) 3 
10A 1 (0.7) 2 (5)   3 
10F 2 (1)    2 
11A 5 (4)  1 (0.8) 2 (2) 8 
12F  2 (5) 1 (0.8) 1 (1) 4 
14 2 (1) 1 (2)  1 (1) 4 
15B 2 (1)  3 (2) 1 (1) 6 
15C 4 (3) 1 (2) 7 (6)  12 (3) 
16F    1 (1) 1 
18A 1 (0.7) 1 (2) 1 (0.8) 3 (4) 6 
18B 1 (0.7)    1 
18C 2 (1) 3 (7) 1 (0.8)  6 
19A 68 (48) 5 (11) 57 (46) 15 (19) 145 (36) 
19F 8 (6) 1 (2) 5 (4) 1 (1) 15 (4) 
22A 1 (0.7)    1 
22F 5 (4)  1 (0.8) 1 (1) 7 
23A 1 (0.7) 1 (2) 1 (0.8) 2 (2) 5 
23B 1 (0.7)  3 (2) 3 (4) 7 
23F 3 (2) 4 (9)   7 
24F 1 (0.7)    1 
33B   1 (0.8)  1 
33F 4 (3) 2 (5) 6 (5)  12 (3) 
34 1 (0.7)   1 (1) 2 
35B 2 (1)  2 (2) 1 (1) 5 
35F 1 (0.7)  2 (2) 1 (1) 4 
38 5 (4) 2 (5) 1 (0.8)  8 
TOTAL 147 44 125 81 397 
 
An increase of 13vPCV-serotypes from 33 isolates (63%) in 2010 to 65 isolates 
(73%) in 2011 was observed, however this was not significant (P=0.9105) (Figure 19). 
No single serotype was associated with this increase. Overall there was no significant 
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overall increase or decrease in 13vPCV (p=0.9105), 15vPCV (p=0.8235) or non-vaccine 
serotypes (p=0.9880). 
Figure 19: Invasive pneumococcal disease in Queensland children from 2007 to 2012.  
Number of IPD cases is shown above each bar. The 13vPCV serotypes listed are the extra six 
serotypes not targeted by the 7vPCV, and the 15vPCV serotypes are the two extra serotypes not 
targeted by the 7vPCV and 13vPCV. Non-vaccine targeted serotypes are those not targeted by 
7vPCV, 13vPCV nor 15vPCV. 
 
There was a significantly higher number of 13vPCV serotypes isolated from 
younger children (0-4 years) compared to older children (p<0.0001), and significantly 
higher numbers of S. pneumoniae associated to IPD in children 0-4 years compared to 
older children (Figure 20 and Figure 21). Upon closer examination of these IPD in age 
groups, the number of 7vPCV-serotypes observed has been decreasing from 2007 
through to 2011 across all age groups, however there is no observed significant 
difference (Figure 22). Interestingly, in the 0-4 year age group, there was a sudden 
decrease of 13vPCV serotypes in 2012 (n=17) compared to earlier years (average n = 
30); the significance of this decrease cannot be determined at this point because we 
would require further time points. In contrast, the number of 13vPCV serotypes has 
increased in older children in 2011-2012; this may appear significant (p=0.0078) 
however further time points would be required for validation.  
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Figure 20: Children age 0-4 years have significantly higher numbers of 13vPCV serotypes 
associated with IPD compared to older children. 
Percentage of IPD cases (%) – the proportion of 13vPCV serotypes associated with IPD in 
children from 2007 to 2012.  One-way ANOVA was performed with cut-off p-value of <0.5 (*** 
p= 0.001). 
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Figure 21: Children age 0-4 years have significantly higher numbers of S. pneumoniae 
associated with IPD compared to older children. 
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There are no significant increases in the number of 15vPCV serotypes (serotypes 
22F and 33F) or non-15vPCV serotypes. However 30% of pneumococcal isolates 
causing IPD in 2010-2012 were caused by non-vaccine serotypes. 
Figure 22: Prevalence of S. pneumoniae serotypes isolated from Queensland children (0-
15 years) from 2007 to 2012.  
The number of IPD cases is shown above bars for 13vPCV serotypes. The 7vPCV pneumococcal 
serotypes include serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. The 13vPCV pneumococcal 
serotypes include the extra six serotypes not targeted by the 7vPCV, including serotypes 1, 3, 5, 
6A, 7F and 19A. The 15vPCV pneumococcal serotypes include the two extra serotypes 22F and 
33F not targeted by 7vPCV or 13vPCV. Non-15vPCV pneumococcal serotypes include all those 
not targeted by the 7vPCV, 13vPCV or 15vPCV. 
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5.3.2 Pneumococcal population structure 
 The overall MLVA eBursts (MLVA1 and MLVA4) for 317 pneumococcal isolates 
demonstrates which invasive S. pneumoniae isolates have been circulating throughout 
Queensland children from 2007 to 2012 (Figure 23 and Figure 24). MLVA1 eBurst 
diagram indicates that there are 22 clonal complexes (CCs). There are three notable 
complexes - CC1 (predominantly serotypes 7F, 3 and 1), CC2 (serotypes 19A, 15B, 15C 
and 22F), and CC3 (serotypes 19A and 18A). CC1 appears to contain three sub-
complexes of serotype 1, 3 and 7F. However, when examining the eBurst diagrams of 
the MLVA4 method (Figure 24), the sub-complexes disappear, and form three separate 
complexes; CC1 (serotype 7F), CC3 (serotype 3) and CC8 (serotype 1). In comparison to 
MLVA1, MLVA4 method detects a total of 32 clonal complexes, indicating a higher 
discrimination. 
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Figure 23: MLVA1 eBurst diagram with serotypes overlayed (n=317) (see opposite page).  
Clonal complexes (CCs) are circled and contain single locus variants (SLV) and double locus variants (DLV). CC1 has been split into four sub-complexes (a, b, c and d). 
MLVA1 genotype is presented inside each circle, and size of circle represents the number of isolates detected in this study. Each colour represents a different serotype, 
as shown in the legend key. Circles with split colours indicate that two or more serotypes have the same MLVA1 genotype, indicating potential capsule switching.
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MLVA4 eBurst indicates that six predominant CCs were present in Queensland 
during 2007-2012, and these included CC1 (serotype 7F), CC2 (serotype 19A and 19F), 
CC3 (serotype 3), CC5 (serotype 19A), CC6 (serotype 15B, 15C and 19A), and CC8 
(serotype 1 and 4) (Figure 24). Some of these complexes are highly clonal, containing a 
single serotype and few MLVA4 genotypes such as CC1 (serotype 7F) and CC5 
(serotype 19A), whereas the other complexes contain more than one serotype with 
diverse MLVA4 genotypes, such as CC6 (serotypes 19A, 15B and 15C), CC22 (serotypes 
22F and 33F) and CC2 (serotypes 19A and 19F). Serotype 19F remains in circulation in 
Queensland despite being targeted by the 7vPCV, which was nationally funded for all 
infants from January 2005 to July 2011 (NCIRS, 2015). These 19F serotypes are all 
multi-drug resistant (unpublished data). CC6 is of interest for further examination as it 
also contains many strains of serotype 15C and 15B, with a potential capsule switch 
from a 19A to 15C.  
MLST eBurst diagram indicates that at least 11 CCs are circulating throughout 
Queensland, however since only 202 isolates were genotyped, this is not a true 
representation of the population structure (Figure 25). Apart from this, all of the 
13vPCV and non-13vPCV serotypes were genotyped using MLST, therefore a 
comparison of MLST and MLVA methods can be made. A number of MLST singletons 
(identified within the red box) are associated with clonal complexes when using either 
MLVA methods. For example, serotype 7F represents a singleton using MLST (ST191) 
however can be further differentiated into a clonal complex using either MLVA 
methods. 
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PLEASE SEE FOLLOWING PAGE FOR FIGURE 24. 
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Figure 24: MLVA4 eBurst of invasive S. pneumoniae isolated from 2007 to 2012 in Queensland children with serotypes overlayed (n=317) (see opposite 
page).  
Clonal complexes (CCs) are boxed and contain single locus variants (SLV) and double locus variants (DLV). CCs linked by a thin black line indicate triple locus variants 
(TLV). MLVA4 genotype is presented inside each circle, and size of circle represents the number of isolates detected in this study. Each colour represents a different 
serotype, as shown in the legend key. Circles with split colours indicate that two or more serotypes have the same MLVA4 genotype, indicating potential capsule 
switching. 
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Figure 25: MLST eBurst population structure of S. pneumoniae in Queensland from 2007 to 2012 with serotypes overlayed (n=202) (see opposite page).  
Clonal complexes (CCs) are circled and contain single locus variants (SLV) and double locus variants (DLV). MLST sequence type (ST) is presented inside each circle, 
and size of circle represents the number of isolates detected in this study. Each colour represents a different serotype, as shown in the legend key. Circles with split 
colours indicate that two or more serotypes have the same MLST genotype, indicating potential capsule switching. Circles within the red box indicate isolates that 
appear to be singletons (i.e. not genetically related to any other ST within this population study) when using MLST genotyping, but become CCs when using any of the 
MLVA methods. 
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A number of MLVA4 genotypes were more prevalent than other genotypes, 
including MT36 (serotype 1; n= 15), MT35 (serotype 1; n= 10), MT60 (serotype 19A; n 
= 10), MT59 (serotype 19A/15C; n= 8), MT27 (serotype 7F; n = 7), MT22 (serotype 7F; 
n= 6), MT21 (serotype7F; n= 4), and MT107 (serotype 6C; n= 4)(Figure 24). 
Closer examination of some of these clonal complexes over time can help identify 
evolutionary trends. The highly clonal (single MLST type ST191) serotype 7F appears 
to be diversifying (meaning more genotypes are emerging) from 2007 to 2012 in 
Queensland (Figure 26), although it is unknown whether this observed change is due to 
diversification within this CC or whether it is because of new introductions of clones to 
Queensland. The variety of serotype 7F MLVA4 genotypes has increased from one 
(2007) to seven (2012), and the total number of isolates has been increasing from 2 
isolates (2007) to 12 isolates (2012). 
Figure 26: CC1 (serotype 7F) using MLVA4 genotyping from 2007 to 2012.  
The MLVA4 genotype is shown beside the earliest detected isolate. Size of the circles indicates 
the number of isolates detected within each particular year. Each colour is associated to a single 
MLVA4 genotype. 
 
On the other hand, serotype 1 (CC8 and CC16) trends over time seem to show 
that CC16 disappears in earlier years, whereas CC8 emerges and expands into several 
genotypes in later years (Figure 27). 
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Figure 27: CC8 (top box) and CC16 (bottom box) (both serotype 1) using MLVA4 
genotyping from 2007 to 2012.  
The MLVA4 genotype is shown beside the earliest detected isolate. Size of the circles indicates 
the number of isolates detected within each particular year. Each colour is associated to a single 
MLVA4 genotype. 
 
 
Also of interest was whether or not there were changing trends of serotype 22F 
and 33F, which are the additional targets of a 15vPCV that is currently in trial to be the 
future pneumococcal vaccine. As shown in Figure 28, the additional 15vPCV serotypes 
(namely serotypes 22F and 33F) have not increased dramatically (4 isolates in 2007 
compared to 5 isolates in 2012). The changing trends over time seem to corroborate 
with this earlier finding, as clonal complexes do not appear to be dramatically changing 
(Figure 28). However, we notice that a small complex of two pneumococcal MLVA4 
genotypes (CC29) had emerged in recent years (2010-2012) and CC22 appears to 
contain both serotype 22F and 33F. 
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Figure 28: CC29 (top box – serotype 22F), CC12 (middle box – serotype 33F) and CC22 
(bottom box - serotype 22F and 33F) using MLVA4 genotyping from 2007 to 2012.  
The MLVA4 genotype is shown beside the earliest detected isolate. Size of the circles indicates 
the number of isolates detected within each particular year. Isolates not contained by a box are 
not genetically related within this population study (i.e. appear as singletons). Colour represents 
serotype (green = serotype 33F; blue = serotype 22F). 
 
 
The eBurst diagrams also allow examination of the changes in the population 
structure over time. Two time periods were examined; 2007 to 2009, which is post-
introduction of 7vPCV in the Australian national immunisation program in 2005, and 
2010-2012, which overlaps with the introduction of 13vPCV in July 2011. Comparison 
of these two equal time periods (3 years) enabled observations of serotype 
replacement between these years. The MLVA4 method shows that from 2007 to 2009, 
there are 17 clonal complexes identified and 40% of isolates were 13vPCV serotypes 
while 23% were 7vPCV serotypes (Figure 29 and Figure 30). The 7vPCV-serotypes 
have declined to 6% of the population however 13vPCV-serotypes have increased to 
61% of the population. 
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Figure 29: The prevalence of Pneumococcal Conjugate Vaccine (PCV) serotypes during 
2007 to 2009 compared to 2010 to 2012.  
The 7vPCV serotypes include serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. The 13vPCV serotypes 
include the extra serotypes 1, 3, 5, 6A, 7F and 19A. The 15vPCV serotypes include serotypes 22F 
and 33F only. Serotypes not targeted by either of these vaccines are represented as ‘none’. 
 
 
There is also evidence from the current data of emerging and disappearing 
complexes in the Queensland pneumococcal population structure. The disappearing 
complexes that were present in 2007-2009 but not observed in 2010-2012 include CC4 
(serotype 38), CC7 (serotypes 18B and 18C), CC13 (serotype 19A), CC15 (serotype 
23F), CC16 (serotype 1), CC21 (serotypes 8), CC22 (serotype 22F), CC23 (serotype 
10A), CC26 (serotype 23F) and CC30 (serotype 10F) (Figure 31). Some of these 
complexes contain serotypes targeted by the 7vPCV (CC7, CC15 and CC26). However, 
other complexes that have disappeared that were not targeted by any vaccines, 
including CC4, CC21 and CC30.  
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Figure 30: MLVA4 eBurst diagram of Queensland invasive S. pneumoniae from 2007 to 2009 with designated pneumococcal conjugate vaccine (PCV) 
serotypes (see opposite page).  
Clonal complexes (CCs) are circled and contain single locus variants (SLV) and double locus variants (DLV). The 7vPCV serotypes include serotypes 4, 6B, 9V, 14, 18C, 
19F and 23F. The 13vPCV serotypes include the extra serotypes 1, 3, 5, 6A, 7F and 19A. The 15vPCV serotypes include serotypes 22F and 33F only. Serotypes not 
targeted by either of these vaccines are represented as ‘none’. 
CHAPTER 5  Changing population structure of invasive 
Streptococcus pneumoniae in Queensland children 
155 
 
 
 
 
 
CHAPTER 5  Changing population structure of invasive 
Streptococcus pneumoniae in Queensland children 
156 
 
On the other hand, CCs have emerged in 2010-2012 including CC8 (serotypes 1 
and 4), CC9 (serotype 6C), CC14 (serotypes 15C), CC17 (serotype 19A), CC18 (serotype 
23B), CC20 (serotype 19A), CC25 (serotype 6C), CC27 (serotype 15C), CC29 (serotype 
22F), and CC32 (serotypes 19F) (Figure 31). All of these complexes (except for CC8, 
CC17, CC20 and CC32) contain serotypes that are not targeted by any current vaccine. 
Overall the 13vPCV and 15vPCV target all of the serotypes in 11 complexes (CC1, CC2, 
CC3, CC5, CC8, CC12, CC13, CC16, CC17, CC20, CC22, and CC29). They do not target all of 
the serotypes observed in 20 complex using MLVA4 (CC4, CC6, CC9, CC10, CC14, CC18, 
CC21, CC23, CC25, CC27, and CC30). eBurst analysis of MLVA4 data indicates that seven 
predominant clonal complexes were present during 2007-2012, and these include CC1 
(serotype 7F), CC2 (serotype 19A and 19F), CC3 (serotype 3), CC5 (serotype 19A), CC6 
(serotypes 19A, 15B and 15C), CC10 (serotype 23A) and CC12 (serotype 33F). 
The comparison of the Queensland S. pneumoniae population in this current 
study against the MLST international database allows identification of genetic founders, 
the original genotype that is thought to have diversified (Figure 32). The comparison of 
the Queensland S. pneumoniae population in this current study against the MLVA1 
online database also identifies a number of genetic founders, and although it contains 
fewer number of isolates, it still identifies a large clonal complex that is also observed 
by MLST (Figure 33). MLVA4 also identified founding genotypes in Queensland, 
however this is only a probable founder based on eBurst model, and the more data 
available the more confident about the founder assignment, therefore it is advised to 
use the whole database if possible. Identification of founding genotypes provides a 
preliminary understanding of the originating/parent genotype and hence how CC may 
have evolved over time. 
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Figure 31: MLVA4 eBurst diagram of Queensland invasive S. pneumoniae from 2010 to 2012 with designated pneumococcal conjugate vaccine (PCV) 
serotype (see opposite page).  
Clonal complexes (CCs) are circled and contain single locus variants (SLV) and double locus variants (DLV). The 7vPCV serotypes include serotypes 4, 6B, 9V, 14, 18C, 
19F and 23F. The 13vPCV serotypes include the extra serotypes 1, 3, 5, 6A, 7F and 19A. The 15vPCV serotypes include serotypes 22F and 33F only. Serotypes not 
targeted by either of these vaccines are represented as ‘none’.
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Figure 32: Queensland MLST genotypes (pink circles) compared to the S. pneumoniae 
international database. 
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Figure 33: Queensland MLVA1 genotypes compared to the MLVA database for S. 
pneumoniae. 
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5.3.3 Examination of clonal complexes 
Clonal complexes (CC) observed in the MLVA4 data were examined closely for 
increasing or decreasing clonality. A clonal complex was defined as containing MLVA4 
genotypes that are single locus variants (SLV) and double locus variants (DLV). 
Increasing clonality is seen as a tendency towards all genotypes being single locus 
variants. Other observations include the number of isolates detected within each study 
period. 
CC 1 – This clonal complex only contains serotype 7F, and with dominant MLVA4 
genotypes MT21 (n=4), MT32 (n=3), MT22 (n=6) and MT27 (n=9). Serotype 7F was the 
second most common serotype observed, below serotype 19A. This complex has 
persisted from 2007 through to 2012, decreasing in clonality in 2010-2012 (i.e. 
becoming more diverse). The assigned founding genotype is MT32. 
CC 2 – This complex contains serotype 19A and 19F, both of which are targeted 
by the 13vPCV. Serotype 19F is also targeted by the original 7vPCV. This complex has 
remained in circulation in Queensland children from 2007 through to 2012. The 
complex has shifted to mainly contain serotype 19A rather than 19F. This is most likely 
due to the serotype 19F being targeted by the 7vPCV. Despite the freely available 
7vPCV implemented in 2005, serotype 19F remains in circulation. There is no founding 
genotype in this complex. MT101 (serotype 19F) has been observed in both 2007-2009 
and the 2010-2012 periods. 
CC 3 – This complex only contains serotype 3, and has persisted from 2007 
through to 2012 without any major changes in the MLVA types in the clonal complex. 
Serotype 3 is the fourth highest IPD causing serotype in Queensland children. 
CC 4 – This complex only contains serotype 38, which is not targeted by any 
current vaccine. This complex was dominant in earlier years (2007 – 2009). 
CC 5 – This complex only contains serotype 19A, and all isolates are single locus 
variants of the dominant genotype MT60. This complex has also persisted from 2007-
2012, and has actually decreased in clonality in 2010-2012.  Of particular interest is the 
predicted founding genotype, MT60, which makes up most of the referred isolates in 
CC2 (10 pneumococcal isolates in 2010-2012). CC2 is more genetically related to CC1 
(serotype 19A/15B/15C) as four MLVA alleles out of 10VNTR are the same. CC2 
isolates share only two alleles with isolates in CC5 (serotypes 19A and 19F) and CC11 
(serotype 19A). CC11 and CC5 are not genetically related as no alleles are common. 
CC 6 - This large complex contains serotypes 15B, 15C and 19A, of which only 
serotype 19A is targeted by the 13vPCV. CC6 has persisted from 2007 through to 2012. 
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The dominant MLVA4 genotype is MT59 (n=11), with a potential capsule switch from a 
serotype 19A to serotype 15C. The number of MTs has declined in the 2010 to 2012 
period, indicating that the complex is becoming more clonal. Serotype 19A in this 
complex is declining in numbers in later years, and the complex is becoming dominated 
by serotypes 15B and 15C. Serogroup 15 is not targeted by any childhood vaccine.  
CC 8 – This clonal complex predominantly contains serotype 1 but also contains a 
potential capsule switch to a serotype 4 (n=1). The complex in 2010-2012 is highly 
clonal, and the majority of strains in this complex are MT35 and MT36. CC8 is not 
clonally related to CC16 (serotype 1) observed in 2007-2009. CC8 appears to have 
emerged in 2010-2012 either from a distantly related strain of CC16 or an independent 
source. Serotype 1 is the third highest serotype referred to the laboratory. 
CC 9 and 25 – These complexes contain serotype 6A/6C and 6C, respectively. 
Both complex have emerged in 2010-2012 and are clonally unrelated to each other. 
Serotype 6C is not targeted by the 13vPCV. The in-trial 15vPCV does not target 
serotype 6C. 
CC 12 – This small complex contains serotype 33F, a target of the future vaccine, 
15vPCV. The MLVA4 genotypes include MT398 (n=1), MT217 (n=3), MT105 (n=2) and 
MT365 (n=2). CC12 has persisted from 2007 through to 2012, however it doesn’t 
appear to be changing. Serotype 33F has been isolated more commonly from younger 
children (<5 years) in this study. 
CC 14 and 27 – Both of these smaller complexes contain serotype 15C and 
15B/15C, respectively. MLVA4 types include MT52 (n=1), MT360 (n=1), MT287 (n=1), 
MT336 (n=1) and MT53 (n=2). Both complexes have emerged in 2010-2012. These 
complexes are not clonally related to CC6 (15B/15C and 19A). No vaccine presently 
targets 15B or 15C. 
CC 18 – This complex only contains serotype 23B which is not targeted by the 
13vPCV or the in-trial 15vPCV. CC18 has emerged in 2010-2012. The total number of 
serotype 23B observed has increased from one (2007-2009) to six (2010-2012). There 
is a potential for serotype 23B to become serotype replacement, and it is not targeted 
by the 13vPCV and 15vPCV. 
CC 22 and 29 – CC22 contains serotype 22F and 33F (serotype 33F MT366 is a 
single isolate in 2010-2012), whereas CC29 only contains serotype 22F. Serotype 22F 
(MT143, n=1) and 33F (MT366, n=1) are single locus variants, despite that serotype 
22F was observed in 2007-2009 and the 33F observed in 2010-2012. CC22 is not 
clonally related to CC29. Both serotype 22F and 33F are targets of the in-trial 15vPCV, 
but are not targeted by the 13vPCV. 
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5.3.4 Capsule switching 
We have observed capsule switches occurring in the Queensland pneumococcal 
population (see Chapter 4). A capsule switch is defined as two pneumococcal isolates 
with identical genotypes that have different capsule types/serotypes. For a more 
accurate depiction of whether a pneumococcus has switched its capsule, a comparison 
of the Queensland population against an international database is ideal.  
Therefore an initial comparison of the MLST results from this study against the 
MLST international database indicated that several Queensland S. pneumoniae isolates 
have potentially undergone capsule switching. Similarly, comparison of our MLVA1 
data with the MLVA international database revealed similar capsule switching. The 
MLVA4 method detected two potential capsule switches in the Queensland S. 
pneumoniae population isolates, including CC8 from a serotype 1 to serotype 4, and CC6 
from a serotype 19A and 15C. Even though there is no larger database to compare the 
MLVA4 results with, these potential capsule switches have been observed by MLVA1 
and MLST. However MLVA1 and MLST also indicate many other potential capsule 
switches. A study of the data generated using the MLST method indicated that there are 
four additional capsule switches, including serotype 22F to 33F (ST1012), serotype 18B 
to 18C (ST1255), serotype 15B to 15C (ST199) and serotype 8 to 11A (ST53) in the 
Queensland S. pneumoniae population. Data generated using the MLVA1 method 
indicated that there are five additional capsule switches, including serotype 19A to 19F 
(MT1190), serotype 8 to 11A (MT18), serotype 18B to 18C (MT2002), and two 
incidents of serotype 15B to 15C (MT58 and MT904).  
A potential capsule switch from serotype 35B to serotype 7F was verified to be 
false in our Queensland data. It was questioned when we noticed that the ST198 was 
common for serotype 35B and not 7F in the MLST international database. Because 
serotype 7F is targeted by the 13vPCV it is hypothesised that a capsule switch would be 
more common to evade the vaccine (i.e. switch from serotype 7F to 35B). Natural 
capsule switching does occur without influence from the vaccine, however to be sure 
the isolate was re-serotyped, re-cultured and re-genotyped. Results indicated that the 
original serotype was false as the serotype 35B had been accidentally serotyped twice. 
A capsule switch from a serotype 35B to 7F has not been detected. 
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5.4 Discussion 
By using MLVA4, we were able to determine the population structure of invasive 
S. pneumoniae in Queensland from 2007 to 2012. This can be used as a guide of 
circulating serotypes causing IPD in Queensland children five years prior to the 
introduction of 13vPCV in 2011. Closer examination of the Queensland pneumococcal 
population structure could reveal whether the pneumococcal population was changing 
over this time, particularly due to the vaccines 7vPCV and 13vPCV. A number of 
objectives were fulfilled in this study. 
Firstly, we wanted to compare the use of MLST, MLVA1 and MLVA4 for 
determining the S. pneumoniae population structure in Queensland. Even though MLST 
was only applied to 202 isolates and MLVA applied to 317 isolates, we observed that a 
number of MLST singletons actually diversified and formed complexes when using 
either MLVA method. Higher discriminatory power can impact interpretations of 
population structures, especially when identifying capsule switches, clonal complexes 
and changes in the population. The MLVA4 method identified fewer capsule switches 
than the other two genotyping methods. MLVA4 genotypes may diversify within a CC, 
but this can make it difficult to detect the capsule switching because by definition we 
identify a capsule switch if two or more isolates have the same genotype but different 
capsules. ST types would stay consistent for longer (given the nature of stable, slow-
changing house-keeping genes that are used for the ST), therefore a capsule switch 
would be easily identifiable because two isolates would still have the same ST even if 
they have different capsules. However, MLVA4 may fail to identify this because even 
though a capsule switch has occurred sometime during the clone’s evolution, the 
MLVA4 type has also diversified and we detect two different MLVA4 types, which 
informs us that no observable capsule switch has occurred. This may be a possible 
limitation of MLVA4.  
On the other hand, comparison of the MLVA4 population structure to patient 
information (not obtained in this study) may glean more accurate information or 
trends that MLST would fail to provide, for example since serotype 7F is known to be 
highly prevalent in the Australian Aboriginal communities, CC1 with a number of 
MLVA4 genotypes may be associated to specific communities, whereas using MLST will 
only determine that all serotype 7F have the same sequence type (ST191) and 
therefore no apparent relationships between ST191 and specific Indigenous 
communities. 
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MLVA4 also identified a number of clonal complexes, some that were only 
identified as singletons when using MLST. The majority of clonal complexes identified 
by the MLVA4 method contain a single serotype, however eight complexes contain a 
mix of two or more serotypes that are genetically related (Figure 24). This may imply 
that MLVA4 could be applied to genotype serotype by serotype. A query about whether 
MLVA could be used only to discriminate serotype by serotype was theorised (Van 
Cuyck et al., 2012). It was determined that this may not be ideal in a population study 
because it may miss clonal relationships between different serotypes, such as those 
observed in this study, for example serotypes 11A and 8, serotypes 18B and 18C, 
serotypes 22F and 33F, and serotypes 19A, 19F, 15B and 15C. Potential capsule 
switching would also not be identified, for example serotype 1 and 4, and serotype 15C 
and 19A detected in this study. It is important to detect these relationships since 
serotypes 11A, 8, 18B, 22F, 33F, 15B and 15C are not targeted by the current childhood 
vaccines. As they are shown to be genetically similar to other serotypes, it may mean 
that they have the ability to switch capsules more easily or become serotype 
replacement strains. 
The second objective was to determine the current pneumococcal population 
structure circulating in Queensland children. Overall IPD notification rates will not 
decline further with continued use of 7vPCV, therefore the introduction of the 13vPCV 
should provide further decrease of IPD since it targets an extra six serotypes not 
targeted by the 7vPCV. We have already noted an increase of 13vPCV-serotypes from 
40% (2007-2009) to 61% (2010-2012) in children less than 15 years, indicating the 
effects of serotype replacement after the introduction of 7vPCV in 2005 (Figure 29). In 
South Australia, it has been reported that increases of non-7vPCV serotypes, with 
serotype 19A as the dominant replacement serotype, has occurred (Tran et al., 2012). 
These authors also commented that non-7vPCV serotypes may be associated with more 
severe diseases, as they noticed higher rates of complications in empyema (Tran et al., 
2012). Oftedah et al. (2013) reported increases of non-7vPCV serotypes (5% to 18%) in 
New South Wales children before and after the 7vPCV was introduced.  
An unusual spike of 13vPCV-serotypes was also detected in 2011. A serotype 1 
outbreak occurred in Northern Territory, Western Australia and Queensland, which 
may have contributed to the unusual spike in IPD cases (Staples et al., 2012; Staples et 
al., 2015). However, even by omitting serotype 1 isolates that may be a part of an 
outbreak, the number of 13vPCV isolates are still unusually high. It is not known why 
the number of 13vPCV-serotypes has increased in 2011 (calculated to not be 
significant), but it appears that the introduction of the 13vPCV has come at an 
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appropriate time. High incidences of IPD in young children have also been reported 
(Roche et al., 2007; Roche et al., 2008; Slaon-Gardner et al., 2011). 
A number of CCs consisted of the same serotype as detected in other CCs, and yet 
these CCs were not identified to be genetically related. These included CC2 (serotype 
19A/19F), CC5 (serotype 19A), CC6 (serotype 19A/15B/15C), CC13 (serotype 19A) and 
CC17 (serotype 19A), indicating that these five complexes may have originated from 
independent sources, or that the complexes have diverged from an original complex 
decades ago. It may be that the success of serotype 19A to cause increasing IPD cases 
after the introduction of the 7vPCV globally could rely on the fact that all strains are not 
clonally related, as demonstrated by the fact that at least five independent clonal 
complexes have been identified in Queensland. This could emerge as a similar issue for 
serotype 22F as we have identified two clonal complexes (CC22 and CC29) that contain 
genetically unrelated isolates of serotype 22F. Since the 13vPCV does not target 22F, it 
is important that these complexes are monitored. Similarly serotype 33F makes up 3% 
of the isolates causing IPD in children, and is not targeted by the 13vPCV. Both serotype 
22F and 33F are targeted by the 15vPCV. 
Serotype 7F (ST191) is highly clonal, and is the second most common serotype 
causing IPD in children in this study. High clonality of serotype 7F has also been 
observed in Scotland, Sweden and the USA (Beall et al., 2006; Jefferies et al., 2004; 
Sandgren et al., 2004). It is interesting to see that serotype 7F appears to be genetically 
diversifying in later years, however it is unknown whether this is due to changes within 
the CC or whether new strains have been introduced from elsewhere into the 
population (Figure 26). If diversification was occurring within the CC, what pressure is 
there for genetic changes, and what are the potential effects on virulence with such 
changes? National routine typing and maintenance of a national database, which could 
also be compared to international data would be required to help determine the reason 
why certain serotypes are genetically diversifying. It is currently unknown why, but by 
using MLVA4 it can be shown that this ‘highly clonal’ serotype appears to become 
genetically diverse. 
Interestingly, despite the introduction of 13vPCV, a number of 7vPCV-serotypes 
are still being observed; particularly serotype 19F which was the fifth most common 
serotype in this study. The 7vPCV was licensed in 2001 and made freely available for 
children in 2005, which means most children should have been vaccinated. There is 
95% vaccine coverage in non-Indigenous citizens and 85% coverage in Indigenous 
citizens across Australia (Barry et al., 2012). In this study we assume that all patients 
have been vaccinated with a pneumococcal vaccine, however due to restricted access to 
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patient data for this study, the vaccination history of 7vPCV is unknown. Therefore we 
are unable to determine whether IPD caused by serotype 19F is due to non-vaccination 
or vaccine failure. A 4% vaccine failure (when an appropriately vaccinated patient 
contracts IPD caused by a pneumococcal serotype that is targeted by the vaccine) in the 
Kimberley Region, Western Australia from 1995 to 2001 has been reported prior the 
introduction of the 23PPV (Mak et al., 2004). Another possibility is that certain strains 
of 19F have developed the ability to evade the vaccine as it has been noted that strain 
MT101 (19F) has been detected in both 2007-2009 and 2010-2012. Further 
examination of specific strains may be required to determine whether the 
microorganisms have developed other mechanisms to evade the effects of the vaccine. 
The third objective of this study was to determine any initial impacts of the 
13vPCV on the pneumococcal population. This is one of the first published studies that 
reports a potential decline in 13vPCV S. pneumoniae serotypes associated with IPD in 
children 0-4 years since the introduction of the vaccine in Queensland, Australia 
(Figure 22), however we are unable to determine if this decline is significant as further 
time points are required. This initial decline is a promising result as there was a 
reported 168% increase in non-7vPCV serotypes in children under five in Australia in 
2008 compared to 2002, with a four-fold increase due to serotype 19A (Barry et al., 
2012). However, it would be desirable to have at least five years surveillance data post-
13vPCV introduction for a more accurate reflection on the impact of the vaccine, as 
recommended by Murray et al. (2014).  
This initial decline may indicate that the 13vPCV is already starting to 
successfully reduce the incidence of IPD in young children, as is being observed 
elsewhere in the world. In the USA, since the introduction of 13vPCV in 2010, there has 
been a 53% decline in IPD in children under 24 months compared to the calculated 
average in 2007-2009. This decline was largely due to falls in 13vPCV-serotype 19A 
(58%), serotype 7F (54%) and serotype 3 (68%) (Kaplan et al., 2013). Similarly, a 
decline in 13vPCV serotypes was also observed in Alaska in 2009-2011 (Singleton et al., 
2013). Picazo et al. (2013) also reported a decrease in IPD caused by 13vPCV serotypes 
in 2010-2011 compared to 2007-2010 in Madrid, Spain, and a study in German 
children has shown an overall decline in 13vPCV-serotypes causing IPD despite an 
increase of serotype 19A in 2010 and 2011 (Van der Linden et al., 2013). A study of 
French children reported observing a significant lowering of carriage rates of serotype 
19A, 7F and 6C with a single dose of 13vPCV, compared to children only vaccinated 
with 7vPCV (Cohen et al., 2011), however lowering carriage rates does not necessarily 
reflect a decrease in invasive disease.  
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A steady decline in 7vPCV-serotypes causing IPD from 12 isolates (2007) to 5 
isolates (2012) has also been observed, which is as expected. Serotype 1, 7F and 19A 
caused most cases of IPD but since the 13vPCV targets these serotypes, it is hoped 
further decline will occur in the future. It has also been shown that serotype 6A 
provides cross-protection against serotype 6C as there was a 96% OPA 
(opsonophagocytic assay) response (Cooper et al., 2011). Since the 13vPCV only targets 
serotype 6A and 6B but not 6C, it is hoped that serotype 6C causing IPD will decline in 
the future due to cross-protection. 
On the other hand this study has not observed a decline in 13vPCV serotypes in 
older children; in fact pneumococcal isolates increased in 2011 and 2012 (significant 
increase observed from 2008 to 2011; p=0.0078). This may be because children older 
than two years do not have access to the free Government funded vaccination schedule 
in Australia and are hence susceptible to the 13vPCV serotypes. However it is 
important to note that increased surveillance, blood culturing or even reporting 
changes may explain the rise in older children. It is hopeful though that as the 13vPCV 
is continued to be implemented for children under two, IPD cases will decline in the 
older age groups as vaccinated children become older. The effects of herd immunity 
may also decrease IPD cases in older children. Herd immunity is an important factor in 
reducing IPD cases in various populations (Reingold et al., 2005). 
The final objective of this study was to determine whether any emergence of non-
13vPCV serotypes in the Queensland population could be predicted. An increase in non-
13vPCV serotypes was not observed, however 33% of IPD cases in children were 
caused by these serotypes in 2010-2012 (Figure 29). A universal vaccine that targets all 
serotypes, or at least more, will most likely be required in the future.  
Serotype replacement has not been observed either since the introduction of the 
13vPCV in 2011 in this study, however there have been increases of serotype 6C and 
23B, both not targeted by the 13vPCV. Altogether, serotype 6C, 15C and 33F (9% of 
isolates) could increase as they are not targeted by the 13vPCV. It is recommended that 
surveillance by way of MLVA continue to enable reporting of future serotype 
replacement. In South Australia there have also been reports of increases in non-
13vPCV serotypes (Johnson et al., 2012). 
A number of clonal complexes have emerged and disappeared in the Queensland 
pneumococcal population over six years (2007 to 2012). Some clonal complexes that 
have disappeared include serotypes that were not targeted by any pneumococcal 
vaccine (CC4 –serotype 38, CC21 – serotype 8 and 11A, and CC30 – serotype 10F), 
indicating that the population structure can change due to natural fluctuations and are 
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not necessarily eliminated by vaccines. Due to some clonal complexes being highly 
clonal and only consisting of a single serotype, it is expected that CC1 (serotype 7F), 
CC3 (serotype 3) and CC8 (serotype 1) will gradually decline and disappear as they are 
targeted by the 13vPCV. However as serotype 1 is more commonly observed in older 
children, the effects of the 13vPCV may not be observed in the short term.  
Conversely, a number of clonal complexes have emerged over the six years (2007 
to 2012), indicating the possible beginnings of serotype replacement, especially those 
complexes containing serotypes not targeted by the 13vPCV. It will therefore be 
important to monitor the changes of CC9 (serotype 6C), CC14 (serotype 15C), CC18 
(serotype 23B), CC25 (serotype 6C), CC27 (serotype 15B/15C), and CC29 (serotype 
22F). Continued surveillance for changes to these clonal complexes, especially CC29, 
will assist in vaccine health policy decision making and the impact of introducing the 
15vPCV (targets serotype 22F and 33F). Increases in serogroup 15 and serotype 22F 
have been reported after the introduction of the 7vPCV (Duggan, 2010; Hicks et al., 
2007; Jacobs et al., 2008). 
Furthermore, two potential capsule switches have been observed when using 
MLVA4. These were a switch from serotype 1 to 4, and serotype 19A to 15C. Both of 
these capsule switches will be verified by molecular typing method, as described in 
Chapter 6. 
Other serotypes that deserve monitoring are serotypes 15B and 15C. Serotype 
15C makes up 3% of IPD pneumococci, and could potentially become a replacement 
serotype. Interestingly, MLVA1 and MLST identify potential capsule switches between 
serotype 15B and 15C, however this can potentially be explained by the fact that 
serotype 15B and 15C can interconvert in vitro and in vivo at low frequencies since they 
only differ in the presence or absence of an acetyl group in the polysaccharide capsule 
(Meats et al., 2003; Venkateswaran et al., 1983). It would be interesting to determine 
whether this interconversion could aid serogroup 15 in evading any future vaccines if it 
did not target all serotype 15 types. 
5.5 Conclusions and future perspective 
Despite the introduction of 13vPCV in July 2011, preliminary results seem to 
indicate that this new vaccine may be already decreasing 13vPCV serotypes in young 
children (<5 years old) in 2012. This is a positive outcome for use of the 13vPCV. 
Unfortunately, an increase of 13vPCV serotypes in the older children (5-9 and 10-15 
years old) was also observed since the introduction of the 13vPCV. Since these children 
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do not have access to the Government funded 13vPCV, it is understandable that 
13vPCV-serotypes continue to cause IPD in older children. Hopefully as 13vPCV is 
increasingly administered to children 0-2 years, IPD cases will drop in this age group as 
vaccinated children become older. Also the effects of herd immunity may start to take 
hold, decreasing the likelihood for older siblings or children to contract IPD caused by 
13vPCV-serotypes. The 2007-2012 MLVA4 genotyping data serves as a baseline for 
future comparisons. No changes in non-targeted serotypes were observed however 
they still cause about 33% of IPD in Queensland children in this study. No serotype 
replacement was observed, however the most dominant non-targeted serotypes that 
could potentially become replacements were serotypes 6B, 15C and 33F (caused 9% of 
IPD in this study). It will be important to continue monitoring the population structure 
for increases in the number of referred isolates within CC’s and for expansion of clonal 
complexes. In this study, two potential capsule switches in S. pneumoniae isolates in 
Queensland were detected (serotype 1 to 4, and serotype 19A to 15C) using MLVA4 
method but these will need to be verified by use of molecular typing methods such as 
sequencing since a number of other capsule switches were also detected using MLST 
and MLVA1. 
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6.1 Introduction 
The pneumococcal capsule of the bacterium Streptococcus pneumoniae acts as an 
important colonisation and virulence factor in regards to causing human diseases. 
Hence this capsule has become the target of childhood vaccines 7vPCV and 13vPCV 
(Bratcher et al., 2011; Kadioglu et al., 2008). Unfortunately, the introduction of these 
vaccines as well as the continued use of antibiotics has resulted in a shift in the 
pneumococcal population structure caused by serotype replacement and capsule 
switching. Capsule switching was first described by Griffiths (1928). A capsule switch 
to a non-vaccine targeted serotype will effectively leave the pneumococci immune to 
the vaccine, at least until a new vaccine is developed that targets the additional 
serotype(s). More alarmingly, capsule switching has also led to vaccine escape strains 
after the pneumococcus has switched its capsule to a non-vaccine targeted capsule 
(previously explained in Chapter 2.10). 
From the previous chapters, a number of potential capsule switches were 
observed in the Queensland pneumococcal population, using MLST, MLVA1 or MLVA4 
combined with traditional serotyping. Using serotyping and a genotyping method (e.g. 
MLST or MLVA) to characterise the background genome, possible capsule switches can 
be detected when two pneumococci with the same genetic background have two 
different capsules. To verify a capsule switch, sequencing or genotyping the capsule 
cassette is required that ideally reveals possible points of recombination 
(Brueggemann et al., 2007).  
The capsular polysaccharide sequence (CPS) is situated between conserved 
regions dexB and aliA for all serotypes except for serotype 3 and 37 where the wchE 
synthase gene is defect and therefore the tts gene located elsewhere in the genome is 
active (Bentley et al., 2006; Jiang et al., 2001; Wyres et al., 2012). DexB and aliA do not 
participate in capsule formation (Jiang et al., 2001). Sequence analysis of 88 CPS loci 
reveals variable lengths (10 – 30kb) and a range of genes (Wyres et al., 2012). The CPS 
consists of homologous regions at 5’ end (wzg, wzh, wzd and wze) followed by wchA 
that encodes for the initial glucose phosphate transferase that most likely aids 
recombination (Bentley et al., 2006; Jiang et al., 2001). The S. pneumoniae serogroups 
are broken into respective serotypes (e.g. serogroup 6 has eight serotypes 6A, 6B, 6C, 
6D, 6E, 6F, 6G and 6H) (Table 19). Some serogroups do not have serotypes, such as 
serogroup 3, and therefore is designated a serotype as itself (e.g. serotype 3). 
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Table 19: The genetic differences between S. pneumoniae serogroups/serotypes based on 
the capsular locus.  
Some serogroups do not contain distinct serotypes, and the “Serotypes” column is therefore left blank. 
Capsular differentiation has not been provided for all serogroups because there is lacking information 
in the literature.  
 
Serogroup Serotypes Capsule differentiation Reference 
1   Bentley et al., 2006 
2   Bentley et al., 2006 
3  Serotype similar to serogroup 25 and serotype 
38. wchE synthase gene defect. 
Bentley et al. 2006; 
Mavroidi et al., 2007 
4   Bentley et al., 2006 
5   Bentley et al., 2006 
6 A, B, C, D, 
E, F, G, H 
6A and 6B differ at wciP by single base pair at 
positions 192, 195 or 254. 6A, 6C and 6D differ at 
wciN locus, which is also longer in 6A than 6C. 6C 
has unique wciN. 6D has added wciPβ. 6H is a 
hybrid of 6A and 6B. 
Mavroidi et al., 2004; 
Bentley et al., 2006; 
Bratcher et al., 2011; 
Calix et al., 2010; 
Elberse et al., 2011c; 
Park et al., 2007; 
Oliver et al., 2013; 
Park et al., 2015 
7 A, B, C, F Serogroup splits into two syntenic groups – 7A 
and 7F have wcwC whereas 7B and 7C don’t. A 
frame shift mutation in wcwD in 7A distinguishes 
it from 7F. 7B and 7C are very similar to serotype 
40. 
Bentley et al., 2006; 
Mavroidi et al., 2007 
8   Bentley et al., 2006 
9 A, L, N, V 9A and 9V differ from 9L and 9N by insertion of 
wcjD in former pair. Another gene wcjE is 
functional in 9V but mutated in 9A, 9L and 9N. 
Bentley et al., 2006 
10 A, B, C, F Serogroup splits into two syntenic groups – a 
present wciG in 10C and 10F differentiate them 
from 10A and 10B 
Bentley et al., 2006; 
Mavroidi et al., 2007 
11 A, B, C, D 
E, F 
Serogroup splits into two syntenic groups – 
11A/11D/11F and 11B/11C. Disruption of wcjE in 
11E distinguishes it from 11A. A frame shift in gct 
in 11F and 11B differ them from 11A and 11C. 
11E has disrupted wcjE. 
Bentley et al., 2006; 
Calix & Nahm, 2010; 
Mavroidi et al., 2007 
12 A, B, F Nucleotide difference in wciI and wcxB separates 
12A from 12F. The capsule cassette is very 
similar to serotype 44 and 46 
Bentley et al., 2006; 
Mavroidi et al., 2007 
13   Bentley et al., 2006 
14  Similar capsule cassette to serogroup 15, except 
3’ end differs with replacement of lrp in serotype 
14 instead of glycerol-2-phosphate related 
genes. 
Bentley et al., 2006 
15 A, B, C, F Linear polymer in 15A and 15F but a branched 
polymer in 15B and 15C. Variable length TA 
repeats at 5’ end of wciZ differentiates 15B from 
15C. Similar capsule cassette to serotype 14. 
Bentley et al., 2006; 
Jones & Lemercinier, 
2005 
16 A, F  Bentley et al., 2006 
17 A, F  Bentley et al.,2006 
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Serogroup Serotypes Capsule differentiation Reference 
18 A, B, C, F Two base pair difference between 18B and 18C. 
Frame shift mutation of wciX in 18B but not 18C. 
Bentley et al., 
2006Mavroidi et al., 
2007  
19 A, B, C, F Serotype 19A and 19F differ from 19B and 19C by 
an extra sugar molecule and disaccharide side 
chain. A difference in polymerisation linkage and 
different wzy differ 19A from 19F. 
Bentley et al., 2006; 
Mavroidi et al., 2007; 
Morona et al., 1999a 
20 A, B There is 99% similarity between 20A and 20B. A 
mutation in whaF in 20A differs from 20B. 
Calix et al., 2012 
21   Bentley et al., 2006 
22 A, F Serotype 22A and 22F are syntenic Bentley et al., 2006; 
Mavroidi et al., 2007 
23 A, B, F All three serotypes are similar. A wzy-19 is 
present in 23B and 23F, whereas wzy-30 is 
present in 23A. 
Bentley et al., 2006; 
Mavroidi et al., 2007; 
Morona et al., 1999b 
24 A, B, F An extra rbsF is present in 24B and 24F but not 
24A. Genes abp1 and rmlC are frame shifted in 
24B. 
Bentley et al., 2006; 
Mavroidi et al., 2007 
25 A, F Both serotypes similar to serotype 3 and 38. Bentley et al., 2006; 
Mavroidi et al., 2007 
27   Bentley et al., 2006 
28 A, F Both serotypes form a sub-complex. Bentley et al., 2006; 
Mavroidi et al., 2007 
29   Bentley et al., 2006 
31   Bentley et al., 2006 
32 A, F Both serotypes form a sub-complex. 32A has a 
sequence difference in wcyH leading to an extra 
acetyl group at -D-Glcp. 
Bentley et al., 2006; 
Mavroidi et al., 2007 
33 A, B, C, D, 
F 
Serogroup splits into two syntenic pairs – 
33A/33F and 33B/33D. 33A contains intact wcjE 
whereas 33F is disrupted 
Bentley et al.,2006; 
Calix & Nahm, 2010; 
Calix et al., 2012; 
Mavroidi et al., 2007 
34   Bentley et al., 2006 
35 A, B, C, F Serogroup 35 similar to serotype 42. A defective 
transposase and frame shift mutation in wcrK 
differentiates 35A fr 
Bentley et al., 2006; 
Mavroidi et al., 2007 
36   Bentley et al., 2006 
37  wchE synthase gene defect. Bentley et al., 2006 
38  Serotype similar to serogroup 25 and serotype 3. 
Serotype 38 differs by presence of wcyV instead 
of wcyE. 
Bentley et al., 2006; 
Mavroidi et al., 2007 
39  Contains a wcrC-related gene that closely 
resembles wefM of Streptococcus oralis. 
Bentley et al., 2006; 
Bush et al., 2014 
40   Bentley et al., 2006 
41 A, F Serotype 41A has 6 carbohydrate units in a 
doubly-branched repeating unit. 
Acetyltransferase acts on the rhamnopyranosyl 
sidechain E in serotype 41F but not 41A. 
Bentley et al., 2006; 
Peterson et al., 2014 
42  Serotype 42 is similar to serogroup 35. Bentley et al., 2006; 
Mavroidi et al., 2007 
43   Bentley et al., 2006 
44  A frame shift of fnlC is present. Very similar 
capsule cassette to serogroup 12 and serotype 
46. 
Bentley et al., 2006; 
Mavroidi et al., 2007 
45   Bentley et al., 2006 
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Serogroup Serotypes Capsule differentiation Reference 
46  Very similar capsule cassette to serogroup 12 
and serotype 44. 
Bentley et al., 2006 
47 A, F  Bentley et al., 2006 
48   Bentley et al., 2006 
 
Besides from vaccine immunity and vaccine escape, capsule switching events can 
also have alarming impacts on pneumococcal virulence. Just to reiterate from Chapter 
2.10, a study demonstrated that capsule switching can enhance S. pneumoniae serotype 
3 virulence in respiratory diseases (Sabharwal et al., 2014). Since serotype 3 is 
common in Australian populations, it would be interesting to discover whether other 
serotype switches have an effect on virulence. The fact that the background genome 
may impact the virulence properties of S. pneumoniae in combination with the capsule 
cassette is interesting. It has been hypothesised that BOX elements used in several 
MLVA methods may have regulatory functions associated with virulence as they are 
located near such genes (Kolkman et al., 1997; Martin et al., 1992). 
Since it is important to accurately detect pneumococcal capsules, several capsule 
typing methods have been developed. The traditional serotyping method (Quellung 
reaction) is universally used and considered the ‘gold standard’; however it is highly 
expensive, limiting its use to large research laboratories, requires pure culture 
capsulated pneumococci and requires multiple Factor serum to distinguish between 
some serotypes. 
On the other hand, complete analysis of the capsule cassette would undoubtedly 
rely on whole sequencing. Sequencers such as Illumina Genome Analyzer or Illumina 
HiSeq have been used (Croucher et al., 2012). Most of the capsule cassettes were 
determined by using Expand Long Template PCR System from Roche which is able to 
sequence up to 20kB (Ansaldi et al., 2011; Bentley et al., 2006; Brueggemann et al., 
2007; Wyres et al., 2013). Expand Long Template PCR system with DNAse I digestion 
and sequencing on AB377A has also been used (Jiang et al., 2001). While whole CPS 
sequencing would produce complete results, the cost of applying this for routine 
diagnosis would be currently too expensive; therefore cheaper and faster PCR 
techniques have been developed to determine capsule types. 
Multiplex PCR has also been adopted for sequencing of short regions within the 
capsule cassette. Pai et al. (2006) developed a seven multiplex PCR with 29 primer 
pairs which could identify 17 serotypes. This method has been widely applied and 
optimised to regional pneumococcal populations around the world. Ahn et al. (2012) 
modified this multiplex PCR to a 35 primer pair; however both methods still utilise gel 
electrophoresis for analysis. 
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Bratcher et al. (2011) sequenced the wciP, wzy and wzx genes for a capsule 
profiling technique for serogroup 6. The wciN gene and flanking regions were 
sequenced to analyse evidence of recombination. However, as wzy and wzx are highly 
conserved across all serotypes, this profiling method would not be suitable as a capsule 
typing method that distinguishes all serotypes.  
Similarly, Elberse et al. (2011c) used a long-PCR method and allele-specific PCR 
using wzy and rmlC to characterise serotypes 19A and 19F, and serogroup 6. This 
method was specific enough to determine capsular subtypes within each serotype that 
could allow further information about microevolution. The significance of determining 
capsule sub-types may reveal a genetic relationship between the emergence or success 
of certain S. pneumoniae strains and the types of vaccines used. Elberse et al. (2011c) 
identifies that serotype 19A subtype II (19A-II) may have enhanced polysaccharide 
production due to a difference in the wzg locus compared to serotype 19A-I, 
particularly since subtype 19A-II has been observed more frequently in vaccinated 
children. Similarly, Mavroidi et al. (2004) devised a CPS profiling method for 
characterising serogroup 6, produced from the presence or absence of 254 homology 
groups within the genome. In this study homology groups were defined as cps genes 
that shared significant sequence homology using the program TribeMCL (Mavroidi et 
al., 2004). Other PCR based serotyping, as previously discussed in Chapter 2 Literature 
Review are presented in Appendix A4: Comparison of various pneumococcal PCR-based 
serotyping methods. While most of these capsule typing methods have enhanced 
knowledge of specific serotypes, there is no current PCR based method that 
characterises all 98 known serotypes. 
This study examines a novel systematic approach for the identification of suitable 
genetic targets to efficiently genotype the capsule locus. A bioinformatics program 
called Minimum SNPs has been used for allele-specific characterisation of certain 
bacteria by selecting highly discriminatory targets or single nucleotide polymorphisms 
(SNPs) within a genome with the maximum Simpson’s Index of Diversity (D) 
(Robertson et al., 2004; Stephens et al., 2007). Minimum SNPs has been applied to 
genotype or characterise Neisseria meningitidis, Enterococcus faecalis, Enterococcus 
faecium, Escherichia coli, Campylobacter jejuni and Staphylococcus aureus as an 
alternative method to MLST (Price et al., 2006; Rathnayake et al. 2011; Sheludchenko et 
al., 2010; Stephens et al., 2007). Stephens et al. (2007) applied this Minimum SNPs to 
characterise mec cassette in S. aureus, by identifying 22 out of 34 target genes to 
genotype 46 Staphylococcal cassette chromosomal mec (SCCmec). The algorithm makes 
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no assumptions concerning the population structure or diversity (Robertson et al., 
2004).  
This similar idea can be applied to the S. pneumoniae cassette-like capsule locus 
to characterise the serotypes. This assay can be used to identify a highly discriminatory 
minimum set of genes (instead of the traditional SNPs) within the CPS cassette that 
characterises all or most of the serotypes (Robertson et al., 2004). The bioinformatics 
computer program Minimum SNPs has been developed to “identify highly informative 
sets of SNPs” by using a binary system of T = present and A = absent to identify each 
binary marker (Figure 34) (Robertson et al., 2004). A pseudoDNA sequence is produced 
for each capsule type and Minimum SNPs analyses the combinations of binary markers 
to maximise the Simpson’s index diversity (D). A minimum set of ‘targets’ (capsule 
genes) are identified with the highest D-value and are used to characterise clinical 
strains of bacteria. In the example shown, binary markers 2 and 3 provide a D=1 i.e. 
they completely differentiate between each serotype (Figure 34). As a result, only 
binary markers 2 and 3 need to be amplified using PCR, and this is called the 
pneumococcal ‘barcode’.  
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Figure 34: An illustration of the Minimum SNPs strategy used to identify the minimum 
‘targets’ to characterise each capsule type (3 types listed).  
To differentiate between 3 strain types (example only), the Minimum SNPs program selects 
binary marker 2 and 3 which provides the highest Simpson’s Index of Diversity (D=1). Binary 
marker 5 could also be selected to replace binary marker 2. Therefore, amplification of binary 
marker 2 (e.g. using PCR) should be present in strain type 1 and 2, but absent in strain type 3. 
Similarly, binary marker 3 should be present in strain type 1 and 3, but absent in strain type 2. 
T= present genes; A= absent gene; pseudoDNA sequence is the combination of T’s and A’s. 
 
 
Primers will be designed for the selected genes (e.g. binary marker 2 and 3 from 
Figure 34), and conventional or real-time PCR will be used to detect the presence or 
absence of genes that determine pneumococcal capsular types. A present gene is 
identified by an amplified band observed using gel electrophoresis (conventional PCR) 
or a melt curve using real-time PCR; on the other hand, an absent gene is identified by 
observing no visible band on gel electrophoresis or no visible melt curve. The barcode 
for each pneumococcal strain is then formed (will vary in length depending on the 
number of target genes required). Allele-specific PCR (e.g. using SNPs within the target 
genes) will be used to distinguish subtypes, if applicable – this would be used if two 
pneumococcal strains appear to have the same barcode associated to a known 
serogroup and we know that the serogroup can be split further into serotypes. 
Furthermore, capsule switching can be verified by combining the Minimum SNPs assay 
with MLVA genotyping.  
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Therefore to summarise, this study aims to develop a novel capsule typing 
method based on the bioinformatics bi-numeral Minimum SNPs assay to characterise 
all 98 known pneumococci capsule genes. The objective is to improve on current 
molecular capsule typing methods. By using gene-specific real-time PCR and allele-
specific real-time PCR, Queensland isolates of invasive S. pneumoniae will be tested. 
This capsule typing method would also be used to determine capsule switching in 
invasive S. pneumoniae in conjunction with our previously developed MLVA4 
genotyping method. It is hypothesised that the novel capsule typing can detect capsule 
types and sub-types of S. pneumoniae and that capsule switching events can be verified 
by combination of the novel capsule typing with MLVA4. This will be a novel 
application of the Minimum SNPs to S. pneumoniae to create real-time PCR and allele-
specific PCR for characterising serotypes, capsule sub-types and capsule switches in 
conjunction with a genotyping method. 
6.2 Method 
6.2.1 In silico analysis and MinimumSNPs 
A search of the NCBI database and literature for all known sequenced S. 
pneumoniae capsule cassettes was performed (Bentley et al., 2006; Bratcher et al., 
2011; Calix et al., 2012; Park et al., 2007;). A “mother template” consisting of 
approximately 182 possible capsular genes that have been found in the available 
pneumococcal capsule sequences was manually created (Appendix A5: In silico analysis 
of 182 targets in the pneumococcal capsule cassette). For each of the known serotypes, 
an artificial binary genetic code called a “pseudoDNA” sequence was created based on T 
= present, and A = absent (example shown in Figure 35). An allele code for each 
serotype was designated to each pseudoDNA sequence (e.g. serotype 1 = cps_1, etc.).  
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Figure 35: An example of a ‘pseudoDNA’ sequence for S. pneumoniae serotype 8 and 11A 
based on the binary system of T = present and A = absent for each capsule gene that 
makes up the ‘mother template’. 
 
 
All S. pneumoniae pseudoDNA sequences were analysed by Minimum SNPs 
program following the software protocol (Stephens et al., 2007). The program 
determined the minimum number of targets (CPS genes) that would provide the 
maximum Simpson’s Index of Diversity (D=1.0) for all known S. pneumoniae serotypes. 
Using the chosen set of target genes, primers were designed using PrimerExpress v2.0 
software (Applied Biosystems, Australia). A Clustal Omega Alignment was performed to 
ensure that the primers would bind across all expected serotypes. If SNP differences 
were found in the primer binding sites, degenerative primers were designed (e.g. 50% 
have alanine (A) and 50% have a cytosine (C) at the same position in the designed 
primer). 
Serotypes that could not be distinguished by the presence/absence of genes 
alone were further analysed for SNP differences, for example serotypes 15B and 15C 
have the same pseudoDNA sequence therefore SNP differences were detected in their 
CPS. Clustal Omega Alignment (accessed https://www.ebi.ac.uk/Tools/msa/clustalo/) 
of the whole CPS cassette revealed SNP differences between these serotypes.  Allele-
specific primers were designed using PrimerExpress v2.0 software, manually restricted 
to contain the SNP at the 3’ end of the forward or reverse primer. A sub-terminal 
mismatch primer was designed if the 3’ end SNP was either going to be a difference 
between A or T because real-time PCR may struggle to detect the difference between 
these two weaker base-pairs (Robertson et al., 2004). For example the true primer 
sequence reads 5’AACTGTATCA3’ while the sub-terminal primer sequence reads 
5’AACTGTACCA3’ where the thymine (T) has been substituted with a cytosine (C) so 
CHAPTER 6  A novel capsular typing method for 
Streptococcus pneumoniae using Minimum SNPs 
184 
 
there is a more noticeable difference when the primer binds to a different SNP at the 3’ 
end. 
6.2.2 Validation of conventional PCR 
Invasive S. pneumoniae isolated from children 15 years or younger from January 
2007 to December 2012 were resuscitated, isolated and re-cultured (using a single 
colony) to ensure colonies were genetically identical to each other on the replicate 
plate. Two ATCC S. pneumoniae control strains (ATCC49619 serotype 19F and 
ATCC6306 serogroup 6) were included in this study. Furthermore, Streptococcus 
agalactiae and Streptococcus pyogenes strains were included for testing. Purified DNA 
was extracted from the two S. pneumoniae ATCC control strains, S. agalactiae and S. 
pyogenes using QIAamp DNA Mini Kit (50) (Qiagen, Australia). 
Minimum SNPs primers (Sigma Life Sciences, Australia) were diluted to 10µM 
with Ultrapure Distilled water (Invitrogen, USA). Primer sequences are shown in Table 
22 of Results. To verify that capsule typing could be applied to the crude DNA 
thermolysate, conventional PCR was performed using a reaction mix containing PCR 
Grade Nucleotide Mix (Roche, USA), Taq DNA polymerase (Roche, USA), 10µM forward 
and reverse primers, MgCl2 (Invitrogen, USA), PCR reaction 10X buffer (Roche, USA) 
and Ultrapure Distilled water (Invitrogen, USA) with 2µL of the DNA thermolysate. 
Heat-gradient PCR was performed using a BioRad C1000 Touch Thermal Cycler 
(BioRad, Australia) as follows: 1min at 95oC, 40 cycles of 95oC for 30sec, gradient 
temperature 60oC to 50oC for 30sec, and 72oC for 30sec, followed by 10min at 72oC 
before finally holding at 4oC. To detect the absent or presence of the capsule genes, gel 
electrophoresis was used (2% agarose, 80V, 400mA, SybrGreen stain). 
Later experiments used AmpliTaq Gold® 360 Master Mix (Applied Biosystems, 
USA), primers and Ultrapure Distilled water for conventional PCR. AmpliTaq Gold® 
produced clearer bands and reduced the need for optimisation. 
Further validation tests were performed to verify if the capsule genes could be 
amplified in the Queensland S. pneumoniae isolates (Table 20). Conventional PCR was 
performed with the appropriately determined annealing temperature, amplifying all 
targeted capsule genes from the available Queensland isolates of known serotypes. 
MinimumSNPs capsule typing was also applied to Streptococcus pyogenes and 
Streptococcus agalactiae to determine whether genes could amplify in a different 
species. 
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Table 20: S. pneumoniae isolates used to validate the initial 23 capsule targets for 
MinSNPs Capsule Typing. 
Serotype has been designated from Quellung reaction; ID (identification) has been assigned to 
each pneumococcal isolate; Year – year that the pneumococcal isolate was taken from patient 
suffering from invasive pneumococcal disease (IPD); MLST – sequence type (ST); MLVA4 – 
MLVA type (MT); Gel # - position of the amplified gene in the gel electrophoresis images 
contained in the results section of Chapter 6; Notes – mention if the isolate has been associated 
with the capsule switch. 
Serotype ID Year MLST MLVA4 Gel # Notes 
1 36 2011 306 39 1 Potential capsule switch with serotype 4. 
3 8 2011 1230 8 2  
4 157 2009 - 157 3  
6A 224 2008 4237 107 4 Potential capsule switch with serotype 6C. 
6B 227 2008 - 227 5  
6C 109 2010 4237 109 6  
7F 21 2011 191 21 7  
8 162 2009 53 162 8 Potential capsule switch with serotype 11A. 
9N 164 2009 66 164 9  
9V 307 2007 - 307 10  
10A 282 2007 2068 282 11  
10F 169 2009 4084 169 12  
11A 93 2010 557 93 13  
12F 48 2011 3523 48 14  
14 277 2007 - 277 15  
15B 50 2011 199 50 16  
15C 54 2011 52 53 17  
16F 375 2012 9667 375 18  
18A 55 2011 241 55 19  
18B 291 2007 1255 291 20 Potential capsule switch with serotype 18C. 
18C 292 2007 - 292 21  
19A 59 2011 411 59 22 Potential capsule switch with serotypes 15B 
and 15C. 
19F 294 2007 - 294 23  
22A 208 2008 3705 208 24  
22F 143 2009 9663 143 25  
23A 4 2011 42 4 26  
23B 144 2009 9664 144 27  
23F 145 2009 - 145 28  
24F 214 2008 72 214 29  
33B 385 2012 - 385 30  
33F 303 2007 60 217 31  
34 220 2008 9665 220 32  
35B 221 2008 9670 221 33  
35F 152 2009 446 152 34  
38 17 2011 393 17 35  
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6.2.3 Real-time PCR and analysis 
Real-time PCR (rtPCR) was determined to be a faster and simpler method to type 
the capsule genes of S. pneumoniae, compared to conventional PCR which requires gel 
electrophoresis for observing the amplified genes. An 18µL reaction containing 
SybrGreen mastermix (Invitrogen, USA), Ultrapure Distilled water and primers (10µM) 
was combined with 2µL S. pneumoniae DNA thermolysate in real-time PCR tubes. These 
were placed into a 72-well ring on a real-time PCR Qiagen RotorGene (Qiagen, 
Australia) or Corbett RotorGene (Corbett, Australia). Real-time PCR conditions were as 
follows: initialise for 10min at 52oC, cycle 40 times at 95oC for 15sec, 67oC for 20sec and 
72oC for 20sec, followed by a standard melt curve (60oC – 90oC) rising 1degree/step, 
and finally performing a High Resolution Melt curve (60oC – 95oC) rising 
0.02degrees/step. 
Analysis of rtPCR results included the Melt A. Green heat curve, and the High 
Resolution Melt (HRM) curve. Since the amplified products are tagged with fluorescent 
SybrGreen dye, the Melt A. Green setting detects the fluorescent dye and a melt curve is 
produced when there is an amplified product (present gene). If no product is present 
(absent gene) then no melt curve should be visible. 
However, because rtPCR is known to be highly sensitive, an HRM curve was also 
performed. During the HRM step, because the melting temperature is raised 
0.02degrees/step, this means that we can detect SNP differences within amplified 
products as they will have slightly different melt curves. To analyse the HRM, a known 
positive control must be included for each gene in every rtPCR run. The positive control 
is used to compare the unknown samples and verify if any positive amplifications 
match the expected positive control – if it does not match, then it is possible that the 
amplified product is significantly different from the positive control and possibly not a 
present gene.  A normalised difference graph using HRM identifies whether amplified 
genes are similar to the positive control (within ±5 units), or different. 
6.2.4 Double-blind test – rtPCR and conventional PCR 
Following the determination of whether rtPCR can be used to amplify capsule 
genes, a double-blinded test was performed. A sample of 48 S. pneumoniae isolates 
were randomly selected (from 317 isolates) within the restrictions that all Queensland 
serotypes were represented (35 serotypes) (Table 21). All isolates were re-labelled 
with a coded number by someone who wasn’t directly involved in the experiment. The 
order in which the isolates were to be tested was randomly assigned by drawing lots 
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from a container. Each gene was amplified twice per isolate, and all targeted capsule 
genes were applied. A positive control was included in each run as well as a negative 
template control and a water control. 
All rtPCR results were analysed using the RotorGene Q Series software v2.3.1 
(Qiagen, Australia). Stringent criteria had to be met when analysing the absence or 
presence of the capsule genes; firstly, quantitative analysis was performed by setting 
the threshold scale on the Cycling A. Green at about half-way on the amplification 
curves. Any genes that fell below this threshold were considered to be absent. A melt 
curve that crossed over the threshold was considered to be present. The negative 
template control and water control always had to fall below this threshold. 
Following this, analysis of the Standard melt curve enabled confirmed detection 
of amplified capsule genes (designated ‘present’). The positive control was used for 
comparison, and any amplified genes that did not match the curve of the positive 
control were considered to be absent (Figure 40). Curves that appeared to slightly 
deviate to the left or right of the positive curve were hesitantly considered a present 
gene because SNPs may be present in these genes which can cause the slight deviations. 
Sequencing would be required to confirm this. 
Finally, analysis of the HRM curve allows even further stringent analysis of those 
genes that have appeared to be present in the S. pneumoniae isolates. Again, the 
positive control is used for comparison by setting it as the normalised peak in the 
difference graph, and is observed as a flat line at position ‘0’ (Figure 42). The other 
genes that deviate more than ±5 units from this normalised line were considered 
significantly different and therefore labelled an ‘absent’ gene. However, similar to the 
standard melt curve, where genes seem to have a nice bell-curve even though it lies 
outside of the ±5 guidelines, they could be ‘present’ despite SNP differences. 
Conventional PCR and gel electrophoresis was also performed on the double-blind to 
determine whether it can be used for capsule typing. 
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Table 21: S. pneumoniae isolates used for the double-blind validation of the novel capsule 
typing method. 
Double blind code – randomly selected for each isolate by another person; ID (identification) 
was only revealed after all isolates were capsule typed; serotype is designated based on 
Quellung serotyping method (performed at QHFSS); Year – year that the pneumococcal isolate 
was taken from patient suffering from IPD; MLST – sequence type (ST); MLVA4 – MLVA type 
(MT); Notes – identify whether a possible capsule switch has been previously detected. 
Double 
blind code 
ID Serotype Year MLST 
(ST) 
MLVA4 
(MT) 
Notes 
1 290 18A 2007 9082 96  
2 291 18B 2007 1255 291 Potential capsule switch with 
serotype 18C using MLST. 
3 297 22F 2007 1012 209 Potential capsule switch with 
serotype 33F using MLST. 
4 299 23A 2007 42 299  
5 300 23F 2007 - 300  
6 301 23F 2007 - 301  
7 32 7F 2011 191 32  
8 34 9V 2011 - 34  
9 37 1 2011 306 35  
10 47 11A 2011 53 47 Potential capsule switch with 
serotype 8 using MLST 
11 77 19A 2011 - 77  
12 98 18C 2010 1255 98 Potential capsule switch with 
serotype 18B using MLST. 
13 112 6C 2010 4237 107 Potential capsule switch with 
serotype 6A using MLVA1. 
14 167 1 2009 304 167  
15 170 10F 2009 9661 170  
16 172 15B 2009 411 172 Potential capsule switch with 
serotype 19A and 15C. 
17 208 22A 2008 3705 208  
18 385 33B 2012 - 385  
19 386 6A 2012 - 386  
20 214 24F 2008 72 214  
21 231 7F 2008 191 27  
22 233 8 2008 53 233 Potential capsule switch with 
serotype 11A using MLST. 
23 261 12F 2008 3523 48  
24 304 6B 2007 - 304  
25 327 19A 2007 63 60  
26 335 11A 2012 9668 93  
27 264 18C 2008 1255 264 Potential capsule switch with 
serotype 18B using MLST. 
28 279 38 2007 393 279  
29 275 3 2007 9673 11  
30 283 10A 2007 9671 283  
31 284 15B 2007 199 284 Potential capsule switch with 
serotype 15C using MLST. 
32 285 15C 2007 411 59 Potential capsule switch with 
serotype 15B and 19A using 
MLVA4. 
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Double 
blind code 
ID Serotype Year MLST 
(ST) 
MLVA4 
(MT) 
Notes 
33 286 15C 2007 199 286 Potential capsule switch with 
serotype 15B using MLST. 
34 343 19F 2012 - 293  
35 344 23B 2012 439 344  
36 345 33F 2012 60 105  
37 366 33F 2012 1012 366 Potential capsule switch with 
serotype 22F using MLST. 
38 368 35F 2012 1635 368  
39 352 35B 2012 198 402  
40 372 7F 2012 191 22  
41 373 9N 2012 66 373  
42 378 4 2012 306 36 Potential capsule switch with 
serotype 1. 
43 382 14 2012 - 171  
44 374 34 2012 1439 374  
45 375 16F 2012 9667 375  
46 376 22F 2012 698 376  
47 ATCC4
9619 
19F - - -  
48 ATCC6
306 
6A - - -  
 
6.3 Results 
6.3.1 In silico analysis of MinimumSNPs 
There was no complete capsule sequence for serotype 6F, 6G, 6H, 11E or 24B 
available in the NCBI database, therefore only 93 CPS (out of 98) were used for 
analysis. The mother template consisted of 182 capsule genes that were found 
associated with 93 serotypes. The ‘pseudoDNA sequence’ for each of the 93 serotype 
was manually created for analysis by the MinimumSNPs program (Appendix A5: In 
silico analysis of 182 targets in the pneumococcal capsule cassette.) The Minimum SNPs 
software narrowed this down to 23 capsule genes that would distinguish between most 
serotypes. Using 23 CPS targets could distinguish 36 out of 93 serotypes, and 39 out of 
46 serogroups, with a Simpson’s Index of Diversity (D) = 0.9895. The serotypes that 
formed complexes (i.e. the capsule profiles were exactly the same) were serotypes 7B 
and 40, serotypes 35A, 35C and 42, serotypes 33A, 33F and 37, and serotypes 12A, 12B, 
12C, 44 and 46. A total of 88 primer sets were initially designed to amplify all 23 CPS 
targets because most gene targets required more than one primer set to ensure all 
expected serotypes were targeted (Table 22).  
The 88 primer sets were then re-analysed using MinimumSNPs to determine 
whether a smaller set of primers could be used to distinguish the Queensland S. 
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pneumoniae isolates. It was determined that 18 primer sets out of the previous 88 
primer sets plus wzg internal control (19 primer sets in total) were required to 
discriminate the 35 Queensland serotypes with a Simpson’s Index of Diversity of 
0.9933. Not all serotypes were 100% distinguishable including serotypes 22A and 22F, 
serotypes 19A and 19F, serotypes 18B and 18C, and serotypes 15B and 15C. 
 
Table 22: The 88 primer set identified to amplify 23 capsule genes in S. pneumoniae. 
Yellow highlighted genes indicates those used for Queensland serotypes only, while all 93 
serotypes can be identified using both the yellow highlighted and purple highlighted genes. All 
primers have been searched in NCBI BLAST to confirm that both forward and reverse primers 
amplify in expected pneumococcal serotypes. The penalty score, calculated by the primer 
designing software ( a score below 100 is considered ideal for the primers), are all below 20. 
Accession number – representative isolate taken from NCBI database and used to design 
primers; Sero. – serotype: L – our designated number for each CPS gene from the 182-gene 
mother template; Gene – targeted CPS gene; Forward and reverse primer are in 5’ to 3’ 
directions; AL – expected length of the amplified product; Tm – melting temperature (oC); Ta – 
annealing temperature (oC); %gc – guanine (G) and cytosine (C) content in the amplified 
products; notes – contain details regarded in silico amplification of primers in expected 
serotypes. 
 
Accession Sero L Gene Forward Primer Reverse Primer AL Tm Ta %gc Notes 
CR931639 6B 15 rmlB TTCGCTTCCACCATGT
ATCG 
GAGGCTGCCTTGGTTGA
TGA 
151 80 58 49 Perfect. 
CR931648 9V 65 wcjD TCAGGCAATTCACCTT
CCAAT 
GAGCGATCGATTAGAGG
ATATTATCTC 
151 73 54 33 Perfect - only 9A and 9V 
annealing 
CR931681 22A 22 glf GCCTTCGTTTTGAGCA
TGAGA 
TCATGCGTGATAACTGTC
TTTGG 
151 76 56 40 Perfect for serotypes 22A, 
22F, 17A, 41A, 41F, 16A, 31 
and 47A only. 
CR931672 18B 22 glf GCCAGCAGAAGCACA
AGCTA 
TTTGCCCCACTGTTTCTCT
GT 
151 75 55 38 Perfect for most serotypes. 
CR931706 35C 22 glf CCGTAGCCTTCGCTTT
GATC 
CGTGATAACTGTCTTTGC
CTGTGT 
151 76 56 40 Perfect for serotypes 35C, 42, 
33A, 33F and 47F only. 
CR931651 10C 22 glf GAGCAAACGACTCAC
ATGCAA 
TGATAAAGGGTGGCAGC
TCAGT 
151 77 57 44 Perfect for serotype 10C only. 
CR931689 25A 22 glf AATTATCAAGGAAAT
GCCGTTGTTA 
AAGGTTCATCTCCACGTT
TCCA 
151 74 55 36 Perfect for serotypes 36, 25A, 
25F and 38 only. 
CR931700 33C 22 glf TGCCCAGCAAACGGC
TAA 
AAATGGCGGAAGGTCTG
TTG 
151 77 57 43 Perfect for serotype 33C only. 
CR931633 2 22 glf GTTGGGCTAGGAGTG
GATTGC 
CAAGCACTTCGTGCTTAA
AACG 
151 77 56 42 Perfect for serotype 2 only. 
CR931680 21 22 glf CATTGGAGGGAACAT
ATACTGTGAGA 
GTTCGCGACAGGTGAAT
TGA 
151 74 54 35 Perfect for serotypes 21 and 
37 only. 
CR931666 15F 22 glf GACGCTCAGCAACGG
AACTT 
ACTTCAACGTCTTTAAGC
ATATTTTCG 
151 74 55 35 Perfect for serotypes21, 15F, 
31, 35C, 42, 33A, 33F, 37, 34, 
47F and 39 only. 
CR931716 43 22 glf CATTGGTGGGAACAT
CTATTGTGA 
GTTTGCGACAGGTGAGT
TGACA 
151 75 56 38 Perfect for serotypes 31, 41A 
and 43 only. 
CR931679 20A 22 glf CGTCAACTCGCCTGTA
GCTAATT 
CGGCTCAACATCCTTCAT
ATCA 
151 77 56 42 Perfect for serotypes 15F, 20, 
31, 33A, 33F, 35A, 35C, 42 and 
47F only. 
CR931649 10A 22 glf CATTAAACGCCTTCCA
GTTCGT 
ACGGTGAGCAAAGAAAT
CAACA 
151 75 55 38 Perfect for serotype 10A and 
10B only. 
CR931652 10F 22 glf AGATTGCTGAGCAGA
CGACTCA 
GGTGGCAGCTCAGTAGC
AGAA 
151 78 57 44 Perfect for serotype 10C and 
10F only. 
CR931707 35F 22 glf GCCAGCAGAAGCACA
AGTTAAGAT 
TTTGCCCCACTGTTTCTCT
GT 
151 75 55 37 Perfect for serotypes 35F, 29 
and degenerative primer for 
48, 41F, 40, 35B, 33D, 33B, 
24F, 24A, 22A, 22F, 19C, 18F, 
18C, 18B, 17A, 17F, 13, 7F, 7A, 
7B, 6A, 6B only. 
CR931633 2 17 wchA TTTTTGCTCAGACGCG
TATAGG 
CGAGGATCATCGTCCAC
CTT 
151 77 56 42 Half of serotypes anneal. 
CR931672 18B 17 wchA AGATGGCGGACCAGC
TATTTT 
CTTAAACATACCACCTTG
CATCGT 
151 76 56 40 Most other half resolved. 
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CR931680 21 17 wchA GGTGCATTGGTAGGG
CTGAT 
CACACA 
TGGAGCGGAACTTG 
151 78 57 45 Perfect for serotypes 21 and 8 
only. 
HM171374 6D 17 wchA GCAGGTCAGTGGACG
AAGTGA 
CCCCTATTTGGCTCCATC
CT 
151 74 55 36 Perfect for serotype 6D and 
6C only. 
CR931709  37 17 wchA GGCAGGTCAGTGAAC
GAAGTG 
ATCTACTTCGCTCCATCC
TTCATC 
151 74 54 34 Perfect for serotype 37 only. 
CR931679 20A 17 wchA CACGCGTCGAAAGAG
TAATGG 
TCATGGGTAGCGTAGGA
AATCA 
151 76 56 41 Perfect for serotypes 20A and 
20B only. 
CR931657 11F 17 wchA TCGCTCCAT 
GTGTGTAGATGCT 
CTGTGGCAGCTCGTCCA
A 
151 78 57 44 Perfect for serotypes 11F and 
8 only. 
CR931654 11B 17 wchA CATGTGATTGCTAAG
CGGGTTA 
GGCGGCCATTTTTTCCTA
TAC 
151 78 57 44 Perfect for serotypes 11B, 11C 
and 23B only. 
CR931633 2 12 ugd GTTTGGATCCCCGTAT
TGGTT 
CGTGTCGAATTGCTCCGT
ACT 
151 78 57 44 Perfect for serotype 2 only. 
CR931632 1 12 ugd AATATCTCGCGGAAA
AAGAATTGA 
TCAATGACAGCCTCGACT
GAA 
151 74 55 36 Perfect for serotype 1 only. 
CR931713 41A 12 ugd TAGCCTTACGTGTTTC
TTATTTCAATGA 
AGGCAATATCCCCCATAT
CCA 
151 75 55 38 Perfect for serotype 41A, 41F, 
31 only. 
CR931669 17A 12 ugd TTGGCCTTACGAGTTT
CGTATTTC 
TTGGCCTTACGAGTTTCG
TATTTC 
151 75 55 38 Perfect for serotype 17A only. 
CR931681 22A 12 ugd GAATCGGTTATTCAAC
AGGTTCAGA 
CTCTTGATTCGCGCAAAA
ATT 
151 74 54 35 Perfect for serotype 22A, 22F 
only. 
CR931689 25A 12 ugd CATCTGCCGTAGAAC
AAGTAATCG 
CGAAGAAATTCTGGGCT
AAACAG 
151 73 54 34 Perfect for 25A, 25F, 38 only. 
CR931645 9A 12 ugd ACTTACCTTGCGTTGC
GTGTT 
ACCCACCGTAGCCAAAG
GAT 
151 76 56 41 Perfect for serotypes 9A, 9V, 
9N and 9L only. 
CR931634 3 12 ugd GAAAATTGCCATTGC
AGGAAGT 
CTCAATCGCCTCATCCTT
AATTG 
151 76 55 39 Perfect for serotype 3 only. 
CR931644 8 12 ugd TGAAGCTGAGGCGGT
CAAG 
GTGAGAGCCGATTCGTG
GAT 
151 77 56 42 Perfect for serotype 8 only. 
CR931637 5 12 ugd GTTTGCAACTCTTTTG
CAGGAA 
CTCCGCATAGGTATCCAA
TTCG 
151 77 55 42 Perfect for serotype 5 only. 
CR931633 2 18 wchF AGGACGAGGCTCCCA
TTTTT 
CGAACTGGCAGGCTCCA
TT 
151 78 58 45 Perfect for serotype 2 only. 
CR931671 18A 18 wchF GATAAGGACCCACGA
GTAAAATTTG 
TCAGTTTAGTTGATGCCA
GAGCTT 
151 77 56 42 Perfect for serotypes 24A, 
24B, 24F, 48, 18A, 23F, 28A, 
28F. 
CR931672 18B 18 wchF CGCTCCACATTAAATA
GCAGTGA 
TAGAGCTAGACGCCAAG
AAACCA 
151 75 55 38 Perfect for serotype 16F, 18B, 
18C only. 
CR931681 22A 18 wchF AGGACGAGGCTCCCA
TTTTT 
CGAACTGGCAAGCTCCA
TTT 
151 78 57 45 Perfect for serotypes 22A, 
22F, 21 only, weak for 2, 32A, 
32F. 
CR931641 7B 18 wchF GGGACGATTTGTCCC
TGAGA 
TGGGTCTTGGTCAAAAC
CTGTT 
151 75 55 37 Perfect for serotypes 7B, 7C, 
40 only. 
CR931691 27 18 wchF TTGTGGGAACAGTCT
ATGACCAA 
AAGCCGACATCCAACAA
CAAG 
151 77 56 43 Perfect for serotypes 21, 27 
only. 
CR931640 7A 18 wchF GCTTGTCGCATTGGTC
CTTT 
TGAGCTGCTCTGAAAATT
TCCA 
151 77 57 44 Perfect for serotypes 7A, 7F 
only. 
CR931683 23A 18 wchF TGGTGGAACAAATCC
TTCGTT 
TTGTTCACTCGCTTCAAT
AACCTT 
151 75 55 39 Perfect for serotype 23A only. 
CR931684 23B 18 wchF TGCCGGTTCGAAAGT
ATTGG 
TCCGTCCCGTAAGCAATA
TAAGTC 
151 74 55 35 Perfect for serotype 23B only. 
CR931670 17F 18 wchF ACGGACATGAAGTTG
GTGGAA 
TCGATTACTTGGGAAAG
CTCATC 
151 76 56 41 Perfect for 16F, 17F, 18B, 18C 
only. 
CR931674 18F 18 wchF GGACTGATACAACAC
GCTCCATAT 
AAAAACCCACGTATCATA
GCCTCAT 
151 74 56 36 Perfect for serotypes 18A, 
18F, 28A, 28F only. 
CR931696 32A 18 wchF AGGACGAGGCTCCCA
TTTTT 
CGAACTGGCATGCTCCAT
TT 
151 78 58 46 Perfect for 32A, 32F, 
degenerative primers 27, 22A, 
22F, 21, 2 only. 
CR931666 15F 66 wcjE GCTTGGACTGTATCA
ATCGGAAA 
TTGCCAGAACTCCTTCAA
ATCC 
151 74 55 36 Perfect for some, but others 
fail to anneal, investigate 
further. 
CR931645 9A 66 wcjE GTTTTTTGCCCTGTCA
GGATACTT 
AGAGGCACCAGCGACCT
TTT 
151 73 54 34 Perfect for serotype 9A, 9V 
only. 
CR931646 9L 66 wcjE CTGTGTATTAGTTGCT
TTTGCGATTT 
TTTCAACATTAGAATCCG
AATCATG 
151 72 53 31 Perfect for all serotypes, weak 
for 43. 
CR931716 43 66 wcjE AAAGGGTTCGCAATA
TTTCTAGTAGTCA 
ATCCTGATAAAGCAAAG
AATACTGGAA 
151 72 53 31 Perfect for serotype 43 only. 
CR931674 18F 82 gct TGATTGTAGTTGTTTC
AAGTGATGAGTT 
AATACGGTACTCTTTAAC
ATCTGACTTTTTC 
170 71 53 29 Perfect for serogroup 18, but 
other serotypes fail to anneal, 
investigate further. 
CR931653 11A 82 gct AGGAGATTATCTCATT
GTTGTAGTTTCAA 
CTGTTCCCAGCTTGTTTC
AGAA 
151 72 53 30 Perfect for serogroup 11. 
CR931667 16A 82 gct TCGTAGAGGCTGTTA
GGTATGTTGA 
TCAACTCCTTCCTTCTCTA
AAAAATCA 
151 75 55 37 Perfect for serotype 16A only. 
CR931718 45 82 gct TGCTGATATCTTTGTT
ATTGGTGATG 
TTATTTTCCACCTTTGGTC
TTGTTT 
151 73 53 32 Perfect for serotype 45 only. 
CR931641 7B 53 wcwK GATATTGGCAATTGTC
TAGCGGTAA 
CTGCATCAAAATTATCTA
TACTTTCACCAT 
165 70 52 26 Perfect for serotype 7B, 7C, 
40, but fail to anneal to 
others. 
CR931679 20A 53 wcwK GATGGTAGGCCGACT
TTAAATGA 
GATTTGCATCCAGCCATT
CA 
151 74 55 36 Perfect for serotype 20A, 20B 
only. 
CR931680 21 53 wcwK CGACCAGCAAAGACC
AAGCT 
GTGCTCAGAGAGACCAG
GAATTC 
151 76 56 41 Perfect for 21 only. 
CR931704 35A 74 wcrH TTTTGGATTGGTATG
GGATGGT 
GAAACTAGCTATTGCTGC
CTCTGA 
151 76 56 41 Perfect for serotype 35A, 35C, 
42, but fail to anneal to 
others. 
CR931705 35B 74 wcrH GTACGGAGTGCGTGT
TGCAA 
GTCTGCAATAGCATTTGT
TGTTTCA 
151 71 53 29 Perfect for serotype 35B only. 
CR931694 29 74 wcrH CCTTTTTGGTCCGAAT
TTTAATATTG 
AGTGTTTCCGCCACAGGT
ATCT 
151 74 54 35 Perfect for serotype 29 only. 
CR931708 36 74 wcrH GTTGCCTACAAGACC
GGCATA 
ACTACCACCGTCCCAAAC
CA 
151 76 56 41 Perfect for serotype 36 only. 
CR931651 10C 74 wcrH GGGCTTTCCTCTGGT GGCATTAGCCGACAGTT 151 79 58 47 Perfect for serotypes 10C, 10F 
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GGTTT CCA only. 
CR931716 43 74 wcrH GGACCTAATTTTACTT
CATCGACTAACA 
TCCCCAGTAATCCCTGAA
CAAG 
152 73 54 34 Perfect for serotype 43 only. 
CR931641 7B 55 rbsF TGAATAAGACGGGAA
TACTGTTTACTGA 
GGTACCCCAACACCATTC
ATAAAT 
151 72 53 30 Perfect for serotype 7B, 7C, 
40, 24F, but fail to anneal to 
others. 
CR931676 19B 55 rbsF CATAGGAATTGTCATC
CTGAGCAA 
GATAACACATTTCTTCAG
TGCCTAACTT 
151 73 54 33 Perfect for 19B, 19C only. 
CR931666 15F 98 wchX AGATACATATTACGA
ATTGCCGGATT 
ACTAGCGGTTCCATTAAA
GATTGG 
151 71 52 27 Perfect. 
CR931700 33C 39 wciN GGCGTGAAGAACGAA
TCGAA 
CCTCAAAAATGGTCATAT
AATTGTATCTTG 
153 72 53 30 Perfect for 33B, 33C but no 
others, investigate further. 
EF538714 6C 39 wciN GGCGATGGCGAATTG
C 
CAAAGCCCTCCCATTTCG
A 
151 78 57 45 Weakly anneal to 6C, 6D, but 
no others. 
CR931638 6A 39 wciN AATTTTGTAGATGTAT
TGAGTGCTTCCA 
TTTCTCTCTGCGCAAATT
GTTTT 
151 71 52 27 Perfect for 6A, 6B, 33D but no 
others. 
CR931681 22A 44 wcwA CTGGTGAAGAGTGGC
GAGTTG 
GGATCGGGATTGGTACT
TGGT 
151 75 55 37 Perfect for all serotypes, 
however weak anneal for 7A, 
7F, 21. 
CR931640 7A 44 wcwA CAAGCACAGTGCGTG
AACAA 
GCCAGAAAAGCGATAGA
ATTGG 
151 79 58 48 Perfect for 7A, 7F only. 
CR931704 35A 73 wciG TGGTTTTTCGGTGCAC
TCATAC 
TGGTTTTTCGGTGCACTC
ATAC 
151 71 52 28 Perfect for some, weak anneal 
for some, fail to anneal for 
some. 
CR931667 16A 73 wciG GGCTTTTCTATTATCT
TTTAGGTGGTTT 
ATGGTATGCAGTCTTCGC
TATGAA 
152 71 52 28 Perfect for 16A only, but not 
others. 
CR931707 35F 73 wciG TTGGTTTTTTGGTGCG
CTTAT 
TGGCATTTGAAGCACAA
TATTTG 
151 71 52 27 Perfect for 35B, 35F, 47F only. 
CR931699  33B 73 wciG TTGGTTTTTCGGTGCA
CTAATACTTA 
TGGCATCTGAAGTAGGA
TATTTAATAACTC 
151 71 52 28 Perfect for 35A, 35C, 42, 33A, 
33F, 20, 33B, 33D, 13 
CR931709  37 73 wciG TTGCATGTGTTGGAG
TCGTTCT 
CTCTTCCCCAACAATAAA
TAACCATT 
151 74 55 36 Perfect for serotypes 37, 33A 
and 33F only. 
CR931651 10C 73 wciG GGTGGCAATTGGGTT
TATAGTTG 
TTTGAGGTTGTCTACATT
GAATTGTG 
151 73 53 32 Perfect for serotypes 10C and 
10F only. 
CR931674 18F 105 wcxM GGTTGTACGTGGAAT
CGGATTT 
GATTCCTTCTTTTGACAG
TGCATCT 
151 74 55 36 Perfect. 
CR931669 17A 112 wcrT GACATATTCAGCCTG
AAGTTCCATT 
TCCAGAAGGAGCTTTCC
ATCA 
151 73 54 33 Perfect for 17A only. 
CR931670 17F 112 wcrT GGCAGAATTGGCTAA
AAAGTATGG 
TTCATTTGCCCAACTCAA
ACAA 
151 72 53 30 Perfect for 17F only. 
CR931700 33C 67 wcjG GGGATGTGGCAAGTT
TCTGGTA 
AATGAGCCCCTTCTCCAG
ACA 
151 76 56 40 Perfect. 
CR931700 33C 67 wcjG TATTGGACCTAGACC
GATTTTGG 
GCTCCATTTCACAGCGTT
CA 
152 77 57 43 Perfect. 
CR931633 2 9 wzy TGGAACTCTTAGAAA
TTGGGAAAATT 
AAGGAAACTTGTCACTG
TTGAATCAG 
151 73 54 33 Serotype specific, investigate 
further. 
CR931635 4 29 wciK CGGGAATCACACTCC
CTTACTAGA 
ATCCTTCATAGGTAAAAC
GAAACCA 
151 73 54 34 Perfect for serotype 4. 
CR931688 24F 140 wcxI AATGATGTGCCTGAT
ACTTTTATTATGC 
TTTGCTTAGCTGACACCA
TTCC 
151 72 53 31 Perfect for serogroup 24. 
CR931689 25A 149 wcyE TTGAGGTGCGATTTTT
ATATTGTGAA 
TGTTTCCATCTTGCTTCTC
CAGTA 
151 72 53 30 Perfect. 
CR931691 27 152 whaK AGCAGTATCTTTTGGA
TGGCAAGT 
AAGGTCCCATCGCTGAC
AAT 
151 76 56 41 Perfect. 
CR931688 24F CO
N 
wzg ATTAGTTCGGTGTCG
CGATCA 
TGCCCGCATGGGTTAATT
TA 
151 77 57 43 Perfect. 
 
Using the 19 primer set (18 primers plus wzg) for Queensland isolates, a barcode 
sequence (only contains the targeted genes) was devised for each serotype previously 
detected in Queensland (Table 23). These barcodes were the expected capsule profiles 
for the Queensland invasive S. pneumoniae, where T represents a present gene and A 
represents an absent gene. A number of serotypes appear to have the same barcode or 
capsule profile, including serotypes 22A and 22F, serotypes 19A and 19F, serotypes 
18B and 18C, and serotypes 15B and 15C. These serotypes can only be differentiated 
using SNPs. Research into the NCBI database revealed several SNP differences within 
the capsule genes from which SNP-specific primers were designed (Table 24 and 25). 
These SNP-specific primers can be used to differentiate between those serotypes with 
the same capsule profile. 
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Table 23: MinimumSNPs 19 primer set for serotyping the 35 S. pneumoniae serotypes 
found in Queensland, and the barcode sequences for Queensland serotypes using the 19 
primer set. 
The top table shows the 19 primer sets for the Queensland isolates. Serotype of NCBI 
pneumococcal isolate; Locus – our designated number for each CPS gene from the 182-gene 
mother template; Gene – targeted CPS gene; Forward and reverse primer are in 5’ to 3’ 
directions; Reverse complement of the reverse primer is given. The bottom table displays the 
‘barcode’ CPS profile for each of the 35 serotypes previously detected in Queensland. The 19 
primers are listed across the top, and the in silico results of expected presence (highlighted pink 
‘T’) of a gene, or absence (not highlighted ‘A’) of a gene. 
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Table 24: Identification of SNP differences within S. pneumoniae capsule genes.  
Accession number was obtained from the NCBI database. ‘Sequence’ numbers indicate the 
location of the SNP and the ‘amino acid’ indicates whether the SNP difference changes the amino 
acid produced when translated. 
Serotype CPS gene Accession # SNP Sequence Amino Acid 
22A 
22F 
wcwA CR931681 
CR931682 
1bp 
difference 
8521-8536 
8521-8540 
Alanine 
Threonine 
19A 
19F 
wchA CR931675 
CR931678 
Lots of SNPs   
18B 
18C 
wzd CR931672 
CR931673 
1bp 
difference 
3398-3412 
3395-3413 
Threonine 
Alanine 
15B 
15C 
15B 
15C 
15B 
15C 
15B 
15C 
wzh 
 
wchM 
 
Unknown 
 
gtp3 
 
CR931664 
CR931665 
CR931664 
CR931665 
CR931664 
CR931665 
CR931664 
CR931665 
4bp 
differences 
2922-2938 
2924-2937 
10189-10200 
10187-10200 
12936-12955 
12938-12954 
17414-17432 
17417-17434 
Lysine 
Arginine 
 
 
 
 
Valine 
Isoleucine 
28A 
28F 
28A 
28F 
wchF 
 
wchF 
CR931692 
CR931693 
CR931692 
CR931693 
2bp 
difference 
6897-6909 
6586-6604 
7679-7693 
7368-7386 
Alanine 
threonine 
Leucine 
Isoleucine 
32A 
32F 
tnp CR931696 
CR931697 
1bp 
difference 
22678-22695 
22774-22789 
 
7A 
7F 
7A 
7F 
7A 
7F 
7A 
7F 
7A 
7F 
wzg 
 
wzd 
 
tnp 
 
tnp 
 
tnp 
 
CR931640 
CR931643 
CR931640 
CR931643 
CR931640 
CR931643 
CR931640 
CR931643 
CR931640 
CR931643 
Lots of SNPs; 
5 SNPs 
examined 
1551-1565 
1579-1597 
3910-3924 
3939-3954 
23569-23605 
23573-23609 
23612-23641 
23616-23645 
23731-23784 
23735-23787 
Arginine 
Glycine 
 
20A 
20B 
20A 
20B 
20A 
20B 
20A 
20B 
wzg 
 
wzg 
 
wzg 
 
wcjE 
CR931679 
JQ653093 
CR931679 
JQ653093 
CR931679 
JQ653093 
CR931679 
JQ653093 
4bp 
difference 
1529-1542 
329-342 
1586-1597 
387-400 
1768-1781 
570-582 
17982-17995 
16784-16797 
 
 
Threonine 
Isoleucine 
Proline 
leucine 
10A 
10B 
wcjG CR931649 
CR931650 
1bp 
difference 
5490-5500 
5194-5211 
 
7B 
40 
glf CR931641 
CR931712 
13bp 
differences 
  
9A 
9V 
9A 
wze 
 
wcjB 
CR931645 
CR931648 
CR931645 
3bp 
differences 
4716-4730 
5035-5046 
10788-10802 
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Serotype CPS gene Accession # SNP Sequence Amino Acid 
9V 
9A 
9V 
 
wcjE 
CR931648 
CR931645 
CR931648 
11104-11118 
18525-18538 
18841-18854 
Lysine 
25A 
25F 
25A 
25F 
25A 
25F 
25A 
25F 
25A 
25F 
25A 
25F 
25A 
25F 
25A 
25F 
glf 
 
wzg 
 
wzg 
 
wzg 
 
tnp 
 
glf 
 
tnp 
 
tnp 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
CR931689-
CR931690 
8bp 
differences 
4882-4891 
4851-4862 
9042-9054 
9014-9024 
9152-9162 
9123-9134 
9198-9208 
9169-9180 
27221-27232 
27193-27205 
4578-4590 
4549-4559 
22995-23006 
22966-22975 
26562-26573 
3888-3899 
Threonine 
Methionine 
Arginine 
Glutamine 
 
 
Aspartic 
Asparagine 
 
 
Glycine 
Aspartic 
 
33A 
33F 
wze 
 
wcjE 
 
tmp 
 
CR931698 
CR931702 
3bp 
differences 
4093-4102 
4093-4104 
16166-16177 
16165-16179 
18258-18267 
16837-16846 
Serine 
Proline 
 
 
Leucine 
Phenylalanine 
 
For the serotypes that cannot be differentiated using the 19 primer set, SNP-
specific primers have been designed to further discriminate these serotypes (Table 25). 
Sub-terminal mismatch forward primers were designed, meaning the 3’ end for each 
serotype contains the SNP. 
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Table 25: SNP-specific primer pairs for S. pneumoniae serotypes. 
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6.3.2 Optimisation of capsule typing on conventional PCR 
Initial validation of whether crude DNA thermolysate could be used for capsule 
typing demonstrated that amplification should be no issue. The wzg was successfully 
amplified using a heat-gradient PCR for serotype 7F and 19A, both common serotypes 
discovered in Queensland (Figure 36). Further validation using heat-gradient identified 
that the most appropriate annealing temperature for all primers was 67oC (Figure 37). 
Figure 36: Heat-gradient PCR of isolate 21SP11 (ID 21) serotype 7F (top) and 57SP11 (ID 
57) serotype 19A (bottom) using thermolysate DNA.  
Lane 2, DNA marker ladder VIII. The heat-gradient temperatures are indicated in the key. 
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Figure 37: Heat-gradient PCR performed on S. pneumoniae serotypes using rmlB, wchA, 
and glf capsule genes identified in this study. 
A DNA marker ladder VIII was used in lane 1 (top and bottom). The heat-gradient temperatures 
are shown in the key. Two S. pneumoniae serotypes per gene is shown, where the top row 
contains positive control (gene should be present in these serotypes), and the bottom row 
contains serotypes that the gene should be absent. 
 
Following this, amplification of the 19 CPS genes was validated (Table 23) in all 
Queensland clinical isolates that were available was performed using conventional PCR, 
this time with the annealing temperature at 67oC. Gel electrophoresis was performed to 
visualise the presence or absence of the genes. All present bands were expected to be 
visualised at 151bp in size, based from in silico results in Table 22. Smaller and fainter 
bands were thought to be primer-dimers, and were confirmed to be <100bp as seen on 
the gels. Where bands were expected to be present, based from the in silico analysis 
previously performed, we could see a present band, for example wciK is only expected 
to amplify in serotype 4, which is what we have observed (Figure 38). An internal 
control gene wzg was also included for identification of S. pneumoniae. This validation 
has confirmed that all S. pneumoniae serotypes have a present wzg (Appendix A6: 
Determination of presence/absence of 19 capsule targets in S. pneumoniae using 
conventional PCR and gel electrophoresis – in gel 12 and 13).  
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Figure 38: Validation of capsule genes wcjG33C, wciK and wzg on S. pneumoniae 
Queensland serotypes using gel electrophoresis. 
A DNA marker ladder XIV was used in lane 1 (top and bottom). Bands falling below 100bp are 
primer-dimers. A strong band at 100-200bp indicate a positive amplification. 
 
In comparison, the wzg gene was not amplifiable in Streptococcus pyogenes 
(Figure 39) or S. agalactiae. Similarly, the other capsular genes could were not 
amplifiable in S. pyogenes or S. agalactiae. 
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Figure 39: MinimumSNPs capsule typing applied to Streptococcus pyogenes.  
A DNA marker ladder VIII was used in lane 1. Lane 2 is blank. The respective capsule genes 
amplified are shown in the key. 
  
 
Generally, where genes were expected to amplify in pneumococcal isolates, a 
band was visualised. However some CPS bands amplified when they were not expected 
to amplify. Closer examination revealed that even though when examining the NCBI 
database several primers pairs for one gene was serotype specific, in reality they could 
amplify more serotypes. For example, wchA21 is amplified in several serotypes 
unexpectedly, however if we examine wchA2 (different primer pair for the same gene) 
the wchA gene is actually present (Table 26). Therefore we had to accommodate the 
fact that as long as one of the primer-set identifies a present gene; we could determine 
that the gene was indeed present. A summary of the amplification of non-amplified 
Minimum SNPs targets indicated that the majority of expected amplifications were 
observed, however a number of unexpected amplifications were also observed (Table 
26). The raw data is available in Appendix A6: Determination of presence/absence of 
19 capsule targets in S. pneumoniae using conventional PCR and gel 
electrophoresis. In addition, one of the ATCC strain failed to amplify the wzg which 
should be present in all pneumococci – it is thought that due to it being a laboratory 
strain that has undergone numerous sub-cultures, it is possible that the wzg has been 
lost from this strain. Sequencing would be required to determine this, which has 
currently not been performed in this study due to limited funding. 
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Table 26: Summary of amplification of MinimumSNPs 19 targets in 35 Queensland S. 
pneumoniae serotypes.   
T = present gene, and A = absent gene. Green highlighted genes are expected presence of the 
gene. Dark orange highlight represents unexpected amplification of a gene. Light orange 
represents unexpected non-amplification of a gene. Allele file code was used for submission of 
pseudoDNA sequences into MinimumSNPs. 
Serotype allele file code wzg rmlB L15 glf L22-25A wchA L17-21 wchA L17-18B wchA L17-6D ugd L12-3 wchA L17-2 wciK L29 glf L22-35F wciN L39-6A wcjE L66-9L ugd L12-9A glf L22-10A wcjG L67-33C wchX L98 wchF L18-18A wchF L18-18B wciG L73-33B
19F ATCC49619 A A A A A A T A A A A A A A A A A A A
6A ATCC6306 T T A A T A A A A A A A A A A A A A A
1 cps_>1 T T A A A A A A A A A A A A A A A A A
7F cps_>13 T T A A T A A A A T A A A A A A A A A
8 cps_>14 T A A T T T A T A A A A A A A A A A A
9N cps_>17 T T A A T A A T A A A T T A A A A A T
9V cps_>18 T T A T T A A T A A A T T A A A A A A
10A cps_>19 T T T A T A A A A A A T T T T A A A A
10F cps_>22 T T A A T A A A A A A T T T T A A A A
11A cps_>23 T T A A T T A T A A A T T A A A A A A
3 cps_>3 T T A A T A T A A A A A A A A A A A A
12F cps_>31 T T A A A A A A A A A A T A A A A A A
14 cps_>33 T A A T T A A T A A A A A A A A A A A
15B cps_>35 T T A A T A A T A A A A A A A T A A A
15C cps_>36 T T A A T A A T A A A A A A A T A A A
16F cps_>39 T T A T T T A T A T A T T A A A T T A
4 cps_>4 T T A A T A A A T A A A A A A A A A A
18A cps_>42 T T A A T A A A A A A A A A A A T A A
18B cps_>43 T T A A T T A T A T A T A T A T T T A
18C cps_>44 T T A A T A A T A T A T A A A A A T A
19A cps_>46 T T A A A T A T A T A A A A A A A T A
19F cps_>49 T T A T T A A T A T A A A T A A A T A
22A cps_>53 T T T T T A A T A T A A A A A A T T A
22F cps_>54 T T A T A T A T A T A A A A A T A T A
23A cps_>55 T T A A T A A A A A A A A A A T A A A
23B cps_>56 T T A T A T A T A A A A A A A A A A A
23F cps_>57 T T A T T A A T A A A A A T A T T T A
6A cps_>6 T T A T T T A T A T A A A A A A A T A
24F cps_>60 T T A A T A A T A T A A A T A A T A A
6B cps_>7 T T A T T A A T A T T A A A A A A A A
33B cps_>71 T T A T A A A T A T A A A A A A T A T
33F cps_>74 T T T T A T A T A T A T T T A A T A A
34 cps_>75 T T T T T A A T A A A A T T A A T A A
35B cps_>77 T T T T A T A T A T A A A T A A A A A
35F cps_>79 T T A A A A A T A T A A A T A A A A A
6C cps_>8 T T A A T T A T A T A A A A A A A A A
38 cps_>82 T T T A A A A A A A A A A A A A A A A  
 
Due to the number of unexpected amplifications of capsule loci, it was theorised 
that performing a heat-melt curve when using real-time PCR could distinguish a ‘true’ 
amplification based from the positive control.  
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6.3.3 Double-blind validation and real-time PCR 
The double-blind validation was performed to determine the capsule types of 
Queensland pneumococcal isolates. The 48 isolates selected contained at least one 
isolate from each of the 35 S. pneumoniae serotypes detected in Queensland children, 
and had not previously been capsule typed during the optimisation stages.  
Real-time PCR could be used to detect the presence and absence of capsule genes. 
Each PCR run required a positive control to compare the samples to. For some primers 
that amplified unexpectedly, we determined that a melt-curve was required when 
performing real-time PCR to allow the distinction of ‘true’ present genes and ‘false’ 
present genes, depending on the SNPs within the genes. Analysis of the rtPCR results 
required examination of the Melt A. Green heat curve (Figure 40) which would give 
clear results of non-amplified genes. A positive control for Locus 15 rmlB CPS gene is 
shown (black line). Amplification of rmlB in other pneumococcal isolates was 
considered ‘present’ if the bell-curve matched the positive control. For rmlB, it is known 
to be present in a number of pneumococcal capsular polysaccharides, therefore we can 
see that a number of pneumococcal isolates appear to have a ‘present’ rmlB. 
Figure 40: Melt A. Green heat curve for rmlB capsule gene (Locus 15). The temperature 
(oC) is shown on the x-axis.  
A positive control (Locus 15 – rmlB) is shown as the black, vertical line. Each coloured peak is a 
different isolate with a ‘positive’ amplification of the gene rmlB – if the bell-curve matches the 
positive control, it is considered a positive amplification and therefore a ‘present’ gene. An 
‘absent’ gene is observed as a flat line across the graph, or a significantly skewed bell-curve that 
does not match the positive control. 
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Following this, analysis of the Normalised High Resolution Melt (HRM) curve 
would identify whether all positive peaks (in comparison to the positive control 
present in each run) appeared to follow a consistent curve (Figure 41). Any samples 
that did not follow the similar curve of the positive control were eliminated 
(considered ‘absent’ gene).  
Figure 41: Normalised High Resolution Melt (HRM) heat curve for rmlB capsule gene 
(Locus 15). 
All samples must follow this similar curve pattern to be deemed a ‘present’ gene (match the 
positive control – undistinguishable in this graph). ‘Absent’ genes will follow a more linear, 
straight line (not shown) or a significantly skewed curve (not shown). 
 
 
The Normalised HRM is used to create the Difference High Resolution Melt 
(HRM) - this is then used to determine whether the tested samples closely match the 
positive control or not as indicated by the presence within ±5 units from the positive 
control line (Figure 42). The rmlB gene is shown as an example and results for the other 
genes are provided in Appendix A7: Real-time PCR analysis of 19 primer targets in the S. 
pneumoniae capsule cassette.  The positive control for rmlB is set as the base-line ‘0’, 
and we can set the threshold line (red) at ±5 so that we can easily determine whether 
the other samples fall outside this threshold. A couple of S. pneumoniae isolates have a 
Difference HRM curve that lies within the threshold and is considered to be definitely 
‘present’, however many other isolates appear to have melt curves that lie outside this 
threshold. 
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Figure 42: Difference High Resolution Melt (HRM) heat curve for rmlB capsule gene 
(Locus 15).  
A positive control was used for comparison (red line at 0 on y-axis), and peaks that fall outside 
of the +5 red line were considered false positives. 
 
 
Unfortunately, as identified before that several genes appeared to amplify 
unexpectedly because of the primer design, distinguishing the pneumococcal serotypes 
in this double-blind validation method and using HRM rtPCR was very difficult. Only 13 
out of 48 isolates (27%) were correctly identified. This ‘correct’ identification was 
based on the known serotype obtained from Quellung serotyping, and the in silico 
expected capsule profile. As a result, we went back to the MinimumSNPs program to 
identify more genes that could help discriminate the S. pneumoniae serotypes. 
6.3.4 Re-analysis of Minimum SNPs and double-blind validation using 
conventional PCR 
Re-analysis of the S. pneumoniae capsule cassettes using the Minimum SNPs 
program was performed to identify additional targets to further discriminate the 
pneumococcal serotypes. A total of 23 CPS genes that was previously selected by 
MinimumSNPs (D = 0.99) was verified to distinguish between the 93 S. pneumoniae 
capsule cassettes, however 12 capsule genes had not been used previously in this study 
(gct, wcwK, wcrH, rbsF, wcwA, wcxM, wcjD, wcrT, wcxD, wcyE, whaK and wciY). It is 
unknown exactly why approximately half the genes selected by Minimum SNPs are 
different when analysing the same 182-gene mother template, however it is thought 
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that these CPS genes are alternatives to provide discrimination, for example we 
previously described that Binary marker 2 or 5 could be used for discrimination 
(Figure 34). 
Primers were designed for all 23 capsule genes. Some primers were designed to 
be degenerative primers so that SNP differences within the primer binding site would 
not affect the ability to amplify the gene (Table 27). Designing primers for ugd was 
difficult as there were no conserved regions within this gene across the S. pneumoniae 
serotypes that contained the gene. This does mean that ugd is discriminatory; therefore 
it was recommended that the Capsule Typing would not initially contain ugd and 
instead would recommend it as a serotype specific gene if required after capsule typing. 
 
Table 27: Re-analysis of the capsule polysaccharide (CPS) genes selected by 
MinimumSNPs for characterisation of S. pneumoniae serotypes.  
Forward and reverse primers (e.g. rmlB-F, forward primer; rmlB-R, reverse primer) have length 
listed (bp). Total expected amplicon length (bp) is shown followed by annealing temperature 
(Tm) and guanine/cytosine percentage content (GC %). The primers were blasted in NCBI 
database (yes, Y) and primers that are degenerative are indicated (D). Asterisks (*) against the 
primer indicates it has been used for the Queensland study. 
Gene Primers bp Amp. 
Length 
Tm GC% Blast Deg. 
rmlB-F* CAATGACCATTCTTCAGGAG 20 192 60.2 45 Y  
rmlB-R* ATCAATCGCATAGCGAAGG 19  63.1 47.4 Y  
glf-F1* GAGTTAGAATACCGTAGCCTTCG 23 121 62.2 47.8 Y  
glf-F2* GAACTAGAGTACCGTAGTCTTCG 23  58.3 47.8 Y  
glf-R1* GYTTGTGTTCGATRATACGAG 21  59.7 42.9 Y D 
glf-R2* GTTTGTGCTCAATAATGCGAG 21  62.6 42.9 Y  
wchA-F1* GCTATTTTTGCTCAGACGCG 20 148 65.1 50 Y  
wchA-F2* GCTATTTTTGCTCAAACTCG 20  59.6 40 Y  
wchA-R1* TCATCGTCCACCTTAAACAT 20  60 40 Y  
wchA-R2* TCATTTTCTATCTTAAACAT 20  48.7 20 Y  
wchF-F1* CTAGTTGTAGGACGTTTTGT 20 325 54.1 40 Y  
wchF-F2* CTAGTGGTGGGACGATTTGT 20  61.9 50 Y  
wchF-R* TCHCGGTTAAAYCCAACATC 20  62.4 44.2 Y D 
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Gene Primers bp Amp. 
Length 
Tm GC% Blast Deg. 
wcjE-F1* GTCTGTGTATTAGTTGCTTTTG 22 152 56.3 36.4 Y  
wcjE-F2* GTCTGTATATTAGTTGCGTTTG 22  56.2 36.4 Y  
wcjE-R* TTTCAACATTAGAATCCGAATCATG 25  64.9 32 Y  
gct-F1 GTACATTTGATTTKCTTCATTATGG 25 265 61 30 Y D 
gct-F2 GAACCTTTGATTTATTGCATTATGG 25  63.4 21 Y  
gct-R1 CCAATCATCCCCCATAACAA 20  64.6 45 Y D 
gct-R2 CCAATCATCACCCATTTCAA 20  63.6 40 Y  
wcwK-F1 ATTGATTTTGTMGTTACATGG 21 178 56.6 31 Y D 
wcwK-F2 ATTGATTTTGTGGTGACATGG 21  62.5 38.1 Y  
wcwK-R1 TTATTAACCCAGGGCGCATGT 21  67.3 47.6 Y  
wcwK-R2 TTATTTACCCAAGGGGCATAT 21  61.2 38.1 Y  
wcrH-F1 TTTGGATTGGTDTGGGATGG 20 173 66.6 46.7 Y D 
wcrH-F2 TTTGGTTTGGTDTGGGAYGG 20  67.6 49.2 Y D 
wcrH-R1 AATACCACAATTATTCTCCT 20  52.4 30 Y  
wcrH-R2 TATACCACACTGCTTATCTA 20  50.4 35 Y  
wcrH-R3 AATTCCAACATTATTTTCTTC 21  54.6 23.8 Y  
rsbF-F* GGTTGGAAAGGMACGATACAAG 22 220 65.2 47.7 Y D 
rsbF-R* GGWCCATGATCTGCWACAAA 20  62.2 45 Y D 
wchX-F* AGATACATATTACGAATTGCCGGATT 26 150 65.3 34.6 Y  
wchX-R* ACTAGCGGTTCCATTAAAGATTGG 24  65.2 41.7 Y  
wciN-F1* TTCTTATAAAGAATTATCTCCAA 23 130-
160 
53.9 21.7 Y  
wciN-F2* CTCATTTGGTGTACTTCCTCCAG 23  64 47.8 Y  
wciN-F3* GCGAACTGAAGAACTAATTGAAG 23  61.2 39.1 Y  
wciN-R1* TTATATKCTTTCYTGCTTCT 20  53.5 30 Y D 
wciN-R2* CTATACGTTCTCTGGCATTT 20  56.5 40 Y  
wciN-R3* TCATATATTCCGCAACCGCC 20  66.9 50 Y  
wcwA-F1 CGGGAGAAGAGTGGCGAGTT 20 ~180 68.2 60 Y  
wcwA-F2 CTGGTGAAGAGTGGCGAGTT 20  64.8 55 Y  
wcwA-R1 GCCATAGCCTCTAGTACCACTG 22  62 54.5 Y  
wcwA-R2 GCCATCGCCTCTAGTACCACTG 22  67.2 59.1 Y  
wciG-F1* CAGTTTTGGTTTTTYGGTKC 20 235 61.7 40 Y D 
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Gene Primers bp Amp. 
Length 
Tm GC% Blast Deg. 
wciG-R1* AACTGAGATATAAAGCCCCCT 21  60 42.9 Y  
wciG-R2* AATTGCGCTATAMAACCACCT 21  62.1 40.5 Y D 
wcxM-F* GGTTGTACGTGGAATCGGAT 20 150 63.9 50 Y  
wcxM-R* GATTCCTTCTTTTGACAGTGC 21  60.8 42.9 Y  
wcjD-F* AGGGAGGGATAGATGCAGGTT 21 221 60 52.4 Y  
wcjD-R* ATCTCCGTACCTGAGAAACCA 21  58 47.6 Y  
wcrT-F1 GCAAAATTAGCTTTAGAGTA 20 ~155 51.5 30 Y  
wcrT-F2 GCAGAATTGGCTAAAAAGTA 20  56.8 35 Y  
wcrT-R1 CCAGCTCTCATTAGCCCAAC 20  64.1 55 Y  
wcrT-R2 CCAGTTTTCATTTGCCCAAC 20  64.5 45 Y  
wcjG-F* GGGATGTGGCAAGTTTCTGGTA 22 150 67.3 50 Y  
wcjG-R* AATGAGCCCCTTCTCCAGAC 20  64.8 55 Y  
wciK-F* CGGGAATCACACTCCCTTACTAGA 24 150 66.4 50 Y  
wciK-R* ATCCTTCATAGGTAAAACGAAACCA 25  64.6 36 Y  
wcxI-F* AATGATGTGCCTGATACTTTTATTAT
GC 
28 150 64.9 32.1 Y  
wcxI-R* TTTGCTTAGCTGACACCATTCC 22  65.4 45.5 Y  
wcyE-F TTGAGGTGCGATTTTTATATTGTGAA 26 150 66.1 30.8 Y  
wcyE-R TGTTTCCATCTTGCTTCTCCAGTA 24  66 41.7 Y  
whaK-F AGCAGTATCTTTTGGATGGCAAGT 24 150 66 41.7 Y  
whaK-R AAGGTCCCATCGCTGACAAT 20  66 50 Y  
wzg-F* ATTAGTTCGGTGTCGCGATCA 21 150 66.9 47.6 Y  
wzg-R* TGCCCGCATGGGTTAATTT 19  67.4 47.4 Y  
wciY-F* TATTTGATAAYTTTGGTGGTAGAGG 25 273 61.3 34 Y D 
wciY-R* CCATCWGAACCATGCCAWGT 20  65.6 50 Y D 
 
The selection of targets was minimised to 16 capsule genes for typing 
Queensland S. pneumoniae isolates, including wzg, rmlB, glf, wchA, wciK, wciN, wcjE, 
wcjG, wchX, wchF, wciG, rbsF, wcxM, wcjD, wcxI and wciY. This Queensland set has a 
discriminatory value of 0.9782, although adding ugd as an extra gene would increase 
the discrimination to 0.9886. The other genes not included in the Queensland set would 
not have added discriminatory value. Additionally, each capsule gene was given a 
different annealing temperature for optimal amplification, based from the annealing 
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temperature (Tm) calculated by GeneWorks, Australia when ordering the primers 
(Table 28).  
Table 28: Annealing temperatures (Tm) for the MinimumSNPs targeted loci. 
Locus Tm (oC) Locus Tm (oC) 
wzg 60 wchX 65 
rmlB 60 wciN 60 
glf 61 wciG 55 
wchA 55 wcxM 60 
wchF 55 wcjD 65 
wcjE 61 wcjG 60 
wcwK 60 wciK 60 
rbsF 55 wcxI 60 
 
A double-blinded capsule typing experiment was performed again, this time 
using conventional PCR and gel electrophoresis targeting the new 16 capsule genes 
after the previous re-analysis. Isolates had been re-labelled by someone else other than 
the person carrying out the experiments. The two S. pneumoniae ATCC controls were 
contained within this double-blinded list of pneumococcal isolates. The double-blind 
validation improved from the initial rtPCV validation: 21 out of 48 isolates (44%) were 
correctly identified based on the 16 targeted capsule genes (Table 29). Half of these (11 
isolates) were still contained within a complex of other potential serotypes that could 
have the same profile as well. The amplified genes were visualised using gel 
electrophoresis (Figure 43 to Figure 56). 
A sequential PCR hierarchy table was designed for ease of assigning a serotype 
based on the amplification of the 16 capsule genes (Figure 57). When simply typing 
wzg, rmlB, glf, wchA and wchF, the Queensland S. pneumoniae serotypes were divided 
into eight clusters, of which serotype 1 and serotypes 6B and 6C could already be 
uniquely identified. After this, amplification of only a few genes could be performed to 
further differentiate the complex of serotypes (Figure 58 to Figure 61).  
Closer examination of whether each individual gene actually amplified in 
expected serotypes indicated that the majority of CPS genes were good at correctly 
typing each serotype. Most of the targeted genes would correctly type more than 70% 
of the 48 isolates, including rmlB, glf, wcjE, wchA, wchF, rbsF, wcjD, wchX, wciG and wciK. 
The other genes, wcxM, wcxI, wciN and wcjG would type less than 60% correctly, but the 
annealing temperatures were lower for these genes (all 60oC) which could be 
increased.  
Additionally, despite the in silico analysis indicating otherwise, several genes 
appeared to consistently be present or absent in particularly serotypes when they 
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shouldn’t. The gene rmlB failed to amplify in serotype 19A when it was expected to be 
present according to the in silico results, but however was present in serotype 4 when it 
was expected to be absent. Similarly, the wchF was absent in all serotype 7F (n=3) and 
serotype 22F (n=2) when it was expected to be present. 
 
Table 29: Double-blind validation of S. pneumoniae using conventional PCR MinSNPs 
Capsule Typing.  
T = present gene (yellow highlight is strong band, pink highlight is faint band and may be 
incorrect); A = absent gene; V – assigned serotype validated by a second person (X – incorrect 
assignation, green tick or serotype – correct assignation). 
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C 
X 18A 
2 T T` T A A A A A A A A A A A A 38 X 18B 
3 T T T T A A A A A A T` A T` A A 6C/B X 22F 
4 T T A T T A A A A T A A T` A A 16F/18
A 
X 23A 
5 T T A T T A A A A T T` A T` A A 16F/18
A 
X 23F 
6 T T A T T` A A A A A A A A A A 19A/F/
23A/B/
F 
23F 23F 
7 T T T T A A A A A A T` A T` A A 6C/B X 7F 
8 T A T` T A T T A A A A A T` A A 9V √ 9V 
9 T T A T A A A A A A T` A T` A T` 6A/19A
/F 
X 1 
10 T A A T A A T A A A T` A T` A T` 9N/11
A 
11A  11A 
11 T A T T` A A A A A A A A A A A 38/34 X 19A 
12 T T T T T A A A A A T` A T` A T` 22A/F/
7F/18B
/C 
18C 18C 
13 T T T` T A A A A A A T` A T` A T` 6A/19A
/F 
X 6C 
14 T T A T A A A A A A T` A T` A T` 6A/19A
/F 
X 1 
15 T A T A A A A T A A A A T` A A 10A X 10F 
16 T A A T A A A T A A T A T` A A ? 15B 15B 
17 T T T T T A A T A A T A T` A A ? 22A 22A 
18 T A T T A A A T` A A T` T A A A 10F/35
B/33B/
F 
33B 33B 
19 T T A T A A A T` A A T A A A A 6A √ 6A 
20 T T T` T T A A T` T A T` A T` A T 24F √ 24F 
21 T T T T A A A T` T` A T A A A T` 6C X 7F 
22 T A A T A A A T` T` A T A T` A T` 8/15B/
C/14 
8 8 
23 T A A T A A A A T` A T A A A T` 8/15B/
C/14 
X 12F 
24 T T A T A A A A T` A T A T` A T` 6A X 6B 
25 T A A T` A A A A A A T` A A A A 3/12F X 19A 
26 T A A A A A A A A A A A A A A 3/12F X 11A 
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C/14 
15C 15C 
34 T T T T` A A A T` A A A A A A A ? 19F 19F 
35 T T` T` T T A A T T` T T T T` A T` 33B X 23B 
36 T A T T A A A T T` A T T A A T` 33B/10
F 
X 33F 
37 T A T T A A T T` A A T` T T` A T` 33F √ 33F 
38 T A T T A A A T A A T T T` A T` 33B X 35F 
39 T A T T A A A T` A A T A T` A T` 35B √ 35B 
40 T T T T A A A T A A T T` A A T` 6C/B X 7F 
41 T A A T A A T A A A A A A A A 9N/11
A 
9N 9N 
42 T T` A T` A A A T` A A T` A A T T` 4 √ 4 
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45 T T A T T A A T` A T T` A T A T` 16F √ 16F 
46 T T` T T A A A T` A A T` A T A T` 6C/B X 22F 
47 T T A T A A A A A A T` A A A A 19A/F 
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Figure 43: Double-blind validation of rmlB on S. pneumoniae isolates.  
Marker ladder MVIII is in lane 1 in every row; gene name is provided above the first 
pneumococcal isolate (#1); 1-48 are the coded numbers assigned to each pneumococcal isolate; 
-ve is negative water control; S. aga is short for S. agalactiae isolate tested. 
 
Figure 44: Double-blind validation of glf on S. pneumoniae isolates. 
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Figure 45: Double-blind validation of wchA on S. pneumoniae isolates. 
 
Figure 46: Double-blind validation of wchF on S. pneumoniae isolates. 
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Figure 47: Double-blind validation of wcjD on S. pneumoniae isolates. 
 
Figure 48: Double-blind validation of wcjE on S. pneumoniae isolates. 
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Figure 49: Double-blind validation of wcjG on S. pneumoniae isolates. 
 
Figure 50: Double-blind validation of rbsF on S. pneumoniae isolates. 
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Figure 51: Double-blind validation of wchX on S. pneumoniae isolates. 
 
Figure 52: Double-blind validation of wciN in S. pneumoniae isolates. 
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Figure 53: Double-blind validation of wciG in S. pneumoniae isolates. 
 
Figure 54: Double-blind validation of wcxM in S. pneumoniae isolates. 
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Figure 55: Double-blind validation of wciK in S. pneumoniae isolates. 
 
Figure 56: Double-blind validation of wcxI in S. pneumoniae isolates. 
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Figure 57: Sequential PCR MinSNP Capsule Typing using wzg, rmlB, glf, wchA and wchF in 
S. pneumoniae.  
Red boxes indicate final serotype that can be given to the S. pneumoniae isolate. The bottom 1, 2, 
3 and 4 links to consecutive hierarchy figures. 
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Figure 58: Consecutive hierarchy number 1 for S. pneumoniae isolates. 
 
CHAPTER 6  A novel capsular typing method for 
Streptococcus pneumoniae using Minimum SNPs 
220 
 
Figure 59: Consecutive hierarchy number 2 for S. pneumoniae isolates. 
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Figure 60: Consecutive hierarchy number 3 for S. pneumoniae isolates. 
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Figure 61: Consecutive hierarchy number 4 for S. pneumoniae isolates. 
 
6.3.5 Validation of capsule switching using the novel capsule typing and 
MLVA4 
In addition to capsule typing of S. pneumoniae, the novel capsule typing was 
combined with MLVA4 (previously described in Chapter 4) to determine whether 
capsule switching events had occurred in Queensland. From the previous study 
(Chapter 4) and combining traditional serotyping with MLVA4, two potential capsule 
switches had been identified, including a switch from serotype 1 to serotype 4, and a 
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switch from serotype 19A to serotype 15C. The capsular profiles based on the novel 
capsule typing have verified that the capsular profiles for these respective S. 
pneumoniae isolates indicate that even though the isolates have the same genotype, 
they have different capsule types (Table 30). Using the novel capsule typing, this 
determined that a potential capsule switch had occurred in Queensland pneumococcal 
population. Examination of the MLST database, which contains the most 
comprehensive data of S. pneumoniae strains worldwide, can be used to determine 
whether the capsular switch has more likely occurred in Queensland or not, for 
example, the result of importation of the strain already “capsule switched” elsewhere. 
From the database, ST306 (n=251) has been observed mainly in serotype 1 (n=244), 
however also serotype 9V (n=2), serogroup 11 (n=2), serotype 14 (n=1) and serotype 
7F (n=1). There have been no reports of serotype 4 (ST306) elsewhere in the world; 
only Queensland. This could possibly indicate that the potential capsule switch from 
serotype 1 to serotype 4 may have occurred in Australia.  
Similarly, ST411 (n=17) has been mainly recorded in Australia (MLST database) 
and associated with serotypes 19A, 15B and 15C – in the UK a serotype 15B (ST411; 
n=1) has been observed, and serotype 15C observed in China (n=1). The serogroup 15 
may have been introduced to Australia from overseas; however the capsule switch 
between serogroup 15 and serotype 19A may have occurred in Australia, since there is 
no record of ST411 serotype 19A elsewhere in the world. However the low number of 
isolates submitted to the MLST international database (n=17) limits our confidence in 
determining this capsule switch. 
Finally, ST53 (n=51), according to MLST database, is mainly associated with 
serotype 8. Only a serotype 9V (n=1) and a non-typeable (NT; n=1) has been reported 
with ST53. Therefore the serotype 11A, ST53 observed in this Queensland study may 
most likely be due to a switch within Queensland. 
Table 30: Capsule profiles observed for S. pneumoniae isolates that may have undergone 
capsule switching. 
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6.3.6 Costs of MinSNP Capsule Typing vs. serotyping 
Comparison of the cost of traditional serotyping compared to the developed 
MinSNP Capsule Typing was performed. To obtain a complete set of antisera through 
Australian agent for the traditional serotyping of any S. pneumoniae serotype costs 
AU$35, 712.00 (May 2014 est.) to completely type and factor type the isolates (H. 
Smith, personal communication, 30 October, 2014). Multiple tests can be performed. On 
the other hand, S. pneumoniae isolates can be directly sent to Statens Serum Institute, 
Denmark, who will charge AU$325.00 per isolate to obtain a complete type and factor 
type. 
In comparison to the serotyping costs, it was estimated that Minimum SNPs 
capsule typing using real-time PCR would cost approximately AU$27.00 per isolate if 
using the 19 target primer set. This cost includes the SybrGreen master mix reaction 
(AU$1390.00 for 1000 reactions) and primers (~AU$15.00 each). 
6.4 Discussion 
Capsule typing of pneumococci has become important in epidemiology studies 
worldwide, particularly since the polysaccharide capsule plays a vital role in virulence 
and hence is the target of several childhood vaccines. For decades, a traditional 
serotyping method based on antisera reaction has been widely used in epidemiology 
studies, however a number of limitations of this method have prompted the 
development of molecular based capsule typing methods. Of particular interest is the 
amplification of the capsule cassette, or discriminatory genes within the capsule 
cassette to characterise the more than 90 different pneumococcal serotypes. Currently, 
no molecular typing method has characterised all 98 serotypes, therefore this study has 
focused on a novel approach to select a minimum set of highly discriminatory capsule 
genes that have the ability to characterise all 98 serotypes. Furthermore, by 
determining the capsule type of each pneumococcal isolate and combining this 
information with the genotype (either MLST or MLVA), verification of whether capsule 
switching has occurred in the Queensland population. It was hypothesised that the 
novel capsule typing can detect S. pneumoniae capsule types and sub-types and that 
capsule switching events can be verified by combination of the novel capsule typing 
with MLVA4. 
A Minimum SNPs software program was used to identify the minimum set of 
highly discriminatory capsule genes within the pneumococcal capsule cassette. This 
software program has previously been used by several studies to identify highly 
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discriminatory SNPs for characterisation of bacteria (Price et al., 2006; Rathnayake et 
al., 2011; Robertson et al., 2004; Sheludchenko et al., 2010; Stephens et al., 2007). In 
this study, we were able to utilise it to identify highly discriminatory genes (rather than 
SNPs) by developing a pseudoDNA sequence that consists of only A (absent gene) and T 
(present gene). The Minimum SNPs program was then able to identify the highly 
discriminatory ‘SNP’ which codes for a particular gene, demonstrating that this 
bioinformatics program can be utilised not only to detect SNPs but also to detect 
discriminatory genes within a cassette.  
In total, 23 capsule genes were identified that would give the highest 
discrimination between all 93 available sequences of pneumococcal capsule types. 
However, more than one primer pair had to be designed for some of these genes 
because it proved difficult to develop a universal primer pair to target all expected 
serotypes. Some primers were also degenerative primers to allow amplification of SNP 
differences between binding sites. A number of the selected genes have been used in 
other capsule typing studies, including ugd (Tarrago et al., 2008), wchF (Tomita et al., 
2011), wcjE (Bentley et al., 2006; Calix & Nahm, 2010; Calix et al., 2012), wciN (Bratcher 
et al., 2011; Carvalho et al., 2009; Jin et al., 2009; Park et al., 2007; Pimenta et al., 2013; 
Tomita et al., 2011) and cpsA or wzg for internal control. This demonstrates that these 
genes have been recognised as suitable capsule typing genes, and that the Minimum 
SNPs program has similarly identified them to be included in this scheme. The wzg 
failed to amplify in S. agalactiae and S. pyogenes as expected and can be used to 
distinguish S. pneumoniae from other streptococcal species. However, other 
pneumococcal related species, such as S. oralis, S. mitis and S. pseudopneumoniae, could 
have been tested, particularly since a study has demonstrated that non- S. pneumoniae 
species can confound serotype-specific PCR due to evolutionary conserved genes 
(Carvalho et al., 2013). This could be a potential limitation of the novel capsular typing 
method. Further studies would include validating the capsule typing method on other 
pneumococcal species, particularly S. mitis. The wzg is contained in a homologous 
region at the 5’ end of the capsule cassette (Bentley et al., 2006), and was consistently 
amplified in all S. pneumoniae isolates in this study. 
For capsule typing the 35 known serotypes found in Queensland, only 16 gene 
targets were required that gave a Simpson’s Index of Diversity of 0.9782, of which 
further genes or SNP-specific primers could then be utilised to further differentiate any 
complex of serotypes that hadn’t been differentiated. Several genes unique for 
differentiation of S. pneumoniae serotypes were observed in this study. For example, 
wciN has been used to distinguish between serotype 6A and 6B (Bratcher et al., 2011), 
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however this study utilised glf for differentiation. The insertion of wcjD in serotype 9A 
and 9V differentiate it from serotype 9L and 9N (Bentley et al., 2006). This study 
observed that serotype 9V had a present wcjD whereas serotype 9N did not. Another 
gene wcjE that is known to be mutated in serotype 9N was still observed to be present 
in this study (Bentley et al., 2006). Similarly, wcjE can be used to differentiate serotype 
11A from 11E (Calix et al., 2010), however no serotype 11E was observed in this study 
to verify this, although wcjE was present in serotype 11A. Serotypes 10C and 10F can 
be differentiated from serotypes 10A and 10B by the presence of wciG in the former 
serotypes (Mavroidi et al., 2007); however this was not observed in this study as both 
serotypes 10A and 10F appeared to lack wciG. Finally, rbsF can be used to distinguish 
serotype 24A from 24F, and this study observed that serotype 24F has a present rbsF 
(Mavroidi et al., 2007). The verification of these genes in practice has reassured the in 
silico analysis when differentiating between S. pneumoniae serotypes. 
Even though 44% is low typeability, further examination of the individual 
targeted loci indicate that further optimisation of the PCR method may improve the 
typeability results. Using conventional PCR and gel electrophoresis improved 
typeability compared to the rtPCR HRM, however this is thought to be because we re-
analysed the mother template using the Minimum SNPs program, and it identified 12 
new CPS targets that could be used instead for differentiation. As a result, new primers 
were designed, and to improve PCR conditions each primer pair was amplified at the 
optimum annealing temperature i.e. there wasn’t one set temperature for all primers, 
instead some primers were amplified at 60oC while others were amplified at 65oC. Due 
to time and limited funds, we couldn’t repeat the experiment with the newly designed 
primers on rtPCR HRM. Several genes could have a more stringent PCR reaction by 
increasing the annealing temperature (Tm) so that faint bands that were amplify would 
disappear, leaving only the ‘true’ present gene. The G/C content of S. pneumoniae 
capsule cassette is lower than the rest of the genome (Bentley et al., 2006). This may 
have made it difficult when designing suitable primers with optimal G/C content. 
Additionally, several targeted capsule genes appeared to be unexpectedly present 
or absent in specific serotypes. Unfortunately for most serotypes there are only one 
capsule sequence available in the NCBI database, therefore it is possible that the 
Queensland isolates have variations which may indicate that the primers will anneal, or 
that the capsule genes are present/absent in contrast to the published sequences. At 
this point none of these capsule genes have been sequenced. It would be of interest to 
examine closely the following genes that this study noticed to be present or absent in a 
specific serotype: rmlB was absent in serotype 19A (should be present), and present in 
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serotype 4 (should be absent), and wchF was absent in serotype 7F and serotype 22F 
(should be present in both serotypes). Since the double-blind validation only tested at 
most 3 isolates per serotype, further validation would be ideal to determine if other 
isolates of the same serotype produce the same results. 
For ease of determine the serotypes from the capsule typing profile, a sequential 
hierarchy diagram was developed. From this only five main genes are necessary to be 
amplified to divide the Queensland serotypes into eight groups, and from which only a 
couple of genes would then differentiate the remainder. This sequential hierarchy 
diagram has only been designed for the identification of Queensland S. pneumoniae 
serotypes, however the principle can be applied for typing all 98 known serotypes 
worldwide. 
The ability to use real-time PCR with a high resolution melt curve has decreased 
time and cost compared to traditional serotyping and conventional PCR. Further 
optimisation is required for the novel capsule typing as only 27% of isolates were 
correctly identified, however this was only when using the original 19 CPS genes 
amplified at an annealing temperature of 67oC; as we explained earlier, this typeability 
was improved to 44% after re-analysing the CPS genes and modifying the PCR 
conditions so that the new 16 CPS targets would be amplified at different annealing 
temperatures. We were unable to repeat the second CPS typing with 16 genes on rtPCR 
HRM due to time and limited funding. The application of rtPCR has been demonstrated 
for developing a novel capsular typing method for S. pneumoniae, although further 
validation and modification of the method is required to obtain a useable method for 
routine diagnostic detection.  
Results, using rtPCR, could be obtained in minutes since it is not necessary to 
wait through full amplification which is important in outbreak situations (Bricker, 
2011). It was estimated that this real-time PCR cost on average AU$27.00 to identify 
each capsule type. In comparison, traditional serotyping with a complete set of antisera 
would cost AU$35, 712.00, or alternatively isolates sent to Statens Serum Institute, 
Denmark, would cost AU$325.00 per isolate. It is clear that using molecular methods 
for capsule typing S. pneumoniae is dramatically cheaper than conventional serotyping. 
Further studies would also need to compare other capsular typing methods, also based 
on PCR (Appendix A4: Comparison of various pneumococcal PCR-based serotyping 
methods). 
The second objective of Aim 4 was to determine whether capsule switching could 
be verified in the Queensland pneumococcal population. A number of capsule switches 
had been identified in the earlier studies (Chapter 5). Often identification of capsule 
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switching is achieved by sequencing the capsule cassette for identification of points of 
recombination. By using the novel capsule typing method, exact points of 
recombination cannot be determined, however identification of rearranged genes could 
be visualised. This study was only able to verify that the serotypes observed were the 
same as determined by the Quellung reaction. The potential capsule switches observed, 
including a switch from a serotype 19A to 15C and serotype 1 to 4, has also been 
observed when combining the novel capsule typing with MLVA4. No evidence of 
vaccine escape strains has been observed in this study. 
6.5 Conclusion and future perspectives 
This final study examines the S. pneumoniae capsule cassettes, which is a 
primary target of the current pneumococcal childhood vaccines. The pneumococcal 
capsule is a major virulence factor, and has been extensively investigated to understand 
how the pneumococcus has the ability to switch this capsule to evade the current 
vaccines. The traditional serotyping method for characterising the more than 90 
capsule types has a number of limitations, prompting the development of molecular 
based capsule typing methods. The newly designed capsule typing method has been 
devised based on the selection of highly discriminatory capsule genes, selected by the 
bioinformatics program Minimum SNPs. A total of 23 capsule genes could be used to 
differentiate 93 serotypes, and a minimised 16 target gene was used to characterise the 
35 Queensland S. pneumoniae serotypes with a 44% success rate. Further optimisation 
is recommended, although the use of conventional PCR and real-time PCR can be used. 
Furthermore, the capsule profiles of S. pneumoniae isolates that were thought to have 
been associated with capsule switching (Chapter 5) was verified by using the novel 
capsule typing method. 
There are a number of future directions for the use of this newly developed 
capsule typing method. Further optimisation of the method, including the validation of 
using real-time PCR is required; however results so far are fairly promising. The novel 
capsular typing method has not been tested with multiple pneumococcal strains with 
different serotypes. Detection of pneumococcal serotypes in co-colonization (i.e. 
multiple serotypes in a sample) has been investigated (Saha et al., 2015). 
At this point, the novel capsule typing has not been developed into a multiplex; 
however there is the potential for this. Fluorescent labels can be incorporated to 
distinguish each primer set within rtPCR. Another study has used fluorescent labels in 
rtPCR by using FAM, HEX, ROX and CY5 with black hole quencher as reporter dyes 
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(Pimenta et al., 2013). Alternatively, the use of melt curves can differentiate the 
different gene products, as we could already see from this study (Bricker, 2011). 
It would also be of interest to investigate whether this capsule typing method 
could be applied directly to clinical samples. Amplification of conserved wzg with a 
TaqMan minor groove binder (MGB) probe was performed directly on pleural fluids 
taken from patients with parapneumonic empyema caused by S. pneumoniae (Tarrago 
et al., 2008). 
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7.1 Summary 
S. pneumoniae is undoubtedly an important bacterium to study, especially since 
the population structure has been changing since the introduction of the childhood 
pneumococcal vaccines. To monitor these changes, and therefore determine the best 
advice that health authorities and the public should be given, epidemiology studies are 
required. Hence this PhD thesis has examined both MLST and MLVA genotyping 
methods for characterising S. pneumoniae in Queensland children, and capsule typing 
methods for identification of the pneumococcal capsule types that the vaccines target.  
To conclude this thesis, the following paragraphs will summarise the four main 
aims investigated and whether the objectives were met with our major findings. These 
sections will outline the original hypotheses and whether these were rejected or 
supported from our results. Following this will be the major outcomes and significance 
of this study, with concluding remarks of the limitations in this study. A final section is 
then included on our final recommendations and future directions. 
The first aim of this PhD was to modify a MLVA method for genotyping invasive 
S. pneumoniae, with the objective of creating a faster, cheaper, highly discriminatory 
and technically less-demanding genotyping method compared to the ‘gold standard’ 
MLST method. MLST is considered the ‘gold standard’ genotyping method for studying 
invasive S. pneumoniae however MLVA has also emerged as an alternative genotyping 
technique as it has higher discriminatory power, is fast and inexpensive (Elberse et al., 
2011a; Koeck et al., 2005). Results in this study support this finding; however MLVA 
would be more suitable for short-term and localised/state-wide epidemiology studies 
rather than long term and international studies due to the high diversity of the VNTR 
loci. The modified MLVA4 method maintains a high discriminatory power whilst 
minimising the number of incomplete genotypes, and is more accurate in representing 
the Queensland pneumococcal population structure than MLST when observing short-
term changes or localised outbreaks. MLST was proven to be less discriminatory 
(S=0.936) than the MLVA1 protocol (S=0.963) and MLVA4 method (S=0.978). MLVA4 
genotyping took less time (3-4 days) compared to MLST (16-20 days) and was 
inexpensive (~AU$24.00 per isolate compared to ~$AU347.00 per isolate, 
respectively). Complexes of isolates can be observed in more detail and can glean more 
information when combined with isolate information such as antibiotic resistance or 
location of disease (not used in this study). Admittedly, additional markers have 
increased resolution (ten loci instead of seven or eight) however we have minimised 
laboratory work to three multiplexes.  
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The main purpose of modifying MLVA was to eliminate or minimise the number 
of non-amplified loci detected in Elberse et al. (2011a) method, which has been 
achieved. This study observed that some loci failed to amplify in specific serotypes, 
such as BOX-06 failing to amplify in 75% of serotype 7F and Spneu19 in several 
serotype 3 isolates. A number of primers were re-designed in this study (including 
BOX-10, BOX-12, BOX-13 and Spneu19) in an attempt to successfully amplify the 
previously failing loci. Improved amplification of these loci was observed after re-
designing primers. It was hypothesised that the non-amplification of loci in specific 
serotypes could provide added discrimination. 
Therefore, the use of MLVA rather than MLST for genotyping S. pneumoniae 
should be favoured, particularly due to its low costs, faster time and high 
discriminatory power. As a result of these advantages, MLVA genotyping is widely used 
for many organisms. Several microorganisms have limited amount of genetic diversity, 
therefore VNTR and MLVA methods have been able useful in epidemiology studies 
because they can allow differentiation of the organisms, including Mycobacterium 
tuberculosis (Spurgiesz et al., 2003), and a number of bioterrorist-organisms such as 
Yersinia pestis (Klevytska et al., 2001), Bacillus anthracis (Lista et al., 2006), and 
Francisella tularensis (Farlow et al., 2001; Jernigan et al., 2002). The speed and 
versatility of MLVA has meant that most bioterrorist-organisms have a MLVA typing 
scheme (Van Belkum et al., 2006). In addition, VNTR loci have been found in a number 
of non-bacterial organisms including parasitic protozoa (Wickstead et al., 2003), 
viruses e.g. Epstein Barr Virus (Xue et al., 2003), and fungus such as Candida albicans, 
Aspergillus furnigatus and Aspergillus flavus (Bart-Delabesse et al., 2001; Lott et al., 
1999; Wang et al., 2012). Development of MLVA protocols for these non-bacterial 
organisms is still in the very early stages, but this demonstrates that the application of 
MLVA is not restricted just to S. pneumoniae but to a range of bacterial and non-
bacterial organisms. It is also considered favourable for epidemiology studies of 
outbreaks, and bioterrorism. 
The second aim of this study was to determine the population structure of 
invasive S. pneumoniae in Queensland isolated from children 15 years or younger from 
2007 to 2012 using MLVA1, MLVA4 and MLST. Our objectives were to observe the 
differences between MLST, MLVA1 and MLVA4 when interpreting the pneumococcal 
population structure, and to provide a current study and baseline of the Queensland 
invasive pneumococcal population.  
Variations in interpreting the population structure of S. pneumoniae were 
observed when using the different genotyping protocols. Serotyping alone identifies 35 
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serotypes but prohibits our understanding of genetic relationships and capsule 
switching. MLST identifies eleven clonal complexes (n=202) circulating throughout 
Queensland, whereas MLVA4 identifies eighteen clonal complexes (n=202) and also 
enables closer examination of eleven MLST singletons, one of which is serotype 7F 
which is commonly associated with IPD in Australian Aborigines. MLVA4 maintains 
high congruence with the other MLVA methods and MLST. MLVA4 combined with 
serotyping, increases our understanding of the Queensland pneumococcal 
epidemiology. Unfortunately the Queensland MLST results cannot contribute to a 
national Australian study/database because none currently exists. Few Australian 
isolates have been submitted to the international MLST database, and we have 
submitted the MLST results from this study to the MLST database.  
Further examination of the MLVA4 pneumococcal population structure reveals 
diverse genetic relationships within the Queensland population, including between 
serotypes 18B and 18C (CC7), serotypes 19A, 15C and 15B (CC6), serotype 8 and 11A 
(CC21), serotype 7F (CC1) and serotype 3 (CC3) which MLST does not reveal. 
Overlaying patient information with diverse genotypes may reveal further information 
about outbreaks, patient susceptibility, vaccine immunisation and tracking of disease. 
The ability to examine CC with higher discrimination using MLVA4 can provide insight 
into which genes are changing, for example serotype 7F (MLVA CC1 or ST191) largely 
diversifies due to BOX-10 and serotype 3 diversifies due to Spneu17. It is unknown 
what the specific functions of these genes are, however it is known that VNTRs and BOX 
elements play a role in bacterial competence and virulence (Knutsen et al., 2006; 
Martin et al., 1992). VNTR loci with high diversity (e.g. Spneu17) would allow increased 
discrimination within localised or short-term studies, whereas VNTR loci with low 
diversity (e.g. BOX-02 and BOX-11) would allow identification of long term changes.  
This epidemiology study so far indicates that the 13vPCV may be having a 
positive impact by reducing IPD cases in young children. This is one of the first 
preliminary studies indicating that S. pneumoniae may be declining in this group. 
Unfortunately, IPD is seen to potentially increase in older children. Continued 
monitoring is essential to determine whether these numbers will decline or not. The 
significance of these increases in older children may impact vaccine strategy. Overall, 
there hasn’t been a decline in 13vPCV serotypes in children under 15 years old, 
however it is too soon to detect any significant changes. 
In addition we can identify that the four most common serotypes 1, 3, 7F and 
19A form the largest clonal complexes circulating in Queensland children from 2007 to 
2012. Keeping in mind that not all serotype 19A were genotyped in this study because 
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they are being examined in another study at QUT, the numbers of serotype 19A are 
underestimated. Since all of these common serotypes are targeted by 13vPCV, this 
signifies that IPD cases will hopefully decline in the future with wide implementation of 
the vaccine. Interestingly, despite the introduction of 13vPCV, a number of 7vPCV-
serotypes were still being observed; particularly serotype 19F which was the fifth 
highest most common serotype in this study. There is 95% vaccine coverage in non-
Indigenous citizens and 85% coverage in Indigenous citizens across Australia (Barry et 
al., 2012). Due to restricted access to patient data for this study, the vaccination history 
of 7vPCV is unknown for this study; therefore we are unable to determine whether IPD 
caused by serotype 19F is due to non-vaccination or a vaccine failure. Genotyping also 
reveals that non-targeted serotypes are genetically related to targeted serotypes e.g. 
serogroup 15 found in CC5 is genetically related to serotype 19A. This could provide 
preliminary insight into potential future serotype replacement.  
As well as identifying genetic relationships between individual serotypes, 
higher discriminatory power can impact interpretations of population structures, 
especially when identifying capsule switches. Already potential capsule switches have 
been observed between a serotype 19A and 15C in CC6 (MT59; ST411), and a serotype 
1 and 4 (MT36; ST306) in CC8 in our Queensland population using MLVA4. Other 
potential capsule switches were observed using MLVA1 or MLST which may be false 
positives due to the lower discriminatory power of these genotyping methods, or could 
actually reflect the limitations of MLVA in detecting all capsule switches. Alternatively, 
MLVA4 is too discriminatory and even though true capsule switch occurs, MLVA4 
identifies two distinct genotypes therefore the assumption is that no capsule switching 
has occurred. Further investigation is required to determine whether MLVA4 could fail 
to detect capsule switches or that MLST is detecting false capsule switches. Since 
MLVA4 is highly discriminatory for short-term studies, it may enable detection of 
capsule switching earlier than MLST would. Because the serotyping methods may not 
be discriminatory enough to identify true capsule types, confirmation of capsule 
switching will be performed by combining a novel capsule typing method that identifies 
capsule types, with the highly discriminatory MLVA4. The significance of accurately 
identifying these capsule switches may impact future vaccine development. 
These possible limitations of vaccination, i.e. vaccine failure, serotype 
replacement and capsule switching, could impact the use of vaccines for combating 
disease in the future.  As demonstrated by the pneumococcal vaccine and how this 
target organism has almost countermanded the effects, this could inform that careful 
consideration is required when developing future vaccines. A number of other 
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microorganisms have polysaccharide capsules similar to the pneumococcus, including 
Gram-negative bacteria such as Escherichia coli (Bayer & Thurow, 1997; Sarkar et al., 
2014), Neisseria meningitidis (Harrison et al., 2013), Klebsiella pneumoniae (Domenico 
et al., 1994), Haemophilus influenzae (Kroll et al., 1990), Pseudomonas aeruginosa 
(Evans & Linker, 1973), Salmonella enterica (Gibson et al., 2006), Gram-positive 
bacteria such as Bacillus megaterium (Baumann-Grace & Tomscik, 1957), Streptococcus 
pyogenes (Obzanska et al., 2011), Streptococcus agalactiae (Bellais et al., 2012), 
Staphylococcus epidermidis (Ziebuhr et al., 1999), Staphylococcus aureus (O’Riordan & 
Lee, 2004), and even fungus such as Cryptococcus neoformans (O’Meara & Alspaugh, 
2012). As a result, vaccines have or are being developed to target the polysaccharide 
capsules of these microorganisms, however as demonstrated by the effects of the 
pneumococcal vaccines on S. pneumoniae a number of concerns remain. Evidence of 
capsule switching have been observed in other microorganisms such as Streptococcus 
agalactiae (Bellais et al., 2012) and Neisseria meningitidis (Swartley et al., 1997), and 
the different types of capsules make vaccine design difficult, for example E. coli has 167 
different O serogroups and more than 80 K polysaccharide antigens (Brumbaugh & 
Mobley, 2012), and more than 20 different serotypes for Pseudomonas aeruginosa 
(Sharma et al., 2013).  Certainly in the case of the pneumococcus, developing a vaccine 
that only targets a smaller set number of serotypes has presented some limitations 
when combating pneumococcal disease. The vaccine has systematically reduced the 
incidence of IPD among the target-vaccinated group in several countries.  However, the 
vaccine has also become a selection pressure against the pneumococcal population, 
causing it to shift from a targeted-serotype population to a non-targeted serotype 
population. On top of this, capsule switching in the pneumococcal populations have 
been observed worldwide, leading to vaccine escape strains that cause increase 
number of pneumococcal disease. It appears that any approach to designing a vaccine, 
not even just for S. pneumoniae but for any organism, needs to achieve complete 
eradication by allowing minimal opportunities to open a niche for the same organism 
to adapt to. 
Following from the previous aims, Aim 3 was to determine whether the genetic 
population of non-vaccine (non-13vPCV) serotypes was changing in the Queensland 
pneumococcal population. By comparing eBurst dendograms of 2007-2009 to 2010-
2012 demonstrates that the population structure appears to be less clonal in later 
years, supporting our original hypothesis that the population structure would be 
changing. This is significant as it indicates that strains are diversifying and increasing in 
numbers. The objective of the vaccine is to reverse this trend. As it is still too early to 
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determine the significant changes after the introduction of the 13vPCV, these results 
are only preliminary observations. 
Detecting relationships between serotypes accurately and quickly may have an 
impact on the selection of serotypes for future vaccine strategies. Ideally vaccine 
strategies should benefit the whole of a nation, however differences in state 
pneumococcal populations have prompted localised strategies, for example the 10vPCV 
was only introduced into Northern Territory since the additional serotypes were not 
common elsewhere in Australia. If a vaccine targets only one serotype in a CC and not 
the other, this may provide pressure for capsule switching or serotype replacement. 
The 13vPCV targets serotype 19A, therefore there might be a selective pressure for the 
serotype 19A to switch capsules to a 15C or 15B (CC6), which are known to be 
genetically related. Serotype 15B and 15C are not included in any current childhood 
vaccines, or the in-trial 15vPCV which targets the extra serotypes 22F and 33F, 
therefore future surveillance is recommended. 
Conversely, a number of clonal complexes have emerged, indicating the possible 
beginnings of serotype replacement, especially those complexes containing serotypes 
not targeted by the 13vPCV. It will therefore be important to monitor the potential 
changes of CC9 (serotype 15C), CC10 (serotype 15B/15C), CC32 (serotype 33F), CC19 
(serotype 22F and 33F) and CC24 (serotype 22F). Continued surveillance for changes 
to these clonal complexes, especially CC19 and CC24, will assist in vaccine health policy 
decision making and the impact of introducing the 15vPCV (targets serotype 22F and 
33F).  
Despite the emergence of clonal complexes, serotype replacement has not been 
observed since the introduction of the 13vPCV in 2011 in this study. However there 
have been increases of serotype 6C and 23B, both not targeted by the 13vPCV. 
Altogether, serotype 6C, 15C and 33F (9% of isolates) could increase by serotype 
replacement as they are not targeted by the 13vPCV. It is recommended that 
surveillance by way of MLVA continue to enable reporting of future serotype 
replacement. Cooper et al. (2011) has demonstrated that the 13vPCV may have cross-
protection against 6C as there was a 96% OPA (238 opsonophagocytic assay) response. 
In South Australia there have also been reports of increases in non-13vPCV serotypes 
(Johnson et al., 2012). 
The final aim of this study builds on the genotyping study in Aims 1, 2 and 3 by 
combining a novel capsule typing method developed in this study with MLVA4 to 
determine capsule types and verify capsule switches. Examination of 93 S. pneumoniae 
capsular cassettes available in the NCBI database was performed so that a ‘mother 
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template’ consisting of all the possible capsular genes could be designed. Using the 
Minimum SNPs bioinformatics program, a binary marker system of T = present and A = 
absent was used to create a pseudoDNA sequence for each of the 93 capsule types 
based from the ‘mother template’. The Minimum SNPs program then analysed the 
combination of binary markers and identified a minimum set of targets (capsule genes) 
to characterise each capsule type. The minimum number of targets identified in this 
study to characterise Queensland invasive S. pneumoniae was 16 capsule genes. These 
selected capsule genes were applied to clinical strains of S. pneumoniae isolated from 
children less than 15 years old during 2007 to 2012. Conventional PCR and real-time 
PCR were both used to demonstrate that the capsule typing method could be applicable 
to both techniques. 
The newly developed novel capsule typing method was applied to 48 isolates, 
with a 44% successful typeability when using conventional PCR. Closer examination of 
the targeted capsule genes identify that most had good typeability, while others will 
require further optimisation. As well as standard capsule typing, the novel capsule 
typing was combined with MLVA4 to verify capsule switching events previously 
observed in the Queensland pneumococcal population structure from Aim 3 (Chapter 
5). Verification of the capsule switch between a serotype 1 and 4, and serotypes 19A 
and 15C was observed. Both serotype 1 and 4 appeared to have a different capsule type 
profile although they both had the same MLVA4 genotype. The application of sequential 
PCR has also been demonstrated for the capsule typing method. A set of five genes 
(wzg, rmlB, glf, wchA and wchF) can differentiate the majority of serotypes in 
complexes, of which only a couple of other genes or SNP-specific primers that can be 
utilised to further differentiate the complexes.  
Future directions of the novel capsule typing include the application to co-
colonisations of S. pneumoniae serotype, direct typing of clinical specimens without the 
need for culture, and the identification of non-capsular S. pneumoniae that do not have 
an expressed capsule. The wider application of molecular capsule typing to other 
microorganisms could be performed, particularly those mentioned before that also 
carry a polysaccharide capsule. The Minimum SNPs bioinformatics program can be 
similarly applied to other microorganisms to determine the minimum number of 
capsule genes that would provide the highest discrimination between all capsule types 
and sub-types.  
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7.2 Major Outcomes and Significance of this study 
1.     Modification of MLVA genotyping method for S. pneumoniae offers a rapid, cost-
effective and highly discriminatory alternative to MLST. MLVA4 also decreases 
the number of incomplete genetic profiles that previous published MLVA 
methods obtained. Any non-amplifications were observed to be serotype 
specific and possibly due to absence of the locus in the pneumococcal genome. 
It is possible to standardise this method between laboratories which will enable 
the sharing of data. 
2.  The modified MLVA4 genotyping method can be used for epidemiology studies 
of invasive S. pneumoniae population structure. It could also be applicable to 
carriage isolates of S. pneumoniae. Importantly, this MLVA4 protocol has 
enabled further subdivision of important pneumococcal serotypes and 
sequence types causing disease in Queensland children, including serotype 7F 
and serotype 19A. 
3.  A number of new sequence types (ST), namely ST8969, ST9082, and ST9660 – 
ST9673 for S. pneumoniae were characterised from the Queensland population. 
Full MLST sequencing was carried out and they are now listed on the MLST 
database (http://pubmlst.org/spneumoniae/). 
4. A novel capsule typing method was developed to identify the pneumococcal 
serotypes. This new technique was based on a novel approach by using 
Minimum SNPs program to identify a minimum set of highly discriminatory 
genes to characterise each known serotype of S. pneumoniae. Real-time PCR was 
used to determine the absence or presence of each selected gene. The 
application of Minimum SNPs for molecular capsule typing of other 
microorganisms based on capsular genes is also feasible. 
5.  The novel capsule typing was applied to Queensland isolates of S. pneumoniae. 
Serotypes could be determined using this novel method. This new technique 
enables a rapid and cost-effective alternative to traditional serotyping methods, 
and has the ability to capsule type all known serotypes whereas other PCR 
based molecular typing methods do not. 
6.  The combination of the novel capsule typing with the modified MLVA4 
genotyping can be used in epidemiology studies, particularly to identify capsule 
switching. Several capsule switching events were identified in this study, 
namely serotype 19A to 15C, and serotype 1 to 4. 
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7.  This research increases our knowledge of the pneumococcal population 
structure of IPD cases in children 15 years or younger in Queensland, and 
emphasises the need for a universal genotyping method and database.   
7.3 Future directions 
1.  After the introduction of a vaccine, it is desirable to survey a population for at 
least five years post introduction; therefore MLVA4 genotyping could be 
performed for 2013-2016 to determine the population structure and determine 
shifts in the population structure post-13vPCV. 
2.  Ethical clearance would be desirable so that further examination of the 
associated patient data with the pneumococcal population can be performed. 
Information such as location, vaccination history, age, gender, etc. could have 
association with the rates of IPD. Furthermore examination of antibiotic 
resistance and MDR strains particularly in non-13vPCV serotypes can be 
examined. 
3.  Due to the lack of a national genetic database in Australia (either MLST or 
MLVA), further collaboration to investigate or establish a universal MLVA 
genotyping method and database for genotyping S. pneumoniae is 
recommended. 
4.  Sequencing of unusual VNTR fragment sizes in serotype 33F, 35F and 7F can be 
performed. This could determine whether the locus is missing or contains large 
insertion sequence (IS) fragments. Study of VNTR genes will be important 
particularly because of their association with virulence genes. Additionally, 
experimentation of the VNTR/BOX locus used in this study and its association 
with downstream loci can be performed to determine whether they play 
regulatory roles in virulence. 
5.     A novel capsule typing method has been developed in this study but has only 
been applied to 35 serotypes available in Queensland, and validated using 
conventional PCR. It would be of interest to further optimise this method by 
validating it using rtPCR, transforming it into multiplex reactions (and 
potentially sequentially like Pai et al. 2006) and apply the method directly to 
clinical samples without the need for culture, and non-capsulated pneumococci. 
Application of rtPCR was attempted in this study, but due to difficulties in 
amplifying capsule genes and time constraints, validation of the method was 
not performed. By multiplexing the reactions, this would provide a faster and 
potentially cheaper method. The ability to capsule type directly from clinical 
CHAPTER 7 Summary, Major Outcomes, Significance and 
Future directions 
242 
 
samples (e.g. blood, sputum, etc.) without the need to culture can decrease time 
and cost of experimentation and furthermore being able to detect non-
capsulated S. pneumoniae is equally important as these strains are difficult to 
detect and yet also cause invasive disease. Furthermore, the capsule typing 
method needs to be tested against other Streptococcal species, particularly S. 
mitis which has been shown to test positive. 
6.  Verification of whether the novel capsule typing can be confidently used to 
determine capsule switching needs to be compared to whole genome 
sequencing or capsule sequencing. 
7.       Exploration into particular serotypes, for example serotype 1 which has a 
potential capsule switch from serotype 4, or serogroup 6 which now has 8 
distinct capsular polysaccharides (A, B, C, D, E, F, G, H) could be performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
243 
 
REFERENCES 
Aanensen, D. M., & Spratt, B. G. (2005). The multilocus sequence typing network: mlst.net. 
Nucleic Acids Research, 33, 728-733. doi: 10.1093/nar/gki415. 
Ahn, J. G., Choi, S. Y., Kim, D. S., & Kim, K. H. (2012). Enhanced detection and serotyping of 
Streptococcus pneumoniae using multiplex polymerase chain reaction. Korean Journal of 
Pediatrics, 55(11), 424-429. 
Ansaldi, F., Canepa, P., de Florentiis, D., Bandettini, R., Durando, P., & Icardi, G. (2011). Increasing 
incidence of Streptococcus pneumoniae serotype 19A and emergence of two vaccine 
escape recombinant ST695 strains in Liguria, Italy, 7 years after implementation of the 
7-valent conjugated vaccine. Clinical and Vaccine Immunology, 18(2), 343-345. doi: 
10.1128/cvi.00383-10. 
Antonio, M., Hakeem, I., Sankareh, K., Cheung, Y. B., & Adegbola, R. A. (2009). Evaluation of 
sequential multiplex PCR for direct detection of multiple serotypes of Streptococcus 
pneumoniae from nasopharyngeal secretions. Journal of Medical Microbiology, 58(3), 
296-302. 
Austrian, R. (1977). Prevention of pneumococcal infection by immunization with capsular 
polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. 
Journal of Infectious Diseases, 136(Suppl.), 38-42. 
Avery, O. T., Macleod, C. M., & McCarty, M. (1944). Studies on the chemical nature of the 
substance inducing transformation of pneumococcal types: Induction of transformation 
by a desoxyribonucleic acid fraction isolated from pneumococcus types III. The Journal 
of Experimental Medicine, 79(2), 137-158. 
Azzari, C., Moriondo, M., Indolfi, G., Cortimiglia, M., Canessa, C., Becciolini, L., . . . Resti, M. (2010). 
Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in 
children with culture negative pneumococcal invasive disease. PLoS One, 5(2). 
doi:10.1371/journal.pone.0009282 
Barry, C., Krause, V., Cook, H., & Menzies, R. (2012). Invasive pneumococcal disease in Australia 
2007 and 2008. Communicable Diseases Intelligence, 36(2). 
Bart-Delabesse, E., Sarfati, J., Debeaupuis, J. P., Van Leeuwen, W., Van Belkum, A., Bretagne, S., & 
Latge, J. P. (2001). Comparison of restriction fragment length polymorphism, 
microsatellite length polymorphism, and random amplification of polymorphic DNA 
analyses for fingerprinting Aspergillus fumigatus isolates. Journal of Clinical 
Microbiology, 39(7), 2683-2686. doi: 10.1128/JCM.39.7.2683-2686.2001. 
Baumann-Grace, J. B., & Tomcsik, J. (1957). The surface structure and serological typing of 
Bacillus megaterium. Journal of General Microbiology, 17(1), 227-237. doi: 
10.1099/00221287-17-1-227. 
Bayer, M. E., & Thurow, H. (1977). Polysaccharide capsule of Escherichia coli: microscope study 
of its size, structure, and sites of synthesis. Journal of Bacteriology, 130(2), 911-936.  
REFERENCES 
244 
 
Beall, B., McEllistrem, M. C., Gertz, J. R. E., Wedel, S., Boxrud, D. J., Gonzalez, A. L., . . . Active 
Bacterial Core Surveillance. (2006). Pre- and postvaccination clonal compositions of 
invasive pneumococcal serotypes for isolates collected in the United States in 1999, 
2001, and 2002. Journal of Clinical Microbiology, 44(3), 999-1017. 
Bellais, S., Six, A., Fouet, A., Longo, M., Dmytruk, N., Glaser, P., . . . Poyart, C. (2012). Capsular 
switching in group B streptococcus CC17 hypervirulent clone: A future challenge for 
polysaccharide vaccine development. Journal of Infectious Diseases, 206(11), 1745-1752. 
doi: 10.1093/infdis/jis605. 
Benson, G. (1999). Tandem repeats finder: a program to analyse DNA sequences. Nucleic Acids 
Research, 27(2), 573-580. 
Bentley, S. D., Aanensen, D. M., Mavroidi, A., Saunders, D., Rabbinowitsch, E., Collins, M., . . . 
Spratt, B. G. (2006). Genetic analysis of the capsular biosynthetic locus from all 90 
pneumococcal serotypes. PLoS Genetics, 2(3), e31. doi:10.1371/journal.pgen.0020031. 
Berglund, J., Vink, P., Fernanda Tavares Da, S., Lestrate, P., & Boutriau, D. (2014). Safety, 
Immunogenicity, and Antibody Persistence following an Investigational Streptococcus 
pneumoniae and Haemophilus influenzae Triple-Protein Vaccine in a Phase 1 
Randomized Controlled Study in Healthy Adults. Clinical and Vaccine Immunology, 
21(1), 56-65. 
Bratcher, P. E., Kim, K., Kang, J. H., Hong, J. Y., & Nahm, M. H. (2010). Identification of natural 
pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological 
characterization. Microbiology, 156(2), 555-560. 
Bratcher, P. E., Park, I. H., Oliver, M. B., Hortal, M., Camilli, R., Hollingshead, S. K., . . . Nahm, M. H. 
(2011). Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6. 
Microbiology, 157(1), 189-198. 
Bricker, B. (2011). Past, present and future of molecular technology applications for the 
epidemiology of bacterial diseases. Journal of Analytical and Bioanalytical Techniques, 
S10:001. doi:10.4172/2155-9872.S10-001. 
Brito, D. A., Ramirez, M., & de Lencastre, H. (2003). Serotyping Streptococcus pneumoniae by 
multiplex PCR. Journal of Clinical Microbiology, 41(6), 2378-2384. 
Brueggemann, A. B., & Spratt, B. G. (2003). Geographic distribution and clonal diversity of 
Streptococcus pneumoniae serotype 1 isolates. Journal of Clinical Microbiology, 41(11), 
4966-4970. 
Brueggemann, A. B., Pai, R., Crook, D. W., & Beall, B. (2007). Vaccine escape recombinants 
emerge after pneumococcal vaccination in the United States. PLoS Pathogens, 3(11), 
e168. doi:10.1371/journal.ppat.0030168. 
Brugger, S. D., Hathaway, L. J., & Muhlemann, K. (2009). Detection of Streptococcus pneumoniae 
strain cocolonization in the nasopharynx. Journal of Clinical Microbiology, 47(6), 1750-
1756. doi: 10.1128/JCM.01877-08. 
REFERENCES 
245 
 
Brumbaugh, A. R., & Mobley, H. L. T. (2012). Preventing urinary tract infection: progress toward 
an effective Escherichia coli vaccine. Expert Review of Vaccines, 11(6), 663-676. doi: 
10.1586/ERV.12.36. 
Calix, J. J., & Nahm, M. H. (2010). A new pneumococcal serotype, 11E, has a variably inactivated 
wcjE gene. The Journal of Infectious Diseases, 202(1), 29-38. 
Calix, J. J., Porambo, R. J., Brady, A. M., Larson, T. R., Yother, J., Abeygunwardana, C., & Nahm, M. H. 
(2012). Biochemical, genetic, and serological characterization of two capsule subtypes 
among Streptococcus pneumoniae serotype 20 strains: discovery of a new 
pneumococcal serotype. Journal of Biological Chemistry, 287(33), 27885. 
Camara, M., Mitchell, T. J., Andrew, P. W., & Boulnois, G. J. (1991). Streptococcus pneumoniae 
produces at least two distinct enzymes with neuraminidase activity: cloning and 
expression of a second neuraminidase gene in Escherichia coli. Infection and Immunity, 
59(8), 2856-2858. 
Carvalho, M. d. G., Hollingshead, S. K., Pilishvili, T., Whitney, C. G., Nahm, M. H., Beall, B. W., . . . 
Park, I. H. (2009). PCR-based quantitation and clonal diversity of the current prevalent 
invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 
to 2007. Journal of Clinical Microbiology, 47(3), 554-559. 
Carvalho, M. D. G., Pimenta, F. C., Moura, I., Roundtree, A., Gertz, R. E., Li, Z. Y., . . . Beall, B. (2013). 
Non-pneumococcal mitis-group streptococci confound detection of pneumococcal 
capsular serotype-specific loci in upper respiratory tract. PeerJ, 1(1), e97. 
doi:10.7717/peerj.97. 
Centers for Disease Control Prevention. (2010). Licensure of a 13-valent pneumococcal 
conjugate vaccine (PCV13) and recommendations for use among children – Advisory 
Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly 
Report, 59(9), 258-261. 
Centers for Disease Control Prevention. (2015). Invasive pneumococcal disease (IPD) 
(Streptococcus pneumoniae, invasive disease) (Streptococcus pneumoniae): 2010 Case 
definition.   Retrieved 28 July, 2015, from 
http://wwwn.cdc.gov/NNDSS/script/casedef.aspx?CondYrID=736&DatePub=1/1/201
0%2012:00:00%20AM. 
Chiavolini, D., Memmi, G., Maggi, T., Iannelli, F., Pozzi, G., & Oggioni, M. R. (2003). The three 
extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different 
impact on virulence in mice. BMC Microbiology, 3(1), 14-14. 
Claverys, J. P., & Martin, B. (1998). Competence regulons, genomics and streptococci. Molecular 
Microbiology, 29(4), 1126-1127. 
Cohen, R., Levy, C., Bingen, E., Koskas, M., Nave, I., & Varon, E. (2012). Impact of 13-valent 
pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children 
with acute otitis media. Pediatric Infectious Disease Journal, 31, 297-301. 
REFERENCES 
246 
 
Cohen, R., Levy, C., Bonnet, E., Thollot, F., Boucherat, M., Fritzell, B., . . . Varon, E. (2011). Risk 
factors for serotype 19A carriage after introduction of 7-valent pneumococcal 
vaccination. BMC Infectious Diseases, 11(1), 95-95. 
Collins, D., Hoskins, A., Bowman, J., Jones, J., Stemberger, N., Richmond, P., . . . Lehmann, D. 
(2013). High nasopharyngeal carriage of non-vaccine serotypes in Western Australian 
Aboriginal people following 10 years of pneumococcal conjugate vaccination: e82280. 
PLoS One, 8(12). doi:10.1371/journal.pone.0082280. 
Cooper, D., Yu, X., Sidhu, M., Nahm, M. H., Fernsten, P., & Jansen, K. U. (2011). The 13-valent 
pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic 
killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine, 
29(41), 7207-7211. 
Cornick, J. E., & Bentley, S. D. (2012). Streptococcus pneumoniae: The evolution of antimicrobial 
resistance to beta-lactams, fluoroquinolones and macrolides. Microbes and Infection, 
14(7-8), 573-583. 
Coskun-Ari, F. F., Guldemir, D., & Durmaz, R. (2012). One-step multiplex PCR assay for detecting 
Streptococcus pneumoniae serogroups/types covered by 13-valent pneumococcal 
conjugate vaccine (PCV13). PLoS One, 7(12). doi:10.1371/journal.pone.0050406. 
Croucher, N. J., Harris, S. R., Barquist, L., Parkhill, J., & Bentley, S. D. (2012). A high-resolution 
view of genome-wide pneumococcal transformation. PLoS Pathogens, 8(6), e1002745. 
doi:10.1371/journal.ppat.1002745. 
Croucher, N. J., Vernikos, G. S., Parkhill, J., & Bentley, S. D. (2011). Identification, variation and 
transcription of pneumococcal repeat sequences. BMC Genomics, 12(1), 120-120. 
Davis, S. M., Deloria-Knoll, M., Kassa, H. T., & O'Brien, K. L. (2013). Impact of pneumococcal 
conjugate vaccines on nasopharyngeal carriage and invasive disease among 
unvaccinated people: review of evidence on indirect effects. Vaccine, 32(1), 133-145. 
Denoël, P., Philipp, M. T., Doyle, L., Martin, D., Carletti, G., & Poolman, J. T. (2011). A protein-
based pneumococcal vaccine protects rhesus macaques from pneumonia after 
experimental infection with Streptococcus pneumoniae. Vaccine, 29(33), 5495-5501. 
Dias, C. A., Teixeira, L. M., Carvalho, M. d. G., & Beall, B. (2007). Sequential multiplex PCR for 
determining capsular serotypes of pneumococci recovered from Brazilian children. 
Journal of Medical Microbiology, 56(9), 1185-1188. 
Domenico, P., Salo, R. J., Cross, A. S., & Cunha, B. A. (1994). Polysaccharide capsule-mediated 
resistance to opsonophagocytosis in Klebsiella pneumoniae. Infection and Immunity, 
62(10), 4495-4499.  
Duggan, S. T. (2010). Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) 
[Prevenar 13®]. Drugs, 70(15), 1973-1986. 
Elberse, K. E. M., van der Heide, H. G. J., Witteveen, S., van de Pol, I., Schot, C. S., van der Ende, A., . 
. . Schouls, L. M. (2012). Changes in the composition of the pneumococcal population 
and in IPD incidence in The Netherlands after the implementation of the 7-valent 
pneumococcal conjugate vaccine. Vaccine, 30(52), 7644-7651. 
REFERENCES 
247 
 
Elberse, K. E. M., Nunes, S., Sa-Leao, R., van der Heide, H. G. J., & Schouls, L. M. (2011). Multiple-
locus variable number tandem repeat analysis for Streptococcus pneumoniae: 
comparison with PFGE and MLST. PLoS One, 6(5), e19668. 
doi:10.1371/journal.pone.0019668. 
Elberse, K. E. M., van de Pol, I., Witteveen, S., van der Heide, H. G. J., Schot, C. S., van Dijk, A., . . . 
Schouls, L. M. (2011). Population structure of invasive Streptococcus pneumoniae in The 
Netherlands in the pre-vaccination era assessed by MLVA and capsular sequence typing. 
PLoS One, 6(5), e20390. doi:10.1371/journal.pone.0020390. 
Elberse, K., Witteveen, S., van der Heide, H., van de Pol, I., Schot, C., van der Ende, A., . . . Schouls, 
L. (2011). Sequence diversity within the capsular genes of Streptococcus pneumoniae 
serogroup 6 and 19. PLoS One, 6(9), e25018. doi:10.1371/journal.pone.0025018. 
Enright, M. C., & Spratt, B. G. (1998). A multilocus sequence typing scheme for Streptococcus 
pneumoniae: identification of clones associated with serious invasive disease. 
Microbiology, 144(11), 3049-3060. 
Evans, L. R., & Linker, A. (1973). Production and characterization of the slime polysaccharide of 
Pseudomonas aeruginosa. Journal of Bacteriology, 116(2), 915-924.  
Fagan, R. L., Hanna, J. N., Messer, R. D., Brookes, D. L., & Murphy, D. M. (2001). The epidemiology 
of invasive pneumococcal disease in children in far north Queensland. Journal of 
Paediatrics and Child Health, 37(6), 571-575. 
Farlow, J., Smith, K. L., Wong, J., Abrams, M., Lytle, M., & Keim, P. (2001). Francisella tularensis 
strain typing using Multiple-Locus, Variable-Number Tandem Repeat Analysis. Journal 
of Clinical Microbiology, 39(9), 3186-3192. doi: 10.1128/JCM.39.9.3186-3192.2001. 
Francisco, A. P., Vaz, C., Monteiro, P. T., Melo-Cristino, J., Ramirez, M., & Carrico, J. A. (2012). 
PHYLOViZ: Phylogenetic inference and data visualization for sequence based typing 
methods. BMC Bioinformatics, 13(1), 87. 
Gibson, D. L., White, A. P., Snyder, S. D., Martin, S., Heiss, C., Azadi, P., . . . Kay, W. W. (2006). 
Salmonella produces an O-antigen capsule regulated by AgfD and important for 
environmental persistence. Journal of Bacteriology, 188(22), 7722-7730. doi: 
10.1128/JB.00809-06. 
Giele, C., Moore, H., Bayley, K., Harrison, C., Murphy, D., Rooney, K., . . . Lehmann, D. (2007). Has 
the seven-valent pneumococcal conjugate vaccine had an impact on invasive 
pneumococcal disease in Western Australia? Vaccine, 25(13), 2379-2384. 
Goldblatt, D., Southern, J., Ashton, L., Richmond, P., Burbidge, P., Tasevska, J., . . . Miller, E. (2006). 
Immunogenicity and boosting after a reduced number of doses of a pneumococcal 
conjugate vaccine in infants and toddlers. The Pediatric Infectious Disease Journal, 25(4), 
312-319. 
Golubchik, T., Brueggemann, A. B., Street, T., Gertz, J. R. E., Spencer, C. C. A., Ho, T., . . . Bowden, R. 
(2012). Pneumococcal genome sequencing tracks a vaccine escape variant formed 
through a multi-fragment recombination event. Nature Genetics, 44(3), 352-356. 
REFERENCES 
248 
 
Gounder, P. P., Bruce, M. G., Bruden, D., Singleton, R., Rudolph, K., Hurlburt, D. A., . . . Wenger, J. D. 
(2014). Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal 
colonization by Streptococcus pneumoniae - Alaska, 2008 - 2012. Journal of Infectious 
Diseases, 209(8), 1251-1258. 
Gratten, M., Morey, F., Dixon, J., Torzillo, P., & Erlich, J. (1995). Invasive type 12F pneumococcal 
disease in central Australia. Communicable Diseases Intelligence, 19(19), 470-473. 
Gratten, M., Nimmo, G., Carlisle, J., Schooneveldt, J., Seneviratne, E., Kelly, R., . . . Fenton, J. (1997). 
Emergence of further serotypes of multiple drug-resistant Streptococcus pneumoniae in 
Queensland. Communicable Diseases Intelligence, 21(10), 133-136. 
Griffith, F. (1928). The significance of pneumococcal types. Journal of Hygiene, 27(2), 113-159. 
Guevara, M., Barricarte, A., Gil-Setas, A., García-Irure, J. J., Beristain, X., Torroba, L., . . . Castilla, J. 
(2009). Changing epidemiology of invasive pneumococcal disease following increased 
coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clinical Microbiology 
and Infection, 15(11), 1013-1013. 
Hall, L. M. C. (1998). Application of molecular typing to the epidemiology of Streptococcus 
pneumoniae. Journal of Clinical Pathology, 51, 270-274. 
Hanage, W. P., Kaijalainen, T. H., Syrjanen, R. K., Auranen, K., Leinonen, M., Makela, P. H., & Spratt, 
B. G. (2005). Invasiveness of serotypes and clones of Streptococcus pneumoniae among 
children in Finland. Infection and Immunity, 73(1), 431-435. 
Hanna, J. N., Gratten, M., Tiley, S. M., Brookes, D. L., & Bapty, G. (1997). Pneumococcal 
vaccination: an important strategy to prevent pneumonia in Aboriginal and Torres 
Strait Island adults. Australian and New Zealand Journal of Public Health, 21(3), 281-
285. 
Hanna, J. N., Humphreys, J. L., & Murphy, D. M. (2006). Invasive pneumococcal disease in 
Indigenous people in north Queensland, 1999-2004. Medical Journal of Australia, 
184(3), 118-121. 
Hanna, J. N., Humphreys, J. L., & Murphy, D. M. (2008). Invasive pneumococcal disease in 
Indigenous people in north Queensland: an update, 2005-2007. Medical Journal of 
Australia, 189(1), 43-46. 
Hanna, J. N., Humphreys, J. L., Murphy, D. M., & Smith, H. V. (2010). Invasive pneumococcal 
disease in non-Indigenous people in north Queensland, 2001-2009. Medical Journal of 
Australia, 193(7), 392-396. 
Hansman, D., & Bullen, M. M. (1967). A resistant pneumococcus. Lancet, 2, 264-265. 
Harrison, O. B., Claus, H., Jiang, Y., Bennett, J. S., Bratcher, H. B., Jolley, K. A., . . . Maiden, M. C. J. 
(2013). Description and nomenclature of Neisseria meningitidis capsule locus. Emerging 
Infectious Diseases, 19(4), 566-573. doi: 10.3201/eid1904.111799. 
Hausdorff, W. P., Bryant, J., Paradiso, P. R., & Siber, G. R. (2000). Which Pneumococcal 
Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine 
Formulation and Use, Part I. Clinical Infectious Diseases, 30(1), 100-121. 
REFERENCES 
249 
 
Hausdorff, W. P., Bryant, J., Kloek, C., Paradiso, P. R., & Siber, G. R. (2000). The Contribution of 
Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for 
Conjugate Vaccine Formulation and Use, Part II. Clinical Infectious Diseases, 30(1), 122-
140. 
Hermans, P. W., Sluijter, M., Hoogenboezem, T., Heersma, H., van Belkum, A., & de Groot, R. 
(1995). Comparative study of five different DNA fingerprint techniques for molecular 
typing of Streptococcus pneumoniae strains. Journal of Clinical Microbiology, 33(6), 
1606-1612. 
Hicks, L. A., Harrison, L. H., Flannery, B., Hadler, J. L., Schaffner, W., Craig, A. S., . . . Active Bacterial 
Core Surveillance Program of the Emerging Infections Program. (2007). Incidence of 
pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in 
the United States during the era of widespread PCV7 vaccination, 1998-2004. The 
Journal of Infectious Diseases, 196(9), 1346-1354. 
Hills, S. L., Hanna, J. N., & Murphy, D. (2002). Invasive pneumococcal disease in north 
Queensland, 2001. Communicable Diseases Intelligence, 26(4), 520-524. 
Hoang, V.-T., Gaëlle, C., Katia, H., Brigitte, F., Harriet, C., Annick, C., . . . Christine, P. (2007). 
Multiple-Locus Variable-Number Tandem-Repeat Analysis for longitudinal survey of 
sources of Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of 
Clinical Microbiology, 45(10), 3175-3183. 
Holleley, C., & Geerts, P. G. (2009). Multiplex Manager 1.0: a cross-platform computer program 
that plans and optimizes multiplex PCR. BioTechniques, 46(7), 511-517. 
Hoskins, J., Fuller, W., Geringer, C., Gilmour, R., Glass, J. S., Khoja, H., . . . Fu, D. J. (2001). Genome 
of the bacterium Streptococcus pneumoniae strain R6. Journal of Bacteriology, 183(19), 
5709-5717. 
Hui, F. M., & Morrison, D. A. (1991). Genetic transformation in Streptococcus pneumoniae: 
nucleotide sequence analysis shows comA, a gene required for competence induction, to 
be a member of the bacterial ATP-dependent transport protein family. Journal of 
Bacteriology, 173(1), 372-381. 
Hunter, P. R., & Gaston, M. A. (1988). Numerical index of the discriminatory ability of typing 
systems: an application of Simpson’s index of diversity. Journal of Clinical Microbiology, 
26(11), 2465-2466. 
Hyams, C., Trzcinski, K., Camberlein, E., Weinberger, D. M., Chimalapati, S., Noursadeghi, M., . . . 
Brown, J. S. (2013). Streptococcus pneumoniae capsular serotype invasiveness 
correlates with the degree of Factor H binding and opsonization with C3b/iC3b. 
Infection and Immunity, 81(1), 354-363. 
Hyytiä-Trees, E. K., Cooper, K., Ribot, E. M., & Gerner-Smidt, P. (2007). Recent developments and 
future prospects in subtyping of foodborne bacterial pathogens. Future Microbiology, 
2(2), 175-185. 
Ichikawa, K., Yagi, T., Inagaki, T., Moriyama, M., Nakagawa, T., Uchiya, K.-i., . . . Ogawa, K. (2010). 
Molecular typing of Mycobacterium intracellulare using multilocus variable-number of 
REFERENCES 
250 
 
tandem-repeat analysis: identification of loci and analysis of clinical isolates. 
Microbiology, 156(2), 496-504. 
Iraurgui, P., Torres, M. J., Gandia, A., Vazquez, I., Cabrera, E. G., Obando, I., . . . Aznar, J. (2010). 
Modified sequential multiplex PCR for determining capsular serotypes of invasive 
pneumococci recovered from Seville. Clinical Microbiology and Infection, 16(9), 1504-
1507. 
Isaacman, D. J., Fletcher, M. A., Fritzell, B., Ciuryla, V., & Schranz, J. (2007). Indirect effects 
associated with widespread vaccination of infants with heptavalent pneumococcal 
conjugate vaccine (PCV7; Prevnar). Vaccine, 25(13), 2420-2427. 
Iyer, R., Baliga, N. S., & Camilli, A. (2005). Catabolite control protein A (CcpA) contributes to 
virulence and regulation of sugar metabolism in Streptococcus pneumoniae. Journal of 
Bacteriology, 187(24), 8340-8349. 
Jacobs, M. R., Good, C. E., Bajaksouzian, S., & Windau, A. R. (2008). Emergence of Streptococcus 
pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation 
to introduction of the protein-conjugated pneumococcal vaccine. Clinical Infectious 
Diseases, 47(11), 1388. 
Jacobs, M. R., Koornhof, H. J., Robins-Browne, R. M., Stevenson, C. M., Vermaak, Z. A., Freiman, I., . 
. . Austrian, R. (1978). Emergence of multiply resistant pneumococci. The New England 
Journal of Medicine, 299(14), 735. 
Jacups, S. P., & Cheng, A. (2011). The epidemiology of community acquired bacteremic 
pneumonia, due to Streptococcus pneumoniae, in the top end of the Northern Territory, 
Australia-over 22 years. Vaccine, 29(33), 5386-5392. 
Jefferies, J., Clarke, S. C., Diggle, M. A., Smith, A., Dowson, C., & Mitchell, T. (2003). Automated 
pneumococcal MLST using liquid-handling robotics and a capillary DNA sequencer. 
Molecular Biotechnology, 24(3), 303-307. 
Jefferies, J. M. C., Smith, A., Clarke, S. C., Dowson, C., & Mitchell, T. J. (2004). Genetic analysis of 
diverse disease-causing pneumococci indicates high levels of diversity within serotypes 
and capsule switching. Journal of Clinical Microbiology, 42(12), 5681-5688. 
Jernigan, D. B., Raghunathan, P. L., Bell, B. P., Brechner, R., Bresnitz, E. A., Butler, J. C., . . . National 
Anthrax Epidemiologic Investigation. (2002). Investigation of bioterrorism-related 
anthrax, United States, 2001: Epidemiologic findings. Emerging Infectious Diseases, 
8(10), 1019-1028. doi: 10.3201/eid0810.020353. 
Jiang, S.-M., Wang, L., & Reeves, P. R. (2001). Molecular characterization of Streptococcus 
pneumoniae type 4, 6B, 8, and 18C capsular polysaccharide gene complexs. Infection and 
Immunity, 69(3), 1244-1255. 
Jin, P., Xiao, M., Kong, F., Oftadeh, S., Zhou, F., Liu, C., & Gilbert, G. L. (2009). Simple, accurate, 
serotype-specific PCR assay to differentiate Streptococcus pneumoniae serotypes 6A, 6B, 
and 6C. Journal of Clinical Microbiology, 47(8), 2470-2474. 
REFERENCES 
251 
 
Johnson, D. R., D’Onise, K., Holland, R. A., Raupach, J. C. A., & Koehler, A. P. (2012). Pneumococcal 
disease in South Australia: vaccine success but no time for complacency. Vaccine, 
30(12), 2206-2211. 
Johnson, H. L., Deloria-Knoll, M., Levine, O. S., Stoszek, S. K., Freimanis Hance, L., Reithinger, R., . . 
. O’Brien, K. L. (2010). Systematic evaluation of serotypes causing invasive 
pneumococcal disease among children under five: the pneumococcal global serotype 
project. PLoS Medicine, 7(10), e1000348. doi:10.1371/journal.pmed.1000348. 
Johnston, C., Campo, N., Bergé, M. J., Polard, P., & Claverys, J.-P. (2014). Streptococcus 
pneumoniae, le transformiste. Trends in Microbiology, 22(3), 113-119. 
Jones, C., & Lemercinier, X. (2005). Full NMR assignment and revised structure for the capsular 
polysaccharide from Streptococcus pneumoniae type 15B. Carbohydrate Research, 
340(3), 403-409. 
Jorgensen, G., Singleton, R., Butler, J., & Cottle, T. (2005). Outbreak of invasive pneumococcal 
disease - Alaska, 2003-2004. Morbidity and Mortality Weekly Report, 54(3), 72-75. 
Jourdain, S., Drèze, P.-A., Vandeven, J., Verhaegen, J., Van Melderen, L., & Smeesters, P. R. (2011). 
Sequential multiplex PCR assay for determining capsular serotypes of colonizing S. 
pneumoniae. BMC Infectious Diseases, 11(1), 100-100. 
Kadioglu, A., Weiser, J. N., Paton, J. C., & Andrew, P. W. (2008). The role of Streptococcus 
pneumoniae virulence factors in host respiratory colonization and disease. Microbiology, 
6(4), 288-301. 
Kang, H. P., & Dunne, W. M. (2003). Stability of repetitive-sequence PCR patterns with respect to 
culture age and subculture frequency. Journal of Clinical Microbiology, 41(6), 2694-
2696. 
Kaplan, S. L., Barson, W. J., Lin, P. L., Romero, J. R., Bradley, J. S., Tan, T. Q., . . . Mason, J. E. O. 
(2013). Early trends for invasive pneumococcal infections in children after the 
introduction of the 13-valent pneumococcal conjugate vaccine. Pediatric Infectious 
Disease Journal, 32(3), 203-207. 
Kelly, T., Dillard, J. P., & Yother, J. (1994). Effect of genetic switching of capsular type on 
virulence of Streptococcus pneumoniae. Infection and Immunity, 62(5), 1813-1819. 
Klevytska, A. M., Price, L. B., Schupp, J. M., Worsham, P. L., Wong, J., & Keim, P. (2001). 
Identification and characterization of Variable-Number Tandem Repeats in the Yersinia 
pestis genome. Journal of Clinical Microbiology, 39(9), 3179-3185. doi: 
10.1128/JCM.39.9.3179-3185.2001. 
Klugman, K. D. (1990). Pneumococcal resistance to antibiotics. Clinical Microbiology Revised, 3, 
171-196. 
Knutsen, E., Johnsborg, O., Quentin, Y., Claverys, J.-P., & Havarstein, L. S. (2006). BOX elements 
modulate gene expression in Streptococcus pneumoniae: impact on the fine-tuning of 
competence development. Journal of Bacteriology, 188(23), 8307-8312. 
Ko, K. S., Baek, J. Y., & Song, J. H. (2013). Capsular gene sequences and genotypes of “serotype 6E” 
Streptococcus pneumoniae isolates. Journal of Clinical Microbiology, 51(10), 3395-3399. 
REFERENCES 
252 
 
Koeck, J., Nanjanpop-Lafourcade, B., Cade, S., Varon, E., Sangare, L., Valjevac, S., . . . Pourcel, C. 
(2005). Evaluation and selection of tandem repeat loci for Streptococcus pneumoniae 
MLVA strain typing. BMC Microbiology, 5(1), 66-74. 
Koeuth, T., Versalovic, J., & Lupski, J. R. (1995). Differential subsequence conservation of 
interspersed repetitive Streptococcus pneumoniae BOX elements in diverse bacteria. 
Genome Research, 5(4), 408-418. 
Kolkman, M. A., Wakarchuk, W., Nuijten, P. J., & van der Zeijst, B. A. (1997). Capsular 
polysaccharide synthesis in Streptococcus pneumoniae serotype 14: molecular analysis 
of the complete cps locus and identification of genes encoding glycosyltransferases 
required for the biosynthesis of the tetrasaccharide subunit. Molecular Microbiology, 
26(1), 197-208. 
Kroll, J. S., Loynds, B., Brophy, L. N., & Moxon, E. R. (1990). The bex locus in encapsulated 
Haemophilus influenzae: a chromosomal region involved in capsule polysaccharide 
export. Molecular Microbiology, 4(11), 1853-1862. doi: 10.1111/j.1365-
2958.1990.tb02034. 
Lawrence, E. R., Griffiths, D. B., Martin, S. A., George, R. C., & Hall, L. M. C. (2003). Evaluation of 
semiautomated multiplex PCR assay for determination of Streptococcus pneumoniae 
serotypes and serogroups. Journal of Clinical Microbiology, 41(2), 601-607. 
Lehmann, D., Willis, J., Moore, H. C., Giele, C., Murphy, D., Keil, A. D., . . . Vaccine Impact 
Surveillance. (2010). The changing epidemiology of invasive pneumococcal disease in 
Aboriginal and non-Aboriginal Western Australians from 1997 through 2007 and 
emergence of nonvaccine serotypes. Clinical Infectious Diseases, 50(11), 1477-1486. 
Lindstedt, B. (2005). Multiple-locus variable number tandem repeats analysis for genetic 
fingerprinting of pathogenic bacteria. Electrophoresis, 26(13), 2567-2582. 
Lista, F., Faggioni, G., Valjevac, S., Ciammaruconi, A., Vaissaire, J., Le Doujet, C., . . . Vergnaud, G. 
(2006). Genotyping of Bacillus anthracis strains based on automated capillary 25-loci 
Multiple Locus Variable-Number Tandem Repeats Analysis. BMC Microbiology, 6(1), 33-
33. doi: 10.1186/1471-2180-6-33. 
Lott, T. J., Holloway, B. P., Logan, D. A., Fundyga, R., & Arnold, J. (1999). Towards understanding 
the evolution of the human commensal yeast Candida albicans. Microbiology, 145(5), 
1137-1143. doi: 10.1099/13500872-145-5-1137. 
Lu, Y.-J., Zhang, F., Sayeed, S., Thompson, C. M., Szu, S., Anderson, P. W., & Malley, R. (2012). A 
bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. 
Vaccine, 30(23), 3405-3412. 
Macleod, C. M., Hodges, R. G., Heidelberger, M., & Bernhard, W. G. (1945). Prevention of 
pneumococcal pneumonia by immunization with specific capsular polysaccharides. The 
Journal of Experimental Medicine, 82(6), 445-465. 
Mak, D. B. (2004). Invasive pneumococcal disease in the Kimberley, 1995-2001. The Australian 
Journal of Rural Health, 12(6), 237-237. 
REFERENCES 
253 
 
Malachowa, N., Sabat, A., Gniadkowski, M., Krzyszton-Russjan, J., Empel, J., Miedzobrodzki, J., . . . 
Hryniewicz, W. (2005). Comparison of multiple-locus variable-number tandem-repeat 
analysis with pulsed-field gel electrophoresis, spa typing, and multilocus sequence 
typing for clonal characterization of Staphylococcus aureus isolates. Journal of Clinical 
Microbiology, 43(7), 3095-3100. 
Malley, R., & Anderson, P. W. (2012). Serotype-independent pneumococcal experimental 
vaccines that induce cellular as well as humoral immunity. Proceedings of the National 
Academy of Sciences of the United States of America, 109(10), 3623-3627. 
Marchese, A., Esposito, S., Coppo, E., Rossi, G. A., Tozzi, A., Romano, M., . . . Principi, N. (2011). 
Detection of Streptococcus pneumoniae and identification of pneumococcal serotypes by 
Real-Time polymerase chain reaction using blood samples from Italian children ≤5 
years of age with community-acquired pneumonia. Microbial Drug Resistance, 17(3), 
419-424. 
Marks, L. R., Reddinger, R. M., & Hakansson, A. P. (2012). High levels of genetic recombination 
during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. 
MBio, 3(5). doi:10.1128/mBio.00200-12. 
Marsh, R. L., Smith-Vaughan, H., Beissbarth, J., Hare, K., Kennedy, M., Wigger, C., . . . Leach, A. J. 
(2007). Molecular characterisation of pneumococcal serotype 16F: established 
predominant carriage and otitis media serotype in the 7vPCV era. Vaccine, 25(13), 
2434-2436. 
Martin, B., Humbert, O., Camara, M., Guenzi, E., Walker, J., Mitchell, T., . . . Hakenbeck, R. (1992). A 
highly conserved repeated DNA element located in the chromosome of Streptococcus 
pneumoniae. Nucleic Acids Research, 20(13), 3479-3483. 
Mavroidi, A., Aanensen, D. M., Godoy, D., Skovsted, I. C., Kaltoft, M. S., Reeves, P. R., . . . Spratt, B. G. 
(2007). Genetic relatedness of the Streptococcus pneumoniae capsular biosynthetic loci. 
Journal of Bacteriology, 189(21), 7841-7855. 
Mavroidi, A., Godoy, D., Aanensen, D. M., Robinson, D. A., Hollingshead, S. K., & Spratt, B. G. 
(2004). Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. Journal 
of Bacteriology, 186(24), 8181-8192. 
Meats, E., Brueggemann, A. B., Enright, M. C., Sleeman, K., Griffiths, D. T., Crook, D. W., & Spratt, B. 
G. (2003). Stability of serotypes during nasopharyngeal carriage of Streptococcus 
pneumoniae. Journal of Clinical Microbiology, 41(1), 386-392. 
Mehr, S., & Wood, N. (2012). Streptococcus pneumoniae–a review of carriage, infection, serotype 
replacement and vaccination. Paediatric Respiratory Reviews, 13(4), 258-264. 
McAuliffe, L., Ayling, R. D., & Nicholas, R. A. J. (2007). Identification and characterization of 
variable-number tandem-repeat markers for the molecular epidemiological analysis of 
Mycoplasma mycoides subspecies mycoides SC. FEMS Microbiology Letters, 276(2), 181. 
McChlery, S. M., Scott, K. J., & Clarke, S. C. (2005). Clonal analysis of invasive pneumococcal 
isolates in Scotland and coverage of serotypes by the licensed conjugate polysaccharide 
REFERENCES 
254 
 
pneumococcal vaccine: possible implications for UK vaccine policy. European Journal of 
Clinical Microbiology and Infectious Diseases, 24(4), 262-267. 
McGee, L., McDougal, L., Zhou, J., Spratt, B. G., Tenover, F. C., George, R., . . . Klugman, K. P. (2001). 
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae 
defined by the pneumococcal molecular epidemiology network. Journal of Clinical 
Microbiology, 39(7), 2565-2571. 
McIntosh, E. D. G., & Reinert, R. R. (2011). Global prevailing and emerging pediatric 
pneumococcal serotypes. Expert Review of Vaccines, 10(1), 109-129. 
Miernyk, K., Debyle, C., Harker-Jones, M., Hummel, K. B., Hennessy, T., Wenger, J., & Rudolph, K. 
(2011). Serotyping of Streptococcus pneumoniae isolates from nasopharyngeal samples: 
use of an algorithm combining microbiologic, serologic, and sequential multiplex PCR 
techniques. Journal of Clinical Microbiology, 49(9), 3209-3214. 
Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P. E., & George, R. C. (2011). Effectiveness of the 
new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine, 29(49), 9127-
9131. 
Moberley, S., Holden, J., Tatham, D. P., & Andrews, R. M. (2013). Vaccines for preventing 
pneumococcal infection in adults. Cochrane Database System Review, 1. 
Moffitt, K. L., Gierahn, T. M., Lu, Y.-J., Gouveia, P., Alderson, M., Flechtner, J. B., . . . Malley, R. 
(2011). TH17-based vaccine design for prevention of Streptococcus pneumoniae 
colonization. Cell Host and Microbe, 9(2), 158-165. 
Morona, J. K., Morona, R., & Paton, J. C. (1999). Comparative genetics of capsular polysaccharide 
biosynthesis in Streptococcus pneumoniae types belonging to serogroup 19. Journal of 
Bacteriology, 181(17), 5355-5364. 
Morona, J. K., Miller, D. C., Coffey, T. J., Vindurampulle, C. J., Spratt, B. G., Morona, R., & Paton, J. C. 
(1999). Molecular and genetic characterization of the capsule biosynthesis locus of 
Streptococcus pneumoniae type 23F. Microbiology, 145(4), 781-789. 
Moore, C. E., Peacock, S. J., Sengduangphachanh, A., Thaojaikong, T., Sirisouk, J., Foster, D., . . . 
Newton, P. N. (2010). Enhanced determination of Streptococcus pneumoniae serotypes 
associated with invasive disease in Laos by using a real-time polymerase chain reaction 
serotyping assay with cerebrospinal fluid. The American Journal of Tropical Medicine 
and Hygiene, 83(3), 451-457. 
Moore, M. R., Gertz, J. R. E., Woodbury, R. L., Barkocy-Gallagher, G. A., Schaffner, W., Lexau, C., . . . 
Beall, B. (2008). Population snapshot of emergent Streptococcus pneumoniae serotype 
19A in the United States, 2005. The Journal of Infectious Diseases, 197(7), 1016-1027. 
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., . . . Whitney, C. G. 
(2015). Effect of use of 13-valent pneumococcal conjugate vaccine in children on 
invasive pneumococcal disease in children and adults in the USA: analysis of multisite, 
population-based surveillance. The Lancet Infectious Diseases (0). doi: 
http://dx.doi.org/10.1016/S1473-3099(14)71081-3. 
REFERENCES 
255 
 
Murray, J., Agocs, M., Serhan, F., Singh, S., Deloria-Knoll, M., O’Brien, K., . . . Cherian, T. (2014). 
Global invasive bacterial vaccine-preventable diseases surveillance - 2008-2014. 
Morbidity and Mortality Weekly Report, 63, 1159-1162. 
NCIRS (Producer). (2015). Significant events in pneumococcal vaccination practice in Australia. 
Retrieved from: http://www.ncirs.edu.au/immunisation/history/Pneumococcal-
history-March-2015.pdf. 
Neufeld, F. (1902). Ueber die Agglutination der Pneumokokken und uber die Theorien der 
Agglutination. Zeitschrift fur Hygiene Infektionskrankheiten, 54-72. 
Nesin, M., Ramirez, M., & Tomasz, A. (1998). Capsular transformation of a multidrug-resistant 
Streptococcus pneumoniae in vivo. The Journal of Infectious Diseases, 177(3), 707-713. 
Njanpop Lafourcade, B.-M., Sanou, O., van der Linden, M., Levina, N., Karanfil, M., Yaro, S., . . . 
Mueller, J. E. (2010). Serotyping pneumococcal meningitis cases in the African 
meningitis belt by use of multiplex PCR with cerebrospinal fluid. Journal of Clinical 
Microbiology, 48(2), 612-614. 
NNDSS. (2015). Disease notification rates, QLD, 1991 to 2012 and year-to-date notifications for 
2015.   Retrieved 12 January, 2015, from http://www9.health.gov.au/cda/source/cda-
index.cfm. 
Nunes, S., Sá-Leão, R., Carriço, J., Alves, C. R., Mato, R., Avô, A. B., . . . de Lencastre, H. (2005). 
Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae 
colonizing preschool-age children attending day care centers in Lisbon, Portugal: a 
summary of 4 years of annual surveillance. Journal of Clinical Microbiology, 43(3), 1285-
1293. 
O’Brien, K. L., Wolfson, L. J., Watt, J. P., Henkle, E., Deloria-Knoll, M., McCall, N., . . . Cherian, T. 
(2009). Burden of disease caused by Streptococcus pneumoniae in children younger 
than 5 years: global estimates. Lancet, 374(9693), 893-902. 
Obszańska, K., Borek, A. L., Izdebski, R., Hryniewicz, W., & Sitkiewicz, I. (2011). Multilocus 
variable number tandem repeat analysis (MLVA) of Streptococcus pyogenes. Journal of 
Microbiological Methods, 87(2), 143-149. 
Oftadeh, S., Gidding, H. F., & Gilbert, G. L. (2013). Laboratory surveillance of invasive 
pneumococcal disease in New South Wales, Australia, before and after introduction of 
7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates. 
Epidemiology and Infection, 141(9), 1797-1806. 
Oggioni, M. R., & Claverys, J. P. (1999). Repeated extragenic sequences in prokaryotic genomes: a 
proposal for the origin and dynamics of the RUP element in Streptococcus pneumoniae. 
Microbiology, 145(10), 2647. 
Oliver, M. B., Van Der Linden, M. P. G., Küntzel, S. A., Saad, J. S., & Nahm, M. H. (2013). Discovery 
of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing 
two differing repeating units. Journal of Biological Chemistry, 288(36), 25976-25985. 
O'Meara, T. R., & Alspaugh, J. A. (2012). The Cryptococcus neoformans capsule: a sword and a 
shield. Clinical Microbiology Reviews, 25(3), 387-408. doi: 10.1128/CMR.00001-12. 
REFERENCES 
256 
 
O'Riordan, K., & Lee, J. C. (2004). Staphylococcus aureus capsular polysaccharides. Clinical 
Microbiology Reviews, 17(1), 218-234. doi: 10.1128/CMR.17.1.218-234.2004. 
Pai, R., Moore, M. R., Pilishvili, T., Gertz, R. E., Whitney, C. G., Beall, B., & Active Bacterial Core 
Surveillance, T. (2005). Postvaccine genetic structure of Streptococcus pneumoniae 
serotype 19A from children in the United States. The Journal of Infectious Diseases, 
192(11), 1988-1995. 
Pai, R., Gertz, R. E., & Beall, B. (2006). Sequential multiplex PCR approach for determining 
capsular serotypes of Streptococcus pneumoniae isolates. Journal of Clinical 
Microbiology, 44(1), 124-131. 
Park, I. H., Geno, K. A., Yu, J., Oliver, M. B., Kim, K.-H., & Nahm, M. H. (2015). Genetic, biochemical, 
and serological characterization of a new pneumococcal serotype, 6H, and generation of 
a pneumococcal strain producing three different capsular repeat units. Clinical and 
Vaccine Immunology , 22(3), 313-318. 
Park, I. H., Pritchard, D. G., Cartee, R., Brandao, A., Brandileone, M. C. C., & Nahm, M. H. (2007). 
Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus 
pneumoniae. Journal of Clinical Microbiology, 45(4), 1225-1233. 
Picazo, J., Ruiz-Contreras, J., Casado-Flores, J., Giangaspro, E., Garcia-de-Miguel, M.-J., Hernandez-
Sampelayo, T., . . . Mendez, C. (2013). Impact of introduction of conjugate vaccine in the 
vaccination schedule on the incidence of pediatric invasive pneumococcal disease 
requiring hospitalization in Madrid 2007 to 2011. Pediatric Infectious Disease Journal, 
32(6), 656-661. 
Pichon, B., Moyce, L., Sheppard, C., Slack, M., Turbitt, D., Pebody, R., . . . George, R. (2010). 
Molecular typing of pneumococci for investigation of linked cases of invasive 
pneumococcal disease. Journal of Clinical Microbiology, 48(5), 1926-1928. 
Pimenta, F. C., Beall, B., Roundtree, A., Soysal, A., Bakir, M., du Plessis, M., . . . Carvalho, M. d. G. 
(2013). Sequential triplex real-time PCR assay for detecting 21 pneumococcal capsular 
serotypes that account for a high global disease burden. Journal of Clinical Microbiology, 
51(2), 647-652. 
Platt, S. (2015). VNTR DIversity and Confidence Extractor.   Retrieved 13 August, 2013, from 
http://www.hpa-bioinformatics.org.uk/cgi-bin/DICI/DICI.pl. 
PMEN. (2015). Pneumococcal Molecular Epidemiology Network (PMEN).   Retrieved 30 June, 
2015, from http://web1.sph.emory.edu/PMEN/pmen_criteria.html..html.  
Poehling, K. A., Talbot, T. R., Griffin, M. R., Craig, A. S., Whitney, C. G., Zell, E., . . . Schaffner, W. 
(2006). Invasive pneumococcal disease among infants before and after introduction of 
pneumococcal conjugate vaccine. Journal of the American Medical Association, 295(14), 
1668-1674. 
Pourcel, C., Minandri, F., Hauck, Y., D'Arezzo, S., Imperi, F., Vergnaud, G., & Visca, P. (2011). 
Identification of Variable-Number Tandem-Repeat (VNTR) Sequences in Acinetobacter 
baumannii and interlaboratory validation of an optimized Multiple-Locus VNTR 
Analysis Typing scheme. Journal of Clinical Microbiology, 49(2), 539-548. 
REFERENCES 
257 
 
Price, E. P., Thiruvenkataswamy, V., Mickan, L., Unicomb, L., Rios, R. E., Huygens, F., & Giffard, P. 
M. (2006). Genotyping of Campylobacter jejuni using seven single-nucleotide 
polymorphisms in combination with flaA short variable region sequencing. Journal of 
Medical Microbiology, 55(8), 1061-1070. 
Prudhomme, M., Martin, B., Mejean, V., & Claverys, J. P. (1989). Nucleotide sequence of the 
Streptococcus pneumoniae hexB mismatch repair gene: homology of HexB to MutL of 
Salmonella typhimurium and to PMS1 of Saccharomyces cerevisiae. Journal of 
Bacteriology, 171(10), 5332-5338. 
Qu, W., Shen, Z., & Zhang, C. (2009). PriDimerCheck. Retrieved 25 June, 2012, from 
http://biocompute.bmi.ac.cn/MPprimer/primer_dimer.html.  
Queensland Government. (2015). Queensland Population Counter.   Retrieved 17 February, 
2015, from http://www.oesr.qld.gov.au/products/briefs/pop-growth-qld/qld-pop-
counter.php. 
Rakov, A. V., Ubukata, K., & Ashley Robinson, D. (2011). Population structure of hyperinvasive 
serotype 12F, clonal complex 218 Streptococcus pneumoniae revealed by multilocus 
boxB sequence typing. Journal of Molecular Epidemiology and Evolutionary Genetics in 
Infectious Diseases, 11(8), 1929-1939. 
Randle, E., Ninis, N., & Inwald, D. (2011). Invasive pneumococcal disease. Archives of Disease in 
Childhood - Education and Practice, 96, 183-190. 
Rathnayake, I. U., Hargreaves, M., & Huygens, F. (2011). Genotyping of Enterococcus faecalis and 
Enterococcus faecium isolates by use of a set of eight single nucleotide polymorphisms. 
Journal of Clinical Microbiology, 49(1), 367-372. 
Rayner, R. E., Savill, J., Hafner, L. M., & Huygens, F. (2015). Genotyping Streptococcus 
pneumoniae. Future Microbiology, 10(4): 653-664. 
Rayner, R. E., Savill, J., Hafner, L. M., & Huygens, F. (2015). Modified MLVA for genotyping 
Queensland invasive Streptococcus pneumoniae. Plos One, 10(4), e0121870. 
doi:10.1371/journal.pone.0121870. 
Reingold, A., Hadler, J., Farley, M. M., & Harrison, L. (2005). Direct and indirect effects of routine 
vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of 
invasive pneumococcal disease – United States, 1998-2003. Journal of the American 
Medical Association, 294(16), 2022-2026. 
Riley, I. D., Andrews, M., Howard, R., Tarr, P. I., Pfeiffer, M., & Challands, P. (1977). Immunization 
with polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a 
New Guinea Highlands community. Lancet, 1(8026), 1338-1341. 
Robertson, G. A., Thiruvenkataswamy, V., Shilling, H., Price, E. P., Huygens, F., Henskens, F. A., & 
Giffard, P. M. (2004). Identification and interrogation of highly informative single 
nucleotide polymorphism sets defined by bacterial multilocus sequence typing 
databases. Journal of Medical Microbiology, 53(Pt 1), 35-45. 
Robbins, J., & Schneerson, R. (1983). Planning for a 2nd (23-valent) generation pneumococcal 
vaccine – with special reference to new developments in our understanding of the 
REFERENCES 
258 
 
structure and biology of polysaccharides. Clinical Respiratory Physiology, 19(2), 215-
226. 
Roche, P. W., Krause, V., Cook, H., Barralet, J., Coleman, D., Sweeny, A., . . . Murphy, D. (2008). 
Invasive pneumococcal disease in Australia, 2006. Communicable Diseases Intelligence, 
32(1), 18-30. 
Roche, P., Krause, V., Cook, H., Bartlett, M., Coleman, D., Davis, C., . . . Enhanced Invasive 
Pneumococcal Diseases Surveillance Working. (2007). Invasive pneumococcal disease 
in Australia, 2005. Communicable Diseases Intelligence, 31(1), 86-100. 
Roche, P., Krause, V., Andrews, R., Carter, L., Coleman, D., Cook, H., . . . Pneumococcal Working 
party of the Communicable Diseases Network. (2003). Invasive pneumococcal disease 
in Australia, 2002. Communicable Diseases Intelligence, 27(4), 466-477. 
Rodgers, G. L., & Klugman, K. P. (2011). The future of pneumococcal disease prevention. Vaccine, 
29(3), 43-48. 
Sabharwal, V., Stevenson, A., Figueira, M., Orthopoulos, G., Trzciński, K., & Pelton, S. I. (2014). 
Capsular switching as a strategy to increase pneumococcal virulence in experimental 
otitis media model. Microbes and Infection, 16(4), 292-299. doi: 
10.1016/j.micinf.2013.12.002. 
Saha, S. K., Luby, S. P., Santosham, M., Crook, D., Darmstadt, G. L., Baqui, A. H., . . . Arifeen, S. E. 
(2008). Identification of serotype in culture negative pneumococcal meningitis using 
sequential multiplex PCR: implication for surveillance and vaccine design. PLoS One, 
3(10), e3576. doi:10.1371/journal.pone.0003576. 
Saha, S., Modak, J. K., Naziat, H., Al-Emran, H., Chowdury, M., Islam, M., . . . Saha, S. K. (2015). 
Detection of co-colonization with Streptococcus pneumoniae by algorithmic use of 
conventional and molecular methods. Vaccine, 33(5), 713-718. doi: 
10.1016/j.vaccine.2014.11.040. 
Saha, S. K., Rikitomi, N., Biswas, D., Watanabe, K., Ruhulamin, M., Ahmed, K., . . . Nagatake, T. 
(1997). Serotypes of Streptococcus pneumoniae causing invasive childhood infections in 
Bangladesh, 1992 to 1995. Journal of Clinical Microbiology, 35(3), 785-787. 
Sá-Leão, R., Pinto, F., Aguiar, S., Nunes, S., Carriço, J. A., Frazão, N., . . . Ramirez, M. (2011). 
Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal 
before widespread use of conjugate vaccines reveals heterogeneous behavior of clones 
expressing the same serotype. Journal of Clinical Microbiology, 49(4), 1369-1375. 
Salter, S. J., Hinds, J., Gould, K. A., Lambertsen, L., Hanage, W., Antonio, M., . . . Bentley, S. D. 
(2012). Variation at the capsule locus, cps, of mistyped and non-typable Streptococcus 
pneumoniae isolates. Microbiology (United Kingdom), 158(6), 1560-1569. 
Sanchez-Beato, A. R., Lopez, R., & Garcia, J. L. (1998). Molecular characterization of PcpA: a novel 
choline-binding protein of Streptococcus pneumoniae. FEMS Microbiology Letters, 164, 
207-214. 
Sandgren, A., Sjostrom, K., Olsson-Liljequist, B., Christensson, B., Samuelsson, A., Kronvall, G., & 
Henriques Normark, B. (2004). Effect of clonal and serotype-specific properties on the 
REFERENCES 
259 
 
invasive capacity of Streptococcus pneumoniae. The Journal of Infectious Diseases, 
189(5), 785-796. 
Sarkar, S., Ulett, G. C., Totsika, M., Phan, M.-D., & Schembri, M. A. (2014). Role of capsule and O 
antigen in the virulence of uropathogenic Escherichia coli. PloS One, 9(4), e94786. doi: 
10.1371/journal.pone.0094786. 
Scott, J. A. G., Hall, A. J., Dagan, R., Dixon, J. M. S., Eykyn, S. J., Fenoll, A., . . . Smart, L. E. (1996). 
Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, 
sex, and geography in 7,000 episodes of invasive disease. Clinical Infectious Diseases, 
22(6), 973-981. 
Schouls, L., & Van der Heide, H. (2012). Streptococcus pneumoniae.   Retrieved April, 12, 2012, 
from http://www.mlva.net/spneumoniae/default.asp. 
Selvey, C. (2011). Information on the Prevenar 13 Supplementary Dose Program.   Retrieved 
May, 29, 2012, from 
http://www.seagp.org.au/documents/Services/PracticeSupport/PublicHealth/201106
02_LETTER_QHIP_to_providers_JS.pdf. 
Severiano, A., Pinto, F. R., Ramirez, M., & Carriço, J. A. (2011). Adjusted Wallace coefficient as a 
measure of congruence between typing methods. Journal of Clinical Microbiology, 
49(11), 3997-4000. 
Sharma, S. K., Roumanes, D., Almudevar, A., Mosmann, T. R., & Pichichero, M. E. (2013). CD4+ T-
cell responses among adults and young children in response to Streptococcus 
pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine, 
31(30), 3090-3097. 
Sheludchenko, M. S., Huygens, F., & Hargreaves, M. H. (2010). Highly discriminatory single-
nucleotide polymorphism interrogation of Escherichia coli by use of allele-specific real-
time PCR and eBURST analysis. Applied and Environmental Microbiology, 76(13), 4337-
4345. 
Siira, L., Kaijalainen, T., Lambertsen, L., Nahm, M. H., Toropainen, M., & Virolainen, A. (2012). 
From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. 
Journal of Clinical Microbiology, 50(8), 2727-2731. 
Simões, A. S., Pereira, L., Nunes, S., Brito-Avô, A., Lencastre, H. d., & Sá-Leão, R. (2011). Clonal 
evolution leading to maintenance of antibiotic resistance rates among colonizing 
pneumococci in the PCV7 era in Portugal. Journal of Clinical Microbiology, 49(8), 2810-
2817. 
Singleton, R., Wenger, J. D., Klejka, J. A., Bulkow, L. R., Thompson, A., Sarkozy, D., . . . Scott, D. A. 
(2013). The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal 
disease in Alaska native children: results of a clinical trial. Paediatric Respiratory 
Reviews, 32(3), 257-263. 
Singleton, R. J., Hennessy, T. W., Bulkow, L. R., Hammitt, L. L., Zulz, T., Hurlburt, D. A., . . . 
Parkinson, A. (2007). Invasive pneumococcal disease caused by nonvaccine serotypes 
REFERENCES 
260 
 
among Alaska native children with high levels of 7-valent pneumococcal conjugate 
vaccine coverage. JAMA, 297(16), 1784-1792. 
Skinner, J. M., Indrawati, L., Cannon, J., Blue, J., Winters, M., Macnair, J., . . . Heinrichs, J. H. (2011). 
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-
CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine, 29(48), 8870 – 
8876. 
Slaon-Gardner, T., Stirzaker, S., Knuckey, D., Pennington, K., Knope, K., Fitzsimmons, G., . . . Group, 
N. A. R. W. (2011). Australia’s notifiable disease status, 2009: annual report of the 
National Notifiable Diseases Surveillance System. Communicable Diseases Intelligence, 
35(2), 61-131. 
Spurgiesz, R. S., Quitugua, T. N., Smith, K. L., Schupp, J., Palmer, E. G., Cox, R. A., & Keim, P. (2003). 
Molecular typing of Mycobacterium tuberculosis by using nine novel Variable-Number 
Tandem Repeats across the Beijing family and low-copy-number IS6110 isolates. 
Journal of Clinical Microbiology, 41(9), 4224-4230. doi: 10.1128/JCM.41.9.4224-
4230.2003. 
Staples, M., Graham, R., Ariotti, L., Cook, H., Krause, V., Giele, C., . . . Smith, H. (2012). Molecular 
characterisation of an Australian serotype 1 Streptococcus pneumoniae outbreak. Paper 
presented at the Australian Society of Microbiology, Brisbane, Queensland. Webpage 
retrieved from http://www.asm2012.org/abstract/70.asp.  
Staples, M., Graham, R. M. A., Jennison, A. V., Ariotti, L., Hicks, V., Cook, H., . . . Smith, H. V. (2015). 
Molecular characterization of an Australian serotype 1 Streptococcus pneumoniae 
outbreak. Epidemiology and Infection, 143(2), 325-333.  
Statens Serum Institut. (2013). Pneumococcus antisera.   Retrieved 20 March, 2014, from 
http://www.ssi.dk/English/SSI%20Diagnostica/Products%20from%20SSI%20Diagno
stica/Antisera_antibodies/Pneumococcus%20antisera.aspx. 
Stephens, A. J., Huygens, F., & Giffard, P. M. (2007). Systematic derivation of marker sets for 
Staphylococcal cassette chromosome mec typing. Antimicrobial Agents and 
Chemotherapy, 51(8), 2954-2964. 
Stock, A. M., Robinson, V. L., & Goudreau, P. N. (2000). Two-component signal transduction. 
Annual Review of Biochemistry, 69(1), 183-215. 
Straume, D., Stamsås, G. A., & Håvarstein, L. S. (2014). Natural transformation and genome 
evolution in Streptococcus pneumoniae. Infection, Genetics and Evolution, In Press. 
doi:10.1016/j.meegid.2014.10.020. 
Swartley, J. S., Marfin, A. A., Edupuganti, S., Cieslak, P., Perkins, B., Wenger, J. D., & Stephens, D. S. 
(1997). Capsule switching of Neisseria meningitidis. Proceedings of the National 
Academy of Sciences of the United States of America, 94(1), 271-276. doi: 
10.1073/pnas.94.1.271. 
Swiatlo, E., & Ware, D. (2003). Novel vaccine strategies with protein antigens of Streptococcus 
pneumoniae. FEMS immunology and medical microbiology, 38(1), 1-7. 
REFERENCES 
261 
 
Tarrago, D., Fenoll, A., Sanchez-Tatay, D., Arroyo, L. A., Munoz-Almagro, C., Esteva, C., . . . Obando, 
I. (2008). Identification of pneumococcal serotypes from culture-negative clinical 
specimens by novel real-time PCR. Clinical Microbiology and Infection, 14(9), 828-828. 
Temime, L., Boelle, P.-Y., Opatowski, L., & Guillemot, D. (2008). Impact of capsular switch on 
invasive pneumococcal disease incidence in a vaccinated population. PLoS One, 3(9), 
e3244. doi:10.1371/journal.pone.0003244. 
Todar, K. (2012). Streptococcus pneumoniae.   Retrieved April, 24, 2012, from 
http://textbookofbacteriology.net/S.pneumoniae.html. 
Tomita, Y., Okamoto, A., Yamada, K., Yagi, T., Hasegawa, Y., & Ohta, M. (2011). A new microarray 
system to detect Streptococcus pneumoniae serotypes. Journal of Biomedicine and 
Biotechnology, 2011, 352736-352721. 
Torzillo, P. J., Morey, F., Gratten, M., Murphy, D., Matters, R., & Dixon, J. (2007). Changing 
epidemiology of invasive pneumococcal disease in central Australia prior to conjugate 
vaccine: a 16-year study. Vaccine, 25(13), 2375-2378. 
Tran, T., Clarke, M., & Marshall, H. (2012). Invasive pneumococcal disease: impact of 
pneumococcal vaccination in South Australian children. International Journal of 
Infectious Diseases, 16, E309-E309. doi:10.1016/j.ijid.2012.05.1002. 
Trappetti, C., Erika van der, M., Amin, Z., Potter, A. J., Chen, A. Y., Paula, M. v. M., . . . Paton, J. C. 
(2013). Site of Isolation Determines Biofilm Formation and Virulence Phenotypes of 
Streptococcus pneumoniae Serotype 3 Clinical Isolates. Infection and immunity, 81(2), 
505-513. 
Trück, J., Snape, M. D., Tatangeli, F., Voysey, M., Yu, L.-M., Faust, S. N., . . . Pollard, A. J. (2014). 
Pneumococcal serotype-specific antibodies persist through early childhood after infant 
immunization: follow-up from a randomized controlled trial. PLoS One, 9(3). 
doi:10.1371/journal.pone.0091413. 
Tyrrell, G. J., Lovgren, M., Chui, N., Minion, J., Garg, S., Kellner, J. D., & Marrie, T. J. (2009). 
Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- 
and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 
2000–2006. Vaccine, 27(27), 3553-3560. 
Van Belkum, A., Sluijuter, M., de Groot, R., Verbrugh, H., & Hermans, P. W. (1996). Novel BOX 
repeat PCR assay for high-resolution typing of Streptococcus pneumoniae strains. 
Journal of Clinical Microbiology, 34(5), 1176-1179. 
Van Cuyck, H., Pichon, B., Leroy, P., Granger-Farbos, A., Underwood, A., Soullie, B., & Koeck, J. L. 
(2012). Multiple-Locus Variable-Number Tandem-Repeat Analysis of Streptococcus 
pneumoniae and comparison with Multiple Loci Sequence Typing. BMC Microbiology, 12, 
241-258. 
Van der Linden, M., Reinert, R. R., Kern, W. V., & Imöhl, M. (2013). Epidemiology of serotype 19A 
isolates from invasive pneumococcal disease in German children. BMC Infectious 
Diseases, 13(1), 70. 
REFERENCES 
262 
 
Venkateswaran, P. S., Stanton, N., & Austrian, R. (1983). Type variation of strains of 
Streptococcus pneumoniae in capsular serogroup 15. The Journal of Infectious Diseases, 
147(6), 1041-1054. 
Verhoeven, D., Xu, Q., & Pichichero, M. E. (2014). Vaccination with a Streptococcus pneumoniae 
trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against 
lethal pneumonia in an infant murine model. Vaccine, 32(26), 3205-3210. 
Wang, X., Huang, B., Blair, B., Eglezos, S., & Bates, J. (2012). Selection of optimal combinations of 
loci by the Optimal Combination Finder computer program from a group of variable 
number tandem repeat loci for use in Staphylococcus aureus food poisoning case 
investigations. Journal of Medical Microbiology, 61(5), 631. 
Walker, J. A., Allen, R. L., Falmagne, P., Johnson, M. K., & Boulnois, G. J. (1987). Molecular cloning, 
characterization, and complete nucleotide sequence of the gene for pneumolysin, the 
sulfhydryl-activated toxin of Streptococcus pneumoniae. Infection and Immunity, 55(5), 
1184-1189. 
Wallace, D. L. (1983). A Method for Comparing Two Hierarchical Complexings: Comment. 
Journal of the American Statistical Association, 78(383), 569-576. 
Weatherholtz, R., Millar, E. V., Moulton, L. H., Reid, R., Rudolph, K., Santosham, M., & O’Brien, K. L. 
(2010). Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine 
use in an American Indian population at high risk for disease. Clinical Infectious 
Diseases, 50(9), 1238-1246. 
Weinberger, D. M., Malley, R., & Lipsitch, M. (2011). Serotype replacement in disease after 
pneumococcal vaccination. Lancet, 378(9807), 1962-1973. 
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., . . .  Schuchat, A. 
(2003). Decline in invasive pneumococcal disease after the introduction of protein-
polysaccharide conjugate vaccine. The New England Journal of Medicine, 348(18), 1737-
1746. 
Wickstead, B., Ersfeld, M., & Gull, K. (2003). Repetitive elements in genomes of parasitic 
protozoa. Microbiology and Molecular Biology Reviews, 67(3), 360-360. 
Williams, S. R., Mernagh, P. J., Lee, M. H. T., & Tan, J. T. (2011). Changing epidemiology of invasive 
pneumococcal disease in Australian children after introduction of a 7-valent 
pneumococcal conjugate vaccine. Medical Journal of Australia, 194(3), 116-120. 
Wright, A. E., Morgan, W. P., Colebrook, L., & Dodgson, R. W. (1914). Prophylactic inoculation 
against pneumococcus infections and on the results which have been achieved by it. 
Lancet, 1, 87-95. 
Wu, K., Yao, R., Wang, H., Pang, D., Liu, Y., Xu, H., . . . Yin, Y. (2014). Mucosal and systemic 
immunizations with a novel attenuated pneumococcal vaccine candidate confer 
serotype independent protection against Streptococcus pneumoniae in mice. Vaccine, 
32(33), 4179-4188. 
REFERENCES 
263 
 
Wyres, K. L., Klugman, K. P., Parkhill, J., Hakenbeck, R., Bentley, S. D., Brueggemann, A. B., . . . 
Beall, B. W. (2013). Pneumococcal capsular switching: a historical perspective. The 
Journal of Infectious Diseases, 207(3), 439-449. 
Xue, S.-A., Jones, M. D., Lu, Q.-L., Middeldorp, J. M., & Griffin, B. E. (2003). Genetic diversity: 
frameshift mechanisms alter coding of a gene (Epstein-Barr Virus LF3 gene) that 
contains multiple 102-base-pair direct sequence repeats. Molecular and Cellular Biology, 
23(6), 2192-2201.  
Yaro, S., Lourd, M., Traore, Y., Njanpop-Lafourcade, B. M., Sawadogo, A., Sangare, L., . . . Gessner, 
B. D. (2006). Epidemiological and molecular characteristics of a highly lethal 
pneumococcal meningitis epidemic in Burkina Faso. Clinical Infectious Diseases, 43(6), 
693-700. 
Yu, J., Lin, J., Kim, K.-H., Benjamin, J. W. H., & Nahm, M. H. (2011). Development of an automated 
and multiplexed serotyping assay for Streptococcus pneumoniae. Clinical and Vaccine 
Immunology, 18(11), 1900-1907. 
Zhou, F., Kong, F., Tong, Z., & Gilbert, G. L. (2007). Identification of less-common Streptococcus 
pneumoniae serotypes by a multiplex PCR-based reverse line blot hybridization assay. 
Journal of Clinical Microbiology, 45(10), 3411-3415. 
Ziebuhr, W., Krimmer, V., Rachid, S., Lößner, I., Götz, F., & Hacker, J. (1999). A novel mechanism 
of phase variation of virulence in Staphylococcus epidermidis: evidence for control of the 
polysaccharide intercellular adhesin synthesis by alternating insertion and excision of 
the insertion sequence element IS256. Molecular Microbiology, 32(2), 345-356.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
264 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
265 
 
APPENDIX A 
Appendix A1: Position of MLST housekeeping primers in five S. 
pneumoniae genomes. 
 Position in S. pneumoniae genome 
Primer G54 CGSP14 TIGR4 Hungary6-19A R6 
aroE F 
(17bp) 
1283903- 1283887 
(34.2, 0.002) 
1352222- 1352206 
(34.2, 0.002) 
1299642- 1299626 
(34.2, 0.002) 
1395063- 1395047 
(34.2, 0.002) 
1232203- 1232187 
(34.2, 0.002) 
aroE R  
(22bp) 
1283425- 1283441 
(26.3, 1.2) 
1351744- 1351761 
(28.2, 0.3) 
1299164- 1299181 
(28.2, 0.3) 
1394585- 1394602 
(28.2, 0.3) 
1231725- 1231742 
(28.2, 0.3) 
LENGTH 478 478 478 478 478 
Gdh F (20) 1111556- 1111575 
(32.2, 0.015) 
1032033- 1032014 
(32.2, 0.015) 
1175299- 1175318 
(32.2, 0.015) 
1258597- 1258616 
(32.2, 0.015) 
1123456- 1123475 
(32.2, 0.015) 
Gdh R 
(18bp) 
1112214- 1112198 
(34.2, 0.003) 
1031375- 1031391 
(34.2, 0.003) 
1175957- 1175941 
(34.2, 0.003) 
1259255- 1259239 
(34.2, 0.003) 
1124114- 1124098 
(34.2, 0.003) 
LENGTH 658 658 658 658 658 
Gki F 
(20bp) 
605585- 605604 
(40.1, 6e-5) 
633259- 633278 
(40.1, 6e-5) 
644274- 644293 
(40.1, 6e-5) 
719036- 719052 
(26.3, 0.93) 
600349- 600368 
(40.1, 6e-5) 
Gki R 
(17bp) 
606210- 606194 
(34.2, 0.002) 
633884- 633868 
(34.2, 0.002) 
644899- 644883 
(34.2, 0.002) 
719658- 719642 
(34.2, 0.002) 
600974- 600958 
(34.2, 0.002) 
LENGTH 625 625 625 622 625 
recP F 
(20bp) 
1846894- 1846875 
(40.1, 6e-5) 
1983668- 1983649 
(40.1, 6e-5) 
1936947- 1936928 
(40.1, 6e-5) 
2009720- 2009701 
(40.1, 6e-5) 
1817870- 1817851 
(40.1, 6e-5) 
recP R 
(20bp) 
1846326- 1846344 
(22.3, 15) 
1983100- 1983118 
(22.3, 15) 
1936379- 1936397 
(22.3, 15) 
2009152- 2009170 
(22.3, 15) 
1817302- 1817320 
(22.3, 15) 
LENGTH 568 568 568 568 568 
Spi F 
(20bp) 
362843- 362827 
(26.3, 0.93) 
398225- 398206 
(40.1, 6e-5) 
383032- 383016 
(26.3, 0.93) 
465369- 465350 
(40.1, 6e-5) 
364453- 364434 
(40.1, 6e-5) 
Spi R 
(20bp) 
362287- 362306 
(32.2, 0.015) 
397666- 397685 
(40.1, 6e-5) 
382476- 382495 
(32.2, 0.015) 
464810- 464829 
(40.1, 6e-5) 
363894- 363913 
(40.1, 6e-5) 
LENGTH 556 559 556 559 559 
Xpt F 
(20bp)  
1668944- 1668963 
(40.1, 6e-5) 
1806225- 1806244 
(40.1, 6e-5) 
1755283- 1755302 
(40.1, 6e-5) 
1823498- 1823517 
(32.2, 0.015) 
1635326- 1635345 
(40.1, 6e-5) 
Xpt R 
(20bp) 
1669515- 1669496 
(40.1, 6e-5) 
1806796- 1806777 
(40.1, 6e-5) 
1755854- 1755835 
(40.1, 6e-5) 
1824069- 1824050 
(40.1, 6e-5) 
1635897- 1635878 
(40.1, 6e-5) 
LENGTH 571 571 571 571 571 
Ddl F 
(20bp) 
1522003- 1521984 
(40.1, 6e-5) 
1615678- 1615659 
(40.1, 6e-5) 
1571797- 1571778 
(40.1, 6e-5) 
1642333- 1642314 
(40.1, 6e-5) 
1493017- 1492998 
(40.1, 6e-5) 
Ddl R 
(20bp) 
1521491- 1521510 
(24.3, 3.7) 
1615166- 1615185 
(32.2, 0.015) 
1571285- 1571304 
(32.2, 0.015) 
1641821- 1641840 
(32.2, 0.015) 
1492505- 1492524 
(32.2, 0.015) 
LENGTH 512 512 512 512 512 
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Appendix A2: BOX primer position in five S. pneumoniae genomes. 
The presence of a red-coloured base-pair in a primer indicates that it was absent when blasted 
against genomes. A substituted base-pair has the new base-pair in the brackets next to red base. 
Symbols for each genome are as follows: *R6, **Hung19A, ***G54, ^CGSP14, ^^TIGR4. 
 
 Position in genome 
Primer Sequence R6 (serotype 2)* Hungary19A-
6 ** (19A) 
G54 
(19F)*** 
CGSP14 
(14)^ 
TIGR4 
(4)^^ 
BOX-01f 
(ms40)  
21-mer 
CCAGAGACATTGATGAAGAGA 1611150- 
1611170 (4e-06, 
42.1) 
1802475- 
1802495 (4e-
06, 42.1) 
1647836- 
1647856 
(4e-06, 
42.1) 
1785224- 
1785244 
(4e-06, 
42.1) 
1731039-
1731059 
(42.1) 
 
BOX-01r 
20-mer 
CGCTTTGATGAACTTGAGTT 1611476-
1611457 (1 e -
05, 40.1) 
1802846-
1802827 (1e-
05, 40.1) 
1648297-
1648278 
(1e-05, 
40.1) 
1785595-
1785576 
(1e-05, 
40.1) 
1731455-
1731436 
(40.1) 
 
BOX-01 LENGTH (bp) 326 371 461 371 377 
BOX-02f 
(ms32) 
21-mer (** is 
reverse) 
TTGCTTGGTACAGAAAACAAA 571757- 571777 
(4e-06, 42.1) 
689614- 
689634 (1e-
05, 42.1) 
576435- 
576455(1e-
05, 42.1) 
603709- 
603729 
(1e-05, 
42.1) 
614986-
615006 
(42.1) 
 
BOX-02r 
21-mer (** is 
forward) 
CCCCATAAAACCCTCCTTATA 572128-572108 
(4 e -06, 42.1) 
690030-
690010 (4e-
06, 42.1) 
576851-
576831 
(4e-06, 
42.1) 
604125-
604105 
(4e-06, 
42.1) 
615447-
615427 
(42.1) 
 
BOX-02 LENGTH 371 416 416 416 421 
BOX-03f 
(ms15) 
19-mer (** is 
reverse) 
TCCAACACGACCTTTATCC 1579329- 
1579347 (1e-04, 
38.2) 
1763019- 
1763037 (1e-
04, 38.2) 
1608845- 
1608863 
(5e-05, 
38.2) 
1741339- 
1741357 
(1e-04, 
38.2) 
1695625-
1695643 
(38.2) 
 
BOX-03r 
20-mer (** is 
forward) 
TTCAGTAAACCCAGCTCGTA 1579996- 
1579977 (1 e -
05, 40.1) 
1763686-
1763667 (1e-
05, 40.1) 
1609376-
1609357 
(1e-05, 
40.1) 
1741781-
1741762 
(1e-05, 
40.1) 
1696336-
1696317 
(40.1) 
 
BOX-03 LENGTH 667 667 531 442 674 
BOX-04f 
(ms33) 
21-mer (*** is 
reverse) 
TGGGTAAAAGTAGACAGGACT 698458- 698478 
(4 e -06, 42.1) 
822567-
822587 (4e-
06, 42.1) 
698658-
698678 
(4e-06, 
42.1) not 
anneal? 
730880-
730900 
(4e-06, 
42.1) 
 
BOX-04r 
25-mer (*** is 
forward)  
CACTTCTACACTAGTTTGTAAA
GCA 
698736- 698712 
(7e-08, 50.1) 
824313- 
824289 (7e-
08, 50.1) 
699025- 
699002 
(9e-08, 
48.1) 
731203- 
731179 
(7e-08, 
50.1) 
 
BOX-04 LENGTH 278 1746 367 323  
BOX 04 F2 
21-mer  
AGGGGATTTACCCACTACAAA 41592- 41612 (4 
e -06, 42.1) 
repeated 
823993 
 - 824013 
 (1e-05, 42.1) 
repeated 
760958-
760978 
(4e-06, 
42.1) 
repeated 
793862-
793882 
(4e-06, 
42.1) 
repeated 
 
BOX 4 Pr 
25-mer 
CACTTCTACACTAGTTTGTAAA
GCA 
698736- 698712 
(7e-08, 50.1) 
824313- 
824289 (7e-
08, 50.1) 
699025- 
699002 
(9e-08, 
48.1) 
731203- 
731179 
(7e-08, 
50.1) 
 
BOX-04 (2) LENGTH - 317 - -  
BOX 06 
Nf**,***,^ 
21-mer 
GAAAAAGGTCAGGAGTAG(A)
GTT 
1911454- 
1911474 (8e-06, 
42.1) 
2117294- 
2117314 (7e-
06, 42.1) 
1946160- 
1946175 
(0.007, 
32.2) not 
anneal? 
2077187- 
2077203 
(0.002, 
34.2) not 
anneal? 
 
BOX 06 R 
19-mer 
TCACTTGAGACAATCAGCC 1911736- 
1911718 (5 e -
05, 38.2) 
2117588-
2117570( 5e-
05, 38.2) 
1946453-
1946435( 
5e-05, 
38.2) 
2077526-
2077508 
(5e-05, 
38.2) 
 
BOX-06 LENGTH 282 294 293 339  
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 Position in genome 
Primer Sequence R6 (serotype 2)* Hungary19A-
6 ** (19A) 
G54 
(19F)*** 
CGSP14 
(14)^ 
TIGR4 
(4)^^ 
BOX 06 F2 
22-mer 
TTATGATTTTTGTCATTTTGCA 1911429- 
1911450 (1 e -
06, 44.1) 
2117269-
2117290 (1e-
06, 44.1) 
1946134-
1946155 
(1e-06, 
44.1) 
2077162-
2077183 
(1e-06, 
44.1) 
 
(367)B(303)OX 
6 Nr2 
24-mer 
GAAATCTTTGAAAAACTAGGAT
TT 
1911706- 
1911683 (3e-07, 
48.1) 
2117558- 
2117535 (3e-
07, 48.1) 
1946423- 
1946400 
(3e-07, 
48.1) 
2077496- 
2077473 
(3e-07, 
48.1) 
 
BOX-06 (2) LENGTH 277 289 289 334  
B10f 
20-mer 
TATGACGCGTATGGAAGTGC 587873 
- 587892 
(40.1) 
705790 
- 705809 
(40.1) 
592613 
- 592632 
(40.1) 
619880 
- 619899 
(40.1) 
631207 
- 631226 
(40.1) 
B10r* 
23-mer 
GATTGTGTAGGTCATGC(A)TCT
GCT 
588335 
- 588313 
(46.1) 
706432  
- 706410 
(38.2) 
593075 
- 593053 
(38.2) 
620432 
- 620410 
(38.2) 
631669 
- 631647 
(46.1) 
BOX -10 LENGTH 462 642 462 552 462 
BOX 11 Vf 
23-mer* ** 
TCCAATAATGACAGG(A)TTTTC
CTC 
411593- 411615 
(9e-07, 46.1) 
512935- 
512957 (2e-
04, 38.2) 
411736- 
411758 
(3e-07, 
46.1) 
447095- 
447117 
(9e-07, 
46.1) 
 
BOX 11 R 
21-mer 
TTCCAATCTACGCCTTTGAAG 412189- 412169 
(4 e -06, 42.1) 
513529-
513509 (4e-
06, 42.1) 
412285-
412265 
(4e-06, 
42.1) 
447644-
447624 
(4e-06, 
42.1) 
 
BOX-11 LENGTH 596 594 549 549  
BOX 12 Pf 
19-mer (** is 
reverse) 
TTGCCCTTTTCATCTTCGA 1350097- 
1350115 (2e-04, 
38.2) 
1501035- 
1501053 (2e-
04, 38.2) 
1389836- 
1389854 
(2e-04, 
38.2) 
1472944- 
1472962 
(2e-04, 
38.2) 
 
BOX 12 R 
18-mer (** is 
forward) 
CAGCAACCATTGAAACGC 1350841- 
1350824 (2 e -
04, 36.2) 
1501824-
1501807 (2e-
04, 36.2) 
1390400-
1390383 
(2e-04, 
36.2) 
1473823-
1473806 
(2e-04, 
36.2) 
 
BOX-12 LENGTH 744 789 564 879  
BOX-13f 
(ms25) 
20-mer  
TCGCCTTTGCTAATCAAACA 101033-101052 
(5e-05, 40.1) 
178817-
178836 (5e-
05, 40.1) 
103496-
103515 
(5e-05, 
40.1) 
101226-
101245 
(5e-05, 
40.1) 
 
BOX-13r 
23-mer  
CTGATTATATCGCTCACAAACC
C 
101512-101490 
(3e-07, 46.1)  
179161-
179139(3e-
07, 46.1) 
103974-
103952 
(3e-07, 
46.1) 
101702-
101680 
(3e-07, 
46.1) 
 
BOX-13 LENGTH 479 344 478 476  
Spneu31f 
21-mer 
CTGGAATAGTCCATCGAGCTT 556641- 556661 
 
673012- 
673032 
 
561723- 
561743 
 
588988- 
589008 
 
598431 
- 598451 
(42.1) 
Spneu31r 
21-mer 
CGAAGGTAAATGTGAACAAAC 557234- 557214 673290- 
673270 
561956- 
561936 
589221- 
589201 
598709 
- 598689 
(42.1) 
Spneu31 LENGTH 593 278 233 233 278 
Sp BOX-12Pf 
NEW 
19-mer (** is 
reverse) 
GATTGCCCTTTTCATCTTC 1350095 
-1350113 
(38.2) 
1501033 
-1501051 
(38.2) 
1389834 
- 1389852 
(38.2) 
1472942 
-1472960 
(38.2) 
1424174 
-1424192 
(38.2) 
Sp BOX-12r 
NEW 
18-mer (** is 
forward) 
CACAGCAACCATTGAAAC 1350843 
- 1350826 
(36.2) 
1501826 
- 1501809 
(36.2) 
1390402 
- 1390385 
(36.2) 
1473825 
- 
1473808 
(36.2) 
1424876 
- 
1424860 
(34.2) 
QHFSS BOX12  748 793 568 883 702 
Spneu15f 
20-mer 
TCCAACACGACCTTTATCCA 1579329- 
1579348 
 
1763019- 
1763038 
 
1608845- 
1608864 
 
1741339- 
1741358 
 
1695625 
- 
1695644 
(40.1) 
Spneu15r 
20-mer 
AGCCTTGCTCCTCATCTTGA 1579835- 
1579816 
1763525- 
1763506 
1609215- 
1609196 
1741620- 
1741601 
1696175 
- 
1696156 
(40.1) 
Spneu15  468 468 332 243 531 
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 Position in genome 
Primer Sequence R6 (serotype 2)* Hungary19A-
6 ** (19A) 
G54 
(19F)*** 
CGSP14 
(14)^ 
TIGR4 
(4)^^ 
ms17f (B17) 
(other 16bp)  
20-mer 
TCGAAAATCTCTGCAAACCA 1783082- 
1783101 
(40.1) 
1974737- 
1974756 
(40.1) 
1812245- 
1812264 
(40.1) 
1945466- 
1945485 
(40.1) 
1901665- 
1901684 
(40.1) 
ms17r ***, ^, 
**, * 
19-mer 
CGGACTAGGCGGCTGATTA 1783248- 
1783234 
(30.2) 
1974993- 
1974979 
(30.2) 
1812365- 
1812351 
(30.2) 
1945676- 
1945662 
(30.2) 
1902235- 
1902217 
(38.2) 
Spneu17  166 256 120 210 570 
ms19f 
21-mer 
TCGGGTGTAGTCGTGTTTACT 1925823- 
1925843 
(42.1) 
2131778- 
2131798 
(42.1) 
1960589- 
1960609 
(42.1) 
2093379- 
2093399 
(42.1) 
2046696- 
2046716 
(42.1) 
Ms19r 
27-mer 
AACTGATGTAGCTAAACCTAAA
AAGAA 
1926485- 
1926459 
(54) 
2132320- 
2132294 
(54) 
1961011- 
1960985 
(54) 
2093981- 
2093955 
(54) 
2047178- 
2047152 
(54) 
Spneu19  662 542 422 602 482 
Ms25f (BOX-
13) 
20-mer 
TCGCCTTTGCTAATCAAACA 101033- 101052 
(40.1) 
178817- 
178836 
(40.1) 
103496- 
103515 
(40.1) 
101226- 
101245 
(40.1) 
106484- 
106503 
(40.1) 
Ms25r 
20-mer 
GACTGGGTAACAATTCCATT 101458- 101439 
(40.1) 
179107- 
179088 
(40.1) 
103920- 
103901 
(40.1) 
101648- 
101629 
(40.1) 
106951- 
106932 
(40.1) 
Spneu25  425 290 424 422 467 
Ms27f (B27)** 
20-mer 
TCAGGAACAGCTATTATCCC 257703- 257722 
(40.1) 
1042289- 
1042303 
(30.2) 
254840- 
254859 
(40.1) 
281039- 
281058 
(40.1) 
257247- 
257266 
(40.1) 
Ms27r** 
20-mer 
CCAACCTCCTTTTCGTTTCA 258049- 258030 
(40.1) 
174444- 
174455 
(24.3) 
255186- 
255167 
(40.1) 
281328- 
281309 
(40.1) 
257548- 
257529 
(40.1) 
Spneu27  346 ? 346 289 301 
Ms33f (BOX-
04) 
(other 19bp) 
20-mer 
CAGCTGAACATGATGGCAAA 698391- 698410 
(40.1) 
822500- 
822519 
(40.1) 
698591- 
698610 
(40.1) 
730813- 
730832 
(40.1) 
743709- 
743728 
(40.1) 
Ms33r 
21-mer 
CATCACTTCTCCCTTCTAATC 698797- 698777 
(42.1) 
824374- 
824354 
(42.1) 
699087- 
699067 
(42.1) 
731264- 
731244 
(42.1) 
744250- 
744230 
(42.1) 
Spneu33  406 1874 496 431 521 
Ms37f (BOX-
12) 
(another 
20bp) 
20-mer 
ATGCGCAAATCGATTAAGGA 1010066- 
1010047 
(40.1) 
1350250- 
1350269 
(40.1) 
1113368-
1113349 
(40.1) 
1501188- 
1501207 
(40.1) 
1389989- 
1390008 
(40.1) 
1146548- 
1146567 
(40.1) 
1473097- 
1473116 
(40.1) 
1053517- 
1053498 
(40.1) 
1424329- 
1424348 
(40.1) 
Ms37r 
20-mer 
CGATGTGCTTCACTCACTCC 1350750- 
1350731 
(40.1) 
1501733- 
1501714 
(40.1) 
1390309- 
1390290 
(40.1) 
1473732- 
1473713 
(40.1) 
1424784- 
1424765 
(40.1) 
Spneu37  500 545 320 635 455 
Ms39f 
(B39)*** 
20-mer 
CCTTGGAC(T)TACCACCTCGTT 1915770- 
1915789 
(40.1) 
2121623- 
2121642 
(40.1) 
1950488- 
1950507 
(32.2) 
2083269- 
2083288 
(40.1) 
2036537- 
2036556 
(40.1) 
Ms39r 
20-mer 
GCCGTGACAGACTTCTGGAA 1916044- 
1916025 
(40.1) 
2121987- 
2121968 
(40.1) 
1950807- 
1950788 
(40.1) 
2083588- 
2083569 
(40.1) 
2036904- 
2036885 
(40.1) 
Spneu39  274 364 319 319 367 
BOX-10F2 GGAGCCGAGTAGGAGATTCTC
AC 
587893- 587915 
(46.1) 
705810- 
705832 
(46.1) 
592633- 
592655 
(46.1) 
619900- 
619922 
(46.1) 
631227- 
631249 
(46.1) 
BOX-10R2 TCGTAGGCTGCTACATTGACCA
G 
588403- 588381 
(46.1) 
706500- 
706478 
(46.1) 
593143- 
593121 
(46.1) 
620500- 
620478 
(46.1) 
631737- 
631715 
(46.1) 
BOX-10 
(NEW) 
 510 690 510 600 510 
BOX-12F2 GAGATTGCCCTTTTCATCTTCG 1350093- 
1350114 
(44.1) 
1501031- 
1501052 
(44.1) 
1389832- 
1389853 
(44.1) 
1472940- 
1472961 
(44.1) 
1424172- 
1424193 
(44.1) 
BOX-12R2 AGCAACCATTGAAACGCCTG 1350840- 
1350821 
(40.1) 
1501823- 
1501804 
(40.1) 
1390399- 
1390380 
(40.1) 
1473822- 
1473803 
(40.1) 
1424874- 
1424855 
(40.1) 
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 Position in genome 
Primer Sequence R6 (serotype 2)* Hungary19A-
6 ** (19A) 
G54 
(19F)*** 
CGSP14 
(14)^ 
TIGR4 
(4)^^ 
BOX-12 
(NEW) 
 747 792 567 882 702 
BOX-13F2 TCAAAAGATTGGAGAGTTCCG
C 
100977- 100998 
(44.1) 
178761- 
178782 
(44.1) 
103440- 
103461 
(44.1) 
101170- 
101191 
(44.1) 
106428- 
106449 
(44.1) 
BOX-13R2 GGATTTGGAGAGCAAGCAGAT
C 
101549- 101528 
(44.1) 
179198- 
179177 
(44.1) 
104011- 
103990 
(44.1) 
101739- 
101718 
(44.1) 
107042- 
107021 
(44.1) 
BOX-13 
(NEW) 
 572 437 571 569 614 
Spneu19-F2 CACTCACCGTTAGCATTGACTC
G 
1925793- 
1925815 
(46.1) 
2131748- 
2131770 
(46.1) 
1960559- 
1960581 
(46.1) 
2093349- 
2093371 
(46.1) 
2046666- 
2046688 
(46.1) 
Spneu19-R2 TAATCAGGGAGTAGTTGGTTG
GG 
1926455- 
1926433 
(46.1) 
2132290- 
2132268 
(46.1) 
1960981- 
1960959 
(46.1) 
2093951- 
2093929 
(46.1) 
2047148- 
2047126 
(46.1) 
Spneu19 
(NEW) 
 662 520 422 602 482 
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Appendix A3: Graphical representation of the diversity of MLVA genes in 
S. pneumoniae. 
Number of occurrence for each locus is out of 317 S. pneumoniae isolates. Copy number 
represents the number of locus repeats for that allele (e.g. copy number 4 for Locus 1: BOX_01 
indicates that BOX-01 has four repeats of boxB in the locus, and was observed in 14 S. 
pneumoniae isolates). A copy number of 99 indicate that the locus failed to amplify.  
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Appendix A4: Comparison of various pneumococcal PCR-based serotyping 
methods. 
Name Methodology Pros. Cons. Ref. 
One-step 
multiplex PCR 
serotyping 
Single 
amplification of 
cpsA, wzy, wciP, 
wcwH 
100% sensitive and 
specific 
Antiserum 
needed for 
serotype 6, 7, 9 
and 18. Detects 
only 13vPCV 
serotypes. 
Coskun-Ari et 
al., 2012 
Triplex real-time 
PCR serotyping 
7 triplexed 
reaction with 
rtPCR; amplifies 
wzy, wciP, wciN, 
wzx, wcwV 
High sensitivity and 
specificity. Tested 21 
serotypes. 
Expensive due 
to limited 
multiplexing 
Pimenta et al., 
2013 
Multiplex PCR 
serotyping 
6 sequential 
multiplex PCR 
Sequential PCR 
reduces time and 
cost; can be 
modified to suit 
various countries 
Not all 
serotypes 
covered 
Antonio et al., 
2009; Azzari et 
al., 2010; Dias 
et al., 2007; 
Iraurgui et al., 
2010; Jourdain 
et al., 2011; 
Miernyk et al., 
2011; Njanpop 
Lafourcade et 
al., 2010; Pai et 
al., 2006; Saha 
et al., 2008; 
Siira et al., 2012  
Microarray 
serotyping 
274 
oligonucleotide 
probes used for 
glycosyltransferase 
Cost-effective and 
reliable. Tested 37 
serotypes. 
Time consuming 
due to number 
of probes 
Tomita et al., 
2011 
Multibead 
serotyping assay 
Use of beads   Yu et al., 2011 
Real-time PCR 
serotyping 
Use of rtPCR to 
amplify the 
capsule cassette 
Directly applied to 
blood samples; 
lower limit of 
detection; tested 
26/31 serotypes; no 
difference in 
sensitivity/specificity 
compared to 
sequential multiplex 
PCR 
 Azzari et al., 
2010; Marchese 
et al., 2011; 
Tarrago et al., 
2008 
Capsule 
Sequence Typing 
(CST) 
Sequence 506bp 
of wzh and other 
specific genes 
Tested serogroup 6 
and 19; determine 
evolution 
Only two 
serogroups 
tested; 
laborious to test 
routinely 
Elberse et al., 
2011c 
Real-time PCR 
serotyping 
3 multiplex 
reactions using 
rtPCR 
100% specificity; 17 
serotypes tested 
Fail to 
distinguish 
between some 
serotypes 
Moore et al., 
2010 
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Name Methodology Pros. Cons. Ref. 
Serotype-
specific PCR 
Two SNP-specific 
sense primers 
wciP584gS and 
wciP584aS 
Distinguishes 
between serotype 
6A, B and C 
Only specific for 
serogroup 6 
Jin et al., 2009 
Multiplex PCR-
based Reverse 
Line Blot 
Hybridisation 
20 sets of primers 
amplify in 
multiplex 
reactions and use 
of reverse line blot 
hybridisation 
Type 90 serotypes Labourious 
technique 
Zhou et al., 
2007 
PCR-RFLP 
serotyping 
Amplify entire cps 
cassette and 
digested to 
produce serotype-
specific patterns 
Tested 46 serotypes Difficult to 
analyse and 
compare 
between 
laboratories 
Brugger et al., 
2009 
Multiplex PCR (7 
reactions) 
7 multiplex 
reaction using PCR 
and gel 
electrophoresis 
Distinguish between 
9 serotypes targeted 
by 11vPCV; 
multiplexed 
Only 9 serotypes 
detected, and 
only 65.9% (of 
446 isolates) 
characterised to 
serogroup level 
Brito et al., 
2003 
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Appendix A5: In silico analysis of 182 targets in the pneumococcal capsule cassette. 
Each of 93 pneumococcal serotypes have a unique ‘pseudoDNA’ sequence consisting of T=gene present (highlighted yellow) and A=gene absent (not highlighted) from 
their capsule cassette (running left to right across table, genes are number 1 to 182). CPS loci are labelled across the top underneath gene number. Accession code is 
from the NCBI database for representative serotype used. Allele file code is designated against each pseudoDNA sequence and is used for the MinimumSNPs program. 
The whole pseudoDNA sequence will not fit across the page, therefore it has been broken up into sections (each section has a different border around the table). 
   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 
A
cc
es
si
o
n
 
Se
ro
ty
p
e
 
al
le
le
 f
ile
 
co
d
e 
Tn
p
 
w
zg
 
w
zh
 
w
zd
 
w
ze
 
w
ch
B
 
w
ch
C
 
w
ch
D
 
w
zy
 
w
zx
 
gl
a 
u
gd
 
rm
lA
 
rm
lC
 
rm
lB
 
rm
lD
 
w
ch
A
 
w
ch
F 
w
ch
G
 
w
ch
H
 
w
ch
I 
gl
f 
w
ch
E 
ga
lU
 
p
gm
 
H
G
2
61
 
w
ci
I 
w
ci
J 
w
ci
K 
w
ci
L 
w
ci
M
 
m
n
aA
 
fn
lA
 
fn
lB
 
CR931632 1 cps_>1 T T T T T T T T T T T T T T T T A A A A A A A A A A A A A A A A A A 
CR931633 2 cps_>2 T T T T T A A A T T A T T T T T T T T T T T A A A A A A A A A A A A 
CR931634 3 cps_>3 T T T T T A A A A A A T A A A A A A A A A A T T T A A A A A A A A A 
CR931635 4 cps_>4 T T T T T A A A T T A A A A A A A A A A A A A A A T T T T T T T T T 
CR931637 5 cps_>5 T T T T T A A A T T A T A A A A A A A A A A A A A A T T A A A A T T 
CR931638 6A cps_>6 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A A A A 
CR931639 6B cps_>7 T T T T T A A A T T A A T T T T T A A A A T A A A A A A A A A A A A 
EF538714 6C cps_>8 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A A A A 
HM171374 6D cps_>9 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A A A A 
CR931640 7A cps_>10 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931641 7B cps_>11 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931642 7C cps_>12 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931643 7F cps_>13 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931644 8 cps_>14 T T T T T A A A T T A T A A A A T A A A A A A A A A A A A A A A A A 
CR931645 9A cps_>15 T T T T T A A A T T A T A A A A T A A A A A A A A A A A A A A T A A 
CR931646 9L cps_>16 T T T T T A A A T T A T A A A A T A A A A A A A A A A A A A A T A A 
CR931647 9N cps_>17 T T T T T A A A T T A T A A A A T A A A A A A A A A A A A A A T A A 
CR931648 9V cps_>18 T T T T T A A A T T A T A A A A T A A A A A A A A A A A A A A T A A 
CR931649 10A cps_>19 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931650 10B cps_>20 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931651 10C cps_>21 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931652 10F cps_>22 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931653 11A cps_>23 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931654 11B cps_>24 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931655 11C cps_>25 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931656 11D cps_>26 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931657 11F cps_>27 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931658 12A cps_>28 T T T T T A A A T T A A A A A A A A A A A A A A A A T T A A A T T T 
CR931659 12B cps_>29 T T T T T A A A T T A A A A A A A A A A A A A A A A T T A A A T T T 
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CR931660 12F cps_>30 T T T T T A A A T T A A A A A A A A A A A A A A A A T T A A A T T T 
CR931661 13 cps_>31 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931662 14 cps_>32 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931663 15A cps_>33 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931664 15B cps_>34 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931665 15C cps_>35 T T T T T A A A T T A A A A A A T A A A A A A A A A A A A A A A A A 
CR931666 15F cps_>36 T T T T T A A A T T A A A A T T T A A A A T A A A A A A A A A A A A 
CR931667 16A cps_>37 T T T T T A A A T T A A T T T T T A A A A T A A A A A A A A A A A A 
CR931668 16F cps_>38 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931669 17A cps_>39 T T T T T A A A T T A T T T T T T A A A A T A A A A A A A A A A A A 
CR931670 17F cps_>40 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931671 18A cps_>41 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931672 18B cps_>42 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931673 18C cps_>43 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931674 18F cps_>44 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931675 19A cps_>45 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A T A A 
CR931676 19B cps_>46 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A T A A 
CR931677 19C cps_>47 T T T T T A A A T T A A T T T T T A A A A T A A A A A A A A A T A A 
CR931678 19F cps_>48 T T T T T A A A T T A A T T T T T A A A A A A A A A A A A A A T A A 
CR931679 20A cps_>49 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A T A A A A 
JQ653093 20B cps_>50 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A T A A A A 
CR931680 21 cps_>51 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931681 22A cps_>52 T T T T T A A A T T A T T T T T T T A A A T A A A A A A A A A A A A 
CR931682 22F cps_>53 T T T T T A A A T T A T T T T T T T A A A T A A A A A A A A A A A A 
CR931683 23A cps_>54 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931684 23B cps_>55 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931685 23F cps_>56 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931686 24A cps_>57 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931687 24B cps_>58 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931688 24F cps_>59 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931689 25A cps_>60 T T T T T A A A T T T T A A A A A A A A A T A A A A T A A A A A A A 
CR931690 25F cps_>61 T T T T T A A A T T T T A A A A A A A A A T A A A A T A A A A A A A 
CR931691 27 cps_>62 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931692 28A cps_>63 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931693 28F cps_>64 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931694 29 cps_>65 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931695 31 cps_>66 T T T T T A A A T T A T T T T T A A A A A T A A A A A A A A A A A A 
CR931696 32A cps_>67 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931697 32F cps_>68 T T T T T A A A T T A A T T T T T T A A A A A A A A A A A A A A A A 
CR931698 33A cps_>69 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931699  33B cps_>70 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931700 33C cps_>71 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
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CR931701 33D cps_>72 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931702  33F cps_>73 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931703 34 cps_>74 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931704 35A cps_>75 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931705 35B cps_>76 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931706 35C cps_>77 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931707 35F cps_>78 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931708 36 cps_>79 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A T A A 
CR931709  37 cps_>80 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931710 38 cps_>81 T T T T T A A A T T T T A A A A A A A A A T A A A A T A A A A A A A 
CR931711 39 cps_>82 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931712 40 cps_>83 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
CR931713 41A cps_>84 T T T T T A A A T T A T T T T T T A A A A T A A A A A A A A A A A A 
CR931714 41F cps_>85 T T T T T A A A T T A T T T T T T A A A A T A A A A A A A A A A A A 
CR931715 42 cps_>86 T T T T T A A A T T A A A A A A T A A A A T A A A A A A A A A A A A 
CR931716 43 cps_>87 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931717 44 cps_>88 T T T T T A A A T T A A A A A A A A A A A A A A A A T T A A A T T T 
CR931718 45 cps_>89 T T T T T A A A T T A A T T T T A A A A A A A A A A T T A T A A T T 
CR931719 46 cps_>90 T T T T T A A A T T A A A A A A A A A A A A A A A A T T A A A T T T 
CR931720 47A cps_>91 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931721 47F cps_>92 T T T T T A A A T T A A A A A A A A A A A T A A A A A A A A A A A A 
CR931722 48 cps_>93 T T T T T A A A T T A A T T T T T T A A A T A A A A A A A A A A A A 
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CR931632 1 cps_>1 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931633 2 cps_>2 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931634 3 cps_>3 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931635 4 cps_>4 T A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931637 5 cps_>5 T T T T A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931638 6A cps_>6 A A A A T T T T A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931639 6B cps_>7 A A A A T A T T T A A A A A A A A A A A A A A A A A A A A A A A A A A 
EF538714 6C cps_>8 A A A A T A T T A A A A A A A A A A A A A A A A A A A A A A A A A A A 
HM17137
4 
6D cps_>9 A A A A T A T T A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931640 7A cps_>10 A A A A A A A A A T T T T T T T A A A A A A A A A A A A A A A A A A A 
CR931641 7B cps_>11 A A A A A A A A A A A A A A A A T T T T T A A A A A A A A A A A A A A 
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CR931642 7C cps_>12 A A A A A A A A A A A A A A A A T T T T T A A A A A A A A A A A A A A 
CR931643 7F cps_>13 A A A A A A A A A T T T T T T T A A A A A A A A A A A A A A A A A A A 
CR931644 8 cps_>14 A A A A A A A A A A A A A A A A A A A A A T T T T T A A A A A A A A A 
CR931645 9A cps_>15 A A A A A A A A A A A A A A A A A A A A A A A A A A T T T T T T A A A 
CR931646 9L cps_>16 A A A A A A A A A A A A A A A A A A A A A A A A A A T T T T A T A A A 
CR931647 9N cps_>17 A A A A A A A A A A A A A A A A A A A A A A A A A A T T T T A T A A A 
CR931648 9V cps_>18 A A A A A A A A A A A A A A A A A A A A A A A A A A T T T T T T A A A 
CR931649 10A cps_>19 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T T T 
CR931650 10B cps_>20 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T T T 
CR931651 10C cps_>21 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T T T 
CR931652 10F cps_>22 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T T T 
CR931653 11A cps_>23 A A A A A A A A A A T A A A A A A A A A A A A A A A A A A A A T A A A 
CR931654 11B cps_>24 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931655 11C cps_>25 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931656 11D cps_>26 A A A A A A A A A A T A A A A A A A A A A A A A A A A A A A A T A A A 
CR931657 11F cps_>27 A A A A A A A A A A T A A A A A A A A A A A A A A A A A A A A T A A A 
CR931658 12A cps_>28 T A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931659 12B cps_>29 T A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931660 12F cps_>30 T A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931661 13 cps_>31 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931662 14 cps_>32 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931663 15A cps_>33 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931664 15B cps_>34 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931665 15C cps_>35 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931666 15F cps_>36 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T A A A 
CR931667 16A cps_>37 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T A 
CR931668 16F cps_>38 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931669 17A cps_>39 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A T A 
CR931670 17F cps_>40 A A A A A A A T A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931671 18A cps_>41 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
CR931672 18B cps_>42 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A 
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Appendix A6: Determination of presence/absence of 19 capsule targets in 
S. pneumoniae using conventional PCR and gel electrophoresis. 
Marker ladder (MVIII) used in first column; targeted gene being amplified is written above the 
first serotype tested (i.e. serotype 1) and is therefore used for the pneumococcal isolates 
following until the next targeted gene is written; pneumococcal serotypes are written above 
each lane. 
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Appendix A7: Real-time PCR analysis of 19 primer targets in the S. 
pneumoniae capsule cassette. 
Melt A. Green heat curve and High Resolution Melt (HRM) Difference curve is presented for each 
locus. Melt A. Green heat curves contain a positive control strain, and peaks indicate a positive 
amplification of the loci. HRM Difference curve is based on the positive control, and a sample 
that is more than ±5 units from the positive control (set as the base line ‘0’) indicates that the 
locus is significantly different than the positive control. HRM Difference samples have replicates 
combined for ease of analysis. 
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APPENDIX B 
Appendix B1: Poster presentation at IHBI Inspires 2012, Gold Coast 
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Appendix B2: Poster presentation at Australian Society for Microbiology 
Annual Conference 2013, Adelaide, and Microbiology at QUT 2014, 
Brisbane 
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Appendix B3: Oral presentation at IHBI Inspires 2013, Brisbane 
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Appendix B4: Oral presentation at IHBI Inspires 2014, Gold Coast 
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Appendix B5: Oral presentation at XIX Lancefield International Symposium 
on Streptococci and Streptococcal Diseases, Buenos Aires, Argentina, and 
Microbiology in Maleny QLD Branch of ASM Scientific meeting, Maleny, 
Australia. 
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Appendix B6: Poster presentation at Australian Society for Microbiology 
Annual Conference 2015, Canberra 
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Appendix B7: Statement of Contribution for manuscript “Genotyping 
Streptococcus pneumoniae” (April 2015) 
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Appendix B8: Published manuscript “Genotyping Streptococcus pneumoniae” 
to Future Microbiology (April 2015) 
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Appendix B9: Statement of Contribution for manuscript “Modified MLVA 
for genotyping Queensland invasive Streptococcus pneumoniae” (April 
2015) 
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Appendix B10: Published manuscript “Modified MLVA for genotyping 
Queensland invasive Streptococcus pneumoniae” to PLoS One (April 2015) 
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Appendix B11: Complete draft manuscript “Changing population 
structure of invasive Streptococcus pneumoniae in Queensland children 
pre- and post-13vPCV”, prepared for PLoS One 
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